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Abstract 
This thesis examined the association between chronic kidney disease (CKD) and both mental 
health disorders and psychoactive drugs, using a large contemporary UK database of routine 
medical record data (Clinical Practice Research Datalink [CPRD]). To fill the gap between 
what is known and what is unknown in this field, I focused on two main topics: (i) severe 
mental illness (SMI), with and without a history of lithium use, and CKD, and (ii) CKD and 
antidepressants (mainly prescribed for common mental health disorders such as depression and 
anxiety) and associated serious adverse outcomes. 
I first conducted a population-level validation study comparing prevalence estimates of 
decreased kidney function (defined as estimated glomerular filtration rate of <60 ml/min/1.73 
m2) and renal replacement therapy (RRT) in the CPRD population with nationally 
representative statistics (Health Survey for England and UK Renal Registry). Findings 
suggested that most patients with decreased kidney function and RRT are probably captured in 
the CPRD. 
Secondly, I conducted a cross-sectional study on the association between SMI, including 
schizophrenia and bipolar disorder, and CKD (defined as two measurements of estimated 
glomerular filtration rate of <60 ml/min/1.73 m2 over ≥3 months in the past five years). Patients 
with SMI, especially lithium users, had a significantly higher prevalence of both CKD and 
RRT than the general population.  
Thirdly, I conducted a matched cohort study comparing the prevalence and incidence of 
antidepressant prescription between patients with and without CKD (matched for age, sex, 
general practice, and calendar time). Patients with CKD were approximately one and a half 
times more likely to receive antidepressants for mental health conditions such as depression 
and anxiety. 
Finally, I examined the gastrointestinal (GI) bleeding risk of selective serotonin reuptake 
inhibitors (SSRIs) by level of kidney function. While the relative risk for GI bleeding 
associated with SSRIs (i.e. the fully-adjusted rate ratio between periods with and without SSRI 
prescription) was constant regardless of baseline kidney function, the excess risk for GI 
bleeding associated with SSRIs (i.e. the fully-adjusted rate difference between periods with 
and without SSRI exposure) increased markedly as baseline kidney function deteriorated.  
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In conclusion, a close association between CKD and mental health disorders was suggested in 
the UK general population. It is evident that patients with CKD are more likely to be prescribed 
antidepressants, and this may cause serious adverse outcomes such as GI bleeding associated 
with SSRIs. The risk-benefit balance of antidepressants for patients with CKD may need to be 
reconsidered in light of this new evidence. 
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Chapter 1: Introduction 
In this introductory chapter, I present a brief overview of chronic kidney disease (CKD), mental 
health disorders and psychoactive drugs. I will then summarise the aims and objectives of the 
thesis and provide an outline of the thesis. 
1.1. General background 
1.1.1. Chronic kidney disease (CKD) 
Kidneys are important organs, the main role of which is to remove metabolic waste products 
in the body by producing urine. CKD is broadly defined as the presence of kidney damage or 
decreased kidney function that persists for three months [1, 2]. A more technical definition of 
decreased kidney function and CKD will be provided in chapter 3. Briefly, this thesis focuses 
on CKD stages 3 to 5, defined as two or more consecutive measurements of decreased kidney 
function (i.e. estimated glomerular filtration rate [eGFR] <60 mL/min/1.73m2) for over three 
months. 
CKD is common in patients with a variety of conditions, including ageing, diabetes, 
hypertension, cardiovascular diseases, smoking, and obesity [1]. The worldwide prevalence of 
CKD, based on evidence of kidney damage or decreased kidney function, is estimated to be 8-
16% [3]. According to the Health Survey for England 2009/2010 (a population representative 
survey), the prevalence of eGFR <60 mL/min/1.73 m2 (as proxy for CKD stages 3 to 5) was 
approximately 6% in men and 7% in women [4]. A study comparing the results of Health 
Surveys for England 2003 and 2009/2010 suggested that the prevalence of eGFR <60 
mL/min/1.73 m2 within each age and gender group decreased slightly over this seven-year 
period [5]. However, because age is a strong determinant of CKD (e.g. the Health Survey for 
England 2009/2010 showed that the prevalence of eGFR <60 mL/min/1.73 m2 was less than 
5% in people aged <55, but it increased up to over 30% in people aged >75 [4]), the overall 
prevalence of CKD is expected to be increasing in most developed countries as the population 
ages [6]. 
One serious consequence of CKD is end-stage renal disease (ESRD) requiring renal 
replacement therapy (RRT); this involves haemodialysis, peritoneal dialysis, and kidney 
transplantation. However, only a very small minority of patients with CKD end up undergoing 
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RRT [7]. According to the UK Renal Registry 2014, the incidence and prevalence of RRT was 
115 (per year) and 913 per million population, respectively [8, 9].  
CKD is a silent disease, meaning that patients with CKD do not have any symptoms until the 
kidney function is severely decreased (e.g. GFR 20–30 mL/min/1.73 m2). However, even 
moderate CKD (e.g. eGFR 45–59 mL/min/1.73 m2) was found to be associated with an 
increased risk of death, cardiovascular events, and hospitalisation [10]. Moreover, 
accumulating evidence suggests that moderate CKD is also associated with non-cardiovascular 
outcomes, including infection [11, 12], bleeding [13, 14], and fracture [15, 16].  
The mainstream of care related to CKD consists of early detection and prevention of CKD 
progression by intervening in modifiable risk factors (e.g. better control of diabetes, smoking 
cessation), and treatment of comorbidities such as high blood pressure and dyslipidemia [1]. In 
addition, when caring for patients with decreased kidney function in daily practice, drug choice 
and dosage need to be carefully considered, as some drugs and their metabolites are cleared by 
the kidneys. 
1.1.2. Mental health disorders and psychoactive drugs 
As represented by the Diagnostic and Statistical Manual of Mental Disorders [17], mental 
health disorders have been sophisticatedly categorised through decades of effort by hundreds 
of international experts (i.e. psychiatrists) across all aspects of mental health. However, the 
focus of this thesis is the association between CKD and mental health problems in the primary 
care setting. Therefore, with reference to the Quality and Outcomes Framework (QOF), a 
system governing the performance management and payment of general practitioners (GPs) 
[18], and National Institute for Health and Care Excellence (NICE) guidance [19], I will focus 
on two broad categories of mental health disorders: (i) severe mental illness (SMI), including 
schizophrenia, bipolar disorder, and other psychoses, and (ii) common mental health disorders, 
including depression and anxiety disorders. 
Psychoactive drug generally suggests a chemical substance that affects mood, perception or 
consciousness as a result of changes in the functioning of the nervous system (brain and spinal 
cord) [20]. In medicine, psychoactive drugs include anaesthetics, analgesics, anticonvulsants, 
antiparkinsonian drugs, antidepressants, anxiolytics, antipsychotics, and stimulant medications. 
14
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Among a range of psychoactive drugs, I will focus on lithium (mainly prescribed for SMI) and 
antidepressants (mainly prescribed for common mental health disorders). 
(i) Severe mental illness (schizophrenia, bipolar disorder, and other psychoses)  
The QOF included SMI as one of its important clinical areas in 2004 [18] and defined SMI as 
comprising schizophrenia, bipolar disorder, and other non-organic psychotic illnesses.  
In brief, schizophrenia is the most common form of the psychotic disorders and is characterised 
by hallucinations (i.e. perception in the absence of any stimulus) and delusions (i.e. fixed or 
falsely held beliefs). Schizophrenia affects approximately seven in 1000 adults, and its onset is 
mostly between the ages of 15 and 35 [21]. The mainstay of the treatment for schizophrenia is 
oral antipsychotic medication under the supervision of psychiatrists, in conjunction with 
psychological interventions (e.g. family intervention and individual cognitive behavioural 
therapy) [22].  
Bipolar disorder is characterised by episodes of mania (i.e. abnormally elevated mood or 
irritability and related symptoms, with severe functional impairment or psychotic symptoms 
for seven days or more) or hypomania (i.e. abnormally elevated mood or irritability and related 
symptoms, with decreased or increased function for four days or more) and episodes of 
depressed mood [23]. The lifetime prevalence of bipolar disorder is estimated at around 1.4% 
of the adult population, and the peak age of onset is 15-19 years. Treatment drugs include 
lithium (as the first-line monotherapy), valproate, and antipsychotics such as olanzapine and 
quetiapine, which may be initiated in secondary care (i.e. by psychiatrists) but continued in 
primary care [24].  
(ii) Common mental health disorders (depression and anxiety disorders) 
The relevant NICE guidance (‘Common mental health problems: identification and pathways 
to care’) regards depression and anxiety disorders (i.e. generalised anxiety disorder, panic 
disorder, obsessive-compulsive disorder, post-traumatic stress disorder, and social anxiety 
disorder) as “common mental health problems” [25]. These conditions may affect up to 15% 
of the population at any one time, with a lifelong course of relapse and remission. According 
to the guidance, the vast majority of diagnosed depressive and anxiety disorders are treated in 
primary care.  
15
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For subthreshold symptoms and mild to moderate common mental health disorders, low 
intensity interventions (e.g. cognitive behavioural therapy, interpersonal therapy, structured 
group physical activity programme, group-based peer support programme) are initially 
recommended. However, if these treatments are ineffective, the next step includes 
antidepressant medication. For people with an initial presentation of moderate or severe 
depression, a psychological intervention in combination with an antidepressant may be the first 
choice. For people with anxiety disorders who have not responded to low-intensity 
interventions, treatment options include cognitive behavioural therapy and antidepressants, 
specifically selective serotonin reuptake inhibitors (SSRIs). Use of benzodiazepine is currently 
discouraged except as a short-term measure during crises [26]. 
1.1.3. Known and unknown associations between CKD and mental health disorders and 
psychoactive drugs 
(i) SMI and CKD 
People with SMI are known to have shorter life expectancy than the general population, by 
around 10-20 years [27-32]. Their premature deaths are attributable not only to suicide and 
accident, but also to physical illnesses, especially cardiovascular diseases such as coronary 
heart disease and stroke [31-35]. The high rate of cardiovascular deaths in patients with SMI 
has been attributed to a high prevalence of lifestyle-related conditions (e.g. smoking and 
obesity) [36-39], sub-optimal screening/assessment of cardiovascular risks [40, 41] and sub-
optimal management of underlying diseases (e.g. hypertension, diabetes, and dyslipidaemia) 
[42-44]. For these reasons, the QOF has focused on the management of physical health 
conditions in people with SMI by including indicators related to annual monitoring of blood 
pressure, total cholesterol:high-density lipoprotein ratio, blood glucose or haemoglobin A1c, 
and body mass index (BMI) [18].  
People with SMI have an increased prevalence of several risk factors for CKD, including 
smoking and diabetes [39, 42, 45]. Moreover, patients with SMI may be treated with lithium, 
which is a known risk factor for kidney function decline [46, 47]. According to a systematic 
review and meta-analysis published in 2012 (which included nine case-control studies) [48], 
the GFR of patients taking lithium was significantly lower than that of matched controls. 
Although only a small number of studies have looked at ESRD as a research outcome, a large 
Swedish study showed that the prevalence of ESRD requiring RRT was 0.5% (18 out of 3369) 
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among ever lithium users, while the prevalence of RRT in the Swedish general population is 
around 0.08% [49]. 
Therefore, it can be hypothesised that people with SMI are more likely to develop CKD than 
those without SMI in the general population. However, there has been limited research 
investigating the prevalence of CKD in people with SMI, especially in non-lithium users [39, 
50, 51]. According to a cross-sectional study in London, UK, the prevalence of recorded 
diagnosis of CKD was 4.9% (212/4,346) and 1.8% (5,487/304,297), in those with and without 
SMI, respectively [39]. A Taiwanese cohort study showed that people with schizophrenia were 
more likely to receive a diagnosis of CKD [50]. A cross-sectional analysis of Scottish primary 
care demonstrated that people with bipolar disorder had a higher prevalence of recorded 
diagnosis of CKD than people without (7.3% vs. 2.4%) [44]. The major limitation of these 
studies was that CKD was defined based on recorded diagnosis of CKD. The validity of this 
measure is generally unsatisfactory compared to biochemical definitions of CKD in electronic 
health records [52]. In addition, the studies did not sufficiently consider differences in known 
CKD risk factors between those with and without SMI. Moreover, the sample sizes employed 
in these studies were insufficient to examine the association between SMI and ESRD requiring 
RRT. 
(ii) CKD and antidepressants for common mental health disorders  
Antidepressant prescription in patients with CKD 
The high prevalence of depression and anxiety among patients with ESRD requiring RRT is 
established [53, 54]. In addition, the association between pre-dialysis CKD and depression and 
anxiety has been well-studied to date. A systematic review and meta-analysis published in 2013 
[55], which included 228 studies, found that (interview-defined) depression affected almost 
one quarter of adults with pre-dialysis CKD. Some of the studies included in the meta-analysis 
also assessed anxiety via the Hospital Anxiety and Depression Scale. For example, Lee et al. 
reported that the prevalence of anxiety based on Hospital Anxiety and Depression Scale was 
27.6% among patients with pre-dialysis CKD [56]. The potential explanations for the 
association between CKD and common mental health disorders include (i) patients’ concerns 
about CKD progression towards dependence on maintenance dialysis [57, 58], (ii) co-existing 
chronic diseases, such as diabetes and heart failure, which are also known to be associated with 
depressive symptoms [59, 60], and (iii) uremic toxins in the advanced stage of CKD [61]. 
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However, a relatively small number of studies have been conducted regarding how 
antidepressants (i.e. the first-line treatment drug for depression and anxiety) are prescribed for 
CKD patients in real-world clinical practice. To the best of my knowledge, there has been no 
such study in the UK, although two large US studies have investigated antidepressant 
prescription among patients with pre-dialysis CKD [62, 63]. In a study based on the US 
Veterans Affairs database, antidepressants were prescribed for nearly 30% of 598,153 veterans 
with non-dialysis-dependent CKD stages 1 to 5 [62]. However, these findings may not be 
generalisable, as veterans are more likely to have common mental health problems than the 
general population [64]. In the baseline cross-sectional survey of the Chronic Renal 
Insufficiency Cohort study, 18.2% of nearly 4,000 patients with pre-dialysis CKD were using 
antidepressants [63]. However, the study population consisted of volunteer participants 
recruited from nephrology clinics, causing selection bias. Moreover, neither study utilised a 
comparison group of people without CKD. Therefore, the extent to which prescription 
frequency differs between patients with and without CKD remains unknown. 
Efficacy and risk of antidepressants in patients with CKD 
In addition to the unknown antidepressant prescription pattern, a recent systematic review 
published in 2012 concluded that the efficacy and safety of antidepressants in patients with 
pre-dialysis CKD have not been studied [65]. Of the 19 relevant articles published between 
1950 and 2011, 17 targeted patients on maintenance dialysis. The remaining two articles, which 
focused on patients with pre-dialysis CKD, were merely case reports [66, 67]. Because 
antidepressants are removed by dialysis, pharmacokinetics and pharmacodynamics are quite 
different in CKD patients with and without dialysis. Therefore, findings obtained from the 
dialysis population cannot be applied to the pre-dialysis CKD population. The lack of safety 
information pertaining to this patient group matters a lot, as patients with pre-dialysis CKD 
account for the vast majority (>95%) of the CKD population [68]. 
Regarding the efficacy of antidepressants among patients with CKD, the results of a 
randomised controlled trial (RCT) from the US have been recently reported [69]. This 
randomised, double-blind, placebo-controlled trial involving 201 patients with non-dialysis-
dependent CKD stages 3 to 5 found that treatment with normal (50 mg/day) to higher dose (up 
to 200 mg/day) of sertraline (an SSRI) for 12 weeks did not significantly improve depressive 
symptoms: the 16-item Quick Inventory of Depression Symptomatology-Clinician Rated 
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(QIDS-SR16) score changed by -4.1 in the sertraline group and by -4.2 in the placebo group 
(between-group difference 0.1 [95% CI, -1.1 to 1.3]; P = 0.82). There was no significant 
difference in the incidence of prespecified serious adverse events (death, dialysis initiation, 
hospitalisation, and bleeding episode) between the groups. However, because the sample size 
was determined based on the drug’s expected efficacy (i.e. difference of improved QIDS-SR16 
score between the groups), the study did not have adequate power to identify the serious 
adverse outcomes associated with this antidepressant. 
In the general population, several studies have suggested an association between antidepressant 
use and increased risk of serious adverse outcomes, including stroke [70], hip fracture [71], 
and gastrointestinal (GI) bleeding [72]. However, these studies did not differentiate between 
patients with and without CKD. Many antidepressants are excreted by the kidneys, with or 
without metabolism in the liver. Therefore, serum antidepressant levels or their metabolites 
may tend to be higher in patients with CKD. In addition, baseline risks of these adverse 
outcomes are higher in patients with CKD, who have a larger number of comorbidities and 
medications, than those without CKD. Therefore, it is of concern that antidepressants may be 
more strongly associated with serious adverse outcomes in patients with CKD than those 
without.  
 
1.2. Aims and objectives of thesis 
The overall aim of the thesis is to better understand the associations between CKD and both 
mental health disorders and psychoactive drugs in the UK general population, by filling the 
gap between what is known and what is unknown in this research field. To this end, I use a 
large, contemporary UK database of routine medical record data (Clinical Practice Research 
Datalink [CPRD]).  
The main reasons why I use this data source are as follows: 
- The CPRD is broadly representative of the UK general population in terms of age and sex 
[73], enabling me to examine the association between CKD and mental health disorders in 
the general population. 
- A large sample size is required for studies examining serious (but uncommon) adverse 
outcomes of antidepressants, such as GI bleeding associated with SSRIs, in patients with 
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CKD. 
- From a practical perspective, the data were available to me as a member of the Electronic 
Health Records Research Team at the London School of Hygiene and Tropical Medicine.  
Considering what remains unknown in the associations between CKD and both mental health 
disorders and psychoactive drugs (as already discussed in section 1.1.3), I established the 
following four research questions: 
1.2.1. Research question 1: What is the prevalence of CKD and RRT in the CPRD, and 
is it similar to the nationally representative statistics? 
This is important groundwork for the following research questions, which examine the 
associations between CKD and both mental health disorders and psychoactive drugs. CKD is 
generally a silent disease until the end-stage, and therefore the diagnosis of pre-dialysis CKD 
is almost entirely driven by laboratory testing. In this thesis, patients with CKD (stages 3 to 5) 
will be identified using the laboratory test results recorded in the CPRD. However, creatinine 
testing is not universal in UK primary care. Therefore, it is vital to understand what proportion 
of patients with CKD can be identified in the current CPRD, and whether these patients are 
representative or only a subset of CKD patients in the community. It is expected that GPs are 
selectively (instead of randomly) testing patients with known CKD risk factors (e.g. diabetes). 
A study comparing the prevalence of CKD between the CPRD and nationally representative 
statistics (Health Survey for England 2009/2010) will reveal whether people without serum 
creatinine testing in the CPRD are likely or unlikely to have CKD. In addition, the prevalence 
of RRT, which can be defined as recorded diagnoses suggesting RRT in the CPRD, will be 
compared with UK Renal Registry, which registers all patients on RRT in the UK. 
1.2.2. Research question 2: Is CKD more common in patients with SMI than those 
without SMI in the general population? 
People with SMI have an increased prevalence of several risk factors for CKD, such as smoking 
and diabetes. Moreover, lithium is also a strong risk factor for decreased kidney function. 
Therefore, it can be hypothesised that patients with SMI are more likely to develop CKD. 
Accordingly, it is expected that patients with SMI show a higher prevalence of CKD and ESRD 
requiring RRT than those without SMI in the general population. However, the prevalence of 
biochemically-defined CKD in the SMI population has not been well-studied to date. Moreover, 
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sample sizes in previous studies were insufficient to examine the association between SMI and 
RRT. Thus, new research using a large population-based database is warranted to address this 
question. 
1.2.3. Research question 3: Are patients with CKD more likely to be prescribed 
antidepressants than those without CKD in the general population? 
Although the association between CKD and common mental health problems is well 
established, a relatively small number of studies have been conducted regarding how 
antidepressants (i.e. the first line of drug treatment for depression and anxiety) are prescribed 
for CKD patients in real-world clinical practice. To my knowledge, there has been no study 
examining this in the UK general population. Frequency and patterns of antidepressant 
prescription need to be compared between patients with and without CKD, as different (class 
of) antidepressants may be used for different purposes (e.g. depression, anxiety, pain and 
insomnia as an off-label use) between the groups. 
1.2.4. Research question 4: Is the risk of serious adverse outcomes associated with 
antidepressants (e.g. GI bleeding risk of SSRIs) increased in patients with lower 
kidney function? 
There has been no study examining the association between antidepressants and serious 
adverse outcomes in the CKD population. Because (i) CKD patients may have limited ability 
to excrete antidepressants into urine, and (ii) CKD patients tend to have a higher baseline risk 
of adverse outcomes due to multi-morbidity and polypharmacy, it can be hypothesised that the 
risk of serious adverse outcomes associated with antidepressants is larger in patients with CKD 
compared to patients without CKD. A large study is warranted to examine the association 
between antidepressants and serious adverse outcomes among patients with CKD, as well as 
to test whether the risks differ between patients with and without CKD.  
GI bleeding is one of the serious adverse outcomes associated with SSRIs, which block 
serotonin reuptake in platelets and inhibit platelet aggregation [74, 75]. A number of studies 
have shown an association between the use of SSRIs and GI bleeding [72, 76-85]. However, 
none of these studies focused on the GI bleeding risk of SSRIs among patients with CKD. 
Therefore, I here take GI bleeding risk of SSRIs as an appropriate example through which to 
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examine the association between antidepressants and serious adverse outcomes by CKD status 
and level of kidney function.  
 
1.3. Outline of thesis 
The thesis is comprised of ten chapters. Owing to the research paper-style format, five research 
papers (including three published papers and two accepted papers in peer-reviewed journals) 
are incorporated into some chapters. A concise summary of these research papers is presented 
in Table 1 below. Each chapter containing a research paper consists of: a brief introduction, 
the published or accepted paper, additional analyses and discussions, and chapter summary. 
Other chapters have their own structures. The outline of the thesis is as follows: 
Chapter 1 introduced the general background, aims, objectives, and research questions. 
Chapter 2 describes the details of the data sources used in the thesis. 
Chapter 3 explains how to estimate kidney function and how to define decreased kidney 
function and CKD (stages 3 to 5) using the CPRD. 
Chapter 4 describes the rationale and method used to create a dataset for cross-sectional studies 
in the first and second research papers. 
Chapter 5 includes the first research paper, which concerns the validity of CKD and RRT 
prevalence estimates in the CPRD. 
Chapter 6 incorporates the second research paper on the association between SMI and CKD. 
Chapter 7 introduces the process used to establish a matched cohort of patients with and 
without CKD (stages 3 to 5) in the third and fourth research papers. 
Chapter 8 includes the third research paper, comparing frequency and patterns of 
antidepressant prescription between matched patients with and without CKD. 
Chapter 9 incorporates the fourth research paper regarding the GI bleeding risk of SSRIs by 
level of kidney function. 
Chapter 10 summarises the main results of each study, explores the implications of the findings 
for clinical practice and future research, discusses the overall strengths and limitations, and 
concludes the thesis. 
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Table 1. Concise summary of published and accepted papers 
Abbreviations: CKD = chronic kidney disease; CPRD = Clinical Practice Research Datalink; GI = gastrointestinal; HES = Hospital Episode Statistics; RRT = 
renal replacement therapy; SSRIs = selective serotonin reuptake inhibitors; SMI = severe mental illness. 
aIwagami M, et al. Validity of estimated prevalence of decreased kidney function and renal replacement therapy from primary care electronic health records 
compared with national survey and registry data in the United Kingdom. Nephrol Dial Transplant. 2017;32(suppl_2):ii142-ii150. 
bIwagami M, et al. Severe mental illness and chronic kidney disease: a cross-sectional study in the United Kingdom. Clin Epidemiol. 2018;10:421-429. 
cIwagami M, et al. Prevalence, incidence, indication, and choice of antidepressants in patients with and without chronic kidney disease: a matched cohort 
study in UK Clinical Practice Research Datalink. Pharmacoepidemiol Drug Saf. 2017;26:792-801. 
dIwagami M, et al. Gastrointestinal bleeding risk of selective serotonin reuptake inhibitors by level of kidney function: a population-based cohort study. Br J 
Clin Pharmacol (in press) 
eIwagami M, et al. CKD and cause-specific hospitalisation: a matched cohort study using Clinical Practice Research Datalink. Br J Gen Pract. (in press) 
 
 Chapter  Short title Study design Study population Exposure Outcome 
CKD is 
regarded as 
Paper 1a 5 Prevalence of CKD and RRT in CPRD 
Cross-
sectional 
People aged ≥25 registered in CPRD at 
31/3/2014 (N = 2,761,755) n/a 
Decreased kidney 
function, CKD 
and RRT 
Outcome 
Paper 2b 6 SMI and CKD People aged 25-74 registered in CPRD at 31/3/2014 (N = 2,418,730) 
SMI (vs. 
no SMI) CKD and RRT Outcome 
Paper 3c 8 CKD and antidepressant prescription 
Cohort 
Matched patients with and without CKD 
(stages 3 to 5) in HES-linked CPRD 
between 2004 and 2014 (N = 484,698) 
CKD (vs. 
no CKD) 
Antidepressant 
prescription Exposure 
Paper 4d 9 GI bleeding risk of SSRIs by kidney function Same cohort as in Paper 3  
SSRIs (vs. 
no SSRIs) 
Hospitalisation 
for GI bleeding 
Effect 
modifier 
Additional 
papere 
Appendix A 
(related to 
chapter 7) 
CKD and cause-specific 
hospitalisation Same cohort as in Paper 3  
CKD (vs. 
no CKD) 
Cause-specific 
hospitalisation Exposure 
23
24 
 
1.4. Chapter summary 
Introduction  
- CKD is common and associated with a variety of outcomes, including cardiovascular and 
non-cardiovascular conditions. 
- In this thesis, I focus on two broad categories of mental health disorders, namely SMI (i.e. 
schizophrenia, bipolar disorder, and other psychoses) and common mental health disorders 
(i.e. depression and anxiety disorders). 
- There have been a limited number of population-based studies on the burden of CKD 
among patients with SMI, with or without lithium use. 
- Although a number of studies have suggested an association between CKD and common 
mental health disorders (depression and anxiety), the frequency and patterns of 
antidepressant prescription in patients with CKD are unknown in real-world clinical 
practice. 
- There has been almost no epidemiological research investigating the serious adverse 
outcomes associated with antidepressants in patients with CKD. 
- This thesis aims to better understand the associations between CKD and both mental health 
disorders and psychoactive drugs in the general population, using the CPRD. 
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Chapter 2: Data sources 
This chapter describes the details of the data sources employed for this thesis, namely the 
CPRD with or without linkages to Hospital Episodes Statistics (HES) and Index of Multiple 
Deprivation (IMD). 
2.1. Healthcare system in the UK 
In the UK, a primary care system acts as a gatekeeper to health care; patients need to be 
registered with a primary care GP to access National Health Service (NHS) nonemergency care 
[86]. Patients are then referred to secondary care (i.e. specialists) as necessary. The NHS is free 
at the point of access for all UK residents, and over 98% of the UK population are registered 
with a GP [87]. 
Primary care practices have used computerised electronic health records since around 1990. 
There is only a limited number of suppliers of electronic health record software including EMIS, 
SystmOne, Vision, and Evolution [88]. GPs or healthcare practitioners in primary care 
electronically record patient information or events in primary care through coded diagnosis and 
free text. Prescriptions and most test results are automatically recorded in the system, while 
reports from secondary care (e.g. key diagnoses by specialists, and discharge data from 
hospitals) are also entered into the system retrospectively by practice staff. 
 
2.2. Clinical Practice Research Datalink (CPRD) 
The CPRD was originally launched in 1987 as the Value Added Medical Products (VAMP) 
dataset. The VAMP grew into the General Practice Research Database in 1993, and expanded 
to become the CPRD in 2012 [73, 89]. The CPRD collates routinely collected anonymised data 
from general practices using the Vision software system (at the time of this thesis), which 
agreed to provide data on a monthly basis. All people registered in participating practices are 
included in the dataset, except for those who have requested to their GPs to opt out of data 
sharing. 
To ensure data quality, the CPRD checks quality indicators of each general practice and 
individual patients. At the practice level, the CPRD suggests an ‘up to standard’ date, based on 
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assurance of continuity in data recording and appropriate death recording. The data recorded 
after the ‘up to standard’ date in each practice are considered to have sufficiently high quality 
for use in research. At the individual level, the CPRD flags patients with records of ‘acceptable’ 
quality, based on over ten quality indicators related to registration date, year of birth, date and 
reason for being transferred out, gender, and the timing of recorded episodes. Data on patients 
where the recorded information is of acceptable quality are recommended for use in research. 
As of July 2013, the CPRD held information on 11.3 million patients whose information was 
of acceptable quality in 674 ‘up to standard’ general practices, 4.4 million of whom were active 
(i.e. alive and registered at July 2013) and represented 6.9% of the total UK population [73]. 
The data in the CPRD are split into several files (see Table 2 below). Each file includes a 
unique patient identifier, by which the patient-level files can be linked. Notably, Read codes 
(used in clinical, referral, immunisation, and test files) were developed in the UK in the early 
1980s by Dr James Read as a hierarchical clinical classification system. At the time of this 
thesis, the CPRD used Read version 2, containing over 96,000 Read codes. In the CPRD, 
Medical codes (‘Medcode’) and Product codes (‘Prodcode’) are used in practice, which 
correspond to Read codes and the British National Formulary codes [90], respectively. 
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Table 2. Data files supplied by the CPRD 
File type What it holds Example of contents 
Patient Demographic and 
registration status of 
patients 
Patient identifier, month and year of birth, 
registration status, death date, transfer out 
date 
Practice Practice administrative 
data 
Practice identifier, geographical region, date 
practice became 'Up to standard', last data 
collection date 
Staff Information about the 
staff members entering 
data 
Staff identifier, gender, role 
Consultation Administrative 
information about the 
consultation 
Date of clinical event, date of data entry, type 
of consultation, staff identifier and duration of 
consultation 
Clinical Clinical data regarding 
medical history 
Date of clinical event, date of data entry, the 
CPRD medical code for the chosen Read 
code, additional details identifier, entity type 
Additional 
Clinical Details  
Specific data about a 
clinical event 
Type of information held, called an 'entity', 
specific clinical details relating to that entity 
Referral Details on referrals to 
secondary care or 
specialists 
The CPRD medical code for the chosen Read 
code, method of referral, referral specialty, 
urgency of referral 
Immunisation Data associated with 
immunisations 
Reason for immunisation, type, stage, status 
and the compound used 
Test Test results Type of test, result, normal range of result, 
unit of measure 
Therapy Information about 
therapies including 
medications and 
appliances 
The CPRD product code for the medication, 
British National Formulary code, quantity of 
product, dose, pack size, number of days 
prescribed 
Note: this table was entirely copied from the paper introducing the CPRD [73]. 
 
There is a linkage scheme in the CPRD. A subset of English practices in the CPRD (around 
75% of all English CPRD practices, and nearly 60% of all UK CPRD practices) have consented 
to link their data with other data sources, including HES and IMD data for deprivation indices. 
The linkages are conducted via a trusted third party, mainly by using patients’ NHS numbers 
for HES and the postcode of patients’ residences for IMD data. 
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2.3. Hospital Episodes Statistics (HES) 
HES is a database containing details of all admissions, outpatient appointments, attendances, 
and emergency admissions at NHS hospitals or independent-sector providers (private or 
charitable hospitals) in England [91, 92]. National data collection started in 1987, but the 
linkage with the CPRD became available in 1997 when patients’ NHS numbers became a 
mandated return from hospitals. Among the entire HES data, I here explain the HES Admitted 
Patient Care only, which was used for part of this thesis. 
HES was originally set up to manage and plan hospital services, and is now also used to 
reimburse hospital activity. In the HES Admitted Patient Care, a hospital admission is referred 
to as a ‘spell’ defined as an uninterrupted inpatient stay at one hospital. A ‘spell’ includes one 
or more ‘episodes’ (Finished Consultant Episode); an ‘episode’ represents a continuous period 
of care under one consultant team. The data recorded in HES Admitted Patient Care include 
age, sex, ethnicity, dates of admission, operations and discharge, admission method 
(emergency or planned), clinical diagnoses, and procedures. For each ‘episode’, up to 20 
International Classification of Diseases version 10 (ICD-10) codes [93] are entered, based on 
a discharge summary completed by the treating clinician(s). The first (primary) diagnosis for 
the first ‘episode’ is expected to relate to the main reason for admission, although 
misclassification of code position is possible, if a patient had several medical conditions at the 
time of admission. For example, for patients admitted with myocardial infarction and heart 
failure, either diagnosis could be considered as the primary diagnosis. 
 
2.4. Index of Multiple Deprivation (IMD) 
The IMD is a deprivation index that is updated by the Department for Communities and Local 
Government every few years [94]. Although it has seen a number of small changes, the IMD 
mainly uses seven indicators: income, employment, health and disability, education, barriers 
to housing and services, living environment, and crime. Deprivation is categorised into 
quintiles, from one (representing the least deprived) to five (representing the most deprived). 
Patient-level IMD is assigned based on the postcode of residence of individual patients, while 
practice level IMD is also available, based on the postcode of general practices. It should be 
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noted that deprivation indices in different UK countries (i.e. England, Northern Ireland, 
Scotland, and Wales) are not comparable.  
 
2.5. Data used for this thesis  
For this thesis, I used the July 2014 version of CPRD. I used the CPRD without linkage in 
Papers 1 (Prevalence of CKD and RRT in CPRD) and 2 (SMI and CKD), while I used the 
CPRD linked to HES version 10 (covering the period from April 1997 to March 2014) in Papers 
3 (CKD and antidepressant prescription) and 4 (GI bleeding risk of SSRIs by kidney function). 
The July 2014 version of the CPRD included data from 685 general practices in the UK. Of 
these practices, 398 (58%) of practices in England had links with HES version 10. The IMD 
evaluated in 2010 was used for this thesis, assuming that the deprivation status did not change 
over time. Practice-level IMD was used as a covariate for Paper 2, while individual-level IMD 
was used for Papers 3 and 4, supplemented by practice-level IMD (for less than 1% of patients 
with missing data from individual-level IMD). 
Details on the cross-sectional datasets and cohorts created for each research question are given 
in the respective chapters. 
 
2.6. Ethical approval 
The CPRD has broad National Research Ethics Service Committee ethical approval for purely 
observational research using the primary care data and established data linkages. Ethical 
approval for this thesis was obtained from the London School of Hygiene and Tropical 
Medicine ethics committee (reference: 9196), as well as the Independent Scientific Advisory 
Committee, which oversees research involving CPRD data (protocol No. 16_055 for Papers 1 
and 2, and protocol No. 15_219R for Papers 3 and 4).  
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2.7. Chapter summary 
Data sources 
- The CPRD is a database of anonymised primary care electronic health record data in the 
UK and includes the information on patient demographics, diagnoses (based on Read 
codes), prescriptions, laboratory test results, and referrals made by GPs. 
- The CPRD can be linked to HES, which contains details of all admissions in English NHS 
trusts and consists of primary and subsidiary diagnoses, based on ICD-10 codes. Nearly 
60% of general practices in the CPRD (75% of English general practices in the CPRD) 
have consented to linkages with HES data for research purposes. 
- The IMD is a composite area-level marker of deprivation and is categorised into quintiles 
to suggest the socio-economic status of individual patients. 
- The current thesis used the July 2014 version of the CPRD, with or without linkages to 
HES version 10 (covering the period from April 1997 to March 2014) and IMD (evaluated 
in 2010). 
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Chapter 3: Definition of decreased kidney function and CKD 
(stages 3 to 5) and estimation of glomerular filtration rate in this 
thesis 
This chapter explains how to define decreased kidney function and CKD (stages 3 to 5) and 
how to estimate GFR of individual patients in this thesis, using the CPRD.  
3.1. Existing guidelines to define decreased kidney function and CKD 
CKD was formally defined in 2002 by the National Kidney Foundation, Kidney Disease 
Outcomes Quality Initiative (NKF K/DOQI) as follows [95]: ‘The presence of chronic kidney 
disease should be established, based on presence of kidney damage and level of kidney function 
(glomerular filtration rate [GFR]), irrespective of diagnosis’. Either the marker(s) of kidney 
damage or decreased GFR, present for over three months, is required for the definition of CKD 
(see Table 3 below). This definition of CKD has been consistent within the subsequent 
guidelines, including the NICE guidance for CKD (published in 2008) [1] and Kidney Disease 
Improving Global Outcomes (KDIGO) guideline for CKD (published in 2012) [96].  
 
Table 3. Definition of chronic kidney disease in the National Kidney Foundation Kidney 
Disease Outcomes Quality Initiative guideline 
 
Notably, within these criteria, a GFR of <60 ml/min/1.73 m2 was considered to be ‘decreased 
kidney function’ [1, 95, 96]. This cut-off was justified by a subsequent meta-analysis led by 
1. Kidney damage for ≥3 months, as defined by structural or functional abnormalities of the 
kidney, with or without decreased GFR, manifest by either: 
- Pathological abnormalities; or 
- Markers of kidney damage, including abnormalities in the composition of the blood 
or urine, or abnormalities in imaging tests 
2. GFR <60 ml/min/1.73 m2 for ≥3 months, with or without kidney damage 
Abbreviation: GFR = glomerular filtration rate. 
Note: this table was entirely copied from the National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative guideline [95]. 
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the CKD Prognosis Consortium, demonstrating that all-cause mortality starts to increase from 
eGFR <60 ml/min/1.73 m2, independent of age [97]. In the classification of CKD, GFR <60 
ml/min/1.73 m2 corresponds to CKD stages 3 to 5 in the NKF K/DOQI guideline [95], CKD 
stages 3a to 5 in the NICE guidance [1], and GFR categories G3a to G5 in the KDIGO guideline 
[96].  
Therefore, throughout this thesis, decreased kidney function is defined as a single GFR <60 
ml/min/1.73 m2, whereas CKD (stages 3 to 5) is defined as two or more consecutive 
measurements of decreased kidney function (i.e. GFR <60 ml/min/1.73 m2) for ≥3 months. 
Notably, decreased kidney function is not equal to CKD (stages 3 to 5), because a single low 
eGFR observed in real-world clinical practice may reflect temporarily decreased kidney 
function due to acute kidney injury (AKI) or increased serum creatinine level due to exercise 
or protein intake [96]. The benefits and limitations by use of the chronicity criterion to define 
CKD in the CPRD will be examined and discussed in detail in the following chapters.  
 
3.2. How to estimate glomerular filtration rate (GFR) in this thesis 
GFR represents the rate at which waste products in the blood are cleared through the kidney 
glomerular capillaries to make urine. The gold standard of GFR measurement is when 
exogenous markers (e.g. inulin, iothalamate) are given to patients and the rate of renal clearance 
of these substances is measured over time [98]. However, using this method, patients need to 
receive a bolus injection and close monitoring of these substances in their blood and urine. 
Alternatively, a single time point measurement of endogenous markers (e.g. serum creatinine, 
serum cystatin C) has been practically carried out to estimate GFR in routine clinical practice. 
The assumption underlying the use of such markers is that these substances are produced in the 
body and cleared by the kidney at a relatively constant rate (i.e. ‘steady state assumption’). 
Creatinine is a waste product of muscle metabolism and is generated in the body at a relatively 
constant rate unless patients are in a catabolic condition. 
In addition to the ‘steady state assumption’, there are further assumptions required to use serum 
creatinine to compare kidney function between different individuals. At a population level, 
creatinine production is influenced by a variety of factors including patients’ demographics 
(age, sex, and ethnicity) and behaviours (exercise and dietary protein). Thus, taking patients’ 
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demographics into account, several GFR estimation equations have been developed and 
validated (by comparing estimated GFRs based on these equations with GFRs estimated by 
exogenous markers) since the 1970s, including the Cockcroft-Gault equation [99], 
Modification of Diet in Renal Disease (MDRD) Study equation [100], and the CKD 
Epidemiology Collaboration (CKD-EPI) creatinine equation [101]. Notably, the MDRD Study 
equation was proposed in 1999 and has been used in the automatic reporting system of eGFR 
in UK laboratories [102]. As of 2016, many UK laboratories are still reporting eGFR based on 
the MDRD Study equation [103]. However, the CKD-EPI creatinine equation (published in 
2009) is more accurate, with smaller extent of measurement error, than the MDRD Study 
equation, especially among older patients and those with mildly decreased kidney function [98, 
104]. Therefore, in this thesis, GFR is estimated from serum creatinine based on the CKD-EPI 
creatinine equation [101]: 
eGFR = 141 × min(Scr/κ, 1)α × max(Scr/κ, 1)-1.209 × 0.993Age × 1.018 [if female] × 1.159 [if 
black ethnicity] 
(where Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for 
females and -0.411 for males, min indicates the minimum of (Scr/κ) or 1, and max indicates 
the maximum of (Scr/κ) or 1) 
More recently, the CKD-EPI cystatin C equation and CKD-EPI creatinine-cystatin C equation 
were proposed in 2012, which may be even more accurate than the CKD-EPI creatinine 
equation, because cystatin C production in the body is not affected by exercise and diet [98]. 
The measurement of cystatin C is recommended for people with a creatinine-based eGFR of 
45–59 ml/min/1.73 m2 and no proteinuria (to confirm or rule out CKD), according to the NICE 
guidance [1]. However, the cystatin C measurement is expensive (at the time of this thesis), 
and the testing rate of cystatin C among these eligible patients is seemingly very low within 
current UK primary care [105]. Thus, an additional use of cystatin C records does not seem to 
be helpful in improved classification of the CKD status in the current thesis.  
 
3.3. Creatinine calibration 
In laboratories, serum creatinine level can be measured by several types of assay methods, 
including CX3 and enzymatic creatinine assays. The CKD-EPI creatinine equation was 
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developed for serum creatinine measured by an internationally standardized enzymatic method, 
which is traceable to isotope dilution mass spectrometry (IDMS) [101]. In the past, the UK 
laboratories used the CX3 assay method and reported non-IDMS-traceable creatinine values. 
However, a phased introduction of laboratory-specific standardisation was proposed in the UK 
in 2006 [102]. It is thus expected that the proportion of laboratories reporting IDMS creatinine 
has increased since then, although the exact timing of standardisation in each laboratory is 
unknown. There is a systematic difference between non-IDMS-traceable and IDMS-traceable 
creatinine values, and it was suggested to multiply non-IDMS-traceable creatinine values by 
0.95 to use the GFR estimation equations established for IDMS-traceable creatinine values 
[106]. 
Considering this temporal change in the assay method in the UK laboratories, in cross-sectional 
studies at 31 March 2014 in Papers 1 (Prevalence of CKD and RRT in CPRD) and 2 (CKD and 
SMI), I assumed that all the UK laboratories reported IDMS-traceable creatinine values in the 
main analysis, and conducted a sensitivity analysis by assuming that all the UK laboratories 
reported non-IDMS-traceable creatinine values. Meanwhile, in cohort studies during the period 
between April 2004 and March 2014 in Papers 3 (CKD and antidepressant prescription) and 4 
(GI bleeding risk of SSRIs by kidney function), the majority (>80%) of patients were included 
into the cohort during the first half of the study period, i.e. before 2010 (see chapter 7 for 
details). Therefore, in the cohort studies, I assumed that all the UK laboratories reported non-
IDMS-traceable creatinine values, and multiplied the recorded creatinine values in the CPRD 
by 0.95 to use the CKD-EPI creatinine equation.  
 
3.4. Determining ethnicity in the CPRD 
Ethnicity information, black or non-black, is required in the use of the CKD-EPI creatinine 
equation [101]. It is known that ethnicity recording is not complete in the CPRD, although the 
QOF improved it greatly by incentivising ethnicity recording between 2006/07 and 2011/12 
[107]. An algorithm was used to determine ethnicity in the CPRD with or without linkage to 
HES, that was established by Rohini Mathur and colleagues in the Electronic Health Record 
Research group at the London School of Hygiene and Tropical Medicine (see Figure 1 below). 
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Figure 1. Algorithm to determine ethnicity in the CPRD  
 
Abbreviations: CPRD = Clinical Practice Research Datalink; HES = Hospital Episode 
Statistics. 
Note: this figure was copied from the reference [108]. 
 
Patients with missing ethnicity information were assumed to be non-black. This strategy is 
reasonable because the proportion of black patients (Black, African, Caribbean, or Black 
British) was low, at 3.5%, according to the 2011 UK census [109]. In particular, among those 
aged 65 or older, who account for the majority of patients with CKD [110], the proportion of 
black patients was 1.5% [109]. Moreover, GPs seem to be more likely to record ethnicity for 
non-white patients [107]. 
 
3.5. Proteinuria and other information related to kidney damage in the 
CPRD 
Patients with no decreased kidney function but persistent proteinuria are classified as CKD 
stage 1 or 2 in the NKF K/DOQI guideline [95]. Moreover, the 2012 KDIGO guideline 
recommends the classification of patients according to GFR categories (G1 to G5) and 
persistent albuminuria categories (A1 to A3) [96]. However, in UK primary care, proteinuria 
is infrequently tested in the general population [111]: even among patients with CKD stages 3 
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to 5, for whom proteinuria testing was incentivised in the QOF [18], the testing rate of urinary 
albumin to creatinine ratio was 35.7% between 2007 and 2013 [112]. In the matched cohort of 
patients with and without CKD (stages 3 to 5) that were established as part of this thesis (see 
chapter 7), even by including dipstick tests, the testing rate of proteinuria in the year prior to 
cohort entry was low at 23.2% in the CKD group and 12.6% in the matched comparison group 
of no-known CKD during the study period between 2004 and 2014 [113]. In the diabetic 
population, in which the rate of urine testing is high [114], it may be accepted to assume that 
those without abnormal records did not have proteinuria [115, 116]. In the general population, 
however, it seems inappropriate to assume that people without urinalysis results did not have 
proteinuria. 
Other information suggesting kidney damage, such as pathology specimens and results of 
imaging tests, are usually unavailable in the CPRD. This information may be recorded by GPs 
in the free text part of the CPRD. A strategy of automatic (computerised) free text searches 
may be useful in the future, but this was unavailable at the time of this thesis. Also, there is a 
limited access to the free texts in the CPRD for ethical reasons [89]. 
Therefore, throughout this thesis, I did not focus on CKD stages 1 and 2 based on proteinuria 
or other information related to kidney damage. Also, I was not able to stratify patients by the 
level of albuminuria or the presence or absence of kidney damage among patients with CKD 
stages 3 to 5. 
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3.6. Chapter summary 
Definition of decreased kidney function and CKD and estimation of GFR in this thesis 
- In this thesis, decreased kidney function is defined as a single GFR <60 ml/min/1.73 m2. 
- CKD (stages 3 to 5) is defined as two or more consecutive measurements of GFR <60 
ml/min/1.73 m2 over three months. 
- GFR is estimated from serum creatinine records in the CPRD by using the CKD-EPI 
creatinine equation.  
- Ethnicity (black or non-black) is determined using a previously established algorithm based 
on the CPRD with or without linkage to HES, and people with missing ethnicity 
information are assumed to be non-black. 
- Proteinuria information is not used in this thesis, because proteinuria is infrequently tested 
in the general population within UK primary care.  
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Chapter 4: Establishing a dataset for cross-sectional studies and 
identifying patients with decreased kidney function and CKD 
This chapter presents the rationale and method for establishing a dataset for the cross-sectional 
studies in Papers 1 (Prevalence of CKD and RRT in CPRD) and 2 (SMI and CKD). I also 
explain how to identify patients with decreased kidney function and CKD (stages 3 to 5) in the 
established cross-sectional dataset. 
4.1. Introduction (rational for the cross-sectional design) 
(i) Paper 1 (Prevalence of CKD and RRT in CPRD) 
The purpose of the first study is to estimate the prevalence of decreased kidney function (in the 
main analysis) and CKD (in a sensitivity analysis) and RRT in the CPRD, and compare it with 
the nationally representative statistics (Health Survey for England 2009/2010 and UK Renal 
Registry 2014). For estimating a disease prevalence, the simplest way is to include all people 
registered in the CPRD on one day as the denominator. I chose 31 March 2014 for the study 
date, which is the most recent end date of a financial or QOF year (i.e. from 1 April to 31 
March) among the available data (i.e. the July 2014 version of CPRD).  
(ii) Paper 2 (SMI and CKD) 
This second study used the same cross-sectional dataset as Paper 1. The general weakness of 
cross-sectional design is that the temporal relationship between SMI and CKD remains 
unknown. A cohort study comparing the incidence of CKD between patients with and without 
SMI would be better than a cross-sectional study in confirming the temporal relationship 
between SMI and CKD. However, an accurate identification of incident CKD is extremely 
difficult in routinely collected general practice data, in which kidney function is not constantly 
monitored for everyone. Moreover, the frequency of serum creatinine measurement changed 
considerably in UK primary care after the introduction of QOF in 2004 [117], causing a large 
detection bias of incident CKD in a cohort study using the CPRD. Therefore, with the currently 
available data, a cohort design does not seem to be more beneficial than a cross-sectional design 
to examine the association between SMI and CKD. 
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4.2. Methods 
For Paper 1 (Prevalence of CKD and RRT in CPRD), using the July 2014 version of CPRD, I 
identified all people ≥25 years of age who were alive and registered in ‘up to standard’ general 
practices in the CPRD for at least one year on 31 March 2014. The choice of age 25 years as a 
lower limit was made for the best comparability between the CPRD and Health Survey for 
England and UK Renal Registry: the Health Survey for England and UK Renal Registry 
collected data of people <25 years of age differently (the Health Survey for England grouped 
people 16–24 years of age [4], while the UK Renal Registry grouped people 18–24 years of 
age [7]). In addition, the number of patients aged <25 with decreased kidney function and RRT 
was very small in the Health Survey for England and UK Renal Registry, limiting power for 
the comparison with the CPRD. One-year registration was considered necessary for GPs to 
record a history of morbidity (including RRT) for newly registered patients [118] and to test 
their kidney function if they had CKD risk factors such as diabetes. 
For Paper 2 (SMI and CKD), I restricted the study participants to patients aged 74 or younger. 
This was because SMI is rare among those aged 75 years or older (as people with SMI are 
known to die earlier, by around 10-20 years, than the general population [27-32]), limiting 
power for the comparison of the CKD prevalence between those with and without SMI. 
After establishing the cross-sectional dataset in the CPRD, the age-sex distribution of these 
study participants was compared with that of the UK Census 2013, to confirm that they are 
broadly representative of the UK general population in terms of age and sex. 
 
4.3. Results (details of the dataset) 
As shown in Figure 2 below, on the study date (i.e. 31 March 2014), I identified 2,761,755 
people aged ≥25 who were alive and registered for at least one year in the CPRD. Of these 
patients, 2,418,730 people were aged 25–74 years and, therefore, were included in Paper 2 
(SMI and CKD). The age-sex distribution of these study participants was broadly similar to 
that of the UK Census 2013 (see Table 4 below). 
 
39
40 
 
Figure 2. Flow chart for the identification of study participants in cross-sectional studies 
 
Abbreviation: CKD = chronic kidney disease; RRT = renal replacement therapy; SMI = severe 
mental illness; CPRD = Clinical Practice Research Datalink. 
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Table 4. Age-sex distribution of the study participants for the cross-sectional studies in 
the CPRD and UK census 2013 
Age (years) 
Study participants for cross-sectional 
studies in the CPRD (on 31 March 2014) UK census 2013 
No. of people Proportion (%) No. of people Proportion (%) 
Total: 2,761,755 100 44,600,143 100 
Men:     
25-29 117,261 4.2 2,171,395 4.9 
30-34 120,023 4.3 2,148,903 4.8 
35-39 120,256 4.4 1,975,110 4.4 
40-44 136,483 4.9 2,221,431 5.0 
45-49 148,763 5.4 2,310,722 5.2 
50-54 144,341 5.2 2,149,309 4.8 
55-59 123,154 4.5 1,854,877 4.2 
60-64 108,541 3.9 1,734,599 3.9 
65-69 109,100 4.0 1,697,784 3.8 
70-74 81,192 2.9 1,201,622 2.7 
75-79 62,543 2.3 954,347 2.1 
80-84 44,307 1.6 650,871 1.5 
>=85 36,294 1.3 491,300 1.1 
Women:     
25-29 114,601 4.1 2,178,575 4.9 
30-34 120,740 4.4 2,177,964 4.9 
35-39 118,908 4.3 1,991,769 4.5 
40-44 134,237 4.9 2,274,838 5.1 
45-49 145,120 5.3 2,375,928 5.3 
50-54 141,266 5.1 2,194,934 4.9 
55-59 121,259 4.4 1,901,770 4.3 
60-64 110,258 4.0 1,806,214 4.0 
65-69 114,370 4.1 1,793,663 4.0 
70-74 88,857 3.2 1,337,533 3.0 
75-79 73,334 2.7 1,137,778 2.6 
80-84 58,348 2.1 899,031 2.0 
>=85 68,199 2.5 967,876 2.2 
Abbreviation: CPRD = Clinical Practice Research Datalink. 
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4.4. Strategy to identify patients with decreased kidney function and CKD 
in the cross-sectional studies 
In the established datasets, patients with decreased kidney function will be identified, based on 
the most recent serum creatinine record in the past five years prior to the study date (i.e. 31 
March 2014). Patients with CKD (stages 3 to 5) will be also identified, based on whether their 
serum creatinine records during the past five years (i.e. from 1 April 2009 to 31 March 2014) 
satisfy the definition of CKD (i.e. two or more consecutive measurements of GFR <60 
ml/min/1.73 m2 for ≥3 months). The five-year period was chosen to identify as many patients 
with decreased kidney function or CKD as possible, since the recent National CKD Audit 
survey (in England and Wales) suggested that people with hypertension (i.e. the most common 
risk factor for CKD) were mostly tested during a period of five years, whereas people with 
diabetes were tested annually [103]. 
By these definitions, it is possible that patients with decreased kidney function do not satisfy 
the definition of CKD, and vice versa (see examples in Figure 3 below). The distribution of 
patients satisfying the definition of decreased kidney function and those satisfying the 
definition of CKD will be shown and discussed in the next chapter 5. People without serum 
creatinine measurement in the past five years are assumed to have neither decreased kidney 
function nor CKD. The validity of this assumption will be substantially tested in Paper 1 
(Prevalence of CKD and RRT in CPRD) in the next chapter 5.  
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Figure 3. Graphical representation of the strategy to identify patients with decreased 
kidney function and CKD in the cross-sectional studies in the CPRD 
 
Abbreviations: CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate. 
Note: Unit of eGFR (i.e. mL/min/1.73m2) was omitted because of limited space. Patient A satisfies the 
definitions of decreased kidney function (i.e. most recent eGFR <60 ml/min/1.73 m2) and CKD (i.e. 
two or more consecutive measurements of GFR <60 ml/min/1.73 m2 for ≥3 months in the past five 
years). Patient B is identified as having decreased kidney function, but not regarded as having CKD. 
Patient C satisfies the definition of CKD, but is not regarded as having decreased kidney function 
(because the most recent eGFR is over 60 ml/min/1.73 m2). Patients D and E are regarded as having 
neither decreased kidney function nor CKD. 
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4.5. Chapter summary 
Establishment of datasets for cross-sectional studies and identification of patients with 
decreased kidney function and CKD 
- Cross-sectional datasets were established for Papers 1 (Prevalence of CKD and RRT in 
CPRD) and 2 (SMI and CKD). 
- On 31 March 2014, there were 2,761,755 people aged ≥25 who were alive and registered 
for at least one year in the CPRD. The age-sex distribution in the dataset was broadly 
similar to the UK Census 2013. 
- Of these patients, 2,418,730 people were aged 25–74 years and, therefore, were included 
in Paper 2. People aged 75 or younger were excluded because SMI is rare among this age 
group due to the shorter life expectancy. 
- In the established cross-sectional datasets, patients with decreased kidney function will be 
identified based on the most recent serum creatinine record prior to the study date (i.e. 31 
March 2014). Patients with CKD (stages 3 to 5) will be identified based on whether their 
serum creatinine records during the past five years (i.e. from 1 April 2009 to 31 March 
2014) satisfy the definition of CKD (i.e. two or more consecutive measurements of GFR 
<60 ml/min/1.73 m2 for ≥3 months). 
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Chapter 5: Validity of estimated prevalence of decreased kidney 
function and renal replacement therapy from primary care 
electronic health records compared with national survey and 
registry data in the United Kingdom (Paper 1) 
5.1. Introduction 
This chapter presents the population-level validation study of decreased kidney function, CKD, 
and RRT in the CPRD, published in Nephrology Dialysis Transplantation [119]. This study is 
important ground work for the following studies: CKD is the study outcome in Paper 2 (SMI 
and CKD), exposure of interest in Paper 3 (CKD and antidepressant prescription) and a 
potential effect modifier in Paper 4 (GI bleeding risk of SSRIs by kidney function), whereas 
RRT is used as part of the exclusion criteria. Therefore, it is important to ensure that most 
patients with CKD and RRT are captured in the current CPRD. 
The main research question is: What is the prevalence of CKD and RRT in the CPRD, and is 
it similar to the nationally-representative statistics? 
Briefly, in the dataset established in the previous chapter 4, which includes 2,761,755 people 
aged ≥25 who were alive and registered for at least one year in the CPRD on 31 March 2014, 
I identified patients with decreased kidney function (in the main analysis), CKD (in a sensitivity 
analysis), and RRT. Then, I compared the prevalence estimates of decreased kidney function 
and CKD (stages 3 to 5) with that of Health Survey for England 2009/2010, and compared the 
prevalence estimates of RRT with that of UK Renal Registry 2014. 
By definition, patients with decreased kidney function (based on the most recent single eGFR 
<60 ml/min/1.73 m2 prior to 31 March 2014) and those with CKD (based on two or more 
consecutive measurements of eGFR <60 ml/min/1.73 m2 for ≥3 months in the past five years) 
may be slightly different populations, as illustrated in Figure 3 in the previous chapter 4. The 
distribution of these patients will be shown and discussed later in this chapter.  
 
5.2. Published paper 
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ABSTRACT
Background. Anonymous primary care records are an import-
ant resource for observational studies. However, their external
validity is unknown in identifying the prevalence of decreased
kidney function and renal replacement therapy (RRT). We thus
compared the prevalence of decreased kidney function and
RRT in the Clinical Practice Research Datalink (CPRD) with
a nationally representative survey and national registry.
Methods. Among all people ≥25 years of age registered in the
CPRD for ≥1 year on 31 March 2014, we identiﬁed patients
with an estimated glomerular ﬁltration rate (eGFR) <60 mL/
min/1.73 m2, according to their most recent serum creatinine
in the past 5 years using the Chronic Kidney Disease Epidemi-
ology Collaboration equation and patients with recorded diag-
noses of RRT. Denominators were the entire population in each
age–sex band irrespective of creatinine measurement. The
prevalence of eGFR <60 mL/min/1.73 m2 was compared with
that in the Health Survey for England (HSE) 2009/2010 and
the prevalence of RRT was compared with that in the UK
Renal Registry (UKRR) 2014.
Results.We analysed 2 761 755 people in CPRD [mean age 53
(SD 17) years, men 49%], of whom 189 581 (6.86%) had an
eGFR <60 mL/min/1.73 m2 and 3293 (0.12%) were on RRT.
The prevalence of eGFR <60 mL/min/1.73 m2 in CPRD was
similar to that in the HSE and the prevalence of RRT was
close to that in the UKRR across all age groups in men and
women, although the small number of younger patients with
an eGFR <60 mL/min/1.73 m2 in the HSE might have ham-
pered precise comparison.
Conclusions.UK primary care data have good external validity
for the prevalence of decreased kidney function and RRT.
Keywords: chronic kidney disease, epidemiology, primary
care, renal replacement therapy, validity
BACKGROUND
Chronic kidney disease (CKD) is amajor public health problem
that increases in prevalence with age and is associated with in-
creased morbidity and mortality [1–3]. The number of people
with end-stage renal disease (ESRD) requiring renal replace-
ment therapy (RRT) has been increasing worldwide and is pre-
dicted to double by 2030 [4]. Appropriate identiﬁcation of CKD
is thus important for early intervention, including prevention of
both CKD progression and cardiovascular diseases [5]. At the
population level, accurate estimation of CKD prevalence is es-
sential to assess the burden of CKD in the community and to
evaluate the effectiveness of population approaches for CKD
[6]. However, potential methodological difﬁculties may make© The Author 201 . Published by Oxford University Press
on behalf of ERA-EDTA. This is an Open Access article distributed under the
terms of theCreativeCommonsAttribution License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction
in any medium, provided the original work is properly cited.
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it problematic to determine the community prevalence of CKD
[7, 8]. For example, people who have kidney function measured
routinely by serum creatinine may not represent the general
population and serum creatinine assays may not be uniformly
standardized.
Data derived from routine patient care, such as the anonym-
ous primary care records held in the UK Clinical Practice Re-
search Datalink (CPRD) [9], are an important resource for
observational studies [10]. Because CRPD broadly represents
the UK population in terms of demographics [11], it can be a
useful source to estimate a disease prevalence in the UK. How-
ever, using routine electronic records to investigate renal disease
is only possible if the general practitioners (GPs) appropriately
test, identify and record everyone in the population who has
kidney disease. Reliable measures of renal disease in electronic
health records would allow a more robust use of primary care
data to investigate renal disease epidemiology; for example, re-
searchers would be able to investigate the association between
kidney diseases and other comorbidities or medications re-
corded in primary care data. To date, a number of deﬁnitions
for diseases or speciﬁc conditions have been validated in the
CPRD at the individual or population level [12, 13]. However,
to our knowledge, there has been no external validation study
for the prevalence of decreased kidney function and RRT in the
CPRD. The best available methods to identify CKD and RRT in
CPRD are to use serum creatinine records measured by GPs
and recorded diagnoses of RRT in the CPRD, respectively, yet
the validity or appropriateness of these methods are unknown.
TheHealth Survey for England (HSE), a nationally represen-
tative survey of health condition, included measurement of kid-
ney function in 2009 and 2010 [14]. Every consenting
participant had kidney function measured, giving representa-
tive statistics for the prevalence of decreased kidney function
in the general population. Meanwhile, the UK Renal Registry
(UKRR), which records information regarding all people on
RRT in the UK, provides annual reports of the prevalence of
RRT [15]. Referring to these two nationally representative
sources of data, we aimed to evaluate the external validity of
the prevalence of decreased kidney function and RRT in the
CPRD.
MATERIALS AND METHODS
Details of the CPRD and study population
In the UK, the primary care system acts as a gatekeeper to
health care—patients need to be registered with a primary
care doctor to access National Health Service (NHS) non-
emergency care. Health care is free at the point of access. Pri-
mary care practices have used computerized electronic health
records since the early 1990s. There are only a limited number
of suppliers of GP electronic health record software. The CPRD
uses data from VISION software system (In Practice Systems,
London, UK) and has evolved as an observational data and
interventional research service provided by the NHS. Currently
>650 GP practices contribute data meeting quality control stan-
dards to the CPRD, covering and representing nearly 7% of the
UK population [11]. Previous studies have suggested that the
distribution of age, sex, ethnicity, practice location deprivation,
and other health indicators such as smoking and morbidities
are similar to that of external UK-based sources [11, 16–19].
The database includes patient demographics, coded diagnoses
and outpatient laboratory test results. The Secretary of State
waived informed consent for CPRD data because data are anon-
ymized and there is an overall beneﬁt for research. Ethical ap-
proval for this study was obtained from the Independent
Scientiﬁc Advisory Committee, which oversees research on
CPRD data (protocol no. 16_055), as well as the London School
of Hygiene and Tropical Medicine Ethics Committee (refer-
ence: 9196).
The study population was all people ≥25 years of age who
were alive and registered in the CPRD for at least 1 year on
31 March 2014. The choice of age 25 years as a lower limit
was made for the best comparability between the CPRD and
HSE or UKRR: the HSE and UKRR collected data of people
<25 years of age differently (the HSE grouped people 16–24
years of age, while the UKRR grouped people 18–24 years of
age). One-year registration was considered necessary for GPs
to record a history of RRT for newly registered patients or to
test their kidney function if they had a key CKD risk factor
such as diabetes [5].
Details of external data
For the prevalence of decreased kidney function, we com-
pared the data from the CPRD with those from the HSE 2009
and 2010 (combined) [14]. Brieﬂy, theHSE 2009/2010 included
a cross-sectional study of kidney disease among people selected
using a multistage stratiﬁed random probability sampling
method. Blood samples were taken from nearly 6000 consent-
ing participants, accounting for 77% for men and 73% for
women among all the HSE participants. Data were weighted
for non-response to reduce response bias. Creatinine was mea-
sured by an internationally standardized enzymatic method,
which is traceable to isotope dilution mass spectrometry
(IDMS) [20]. Estimated glomerular ﬁltration rate (eGFR) was
calculated from the serum creatinine value using the Modiﬁca-
tion of Diet in Renal Disease Study equation in the original HSE
report [14], whereas a post hoc analysis was conducted using the
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation [21]. The prevalence of people with a sin-
gle eGFR <60 mL/min/1.73 m2 was reported according to age
(every 10 years) and sex.
For RRT prevalence, we referred to the data from the UKRR
2014 [15]. The UKRR 2014 collected data from all 71 renal cen-
tres in the UK. The prevalence of RRT in 2013 was estimated by
dividing the number of patients on RRT by the 2013 UK popu-
lation, according to age (every 10 years), sex and RRTmodality:
haemodialysis, peritoneal dialysis or kidney transplantation.
Deﬁnition of decreased kidney function and
RRT in the CPRD
We identiﬁed patients with an eGFR <60 mL/min/1.73 m2
according to their most recent single serum creatinine mea-
sured by a GP in the past 5 years (i.e. the period between 1
April 2009 and 31 March 2014) using the CKD-EPI equation
[22]. We used a single eGFR to deﬁne decreased kidney
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function in the main analysis because the HSE (reference data
in this study), as well as previous large epidemiological studies
[23, 24], have used this deﬁnition. For the main analysis, we
made the following assumptions: (i) all the UK laboratories re-
ported IDMS-traceable creatinine; (ii) people with a missing re-
cord of ethnicity in the CPRD had non-black ethnicity and (iii)
people without any creatinine measurement for the past 5 years
did not have decreased kidney function.
We identiﬁed patients on RRT based on the diagnoses re-
corded in the CPRD anytime from the date of their registration
to 31 March 2014. The list of diagnosis codes (Read codes) in-
dicative of RRTwas determined by using a recommended strat-
egy [25] and agreed upon among the authors (Supplementary
data, Table S1). In addition, in order to examine the validity of
diagnoses of different RRTmodality in CPRD, we classiﬁed pa-
tients with RRT into those with haemodialysis, peritoneal dia-
lysis or kidney transplantation. We used the most recent
recorded diagnosis, as this is the best available approach to es-
timate the prevalence of the current RRT modality in CPRD.
Data analysis
We calculated the prevalence [95% conﬁdence interval (CI)]
of eGFR <60 mL/min/1.73 m2 according to age (every 10 years)
and sex in the CPRD andHSE, respectively, using the CKD-EPI
equation. Denominators in the CPRD were the entire popula-
tion in each age–sex band irrespective of creatinine measure-
ment in the past 5 years. Patients ≥75 years of age were
grouped in the CPRD to be consistent with the HSE. We calcu-
lated the difference (95% CI) in the prevalence of eGFR <60
mL/min/1.73 m2 between the CPRD and HSE. We also re-
ported the proportion of patients with at least one creatinine
measurement for the past 5 years in the CPRD.
Similarly, we calculated the prevalence of RRT in the CPRD
and UKRR, respectively, and then the difference between the
CPRD and UKRR, in 10-year age bands by sex. We also re-
ported results by RRT modality.
All statistical analyses were conducted using Stata 14 soft-
ware (StataCorp, College Station, TX, USA).
Sensitivity analyses
We repeated our analyses using a number of alternative
eGFR deﬁnitions and restricted study populations in order to
determine the impact of the deﬁnition for decreased kidney
function that we used. We deﬁned decreased kidney function
as follows: (i) we assumed that all the UK laboratories reported
non-IDMS-traceable creatinine, and therefore multiplied the
recorded creatinine value by 0.95 to use the CKD-EPI equation
for IDMS-traceable creatinine [26]; (ii) we conducted a com-
plete case analysis for ethnicity (restricting the analysis to peo-
ple with recorded ethnicity in the CPRD); (iii) we used the
participants’ most recent creatinine in the past 2 years, instead
of 5 years; (iv) we restricted the region to England, by excluding
data from Scotland, Wales and Northern Ireland; (v) we add-
itionally required a measure of chronicity to deﬁne decreased
kidney function [27]: two or more eGFR results <60 mL/min/
1.73 m2 needed to be recorded consecutively ≥3 months apart
in the past 5 years; and (vi) we conducted a complete caseTa
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analysis for creatinine by restricting the analysis to people with
at least one creatinine measurement in the past 5 years.
We also compared the prevalence of eGFR <45 mL/min/
1.73 m2 (calculated from the most recent creatinine in the
past 5 years) between the CPRD and HSE, which may be a
more robust indicator of decreased kidney function with prog-
nostic implications [28, 29].
RESULTS
From 685 GP practices, we identiﬁed 2 761 755 people [mean
age 53 (SD 17) years, men 49%] who were alive and registered
in the CPRD for ≥1 year on 31 March 2014. Their age–sex dis-
tribution was broadly similar to that of the UK Census 2013
(Supplementary data, Table S2). Of those identiﬁed, 189 581
patients (6.86%) had an eGFR <60 mL/min/1.73 m2 and 3293
patients (0.12%) were on RRT.
The prevalence of eGFR <60 mL/min/1.73 m2 increased
steeply with age (Table 1 and Figure 1). There was no evidence
that the prevalence of eGFR <60 mL/min/1.73 m2 in the CPRD
was different from that in theHSE across age groups, both inmen
and women, except for the group of men 25–34 years of age, in
which no one had an eGFR <60 mL/min/1.73 m2 in the HSE.
The proportion of people who had a recorded measurement of
creatinine increased with age, with 26% of men and 46% of
women 25–34 years of age with tests in the past 5 years, up to
92% (both men and women) among people 75 years of age.
The prevalence of RRT gradually increased according to age
(Table 2 and Figure 2). The difference between the CRPD and
the UKRR was small across all age groups, both in men and
women. Table 3 shows the subgroup analysis by RRT modality.
The prevalence of patients with haemodialysis in the CPRDwas
slightly lower than that in the UKRR across all age groups, while
the prevalence of those with peritoneal dialysis and kidney
transplantation in the CPRD were similar to or slightly higher
than those in the UKRR.
Table 4 shows the results of sensitivity analyses. By assuming
all creatinine results were non-IDMS traceable, the prevalence
of eGFR <60 mL/min/1.73 m2 in the CPRD decreased predom-
inantly among older people, and overall prevalence decreased
from 6.86 to 5.35%. Restricting to people with recorded ethni-
city in the CPRD, using a serum creatinine value in the past 2
years and restricting to English data produced similar results to
the main analysis. By deﬁning decreased kidney function in-
cluding a measure of chronicity, the prevalence decreased
slightly in each age group, and overall prevalence decreased
from 6.86 to 6.27%. Finally, in a complete case analysis (using
as the denominator only those with serum creatinine tests) the
prevalence of eGFR <60 mL/min/1.73 m2 increased substan-
tially compared to that in the main analysis.
The overall prevalence of eGFR <45 mL/min/1.73 m2 was
2.33% (64 425/2 761 755) in the CPRD. The number of people
with an eGFR <45 mL/min/1.73 m2 was small and CIs of the
prevalence estimates were large in the HSE (Table 5). The pro-
portion of people with an eGFR <45 mL/min/1.73 m2 in the age
group≥75 years in the CPRDwas signiﬁcantly higher than that
of the HSE, both in men and women.
DISCUSSION
In this study, we examined the external validity of the preva-
lence of decreased kidney function (based on serum creatinine
measured by GPs) and RRT (based on recorded diagnoses) in
the CPRD by comparing them with results from two nationally
representative sources (the HSE and UKRR). Across all ages for
men and women the prevalence of eGFR <60 mL/min/1.73 m2
in the CPRD was similar to that in the HSE, although the small
number of younger patients with an eGFR <60 mL/min/1.73
F IGURE 1 : Prevalence of eGFR <60 mL/min/1.73 m2 in the CPRD and HSE.
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m2 in the HSE might have hampered precise comparison. The
prevalence of RRT in the CPRD was broadly similar to that ob-
tained from the UKRR, although there were differences in the
RRT modality-speciﬁc prevalence between the CPRD and
UKRR.
Routinely collected primary care data can be a useful re-
source for epidemiological studies, particularly in the UK,
where >98% of citizens are registered with NHS GPs [11]. Al-
though the prevalence or incidence of various diseases in the
CPRD have good comparability with other UK-based data
sources [12, 13], the external validity of the prevalence of de-
creased kidney function and RRT has not been studied. Con-
cerns speciﬁc to kidney diseases include that GPs do not test
every registered patient’s kidney function, which could lead to
underestimation of the true prevalence of decreased kidney
function. In our study, the proportion of people with creatinine
measurement was small among young andmiddle-aged people,
especially men. However, using the entire practice population
as a denominator, the prevalence of eGFR <60 mL/min/1.73
m2 in the CPRD was close to that in the HSE across all age
groups, both in men and women. A possible explanation
would be that, in line with the current National Institute for
Health and Care Excellence (NICE) guidance for CKD [5],
GPs are efﬁciently testing kidney function for people with
CKD risk factors, including hypertension, diabetes, cardiovas-
cular diseases and hereditary kidney disease (e.g. autosomal
dominant polycystic kidney disease). In addition, the Quality
and Outcome Framework (QOF) incentivizes GPs to register
and manage patients with CKD [30]. Since the launch of the
QOF for CKD in 2006/7, the identiﬁcation and management
of patients with CKD have been improving in the UK [31], al-
though there are delays in coding patients with CKD in the sys-
tem [32]. In older age groups, very high proportions had
undergone testing of kidney function, and it is likely that
those not tested are healthier, with a lower risk of CKD.
In sensitivity analyses, we examined to what extent the
prevalence estimates for decreased kidney function changed
under different assumptions related to uncertainties in the
CPRD. First, the estimation changed considerably with the as-
sumption of whether the UK laboratories reported creatinines
traceable to IDMS or not. We expect that most of the UK la-
boratories reported IDMS-traceable creatinines during the
study period, yet if a few laboratories reported non-IDMS-
traceable creatinines, the true prevalence of eGFR <60 mL/
min/1.73 m2 in the CPRD would become lower than our esti-
mation in the main analysis. Standardization of serum creatin-
ine assays is thus important in studies regarding CKD
epidemiology. Second, the assumption of non-black ethnicity
for people with missing ethnicity data in the CPRD affected
the prevalence estimates only slightly. This is probably because
the proportion of people with black ethnicity is small in the UK,
at ∼3% [18]. Third, using creatinine records for the past 2 in-
stead of 5 years made little change to prevalence estimates for
decreased kidney function. This may relate to recommenda-
tions for regular testing in line with the QOF and the current
NICE guidance for CKD [5]. Fourth, in the CPRD the preva-
lence of eGFR <60 mL/min/1.73 m2 in England was similar
to that in the whole UK, ensuring comparability between theTa
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HSE and CPRD in our study. Fifth, the prevalence estimates
slightly decreased by using the CKD criteria including chron-
icity. This may suggest that some patients with a single eGFR
<60 mL/min/1.73 m2 had transient kidney dysfunction, prob-
ably because serum creatinine was measured at the time of
acute illness when theymay have developed acute kidney injury.
Finally, the prevalence of decreased kidney function was likely
to be overestimated by restricting the denominator to only peo-
ple with creatinine measurement. This suggests that GPs select-
ively test people at high risk of CKD, especially among younger
people.
The prevalence of RRT was also similar between the CPRD
and UKRR across all age groups in men and women. Patients
receiving RRT are in frequent contact with kidney units, so
GPs do not provide comprehensive routine care for these indi-
viduals. However, patients on RRT remain registered with their
GPs and therefore we would anticipate that GPs update patient
records to reﬂect commencement of RRT. Our results suggest
that the estimated prevalence of RRT based on recorded diag-
noses in the CPRD was broadly valid when compared against
comprehensive UKRR. However, using the most recent diagno-
sis indicating RRT modality, the prevalence of haemodialysis
was underestimated in the CPRD, while those of peritoneal dia-
lysis and kidney transplantation were similar, or somewhat
overestimated, especially among older people. This may be be-
cause patients with peritoneal dialysis and kidney transplant-
ation are often healthier and have more regular contact with
their GPs compared with those on haemodialysis. In addition,
for patients with a change in their RRTmodality (e.g. from peri-
toneal dialysis to haemodialysis) there may be a delay in updat-
ing the modality in the GP record. Therefore, some patients
currently on haemodialysis might be misclassiﬁed into the
group of peritoneal dialysis or kidney transplantation because
their previous diagnoses (i.e. peritoneal dialysis or kidney trans-
plantation) are not yet updated. Another possibility is that
patients commencing haemodialysis died before this was re-
corded in the CPRD, given the high early mortality rates of
these patients [33].
There are several limitations to our study. First, this is a
cross-sectional study examining the validity of prevalence of de-
creased kidney function and RRT. Our results do not ensure
that UK primary care data are reliable for identifying the inci-
dence of CKD and RRT. Second, our comparison of data be-
tween the CPRD and HSE or UKRR was only at the
population rather than the individual level. Our analyses did
not allow us to calculate the sensitivity or speciﬁcity of RRT
diagnoses. In the absence of linked data, it is possible that
there was a similar extent of misclassiﬁcation between cases
and non-cases, resulting in an overall agreement of the preva-
lence estimates in the CPRD with those in the HSE and UKRR.
Third, the prevalence of decreased kidney function in the HSE
was the best available estimate, but not a perfect reference
standard. The survey did not include people who were tempor-
arily hospitalized for acute illness or were in residential care
[14]. In addition, people with poor health might be reluctant
to give a blood sample, and the existing adjustment for non-
response in the HSE may not have fully dealt with this bias.
This may explain the ﬁnding in our sensitivity analysis that
the proportion of people with an eGFR <45 mL/min/1.73 m2
in the oldest age group in the CPRD was signiﬁcantly higher
than that of the HSE. Blood sampling was conducted on only
one occasion in the HSE. Accordingly, we deﬁned decreased
kidney function in the CPRD using one serum creatinine meas-
urement in our main analysis. However, some patients might
have had their kidney function checked as a result of acute ill-
ness, and therefore their decreased kidney function might have
been transient. Previous research has shown that creatinine
ﬂuctuation can affect the CKDprevalence estimates in routinely
collected data [34], although the inﬂuence was not large in our
study. At ∼6000, the sample size in the HSE was not small, yet
F IGURE 2 : Prevalence of RRT in the CPRD and the UKRR
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the relatively wide 95% CIs for the prevalence estimates in each
age–sex group hamperedmore precise comparisons. In particu-
lar, the number of patients with an eGFR <60 mL/min/1.73 m2
was small among younger age groups. We could not compare
the prevalence of more severe kidney dysfunction, because pa-
tients with an eGFR <30 mL/min/1.73 m2 were rare, even
among older people in the HSE [14]. Meanwhile, testing of al-
buminuria is known to be incomplete in UK primary care elec-
tronic health records [32], which prevented us from comparing
the prevalence of albuminuria, or CKD stages 1 and 2, between
the CPRD andHSE. Because albuminuria is an important prog-
nostic factor in people with and without low eGFR [35], the un-
known validity of albuminuria in UK primary care remains an
obstacle to the study of CKD using the CPRD. Finally, our ﬁnd-
ings may not be generalizable to other GP practices in the UK if
GP practices contributing to the CPRD were more likely to
measure kidney function and record the diagnoses of RRT.
Generalizability to primary care electronic health records in
other European countries is also uncertain, because the fre-
quency of practices such as blood testing, chronic disease mon-
itoring, recording of diagnoses, incentives and access to public
primary care clinics differ.
In the era of a rising global prevalence of ESRD [4], high-
quality epidemiological research on kidney diseases is becom-
ing more important. Routinely collected electronic health re-
cord data would play an important role for kidney research,
because most patients with CKD are diagnosed and managed
in primary care. Accurate identiﬁcation of CKD and RRT in
the CPRD would allow investigation of the association between
kidney diseases and other comorbidities or medications. It is
also possible to investigate equity of care (e.g. referral to ne-
phrologists), given that the database is less biased for ascertain-
ing advanced CKD than population surveys and disease
registries. In this study, we demonstrated that identifying the
prevalence of CKD and RRT is valid at the population level
in the CPRD. Although further validation of individual-level
data is needed, our ﬁndings support the use of UK primary
care data for research into kidney disease.
CONCLUSIONS
We examined the external validity of the prevalence of de-
creased kidney function and RRT in the CPRD. The prevalence
of eGFR <60 mL/min/1.73 m2 in the CPRD was similar to that
in a national sampling survey (HSE 2009/2010), and the preva-
lence of RRT in the CPRD was close to that obtained from a
national disease registry (UKRR 2014) across all age groups,
in both men and women. These ﬁndings suggest that UK pri-
mary care data can be used to identify the prevalence of de-
creased kidney function and RRT in future studies.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford-
journals.org.Ta
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Supplementary data Table 1. List of diagnosis codes indicative of renal replacement therapy in Clinical 
Practice Research Datalink 
Medcode Read code Read term 
Haemodialysis:  
2996 7L1A200 Haemodialysis NEC 
11773 7L1A.11 Dialysis for renal failure 
20073 7L1A000 Renal dialysis 
20196 14V2.00 H/O: renal dialysis 
22252 ZV45100 [V]Renal dialysis status 
28158 TB11.00 Kidney dialysis with complication  without blame 
31549 7L1A.00 Compensation for renal failure 
35921 TA22.00 Failure of sterile precautions during perfusion 
44422 14V2.11 H/O: kidney dialysis 
46145 ZV56011 [V]Aftercare involving renal dialysis NOS 
48022 7L1Ay00 Other specified compensation for renal failure 
54844 U612200 [X]Failure sterile precautions dur kidney dialys/other perf 
60302 7A60600 Creation of graft fistula for dialysis 
60743 ZV56.00 [V]Aftercare involving intermittent dialysis 
64636 7L1Az00 Compensation for renal failure NOS 
65089 7L1Cz00 Placement other apparatus- compensate for renal failure NOS 
66714 TB11.11 Renal dialysis with complication  without blame 
69266 TA22000 Failure of sterile precautions during kidney dialysis 
69427 TA02z00 Accid cut puncture perf h'ge - perfusion NOS 
69760 ZVu3G00 [X]Other dialysis 
71124 7L1A300 Haemofiltration 
83513 7L1C.00 Placement other apparatus for compensation for renal failure 
96184 TA02000 Accid cut puncture perf h'ge - kidney dialysis 
101756 7L1A011 Thomas intravascular shunt for dialysis 
Peritoneal dialysis:  
2994 7L1A100 Peritoneal dialysis 
8037 7L1B000 Insertion of ambulatory peritoneal dialysis catheter 
23773 7L1B100 Removal of ambulatory peritoneal dialysis catheter 
30709 7L1C000 Insertion of temporary peritoneal dialysis catheter 
30756 7L1A500 Continuous ambulatory peritoneal dialysis 
36442 7L1B.11 Placement ambulatory dialysis apparatus - compens renal fail 
56760 7L1B.00 Placement ambulatory apparatus compensation renal failure 
59194 7L1By00 Placement ambulatory apparatus- compensate renal failure OS 
64828 7L1A600 Peritoneal dialysis NEC 
56
88597 7L1A400 Automated peritoneal dialysis 
Kidney transplantation:  
2997 7B00.00 Transplantation of kidney 
5504 7B00z00 Transplantation of kidney NOS 
5911 ZV42000 [V]Kidney transplanted 
11553 SP08300 Kidney transplant failure and rejection 
11745 7B00100 Transplantation of kidney from live donor 
17253 8L50.00 Renal transplant planned 
18774 TB00111 Renal transplant with complication  without blame 
24361 7B00200 Transplantation of kidney from cadaver 
26862 7B06300 Exploration of renal transplant 
48057 K0B5.00 Renal tubulo-interstitial disordrs in transplant rejectn 
49028 14S2.00 H/O: kidney recipient 
54990 TB00100 Kidney transplant with complication  without blame 
66705 7B00111 Allotransplantation of kidney from live donor 
70712 SP08011 Det.ren.func.after ren.transpl 
70874 7B00y00 Other specified transplantation of kidney 
72004 7B01511 Excision of rejected transplanted kidney 
89924 7B00300 Allotransplantation of kidney from cadaver  heart-beating 
90952 7B0F100 Pre-transplantation of kidney work-up  recipient 
93366 7B0F.00 Interventions associated with transplantation of kidney 
94964 7B0F400 Post-transplantation of kidney examination  live donor 
96095 7B0F200 Pre-transplantation of kidney work-up  live donor 
96133 7B00400 Allotransplantation kidney from cadaver  heart non-beating 
98364 7B00211 Allotransplantation of kidney from cadaver 
100693 Kyu1C00 [X]Renal tubulo-interstitial disorders/transplant rejection 
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Supplementary data Table 2. Age-sex distribution in Clinical Practice Research Datalink and UK census 2013 
Age 
(years) 
Clinical Practice Research Datalink UK census 2013 
No. of people Proportion (%) No. of people Proportion (%) 
Men:     
25-29 117,261 4.2 2,171,395 4.9 
30-34 120,023 4.3 2,148,903 4.8 
35-39 120,256 4.4 1,975,110 4.4 
40-44 136,483 4.9 2,221,431 5.0 
45-49 148,763 5.4 2,310,722 5.2 
50-54 144,341 5.2 2,149,309 4.8 
55-59 123,154 4.5 1,854,877 4.2 
60-64 108,541 3.9 1,734,599 3.9 
65-69 109,100 4.0 1,697,784 3.8 
70-74 81,192 2.9 1,201,622 2.7 
75-79 62,543 2.3 954,347 2.1 
80-84 44,307 1.6 650,871 1.5 
>=85 36,294 1.3 491,300 1.1 
Women:     
25-29 114,601 4.1 2,178,575 4.9 
30-34 120,740 4.4 2,177,964 4.9 
35-39 118,908 4.3 1,991,769 4.5 
40-44 134,237 4.9 2,274,838 5.1 
45-49 145,120 5.3 2,375,928 5.3 
50-54 141,266 5.1 2,194,934 4.9 
55-59 121,259 4.4 1,901,770 4.3 
60-64 110,258 4.0 1,806,214 4.0 
65-69 114,370 4.1 1,793,663 4.0 
70-74 88,857 3.2 1,337,533 3.0 
75-79 73,334 2.7 1,137,778 2.6 
80-84 58,348 2.1 899,031 2.0 
>=85 68,199 2.5 967,876 2.2 
Total: 2,761,755 100 44,600,143 100 
 
58
59 
 
5.3. Additional data and discussions 
Further to the results and discussions presented in the published paper, here I show the 
additional data and related discussions regarding the serum creatinine testing rate by known 
CKD risk factors, as well as the distribution of patients satisfying the definition of decreased 
kidney function and those satisfying the definition of CKD (stages 3 to 5). 
5.3.1. Serum creatinine testing rate by known CKD risk factors 
(i) Backgrounds and methods 
In the published paper, the serum creatinine testing rate (i.e. the proportion of people receiving 
at least one serum creatinine measurement during the five years between 1 April 2009 and 31 
March 2014) was shown only by age category and sex. Here I present the serum creatinine 
testing rate by known CKD risk factors, in order to confirm that GPs are selectively (instead of 
randomly) testing patients at risk of CKD. The known CKD risk factors here include diabetes, 
hypertension, cardiovascular disease (myocardial infarction, chronic heart failure, peripheral 
arterial disease, or stroke), urological disease (vesicoureteral reflux, renal tract stone, or 
prostatic hypertrophy), systematic lupus erythematosus, and polycystic kidney disease [1, 18]. 
I also show the testing rate of people without any known CKD risk factors.  
(ii) Results and discussions 
Patients with known CKD risk factors had a very high serum creatinine testing rate (over 90% 
except for those with polycystic kidney disease) in the testing period (see Table 5 below). In 
particular, those with diabetes, hypertension, and cardiovascular disease showed testing rates 
of approximately 97%. On the contrary, people with no known CKD risk factors showed a low 
serum creatinine testing rate, with approximately 50%. This data indeed suggests that GPs are 
selectively testing patients at risk of CKD. In addition, with or without CKD risk factors, the 
proportion of serum creatinine testing increased with age, probably because of increased 
opportunities to receive blood tests. As CKD mostly occurs in patients with known CKD risk 
factors or older people, the current serum creatinine testing strategy in UK primary care (i.e. 
selective testing of patients at risk of CKD and frequent testing of older patients) is expected 
to identify most patients with decreased kidney function.  
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Table 5. Serum creatinine testing rate by known CKD risk factors in CPRD during the five years between April 2009 and March 2014 
Abbreviation: CKD = chronic kidney disease. 
 
Gender Men Women 
Overall 
Age category 25-34 35-44 45-54 55-64 65-74 ≥75 25-34 35-44 45-54 55-64 65-74 ≥75 
Overall (N = 2,761,755), % 25.9 38.5 55.6 72.4 86.2 92.3 46.2 55.3 67.4 75.3 84.5 91.9 63.7 
Patients with diabetes 
(N = 232,824), % 89.4 94.1 96.7 98.3 99.1 99.4 88.0 92.6 96.2 98.0 98.9 99.2  98.0 
Patients with hypertension 
(N = 569,922), % 83.8 90.4 93.9 96.4 97.9 98.5 83.7 89.5 94.7 96.2 97.6 97.9 96.8 
Patients with cardiovascular disease 
(N = 152,310), % 65.0 85.1 93.9 96.9 98.3 98.6 78.5 85.5 93.1 96.6 98.0 98.0 97.5 
Patients with urological disease 
(N = 116,884), % 44.6 61.5 77.5 89.6 94.9 97.0 64.9 72.4 82.2 87.9 92.7 96.1 91.0 
Patients with systematic lupus 
erythematosus (N = 4,100), % 65.2 74.6 77.7 89.3 92.9 98.1 84.6 82.7 89.7 91.6 95.1 97.2 90.3 
Patients with polycystic kidney disease 
(N = 2,229), % 58.2 79.5 81.3 93.7 94.1 99.0 68.5 79.4 87.0 90.1 96.8 99.1 85.4 
People with no known CKD risk factor 
(N = 1,984,217), % 24.6 34.7 47.0 57.4 68.6 73.0  45.2 53.0 62.7 66.7 72.7 78.2  51.2 
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5.3.2. Distribution of patients satisfying the definition of decreased kidney function and 
those satisfying the definition of CKD 
(i) Backgrounds and methods 
In the published paper, the prevalence of patients with decreased kidney function (i.e. most 
recent eGFR <60 ml/min/1.73 m2 prior to 31 March 2014) was estimated in the main analysis, 
and that of patients with CKD (i.e. satisfying two or more consecutive measurements of eGFR 
<60 ml/min/1.73 m2 for ≥3 months in the past five years) was estimated in a sensitivity analysis. 
However, some patients may satisfy the definition of decreased kidney function but not the 
definition of CKD, and vice versa (as illustrated in Figure 3 in the previous chapter 4). To 
further explore this, I created a two by two table showing the distribution of these patients and 
interpreted the results.  
(ii) Results and discussions 
Some discrepancy was observed between patients satisfying the definition of decreased kidney 
function and those satisfying the CKD definition (see Table 6 below).  
 
Table 6. Distribution of patients satisfying the definition of decreased kidney function 
and those satisfying the definition of CKD 
Abbreviations: CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate. 
 
 
CKD (i.e. two or more consecutive 
measurements of eGFR <60 ml/min/1.73 
m2 for ≥3 months in 5 years between  
1 April 2009 to 31 March 2014) Total 
Yes No 
Decreased kidney function  
(i.e. most recent single 
eGFR <60 ml/min/1.73 m2 
prior to 31 March 2014) 
Yes 144,913 (83.7%) (76.4%) 
44,668 
(23.6%) 
189,581 
(100%) 
No 28,141 (16.3%) 2,544,033 2,572,174 
Total 173,054 (100%) 2,588,701 2,761,755 
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On the one hand, among 189,581 patients with decreased kidney function, 144,913 (76.4%) 
satisfied the CKD criteria in the past five years, while 44,668 (23.6%) did not. These 44,668 
people are probably a mixture of (i) patients with temporarily low eGFR, and (ii) patients who 
had continuously decreased kidney function but received only one serum creatinine 
measurement in the past five years. On the other hand, among 173,054 patients satisfying the 
CKD criteria in the past five years, 144,913 (83.7%) patients showed their most recent eGFR 
<60 ml/min/1.73 m2, whereas 28,141 (16.3%) showed their most recent eGFR ≥60 ml/min/1.73 
m2. Probably these 28,141 patients do not have continuously decreased kidney function, but by 
chance satisfied the CKD criteria when they received two or more blood samplings at the time 
of AKI or post-exercise/protein intake. 
These data highlight the difficulty in identifying patients with “true CKD” in routinely 
collected data. There is a risk that patients with a single measurement of eGFR <60 ml/min/1.73 
m2 includes patients with temporarily decreased kidney function (i.e. AKI) or increased serum 
creatinine level due to exercise or protein intake. Meanwhile, there is a risk that the CKD 
chronicity criterion (i.e. two or more consecutive measurements of decreased kidney function 
over ≥3 months) may inadvertently exclude patients with “true CKD” who received only one 
serum creatinine measurement during a study period.  
Another difficulty found is that even patients satisfying the chronicity criterion of CKD may 
not show continuously decreased kidney function thereafter. This was already suggested in 
previous studies using routinely collected data. For example, in a UK study recruiting people 
who previously satisfied the definition of CKD (i.e. at least two measurements of eGFR <60 
ml/min/1.73 m2 for ≥3 months) in primary care records, 24% had an eGFR of ≥60 ml/min/1.73 
m2 at the first study visit for baseline assessment of the study [120], and five years later 19.3% 
still showed eGFR >60 ml/min/1.73 m2 and no albuminuria [121]. In a Norwegian study based 
on routinely collected primary and secondary care data, among patients satisfying the definition 
of CKD, 4.8% showed a subsequent improvement of GFR [122]. Even when they extended the 
chronicity criterion of three months to six months, nine months, and one year, the subsequent 
improvement of GFR was observed in 3.7%, 2.8%, and 2.3% of the study participants, 
respectively.  
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In summary, the strategies (i) to use a single measurement of decreased kidney function, and 
(ii) to apply the internationally accepted criteria of CKD (including the chronicity criterion) to 
routinely collected data, have their own limitations. However, proposing alternative criteria to 
identify “true CKD” in routinely collected data seems to be beyond the scope of this thesis 
focusing on kidney disease and mental health disorders. Therefore, in the next cross-sectional 
study in Paper 2 (SMI and CKD), I will simply compare the proportion of patients satisfying 
the definition of CKD (i.e. two or more consecutive measurements of decreased kidney 
function over ≥3 months in the past five years) between people with and without SMI, and will 
conduct a sensitivity analysis to examine the proportion of patients satisfying the definition of 
decreased kidney function (i.e. most recent eGFR <60 ml/min/1.73 m2 prior to 31 March 2014).  
It should be noted that the strategy to identify patients with decreased kidney function and CKD 
and associated limitations in cross-sectional studies (which used the serum creatinine records 
retrospectively among people who are currently alive) may not be directly applicable to cohort 
studies (which use the serum creatinine records prospectively). Therefore, for the cohort studies 
in Papers 3 (CKD and antidepressant prescription) and 4 (GI bleeding risk of SSRIs by kidney 
function), the strategy to identify patients with CKD and associated limitations will be 
differently discussed in chapter 7. 
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5.4. Chapter summary 
Prevalence of CKD and RRT in CPRD 
- Among patients aged ≥25 registered in the CPRD on 31 March 2014, the prevalence of 
patients with decreased kidney function (i.e. most recent single eGFR <60 mL/min/1.73m2), 
CKD (two or more consecutive measurements of eGFR <60 ml/min/1.73 m2 for ≥3 months 
in the past five years), and RRT (based on recorded diagnoses) was 6.86% 
(189,581/2,761,755), 6.27% (173,054/2,761,755), and 0.12% (3,293/2,761,755), 
respectively. 
- The prevalence of decreased kidney function (in the main analysis) and CKD (in a 
sensitivity analysis) in the CPRD was broadly similar to that in the Health Survey for 
England 2009/2010, and the prevalence of RRT in the CPRD was similar to that estimated 
from the UK Renal Registry 2014, across all age groups in men and women. 
- Serum creatinine testing rate was very high (over 90%) among patients with known CKD 
risk factors such as diabetes, hypertension, and cardiovascular disease, and among people 
aged 75 or older. 
- These results indicate that most patients with decreased kidney function or CKD and RRT 
are probably captured with the current serum creatinine testing strategy and recording 
practice in the CPRD. 
- The findings of discrepancy between patients satisfying the definition of decreased kidney 
function and those satisfying the definition of CKD criteria highlight the difficulty in 
identifying patients with “true CKD” in routinely collected data such as the CPRD.  
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Chapter 6: Severe mental illness and chronic kidney disease: a 
cross-sectional study in the United Kingdom (Paper 2) 
6.1. Introduction 
This chapter presents a cross-sectional study on the association between SMI, including 
schizophrenia and bipolar disorder, and CKD in the CPRD, which is published in Clinical 
Epidemiology [123].  
The main research question is: Is CKD more common in patient with SMI than those without 
in the UK general population? 
Briefly, in the dataset established in chapter 4, which includes 2,418,730 people aged 25–74 
who were alive and registered for at least one year in the CPRD on 31 March 2014, I compared 
the prevalence of patients satisfying the definition of CKD in the past five years and RRT 
between people with a recorded diagnosis of SMI (with and without a history of lithium 
prescription in the CPRD) and those without SMI in the general population. I also compared 
the prevalence of several conditions associated with CKD (e.g. diabetes and smoking) between 
the groups, and conducted adjusted logistic regression analyses to examine to what extent these 
factors explain the association between SMI and CKD. Diagnosis codes (Read codes) 
suggesting SMI are shown in Appendix B. 
Although the assumption that people without serum creatinine measurement in the past five 
years do not have CKD was suggested to be valid in Paper 1 (Prevalence of CKD and RRT in 
CPRD), this will be further explored later in the context of this study. 
 
6.2. Published paper 
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Objective: We investigated the burden of chronic kidney disease (CKD) among patients with 
severe mental illness (SMI).
Methods: We identified patients with SMI among all those aged 25–74 registered in the UK 
Clinical Practice Research Datalink as on March 31, 2014. We compared the prevalence of CKD 
(two measurements of estimated glomerular filtration rate <60 mL/min/1.73 m2 for ≥3 months) 
and renal replacement therapy between patients with and without SMI. For patients with and 
without a history of lithium prescription separately, we used logistic regression to examine the 
association between SMI and CKD, adjusting for demographics, lifestyle characteristics, and 
known CKD risk factors.
Results: The CKD prevalence was 14.6% among patients with SMI and a history of lithium 
prescription (n = 4,295), 3.3% among patients with SMI and no history of lithium prescription 
(n = 24,101), and 2.1% among patients without SMI (n = 2,387,988; P < 0.001). The prevalence 
of renal replacement therapy was 0.23%, 0.15%, and 0.11%, respectively (P = 0.012). Compared 
to patients without SMI, the fully adjusted odds ratio for CKD was 6.49 (95% CI 5.84–7.21) for 
patients with SMI and a history of lithium prescription and 1.45 (95% CI 1.34–1.58) for patients 
with SMI and no history of lithium prescription. The higher prevalence of CKD in patients with SMI 
may, in part, be explained by more frequent blood testing as compared to the general population.
Conclusion: CKD is identified more commonly among patients with SMI than in the general 
population.
Keywords: severe mental illness, schizophrenia, bipolar disorder, chronic kidney disease, lithium
Introduction
People with severe mental illness (SMI), including schizophrenia, bipolar disorder, 
and other nonorganic psychotic illnesses, are known to have shorter life expectancy, 
by ~10–20 years, than the general population.1–6 Their premature death is attributed not 
only to suicide and accident but also to physical illnesses – especially cardiovascular 
diseases such as coronary heart disease and stroke.5–9 The high rate of cardiovascular 
deaths in patients with SMI has been attributed to the high prevalence of lifestyle-
related conditions (eg, smoking and obesity),10–13 suboptimal screening/assessment 
of cardiovascular risks,14,15 and suboptimal management of underlying diseases (eg, 
hypertension, diabetes, dyslipidemia).16–18
Chronic kidney disease (CKD) – the continuous presence of kidney damage 
and/or decreased level of kidney function19 – is independently associated with 
increased risk of death, cardiovascular events, and all-cause hospitalization.20 CKD 
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can progress to end-stage renal disease (ESRD) requiring 
renal replacement therapy (RRT), a substantial burden for 
both – quality of life of patients and health budgets. The UK 
National Institute for Health and Care Excellence guidance 
for CKD recommends early identification and appropriate 
management of CKD.21
People with SMI have an increased prevalence of several 
risk factors for CKD, including smoking and diabetes.13,16,22 
Moreover, patients with SMI may be treated with lithium, 
which is associated with the development of CKD.23,24 
However, there has been limited research investigating the 
prevalence of, and risk factors for, CKD in people with 
SMI.13,25,26 In the UK, primary care plays an important role 
in the management of physical health conditions in people 
with SMI. As part of the Quality and Outcomes Framework 
(QOF), there have been recent financial incentives for general 
practitioners (GPs) to undertake physical health checks in 
people with SMI.27 However, it is unclear whether CKD in 
patients with SMI is appropriately recognized and managed 
by GPs.
Therefore, we used a UK primary care database to: 1) 
compare the prevalence of CKD and RRT among patients 
with SMI (with and without a history of lithium use) and 
those without SMI; 2) investigate whether there is an inde-
pendent association between SMI and CKD after adjusting 
for known CKD risk factors; and 3) compare the recognition 
and management of CKD between CKD patients with and 
without SMI.
Materials and methods
Data source
The Clinical Practice Research Datalink (CPRD) is an 
observational data and interventional research service pro-
vided by the National Health Service. Around 98% of the 
UK population are registered with a primary care practice. 
Currently, >650 general practices contribute data conforming 
to quality control standards to the CPRD, including ~ 7% of 
the UK population. The included practices are representative 
of the UK general population in terms of age and sex.28 The 
database includes the following data: patient demograph-
ics, diagnoses based on Read codes (a hierarchical coding 
system), prescriptions based on British National Formulary 
codes, laboratory test results, and referrals made by GPs. 
Ethical approval for this study was obtained from the Inde-
pendent Scientific Advisory Committee of CPRD (protocol 
no. 16_055). Informed consent was waived because data are 
anonymized for research purposes.
study population
Our study population included all people, aged 25–74 years, 
registered in the CPRD for at least 1 year as on March 31, 
2014 (ie, the end of a financial or QOF year). We selected the 
25–74 age range because our preliminary analysis suggested 
that CKD and/or SMI were rare in people outside these param-
eters, thereby limiting the power for comparative prevalence 
analyses. To ensure that we had reliable measures of morbidity 
(to allow time for the recording of past medical history in 
newly registered patients), we required that all participants 
had at least 1 year of continuous registration in the CPRD.
Disease definition
We identified SMI using Read morbidity codes that have 
been validated in UK primary care data, with high sensitiv-
ity (91%), specificity (99.9%), and positive predictive value 
(91%).29 Patients with SMI were further classified as those 
with and without any record of lithium prescription in the 
period between the CPRD registration and March 31, 2014. 
We excluded patients who had been prescribed lithium with-
out recorded SMI from the general population comparison 
group because the indication for treatment was not known.
Our definition of CKD was based on two measurements 
of estimated glomerular filtration rate <60 mL/min/1.73 m2 
separated by 3 months or longer,19 calculated from serum 
creatinine records in the CPRD in the past 5 years, using the 
Chronic Kidney Disease Epidemiology  Collaboration equa-
tion.30 RRT was characterized on the basis of diagnosis codes 
suggesting hemodialysis, peritoneal dialysis, or kidney trans-
plantation. Previous research has shown that the prevalence of 
estimated glomerular filtration rate <60 mL/min/1.73 m2 and 
RRT in the CPRD is similar to that estimated in a nationally 
representative population survey (Health Survey for England) 
and disease registry (UK Renal Registry), suggesting that 
most cases of CKD and RRT are captured in the CPRD.31
Covariate definition
We defined baseline characteristics of patients with and 
without SMI: age, sex, ethnicity, socioeconomic status (SES), 
country of the UK (ie, England, Northern Ireland, Scotland, 
and Wales) body mass index (BMI), smoking status, chronic 
diseases that are associated with CKD21 – diabetes, hyper-
tension, cardiovascular disease (ie, myocardial infarction, 
chronic heart failure, peripheral arterial disease, and stroke), 
urological disease (ie, vesicoureteral reflux, renal tract stone, 
and prostatic hypertrophy), systematic lupus erythematosus, 
and polycystic kidney disease – based on relevant diagnosis 
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codes. Based on previous studies using UK primary care 
data,32,33 we grouped patients with no record of ethnicity 
into those of white ethnicity. SES was assigned at the gen-
eral practice level using quintiles of the Index of Multiple 
Deprivation in each country of the UK.34 BMI and smoking 
status were based on the most recent records prior to the date 
of study inclusion (ie, March 31, 2014). For chronic diseases, 
if a diagnosis code was recorded for a patient during the 
period between CPRD registration and the study date, then 
that disease was regarded as being present.
Data analysis
We compared baseline characteristics and overall prevalence 
of CKD (including patients on RRT) among the three groups: 
patients with SMI with and without a history of lithium 
prescription as well as those without SMI, using chi-squared 
tests. We stratified CKD prevalence by age (using 10-year age 
bands) and sex. We estimated the prevalence of RRT among 
the three groups and compared it overall by chi-squared tests. 
Moreover, we compared the distribution of the most recent 
category of RRT modality (hemodialysis, peritoneal dialysis, 
or kidney transplantation) between patients with and without 
SMI using chi-squared tests.
Next, we carried out logistic regression analyses to exam-
ine the association between SMI (with and without a history 
of lithium use) and CKD. To understand which factors are 
more likely to explain the association between SMI and CKD, 
we adjusted step-by-step for age and sex, ethnicity, SES, BMI, 
smoking status, and chronic diseases associated with decline 
in kidney function (ie, diabetes, hypertension, cardiovascular 
disease, urological disease, systemic lupus erythematosus, 
and polycystic kidney disease).21 Patients with missing data of 
BMI and smoking status were excluded from the analysis. We 
took into account variations in coding and testing practices 
by different general practices through clustering by general 
practice in the logistic regression models.
Finally, we restricted analysis to patients with CKD who 
were not on RRT and compared the recognition and manage-
ment of CKD between patients with and without SMI. We 
used the QOF CKD indicators (QOF version 2013/14) as 
markers of the recognition and management of CKD in the 
UK primary care.27 We determined the proportion of CKD 
patients with and without SMI who had: 1) a record of a 
diagnostic code for CKD, using CKD codes listed in the QOF 
version 2013/14;35 2) the most recent blood pressure measure 
≤140/90 mmHg (recorded in the year before the date of the 
study); 3) urine test for proteinuria/albuminuria (including 
dipstick test) in the year before the date of the study; and 4) 
for those with hypertension and proteinuria (recorded any 
time between CPRD registration and study date), at least one 
prescription for a renin–angiotensin system antagonist in the 
past 3 months. In addition, because the National Institute for 
Health and Care Excellence guidance for cardiovascular dis-
ease recommends statins as primary prevention for all CKD 
patients regardless of serum cholesterol levels,36 we compared 
the proportion of CKD patients with and without SMI who 
had at least one prescription for a statin in the past 3 months.
All statistical analyses were conducted using Stata 14 
(Stata Corp, College Junction, TX, USA).
Results
Of the 2,418,730 people aged 25–74 years who were registered 
in the CPRD for >1 year on March 31, 2014, we identified 
28,396 (1.17%) patients with SMI, including 4,295 patients 
with a history of lithium prescription in the CPRD and 24,101 
without (Figure 1). In patients with SMI (both with and  without 
Figure 1 Flow chart showing identification of study participants.
Abbreviations: CPrD, Clinical Practice research Datalink; sMi, severe mental illness.
People aged 25–74 registered in the CPRD (for ≥1 year)
on March 31, 2014, N = 2,418,730
People without SMI diagnosis
N = 2,390,334
Patients with lithium
prescription in CPRD
N = 2,346
Patients without SMI diagnosis
(and no lithium use in CPRD)
N = 2,387,988
Patients with no history
of lithium use in CPRD
N = 24,101
Patients with history of
lithium use in CPRD
N = 4,295
People with SMI diagnosis
N = 28,396
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a previous lithium prescription) compared to those without, the 
SES was generally lower and the proportions of black ethnicity, 
obesity (BMI ≥30 kg/m2), and current smokers were higher. 
Diabetes, hypertension, and cardiovascular diseases were more 
common in patients with SMI, whereas the prevalence of other 
diseases (urological disease, systematic lupus erythematosus, 
and polycystic kidney disease) was similar between patients 
with and without SMI (Table 1).
Overall, the prevalence of CKD was 14.64% (629/4,295) 
in patients with SMI and history of lithium prescription, 
3.34% (805/24,101) in patients with SMI and no history 
of lithium prescription, and 2.09% (49,870/2,387,988) in 
patients without SMI (P < 0.001). The absolute difference 
in CKD prevalence among the three groups increased with 
age in both men and women (Figure 2). Moreover, there was 
evidence (P = 0.012) that the overall prevalence of RRT was 
higher in patients with SMI (0.23% [10/4, 295] and 0.15% 
[36/24, 101] in those with and without a history of lithium 
prescription, respectively) than those without SMI (0.11% 
[2,645/2,387,988]). There was strong evidence that the dis-
tribution of RRT modalities was different between patients 
with and without SMI (P = 0.001). In patients with SMI, 
50% (23/46) were receiving hemodialysis and 2% (1/46) 
peritoneal dialysis, and 48% (22/46) underwent kidney 
transplantation. However, in patients without SMI, the cor-
responding figures were 26% (700/2,645), 7% (194/2,645), 
and 66% (1,751/2,645).
The age–sex-adjusted odds ratio (OR) for CKD was 7.13 
(95% confidence interval [CI] 6.47–7.85) for patients with 
SMI and history of lithium use, and 1.69 (1.56–1.83) for 
those with SMI and no history of lithium use, compared to 
those without SMI. After adjusting for SES, BMI, smoking, 
and chronic diseases associated with CKD, the adjusted ORs 
decreased to 6.49 (5.84–7.21) and 1.45 (1.34–1.58) but were 
still significant in patients with SMI with and without previ-
ous lithium prescription, respectively (Table 2).
Among patients with biochemically defined CKD (not on 
RRT), a higher proportion of people with SMI had a recorded 
diagnosis of CKD (SMI 70.3%, without SMI 65.5%) and 
a recorded blood pressure ≤140/90 mmHg (SMI 80.1%, 
without SMI 75.6%; Table 3). However, a lower proportion 
of patients with SMI had recently been prescribed statins 
(SMI 50.5%, without SMI 59.0%).
Discussion
Main findings
We found that, in UK primary care, patients with SMI 
had a greater prevalence of CKD compared to the general 
 population. This was pronounced (6.5-fold increase) in 
patients with a history of lithium prescription, but there was 
a 1.5-fold increase in odds of CKD even among patients 
never known to be prescribed lithium and after adjustment 
for differences in known risk factors for CKD. In addition, 
patients with SMI had an increased prevalence of RRT and 
were more likely to be receiving hemodialysis as their modal-
ity than patients without SMI on RRT.
Strengths and limitations
There are several strengths of our study. There is likely to 
be a good recording of the diagnoses examined because GPs 
manage patients with SMI for their physical and mental health 
– with or without the support of psychiatrists in secondary 
care. In addition, the QOF – the reward and incentive pro-
gram for GPs – included both SMI and CKD during this time 
period.27 Moreover, the diagnosis of SMI has been validated 
at the individual level,29 and the prevalence estimates of 
CKD and RRT have been validated at the population level.31
However, we need to acknowledge several limitations. 
First, this is a cross-sectional study, in which temporal rela-
tionships cannot always be clarified. The majority of patients 
with SMI have developed symptoms by early adulthood,37 
whereas the prevalence of CKD starts to increase after age 
55.31 Therefore, it is unlikely that CKD precedes the onset of 
SMI. However, the interpretation of potential risk factors in 
the association between SMI and CKD requires caution. For 
example, cessation of smoking and lithium may be as a result 
of the development of CKD. Therefore, we did not differenti-
ate previous and current users in the regression models. Sec-
ond, a greater prevalence of CKD among patients with SMI 
may, in part, be influenced by surveillance or ascertainment 
bias. Patients with SMI take medications, such as lithium and 
other psychotropic drugs, which need regular monitoring. In 
addition, in 2013–2014, GPs were incentivized to monitor 
blood glucose and cholesterol levels for people with SMI; 
therefore, many patients would have had concurrent testing 
of renal function.38 In contrast, in the general population, cre-
atinine testing in primary care is not universal: in 2013–2014, 
this was recommended and incentivized only for people with 
known CKD risk factors.21,27 However, we have previously 
demonstrated that the prevalence of CKD identified in the 
CPRD was very similar to that seen in the Health Survey for 
England, a nationally representative survey of the general 
population.31 This suggests that most patients with CKD are 
captured by the current testing strategy in primary care, and 
the proportion of patients with unmeasured CKD in CPRD 
is small. Therefore, underascertainment of CKD in people 
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Table 1 Characteristics of patients by sMi diagnosis and history of lithium use
Characteristic Patients without 
SMI diagnosis  
N = 2,387,988
Patients with SMI diagnosis (N = 28,396)
Patients with no history of 
lithium use N = 24,101
Patients with history of 
lithium use N = 4,295
n (%) n (%) n (%)
Type of SMI diagnosis
schizophrenia – 9,134 (37.9) 448 (10.4)
Bipolar disorder – 5,881 (24.4) 3,374 (78.6)
Other nonorganic psychosis – 9,086 (37.7) 473 (11.0)
Age category (years)
25–34 468,602 (19.6) 3,654 (15.2) 242 (5.6)
35–44 503,405 (21.1) 5,475 (22.7) 688 (16.0)
45–54 571,325 (23.9) 6,361 (26.4) 1,187 (27.6)
55–64 456,457 (19.1) 4,844 (20.1) 1,209 (28.2)
65–74 388,199 (16.3) 3,767 (15.6) 969 (22.6)
sex (male) 1,193,218 (50.0) 13,183 (54.7) 1,761 (41.0)
Ethnicity
White/unrecorded* 2,232,403 (93.5) 22,051 (91.5) 4,184 (97.4)
Black 42,339 (1.8) 836 (3.5) 35 (0.8)
south asian 72,190 (3.0) 734 (3.1) 42 (1.0)
Other 41,056 (1.7) 480 (2.0) 34 (0.8)
Country
England 1,739,874 (72.9) 17,507 (72.6) 2,815 (65.5)
north ireland 92,714 (3.9) 931 (3.9) 234 (5.5)
scotland 307,936 (12.9) 3,084 (12.8) 765 (17.8)
Wales 247,464 (10.4) 2,579 (10.7) 481 (11.2)
Socioeconomic status
1 (least deprived) 468,867 (19.6) 3,463 (14.4) 856 (19.9)
2 496,229 (20.8) 4,295 (17.8) 864 (20.1)
3 483,617 (20.3) 4,706 (19.5) 833 (19.4)
4 508,424 (21.3) 6,084 (25.2) 948 (22.1)
5 (most deprived) 430,851 (18.0) 5,553 (23.0) 794 (18.5)
Body mass index (kg/m2)
<18.5 37,526 (1.6) 497 (2.1) 56 (1.3)
18.5 to <25 772,208 (32.3) 6,868 (28.5) 988 (23.0)
≥25 to <30 716,303 (30.0) 7,480 (31.0) 1,482 (34.5)
≥30 530,065 (22.2) 8,281 (34.4) 1,724 (40.1)
Missing data 331,886 (13.9) 975 (4.1) 45 (1.1)
Smoking status
nonsmoker 962,061 (40.3) 5,578 (23.1) 1,123 (26.2)
Current smoker 516,109 (21.6) 10,677 (44.3) 1,485 (34.6)
Ex-smoker 861,414 (36.1) 7,773 (32.3) 1,685 (39.2)
Missing data 48,404 (2.0) 73 (0.3) <5 (<0.1)
Chronic diseases associated with CKD
Diabetes mellitus 166,917 (7.0) 3,421 (14.2) 718 (16.7)
hypertension 682,868 (28.6) 8,826 (36.6) 2,138 (49.8)
Cardiovascular disease
Myocardial infarction 31,659 (1.3) 390 (1.6) 81 (1.9)
Chronic heart failure 10,997 (0.5) 192 (0.8) 38 (0.9)
Peripheral arterial disease 15,383 (0.6) 232 (1.0) 47 (1.1)
stroke 24,097 (1.0) 419 (1.7) 96 (2.2)
Urological disease
Vesicoureteral reflux 1,676 (0.1) 16 (0.1) 5 (0.1)
renal tract stone 30,665 (1.3) 266 (1.1) 41 (1.0)
Prostatic hypertrophy 40,855 (1.7) 379 (1.6) 105 (2.4)
Other
systemic lupus erythematosus 3,423 (0.1) 47 (0.2) 5 (0.1)
Polycystic kidney disease 1,980 (0.1) 22 (0.1) <5 (<0.1)
Note: *number of patients without recorded ethnicity was 1,141,478 (47.8%), 9,687 (40.2%), and 2,045 (47.6%), respectively.
Abbreviations: CKD, chronic kidney disease; sMi, severe mental illness.
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without SMI is unlikely to be a substantial contributor to our 
results. Third, RRT is a rare outcome: the incidence of RRT 
in the UK is ~100 per million population.39 Combined with 
the cross-sectional design, this meant that, despite the large 
sample size, the number of patients with SMI and RRT was 
limited (n = 46). Although there was a statistically significant 
difference in the prevalence of RRT between patients with 
and without SMI, more detailed comparison (eg, stratification 
Figure 2 Prevalence of CKD in patients with and without sMi by age in men and women.
Abbreviations: CKD, chronic kidney disease; sMi, severe mental illness.
CKD prevalence (%), men
5
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CKD prevalence (%), women
SMI and history of lithium use
SMI and no history of lithium use
No SMI
Table 2 adjusted logistic regression analyses of the association between sMi and chronic kidney disease
Model Adjusted odds ratio (95% CI) for chronic kidney disease
Patients without SMI Patients with SMI and no 
history of lithium use
Patients with SMI and  
history of lithium use
Model 1: adjusted by age and sex 1 (ref) 1.69 (1.56–1.83) 7.13 (6.47–7.85)
Model 2: Model 1 + adjusted by ethnicity, country, and 
socioeconomic status
1 (ref) 1.65 (1.52–1.79) 7.13 (6.48–7.86)
Model 3: Model 2 + adjusted by smoking status 1 (ref) 1.60 (1.48–1.74) 6.91 (6.27–7.61)
Model 4: Model 3 + adjusted by body mass index 1 (ref) 1.53 (1.42–1.66) 6.44 (5.84–7.09)
Model 5: Model 4 + adjusted by diabetes 1 (ref) 1.42 (1.31–1.54) 6.23 (5.64–6.88)
Model 6: Model 5 + adjusted by other chronic diseases* 1 (ref) 1.45 (1.34–1.58) 6.49 (5.84–7.21)
Note: *Hypertension, cardiovascular disease (myocardial infarction, chronic heart failure, peripheral arterial disease, and stroke), urological disease (vesicoureteral reflux, 
renal tract stone, and prostatic hypertrophy), systematic lupus erythematosus, and polycystic kidney disease.
Abbreviations: CI, confidence interval; ref, reference; SMI, severe mental illness.
Table 3 recognition and management of CKD in CKD patients with and without sMi
Indicator of CKD recognition/management Patients with biochemically defined CKD (not on RRT)
With SMI N = 1,388,
n (%)
Without SMI N = 47,225,
n (%)
1) recorded diagnosis of CKD 976 (70.3) 30,922 (65.5)
2) Most recent blood pressure ≤140/90 mmhg 1,112 (80.1) 35,705 (75.6)
3)  Prescription of renin–angiotensin system antagonists (among patients with 
hypertension and proteinuria diagnoses), numerator/denominator (%)
52/66 (78.8) 2,905/3,428 (84.7)
4) Proteinuria/albuminuria testing in the past year 421 (30.3) 15,263 (32.3)
5) Prescription of statins 701 (50.5) 27,853 (59.0)
Abbreviations: CKD, chronic kidney disease; rrT, renal replacement therapy; sMi, severe mental illness.
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by age and sex) or analysis of risk factors for RRT was not 
possible with these numbers. Finally, our adjusted analyses 
suggested that differences in the prevalence of risk factors 
between patients with and without SMI did not completely 
explain the association between SMI and CKD. This finding 
may be due to additional unconsidered risk factors, differ-
ences in patient management, or residual confounding. For 
example, antipsychotics used for SMI have been suggested 
to cause acute kidney injury,40,41 which is a known risk fac-
tor for subsequent CKD.21 Furthermore, insufficient control 
– or later initiation – of treatment for the CKD risk factors 
(eg, high blood pressure, diabetes, and obesity) may lead to 
higher incidence of CKD in the SMI population; however, 
this information could not be adequately captured in this 
cross-sectional study. Using recorded CPRD diagnoses, 
moreover, means that the misclassification or underiden-
tification of disease status (eg, diabetes and heart failure) 
is possible. We did not have any information on the use of 
lithium before the CPRD registration and, therefore, some 
patients may have been wrongly classified as not having used 
lithium. This also meant that we were unable to examine the 
association between the length or cumulative dose of lithium 
prescription and CKD.
Comparison with other studies
Few studies have examined the prevalence of CKD in the pop-
ulation with SMI. A small cross-sectional study in London, 
UK, found a similar relative difference in CKD prevalence 
between those with and without SMI despite a less accurate 
CKD definition than in the present study.13 A Taiwanese 
cohort study showed that people with schizophrenia are more 
likely to develop CKD,25 whereas a cross-sectional analysis 
of Scottish primary care demonstrated that people with 
bipolar disorder had a higher prevalence of CKD than people 
without the condition.18 Several studies have focused on the 
prevalence or incidence of CKD in patients using lithium. 
A Swedish cohort study showed that the prevalence of CKD 
(defined as serum creatinine level >150 μmol/L) and ESRD 
requiring RRT was higher in people ever exposed to lithium 
than in the general population,42 whereas a Danish cohort 
study also showed that lithium prescription was associated 
with an increased rate of CKD diagnosis.26
The relative risk of lithium use for the prevalence of 
CKD in our study (the fully adjusted OR of 6.5) was larger 
than those estimated in previous studies: the adjusted hazard 
ratio by lithium for CKD was nearly 2 in a cohort study in 
Oxford, UK,43 and around 3 in the Danish cohort study.26 
These differences can be explained by the different nature of 
the study population in each study. We compared people with 
lithium prescription for SMI and those without SMI in the 
general population, whereas the UK cohort study compared 
those with and without lithium use among people with at 
least two blood samplings in hospitals in Oxford,43 and the 
Danish study estimated the risk of lithium prescription in the 
population with a single manic episode or bipolar disorder.26 
Therefore, our comparison group is healthier than in the other 
studies, although again, ascertainment bias may play a role 
to some extent in our study.
The management of CKD includes prevention of car-
diovascular events. Several previous studies have focused 
on inequalities in medication use for cardiovascular risk 
between patients with and without SMI. Studies from the 
UK showed that statin prescribing is lower in patients with 
schizophrenia and bipolar disorder than in the general popula-
tion, although their cardiovascular risks are higher.16,18 A US 
study suggests that prescribing of renin–angiotensin system 
antagonists and statins is suboptimal in patients with SMI 
and type 2 diabetes.17 Our finding of lower prescribing of 
statins among patients with SMI and CKD, compared to the 
general population, are consistent with these earlier studies.
Explanation of findings and clinical 
relevance
CKD is strongly and independently associated with mortality 
and cardiovascular risk.20 Therefore, the higher prevalence 
of CKD we have established may contribute to the known 
shorter life expectancy in people with SMI. Moreover, we 
have shown that the difference in CKD prevalence between 
patients with and without SMI increased with age. It is pos-
sible that progressive accumulation and biological effect of 
CKD risk factors in patients with SMI (eg, obesity, smoking, 
and diabetes) leads to an increased incidence of CKD at an 
older age.
We have confirmed a higher burden of CKD risk factors 
among patients with SMI, and adjustment for these partially 
explained the association between SMI and CKD. However, 
many questions about the cause of the higher prevalence of 
CKD remain unanswered. Our snapshot of GP’s management 
of patients with SMI suggests that CKD is more commonly 
coded as a diagnosis than in the general population. The 
extent to which this is driven by incentivized management 
schemes and regular testing of renal function for patients with 
SMI – particularly those prescribed lithium and other psy-
chotropic medications – is unknown. Whereas blood  pressure 
appeared better controlled among SMI patients, this may 
reflect different underlying renal pathologies associated with 
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lower rates of hypertension (eg, interstitial nephritis related 
to lithium). Other aspects of management – proteinuria test-
ing as well as prescription of statins and renin–angiotensin 
system antagonists – were lower among patients with SMI.
Of greatest concern is our finding of the substantial 
increase in the prevalence of RRT among patients with SMI. 
The development of ESRD results in markedly reduced qual-
ity of life and psychological stress. Renal transplantation is 
associated with better quality of life and, possibly, longer 
survival.44 However, our results showed that the proportion 
of patients receiving kidney transplantation was substantially 
lower in patients with SMI than those without. It is important 
to understand why this difference arises and ensure that there 
are no inappropriate barriers to the consideration for renal 
transplantation for people with SMI.
Conclusion
We found that the prevalence of CKD and RRT was sub-
stantially higher in patients with SMI as compared to the 
general population. There was a greater burden of risk 
factors among patients with SMI, but these did not fully 
explain the increased prevalence of CKD. Further informa-
tion about the management of CKD in SMI patients such as 
referral to specialist care and management of comorbidities 
is needed to identify opportunities for prevention of CKD 
and its progression.
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6.3. Additional data and discussions  
Further to the results and discussions presented in the published paper, here I show the 
additional data on the prevalence of decreased kidney function (i.e. most recent single eGFR 
<60 mL/min/1.73m2 prior to 31 March 2014), instead of CKD (i.e. two or more consecutive 
measurements of eGFR<60 mL/min/1.73m2 for ≥3 months in the past five years), and that of 
severely decreased kidney function (i.e. most recent eGFR <30 mL/min/1.73m2). I also show 
the serum creatinine testing rate by SMI status and known CKD risk factors to discuss potential 
ascertainment/surveillance bias in more detail. 
6.3.1. Prevalence of decreased kidney function and severely decreased kidney function 
by SMI status and history of lithium use 
(i) Backgrounds and methods 
The published paper estimated the prevalence of CKD, defined as two or more consecutive 
measurements of eGFR <60 mL/min/1.73m2 for ≥3 months during the five years between 1 
April 2009 and 31 March 2014, by SMI status and history of lithium use. However, according 
to Paper 1 (Prevalence of CKD and RRT in CPRD), there may be some discrepancy between 
patients satisfying the definition of decreased kidney function and those satisfying the 
internationally-accepted CKD criteria in the past five years. Therefore, as a sensitivity analysis, 
I here show the prevalence of decreased kidney function by SMI status and history of lithium 
use, to confirm that my conclusion regarding the association between SMI and kidney diseases 
does not change by different definitions of kidney function. Moreover, I examine whether the 
prevalence of severely decreased kidney function, defined as the most recent single eGFR <30 
mL/min/1.73m2, is also higher in patients with SMI. 
(ii) Results and discussions 
The prevalence of decreased kidney function was broadly similar to that of CKD in each 
subgroup (see Table 7 below). People with severely decreased kidney function accounted for 
a very small minority among people with decreased kidney function. However, the association 
between SMI and severely decreased kidney function was similarly observed. These additional 
findings support the robustness of the main finding in the association between SMI and kidney 
function. 
76
77 
 
Table 7. Prevalence of CKD, decreased kidney function, and severely decreased kidney function by SMI status and lithium use 
Abbreviations: CKD = chronic kidney disease; SMI = severe mental illness. 
a CKD is defined as two measurements of eGFR for ≥3 months during the five years between 1 April 2009 and 31 March 2014. 
b Decreased kidney function is defined as the most recent eGFR <60 mL/min/1.73m2 in the past five years prior to 31 March 2014. 
c Severely decreased kidney function is defined as the most recent eGFR <30 mL/min/1.73m2 in the past five years prior to 31 March 2014. 
 
Outcome 
Gender Men Women 
Overall 
Age category 25–34 35–44 45–54 55–64 65–74 25–34 35–44 45–54 55–64 65–74 
Prevalence of 
CKDa, %  
(main analysis) 
No SMI 0.1 0.2 0.5 1.9 8.8 0.1 0.2 0.6 2.3 9.6 2.1 
SMI and no lithium use 0.1 0.2 1.1 3.1 11.4 0.1 0.6 1.6 5.3 14.4 3.3 
SMI and lithium use 0 2.0 4.9 15.1 31.7 0 1.0 6.8 20.8 34.7 14.6 
Prevalence of 
decreased kidney 
functionb, % 
No SMI 0.1 0.2 0.7 2.6 10.1 0.1 0.3 0.9 3.1 11.0 2.5 
SMI and no lithium use 0.2 0.4 1.3 3.1 11.3 0.2 0.6 2.2 6.0 14.8 3.6 
SMI and lithium use 0 1.4 4.9 15.3 29.8 0 1.3 7.2 17.0 33.5 13.8 
Prevalence of 
severely decreased 
kidney functionc, % 
No SMI 0.1 0.1 0.2 0.3 0.7 0.1 0.1 0.2 0.3 0.5 0.2 
SMI and no lithium use 0.1 0.2 0.3 0.4 1.3 0 0.3 0.2 0.7 0.9 0.4 
SMI and lithium use 0 0.3 0.4 1.6 4.3 0 0 0.6 1.6 3.5 1.5 
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6.3.2. Serum creatinine testing rate by SMI status and known CKD risk factors to 
explore potential ascertainment/surveillance bias 
(i) Backgrounds and methods 
Generally, ascertainment or surveillance bias could happen when there is more intense 
surveillance for the outcome among exposed than among unexposed, or vice versa [124]. In 
the context of this study, if patients with SMI were more likely to have serum creatinine testing 
than those without SMI (or if patients without SMI in the general population were less likely 
to have serum creatinine testing than those with SMI), this may explain part of the higher 
prevalence of CKD in patients with SMI. To estimate the size of ascertainment/surveillance 
bias accurately, all people without serum creatinine testing in the CPRD need to be tested, but 
this is unrealistic. Meanwhile, Paper 1 (Prevalence of CKD and RRT in CPRD) suggested that 
most cases with decreased kidney function or CKD are probably captured in the current CPRD 
[119], as GPs are selectively testing patients at risk of CKD, and those without serum creatinine 
testing are unlikely to have CKD. This implies that under-ascertainment of CKD is limited in 
the current CPRD, and therefore ascertainment/surveillance bias is expected to be small. 
To better explain this in the context of the study, here I show the serum creatinine testing rate 
(i.e. the proportion of people with at least one serum creatinine measurement in the past five 
years prior to 31 March 2014), according to the presence or absence of known CKD risk factors 
(diabetes, hypertension, cardiovascular disease, renal tract disease, systemic lupus 
erythematosus, and polycystic kidney disease), by SMI status and lithium use. Then, I calculate 
the prevalence of CKD among people with and without serum creatinine testing in each 
subgroup, to discuss whether the influence of ascertainment/surveillance bias is small or large 
in the current study. 
(ii) Results and discussions 
The serum creatinine testing rate was substantially different among people with no known CKD 
risk factors: 45.7% in the no SMI group, 73.8% in the SMI and no lithium group, and 95.2% 
in the SMI and lithium group (see Table 8 below). This suggests that people with SMI indeed 
had more testing opportunities than people without SMI. However, there was less difference in 
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the testing rate among people with ≥1 known CKD risk factors, at 87.7%, 92.8%, and 99.0% 
respectively.  
Then, looking at the prevalence of CKD among people tested, most cases with CKD came from 
the subgroups with ≥1 known CKD risk factors. Among people with no known CKD risk 
factors, even if they were tested, the prevalence of CKD was very low in people without SMI 
(0.66%) and people with SMI and no lithium use (1.19%). The lithium users showed high 
prevalence of CKD, even without other known CKD risk factors (7.82%). These results suggest 
that GPs are selectively testing people at risk of CKD (i.e. people with ≥1 known CKD risk 
factors or lithium users), and that CKD is unlikely to be identified among people with no known 
CKD risk factors. Therefore, the large difference in the serum creatinine testing rate (between 
people with and without SMI) among those with no known CKD risk factor is unlikely to be 
causing substantial ascertainment/surveillance bias. 
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Table 8. Serum creatinine testing rate (in the past five years prior to 31 March 2014) and prevalence of CKD among people with serum 
creatinine testing by SMI status (with and without a history of lithium use) and known CKD risk factors 
 
 
 
People without SMI 
(N = 2,387,988) 
Patients with SMI and no lithium use 
(N = 24,101) 
Patients with SMI and lithium use 
(N = 4,295) 
No known CKD 
risk factorsa 
(N = 1,615,097) 
≥1 known CKD 
risk factorsa 
(N = 772,891) 
No known CKD 
risk factorsa 
(N = 13,649) 
≥1 known CKD 
risk factorsa 
(N = 10,452) 
No known CKD 
risk factorsa 
(N = 1,881) 
≥1 known CKD 
risk factorsa 
(N = 2,414) 
Serum creatinine testing rate, % 45.7 87.7 73.8 92.8 95.2 99.0 
Prevalence of CKD among 
people with creatinine testing,  
% (numerator/denominator) 
0.66 
(4,891/738,614) 
6.61 
(44,761/677,679) 
1.19 
(120/10,072) 
7.06 
(685/9,700) 
7.82 
(140/1,790) 
20.46 
(489/2,390) 
Abbreviations: CKD = chronic kidney disease; SMI = severe mental illness. 
a Known CKD risk factors include diabetes mellitus, hypertension, cardiovascular diseases (myocardial infarction, chronic heart failure, peripheral arterial 
disease, and stroke), renal tract diseases (vesicoureteral reflux, renal tract stone, prostatic hypertrophy), systemic lupus erythematosus, and polycystic kidney 
disease.  
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6.4. Chapter summary 
SMI and CKD 
- The association between SMI, including schizophrenia and bipolar disorder, and CKD was 
examined in a cross-sectional study on 31 March 2014 among people aged 25–75 years in 
the CPRD. 
- The prevalence of CKD (i.e. two or more consecutive measurements of eGFR <60 
mL/min/1.73m2 for ≥3 months in the past five years) was 14.6% among patients with SMI 
and history of lithium prescription, 3.3% among patients with SMI and no history of lithium 
prescription, and 2.1% among people without SMI.  
- The prevalence of RRT, as well as that of severely decreased kidney function (i.e. eGFR 
<30 mL/min/1.73m2), was also highest among patients with SMI and history of lithium 
prescription, followed by patients with SMI and no history of lithium prescription, and 
people without SMI. 
- Adjustment for known CKD risk factors, including obesity, smoking, and diabetes, 
attenuated the odds ratios between SMI and CKD in the logistic regression analysis, 
suggesting that these factors are confounding or mediating the association between SMI 
and CKD. 
- Among patients with biochemically-defined CKD, although blood pressure control and 
proteinuria testing rate were not very different between those with and without SMI, the 
proportion of patients receiving potentially beneficial drugs for CKD (ACEI/ARBs for 
patients with proteinuria, and statins) was lower in those with SMI than those without. 
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Chapter 7: Establishing a matched cohort of patients with and 
without CKD (stages 3 to 5) 
This chapter presents the rationale and method for establishing a matched cohort of patients 
with and without CKD (stages 3 to 5) in the CPRD linked to HES, which will be used in the 
following studies in Papers 3 (CKD and antidepressant prescription) and 4 (GI bleeding risk of 
SSRIs by kidney function). I also demonstrate cohort details and discuss the limitations of the 
cohort. 
7.1. Rationale for establishing a matched cohort of patients with and 
without CKD 
The study hypothesis in Paper 3 (CKD and antidepressant prescription) is that patients with 
CKD are more likely to receive antidepressants for mental health problems (e.g. depression, 
anxiety, pain) than those without CKD. A cohort study comparing the incidence of 
antidepressant prescription between patients with and without CKD would better suggest the 
temporal relationship, compared with a cross-sectional study. A cross-sectional analysis only 
cannot deny the possibility that mental health conditions such as depression and anxiety 
resulted in CKD. 
To better understand the characteristics of patients with CKD, a comparison group of patients 
without CKD is required. Therefore, after identifying patients with CKD, I decided to make a 
comparison group of patients without known CKD, matched for age, sex, general practice, and 
calendar time. Matching on age and sex is important to fairly and efficiently compare patients 
with and without CKD, because the CKD prevalence is largely influenced by age and sex [119]. 
Matching on general practice and calendar time is also effective to remove the confounding 
effect of these factors between patients with and without CKD. This is because identification, 
recording, and management of CKD and comorbidities appear to depend on general practice 
[103] and calendar time [117] in UK primary care. Therefore, patients with and without CKD 
in different general practices, or with different cohort entry timing, may not have good 
comparability. Moreover, adjusting for these factors in a statistical analysis may be difficult, 
due to too many fixed parameters (i.e. nearly 400 general practices in the HES-linked CPRD).  
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7.2. A preliminary analysis to decide whether I should include patients 
based on one or two measurements of decreased kidney function 
(i) Backgrounds 
In the cross-sectional dataset established in chapter 4, patients satisfying the definition of 
decreased kidney function (i.e. the most recent eGFR<60 ml/min/1.73 m2 prior to 31 March 
2014) and those satisfying the definition of CKD (i.e. two or more consecutive measurements 
of eGFR <60 ml/min/1.73 m2 for ≥3 months in the past five year) were slightly different 
populations. Patients with a single measurement of eGFR <60 ml/min/1.73 m2 probably include 
patients with temporarily decreased kidney function (i.e. AKI) or increased serum creatinine 
level due to exercise or protein intake. Meanwhile, the chronicity criterion requiring ≥2 
measurements of kidney function may inadvertently exclude patients with “true CKD” who 
received only one serum creatinine measurement during a study period.  
In a cohort study, I also need to decide whether I should include patients into the cohort 
suggesting kidney disease (i.e. “decreased kidney function cohort” or “CKD cohort”), based 
on one or two measurements of eGFR <60 ml/min/1.73 m2. To examine the benefits and 
limitations of each strategy, I conducted a preliminary analysis looking at the association 
between the first record of eGFR <60 ml/min/1.73 m2 and the next measurement of kidney 
function in a cohort using the CPRD. 
(ii) Methods 
Using the July 2014 version of CPRD, I identified adult patients (not on RRT) with the first 
record of eGFR <60 ml/min/1.73 m2 during the period between April 2004 and March 2014 
(with or without existing records of eGFR <60 ml/min/1.73 m2 before April 2004). Among 
these patients, I looked at the timing of the next serum creatinine measurement in primary care, 
and whether the next eGFR was consistently less than 60 ml/min/1.73 m2. 
(iii) Results  
Among nearly seven million adults registered in the CPRD during the period between April 
2004 and March 2014, I identified 635,523 adult patients (mean age 73.9±11.2 years old, 
39.4% male) with the first record of eGFR <60 ml/min/1.73 m2. Of these patients, 74,481 
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(11.7%) patients did not receive a subsequent measurement of serum creatinine until March 
2014 in the CPRD, whereas 561,042 (88.3%) received the next serum creatinine measurement 
at median 184 days (IQR 58–370 days) later (see Figure 4 below). Among these 561,042 
patients with the first record eGFR <60 ml/min/1.73 m2, 361,595 (64.5%) patients consistently 
showed eGFR less than 60 ml/min/1.73 m2, whereas 199,447 (35.6%) patients showed eGFR 
over 60 ml/min/1.73 m2 in their next creatinine measurement. 
 
Figure 4. Distribution of the duration between the date of first record of eGFR <60 
ml/min/1.73 m2 and date of next serum creatinine measurement 
 
Abbreviation: eGFR = estimated glomerular filtration rate. 
 
(iv) Discussions  
According to this preliminary analysis, it seems inappropriate to include patients into 
“decreased kidney function cohort” based on a single eGFR <60 ml/min/1.73 m2, because 
around one third of patients with the first record of eGFR <60 ml/min/1.73 m2 no longer 
showed decreased kidney function in the next measurement. In these patients, the first observed 
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eGFR <60 ml/min/1.73 m2 was probably due to AKI or temporarily increased serum creatinine 
level due to exercise or protein diet. This (i.e. the fact that many patients included into the 
“decreased kidney function cohort” subsequently show no decreased kidney function) would 
matter when creating a matched cohort of patients with and without decreased kidney function. 
As shown later in section 7.3, a matched cohort needs a prerequisite that patients selected as a 
case (i.e. those with decreased kidney function) continue to be a case, whereas patients selected 
as a control (i.e. those without decreased kidney function) may become a case later (but this is 
only one time). 
The vast majority of patients with the first record of eGFR <60 ml/min/1.73 m2 received the 
second measurement of kidney function during their observation in the CPRD. Around 10% of 
patients with the first record of eGFR <60 ml/min/1.73 m2 did not receive the next serum 
creatinine measurement. They are probably a mixture of unhealthy patients (who were 
hospitalised, sent to a nephrologist, or died) and healthy patients (who no longer came to GPs 
or received blood testing). Around half of patients with the first record of eGFR <60 
ml/min/1.73 m2 were re-measured within six months, and around three quarters were re-
measured in one year. Therefore, even by using the chronicity criterion of CKD, the risk that 
patients with “true CKD” are not included into the CKD cohort for a long time (until the second 
serum creatinine measurement is done in primary care) is seemingly small. 
In conclusion, I decided to include patients into the “CKD cohort” based on the internationally-
accepted criteria of CKD (i.e. two or more consecutive measurements of eGFR <60 
ml/min/1.73 m2 for ≥3 months). This strategy appears to be better than the other strategy to 
include patients into the “decreased kidney function cohort” based on single measurement of 
eGFR <60 ml/min/1.73 m2, in which around one third of patients returned to eGFR >60 
ml/min/1.73 m2 in the next measurement. 
However, as suggested in the cross-sectional dataset in chapter 4 and previous studies using 
routinely collected data [120-122], even if satisfying the chronicity criterion of CKD, some 
patients still may not show consistently decreased kidney function thereafter. One possible 
solution may be to extend the chronicity criterion of three months to longer (e.g. six, nine, and 
one year), as suggested in a Norwegian study [122]. However, the Norwegian study also 
reported that, by using the longer chronicity criterion, unhealthier patients with higher mortality 
tended to be excluded, causing selection bias. Therefore, I here decide not to modify the 
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chronicity criterion of three months, and simply follow the internationally-accepted criteria of 
CKD. 
 
7.3. Method for establishing a matched cohort of patients with and without 
CKD 
7.3.1. Study population 
All individuals aged 18 and older in the HES-linked CPRD from 1 April 2004 to 31 March 
2014 were potentially eligible for inclusion. The choice of start date was related to the launch 
of QOF on 1 April 2004, which improved the identification, recording, and management of 
CKD and comorbidities in UK primary care [73, 117]. Patients were eligible for inclusion at 
the latest of: one year after practice registration (for GPs to record previous medical history 
[118]); the ‘up-to-standard’ date that the general practice achieved the CPRD quality standards 
[73]; or 1 April 2004. Patients with a recorded diagnosis of RRT (haemodialysis, peritoneal 
dialysis, and kidney transplantation) at the time of study eligibility were excluded, as most 
patients with RRT are not primarily managed by GPs. Patients were no longer eligible for 
follow-up at the earliest of: death, initiation of RRT (defined as the first date of recorded 
diagnosis suggesting RRT), change of practice, final data collection from the practice, or 31 
March 2014.  
7.3.2. Identification of patients with CKD 
Among the eligible patients, I first identified patients with CKD, which was defined as two or 
more consecutive measurements of eGFR <60 ml/min/1.73m2 for ≥3 months. As explained in 
chapter 3, eGFR was calculated from serum creatinine records in the CPRD, after 
multiplication of 0.95 to allow for a lack of creatinine calibration [106], using the CKD-EPI 
creatinine equation [101]. Patients, including those who had CKD prior to April 2004, were 
included in the cohort on the date when they satisfied the CKD definition (i.e. second eGFR 
<60 ml/min/1.73m2) following their eligibility (see Figure 5 below). Once a patient was 
identified as having CKD, they were considered to have CKD for the rest of the follow-up. 
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Figure 5. Graphical representation of the identification of patients with CKD 
 
Abbreviations: CKD = chronic kidney disease; CPRD = Clinical Practice Research Datalink; eGFR = 
estimated glomerular filtration rate.  
Note: Unit of eGFR (mL/min/1.73m2) was omitted because of limited space. Patient A was registered 
to the CPRD after 1 April 2004 and included into the CKD cohort at the time of second eGFR <60 
ml/min/1.73m2. Patient B was registered to the CPRD before 1st April 2004 and included into the 
CKD cohort when the second eGFR <60 ml/min/1.73m2 was observed after 1 April 2004. 
 
7.3.3. Identification of a comparison group of patients without known CKD 
Next, as a comparison group, I selected patients without known CKD (with or without serum 
creatinine measurement) randomly from the rest of the HES-linked CPRD population at a 1:1 
ratio, matched for age, sex, general practice, and calendar time (i.e. same date of cohort entry) 
(see Figure 6 below). The matching was done, using the STATA commands of Dr Krishnan 
Bhaskaran of the Electronic Health Records Research group at the London School of Hygiene 
and Tropical Medicine, which had been created for a previous matched cohort study [125]. 
Individuals selected to a comparison group (i.e. patients without known CKD) could be found 
to have CKD later; in this situation they were censored at the time of satisfying CKD definition, 
because they were already included in the CKD group from that point forward (with their own 
matched control).  
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Figure 6. Graphical representation of matching patients with and without CKD for age, 
sex, general practice, and calendar time 
 
Abbreviations: CKD = chronic kidney disease; RRT = renal replacement therapy.  
Note: Patients C and D were matched, whereas Patients E and F were matched. Because Patient F 
subsequently satisfied the CKD criteria, he/she was censored from the comparison cohort at that time 
and included in the CKD cohort from that point forward (with their own matched control). 
 
7.4. Results (details of the cohort) 
Figure 7 shows the flow chart for the selection of matched patients with and without CKD. 
There were 4,073,639 eligible people in the HES-linked CPRD between 1 April 2004 and 31 
March 2013. Among them, 2,833 patients already receiving RRT were excluded. Among the 
remaining 4,070,806 eligible people not receiving RRT (median age 39 [IQR 27–56] at the 
time of satisfying the eligibility; male, 48.8%), there were 264,628 (6.5%) patients with CKD 
(median age 77 [IQR 71–83] at the time of cohort entry; male, 38.7%). Of those with CKD, 
242,349 (91.6%) (median age 76 [IQR 70–82]; male, 39.3%) were matched with patients 
without CKD. Unmatched 22,279 (8.4%) patients with CKD were older and more likely to be 
female (mean age 88 [IQR 84–92]; male, 31.5%).  
88
89 
 
 
Figure 7. Flow chart for the selection of matched patients with and without CKD 
 
Abbreviations: CKD = chronic kidney disease; CPRD = Clinical Practice Research Datalink; HES = 
hospital episode statistics; RRT = renal replacement therapy.  
 
The age-sex distribution was largely different between eligible people not receiving RRT in 
the HES-linked CPRD (see Figure 8 below) and patients with CKD (see Figure 9 below). 
After matching, the age-sex distribution of patients with and without CKD became comparable 
(see Figure 10 below).  
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Figure 8. Age-sex distribution of eligible patients without RRT in the HES-linked CPRD 
 
Figure 9. Age-sex distribution of unmatched patients with CKD 
 
Figure 10. Age-sex distribution of matched patients with and without CKD 
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Table 9 shows the baseline characteristics of matched patients with and without CKD. The 
majority of matched patients with and without CKD were included into the cohort in the early 
years of the 10-year study period, probably because patients with prevalent CKD (i.e. those 
who had CKD prior to April 2004) were confirmed soon after the start of the study period.  
 
Table 9. Baseline characteristics of matched patients with and without CKD 
Abbreviation: CKD = chronic kidney disease. 
 
The total follow-up lengths were 960,686 person-years (median 3.4 years [IQR 1.4–6.2 years]) 
and 108,654 person-years (median 4.2 years [IQR 1.8–6.9 years]) in matched patients with and 
without CKD, respectively. Table 10 shows the reasons for stopping the follow-up of matched 
patients with and without CKD. The mortality was nearly double in patients with CKD than 
 Patients without known CKD 
(N = 242,349) 
Patients with CKD 
(N = 242,349) 
P value  
(by χ2 test) 
Age (years):   - 
 <55 6,845 (2.8) 6,845 (2.8)  
 55-64 23,556 (9.7) 23,556 (9.7)  
 65-74 71,112 (29.3) 71,112 (29.3)  
 75-84 102,594 (42.3) 102,594 (42.3)  
 ≥85 38,242 (15.8) 38,242 (15.8)  
Sex:   - 
 Men 95,318 (39.3) 95,318 (39.3)  
 Women 147,031 (60.7) 147,031 (60.7)  
Financial year of 
cohort entry: 
  - 
 2004 80,947 (33.4) 80,947 (33.4)  
 2005 35,413 (14.6) 35,413 (14.6)  
 2006 27,577 (11.4) 27,577 (11.4)  
 2007 23,136 (9.6) 23,136 (9.6)  
 2008 18,560 (7.7) 18,560 (7.7)  
 2009 15,142 (6.3) 15,142 (6.3)  
 2010 11,706 (4.8) 11,706 (4.8)  
 2011 10,552 (4.4) 10,552 (4.4)  
 2012 10,063 (4.2) 10,063 (4.2)  
 2013 9,253 (3.8) 9,253 (3.8)  
Ethnicity:   <0.001 
 White 97,749 (40.3) 102,019 (42.1)  
 South Asian  1,796 (0.7) 2,317 (1.0)  
 Black 1,156 (0.5) 1,060 (0.4)  
 Other ethnicity 864 (0.4) 834 (0.3)  
 Not recorded 140,784 (58.1) 136,119 (56.2)  
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those without known CKD during follow-up (30.2% vs. 16.9%). There were 1,672 patients 
starting RRT among those with CKD, and a further 23 patients commenced RRT without 
fulfilling a prior definition of CKD. The proportion of patients finishing follow-up for other 
reasons (i.e. change of practice, last data collection from the practice, and end of the study 
period) was similar between matched patients with and without CKD. Finally, 17% of patients 
without known CKD were identified as having CKD during follow-up.  
 
Table 10. Reasons for stopping the follow-up of matched patients with and without CKD 
Abbreviations: CKD = chronic kidney disease; RRT = renal replacement therapy.  
 
7.5. Discussion 
In this chapter, I established a matched cohort of patients with and without CKD for the 
subsequent studies on antidepressant prescription and associated adverse outcomes. An ideal 
cohort study comparing patients with and without CKD may be achieved by measuring the 
serum creatinine of all eligible patients at a particular time point (e.g., 1 July 2007) or during a 
short recruitment period (e.g. from 1 January to 31 December, 2007), classifying them into 
patients with and without CKD, and following up on them in the same manner. However, in 
routinely collected data, the timing of serum creatinine measurement varies widely, and 
therefore, patients with CKD can be identified at any time point during a long study period. 
Therefore, recruiting patients over a short period does not seem to be a good idea. In this 
matched cohort, patients with CKD could enter the cohort at any time during the 10-year study 
period between 1 April 2004 and 31 March 2014. 
 Patients without known 
CKD (N = 242,349) 
n (%) 
Patients with CKD 
(N = 242,349) 
n (%) 
Death 40,952 (16.9) 73,121 (30.2) 
Initiation of RRT 23 (<0.1) 1,672 (0.7) 
Change of practice 43,035 (17.8) 35,100 (14.5) 
Last data collection from the practice  35,694 (14.7) 41,356 (17.1) 
End of the study period (31 March 2014) 81,494 (33.6) 91,100 (37.6) 
Identification of CKD 41,151 (17.0) 0 (0) 
Total  242,349 (100) 242,349 (100) 
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A strength of this cohort is that it includes an appropriate comparison group, i.e. patients 
without known CKD, sampled from the general population, of the same age, sex, general 
practice, and the same cohort entry timing as patients with CKD. As shown in Figures 8 and 
9, the age-sex distribution was largely different between the general population (median age 
39, male 48.8%) and patients with CKD (median age 77, male 38.7%). Therefore, matching 
according to age and sex is important for making the two groups (i.e. patients with and without 
CKD) more comparable.  
I kept patients who had never had a kidney function tested in the denominator when creating 
the comparison group. This strategy is supported by the validation study in Paper 1 (Prevalence 
of CKD and RRT in CPRD) [119], which suggests that most patients with CKD are captured 
in the CPRD at some point prior to 31 March 2014, and people without creatinine tests are 
unlikely to have CKD. If I excluded healthy people without serum creatinine testing from the 
denominator, the comparison group would not represent the general population with the same 
age and sex as patients with CKD.  
However, a limitation of this cohort is that the comparison group may include some patients 
with unmeasured CKD. Moreover, there may be a time lag between the actual incidence of 
CKD and its identification in the CPRD. This misclassification of CKD status will dilute the 
true association between CKD and observed outcomes in following studies.  
Another limitation may arise from the fact that patients with CKD were quite an old population 
(median age 77 [IQR 71–83]; male, 38.7%). As kidney function declines with age, matching 
according to age may have resulted in limited differences in renal function between patients 
with and without CKD among older people. Misclassification of CKD status is also possible 
among older patients with the boundary level of eGFR (i.e. 60 mL/min/1.73m2) even if the 
chronicity criterion of CKD was used.  
Despite these limitations, I consider the established cohort to be useful for comparing the 
outcomes in subsequent studies (i.e. antidepressant prescription and associated serious adverse 
outcomes) between patients with and without CKD, and for examining the contribution of CKD 
to study outcomes. 
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7.6. Use of the established cohort for research on CKD 
I conducted a study outside the scope of my PhD thesis by using the established cohort, and 
published a paper entitled ‘Chronic kidney disease and cause-specific hospitalisation: a 
matched cohort study using Clinical Practice Research Datalink’ in British Journal of General 
Practice [113]. Briefly, I compared the matched patients with and without CKD in terms of the 
incidence of hospitalisations for ten common conditions as the primary admission diagnosis: 
myocardial infarction; heart failure; cerebral infarction; pneumonia; urinary tract infection; 
gastrointestinal bleeding; intracranial bleeding; venous thromboembolism; hip fracture; and 
AKI. The main finding was that, among the range of cause-specific hospitalisations, those for 
heart failure, infection, and AKI showed strong associations with CKD in absolute and/or 
relative terms. My conclusion is that, aside from prevention of ESRD, there are high-priority 
outcomes that warrant detection of CKD in primary care and improvement of preventive care 
for patients with CKD in the community. More details are given in the accepted paper included 
in Appendix A.  
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7.7. Chapter summary 
Establishment of a matched cohort with and without CKD 
- A matched cohort of patients with and without CKD was established in the HES-linked 
CPRD for the following studies in Papers 3 (CKD and antidepressant prescription) and 4 
(GI bleeding risk of SSRIs by kidney function). 
- Patients with CKD (stages 3 to 5) were identified based on two or more consecutive 
measurements of eGFR <60 ml/min/1.73m2 for ≥3 months. 
- To establish a balanced comparison group in terms of important patient characteristics, I 
randomly selected a patient without known CKD of the same age, sex, general practice, 
and calendar time (i.e. same date of cohort entry) as a patient with CKD. 
- Among approximately four million adults not requiring RRT in the HES-linked CPRD 
between 31 March 2004 and 1 April 2014, I identified 264,628 patients with CKD, of which 
242,349 were matched with 242,349 patients without known CKD. 
- A potential limitation of this cohort is a possible misclassification of CKD status, which 
may dilute the true association between CKD and observed outcomes in further studies.  
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Chapter 8: Prevalence, incidence, indication, and choice of 
antidepressants in patients with and without chronic kidney 
disease: a matched cohort study in the UK Clinical Practice 
Research Datalink (Paper 3) 
8.1. Introduction 
This chapter presents a matched cohort study comparing the prevalence, incidence, indication, 
and choice of antidepressants between patients with and without CKD, published in 
Pharmacoepidemiology and Drug Safety [126].  
The main research question is: Are patients with CKD more likely to be prescribed 
antidepressants than those without CKD in the general population? 
Briefly, using the matched cohort of 242,349 pairs with and without CKD established in 
chapter 7, I compared the frequency (prevalence and incidence) and patterns (indication and 
choice) of antidepressant prescription between patients with and without CKD. The prevalence 
of antidepressant prescription was defined as the proportion of patients receiving 
antidepressants in the past six months prior to cohort entry (i.e. the date of satisfying CKD 
definition for CKD patients, and the same date for matched controls without CKD), whereas 
the incidence of antidepressant was defined as the initiation of antidepressants among non-
prevalent users.  
Later in this chapter, I am showing additional data on the characteristics of 22,279 unmatched 
patients with CKD when establishing the matched cohort, as well as temporal trend in the 
prevalence of antidepressant prescribing by CKD status. 
 
8.2. Published paper 
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Prevalence, incidence, indication, and choice of antidepressants in
patients with and without chronic kidney disease: a matched cohort
study in UK Clinical Practice Research Datalink
Masao Iwagami* , Laurie A. Tomlinson, Kathryn E. Mansﬁeld , Helen I. McDonald, Liam Smeeth
and Dorothea Nitsch
Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
ABSTRACT
Purpose People with chronic kidney disease (CKD) have an increased prevalence of depression, anxiety, and neuropathic pain. We
examined prevalence, incidence, indication for, and choice of antidepressants among patients with and without CKD.
Methods Using the UK Clinical Practice Research Datalink, we identiﬁed patients with CKD (two measurements of estimated glomerular
ﬁltration rate < 60 mL/min/1.73m2 for ≥3 months) between April 2004 and March 2014. We compared those with CKD to a general
population cohort without CKD (matched on age, sex, general practice, and calendar time [index date]). We identiﬁed any antidepressant
prescribing in the six months prior to index date (prevalence), the ﬁrst prescription after index date among non-prevalent users (incidence),
and recorded diagnoses (indication). We compared antidepressant choice between patients with and without CKD among patients with a
diagnosis of depression.
Results There were 242 349 matched patients (median age 76 [interquartile range 70–82], male 39.3%) with and without CKD. Prevalence
of antidepressant prescribing was 16.3 and 11.9%, and incidence was 57.2 and 42.4/1000 person-years, in patients with and without CKD,
respectively. After adjusting for confounders, CKD remained associated with higher prevalence and incidence of antidepressant prescription.
Regardless of CKD status, selective serotonin reuptake inhibitors were predominantly prescribed for depression or anxiety, while tricyclic
antidepressants were prescribed for neuropathic pain or other reasons. Antidepressant choice was similar in depressed patients with and
without CKD.
Conclusions The rate of antidepressant prescribing was nearly one and a half times higher among people with CKD than in the general
population. © 2017 The Authors. Pharmacoepidemiology & Drug Safety Published by John Wiley & Sons Ltd
key words—antidepressants; chronic kidney disease; prevalence; incidence; depression
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INTRODUCTION
Antidepressants are among the most commonly
prescribed classes of medication in industrialized
countries, including the USA1 and UK.2 The recent
increase in the prescription of antidepressants is
dramatic, with an average 10% increase per year from
1998 to 2010.3 Antidepressants can be prescribed not
only for depressive symptoms but also for other
conditions such as anxiety and neuropathic pain.4
In addition, off-label use of antidepressants is
common for chronic pain, including non-neuropathic
pain, and conditions where non-speciﬁc sedation is
required.5–7
Chronic kidney disease (CKD), an impairment of
kidney structure or function, is now recognized as a
major public health problem.8 Chronic kidney disease
is associated with a range of comorbidities including
obesity, hypertension, diabetes, and cardiovascular
disease.9,10 Level of kidney function, expressed as
estimated glomerular ﬁltration rate (eGFR), is closely
associated with increased risk of death, cardiovascular
events, and hospitalization.11
Chronic kidney disease is also associated with a
range of mental health problems including anxiety12
and depression;13 almost one quarter of adults with
pre-dialysis CKD are depressed. These conditions
*Correspondence to: M. Iwagami, Department of Non-Communicable Disease
Epidemiology, London School of Hygiene and Tropical Medicine, Keppel
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may be due to co-existing chronic diseases such as
diabetes and heart failure, which are also associated
with depression and anxiety symptoms,14,15 or directly
related to CKD. In addition, other indications for
antidepressants such as chronic pain and insomnia
are more common among patients with CKD.16,17
Patients with CKD are frequently excluded from
clinical trials,18,19 and concerns have been recently
raised about the lack of knowledge regarding how
kidney function is related to adverse effects of
antidepressants.20,21 Despite this, there has been no
systematic research investigating frequency and
patterns of antidepressant prescribing among patients
with CKD. Understanding how antidepressants are
actually prescribed in patients with CKD, compared
to those without CKD, is important groundwork for
the planning of future studies on the safety of
antidepressants in this population. Therefore, we
aimed to compare the frequency (prevalence and
incidence), indications for, and choice of
antidepressant prescription between patients with and
without CKD, in the UK general population.
METHODS
Data sources
The Clinical Practice Research Datalink (CPRD) is a
database of routinely recorded primary care electronic
health record data from 7% of the UK population.22
The database includes the following data: patient
demographics; diagnoses; prescriptions; laboratory test
results; and referrals made by general practitioners
(GPs). Diseases can be identiﬁed using diagnostic codes
(Read codes) recorded in routine data. We used CPRD
linked to additional data sources: the inpatient Hospital
Episodes Statistics (HES) database to provide data on
ethnicity (to improve data completeness);23 Ofﬁce for
National Statistics (ONS) data for mortality; and Index
of Multiple Deprivation (IMD) data for deprivation
indices. We obtained study approval from the
institutional review board of the London School of
Hygiene and Tropical Medicine (reference: 9196), as
well as the Independent ScientiﬁcAdvisoryCommittee,
which oversees research involving CPRD data
(Protocol 15_219R). Informed consent from individual
patients was waived because the data are anonymous.
Study population and matched cohort
All adults (age 18 or older) alive and contributing to
HES-linked CPRD anytime from 1 April 2004 to 31
March 2014 were potentially eligible for inclusion.
Patients were eligible for inclusion at the latest of:
one year after practice registration,24 the date that the
practice reached CPRD quality control standards, or
1 April 2004. Patients were no longer eligible for
follow-up at the ﬁrst of renal replacement therapy
(RRT) initiation, death, change of practice, last data
collection from the practice, or 31 March 2014.
We excluded patients already receiving RRT
(hemodialysis, peritoneal dialysis, and kidney
transplantation) prior to cohort entry.
First, we identiﬁed patients with CKD based on two
consecutive measurements of eGFR <60 mL/min/
1.73 m2 more than three months apart.25 Estimated
GFR was calculated from serum creatinine values
recorded in CPRD, using the Chronic Kidney Disease
Epidemiology Collaboration equation.26 Patients,
including those who had CKD before April 2004, were
included in the cohort on the datewhen theyﬁrst satisﬁed
the CKD deﬁnition (i.e. second eGFR <60 mL/min/
1.73 m2) during eligible follow-up (index date).
Next, as a control group, we selected at random
patients without CKD from the general population.
Because (i) CKD status largely depends on age and
sex, and (ii) pattern of antidepressant prescription is
expected to depend on general practice and calendar
time, we matched controls to patients with CKD by
age (same year of birth), sex, general practice, and
calendar time. Each control entered the cohort on the
same index date as their CKD counterpart. Individuals
selected as controls (i.e. non-CKD patients) may be
found to have CKD later; in this situation, they were
censored as a control at the time of satisfying CKD
deﬁnition and contributed separately as an incident
patient with CKD from that time point forward (with
their own matched control).
Prevalence and incidence of antidepressant
prescription
We estimated the prevalence of existing users of
antidepressants, deﬁned as receiving an antidepressant
prescription within six months prior to the index date.
Incidence of antidepressant prescription was based on
the ﬁrst antidepressant prescription after index date,
after exclusion of existing users.27
Covariates
In order to examine the independent association
between CKD status and antidepressant prescription,
we considered baseline characteristics of patients:
age and sex; ethnicity; socio-economic status (SES);
smoking status; body mass index (BMI); and common
chronic physical illnesses that are considered to be
associated with mental health conditions (diabetes
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mellitus, congestive heart failure, myocardial
infarction, stroke, chronic obstructive pulmonary
disease, rheumatoid arthritis, cancer, Parkinson’s
disease, and epilepsy).28,29 Based on previous studies
using UK primary care data,30,31 we classiﬁed patients
with no record of ethnicity as white. Socio-economic
status was assigned by quintile at an individual level,
using 2010 ONS estimates of the IMD (a composite
area-level marker of deprivation).32 For patients with
missing individual-level SES, we used the SES for
the patient’s general practice. Smoking status and
BMI were assigned using the data recorded closest to
the index date. We deﬁned each chronic physical
illness as present if a relevant diagnosis code of that
illness was recorded at least once before a patient’s
index date.
Indication
We identiﬁed morbidity codes for three common
diagnoses suggesting indications for antidepressant
prescription:4 depression, anxiety, and neuropathic pain
(included in Appendix 1). We included symptom codes
as well as diagnostic codes because GPs in the UK
commonly use symptom codes (e.g. “depressive
symptoms”, “anxiousness”) rather than deﬁnitive
diagnostic codes (e.g. “major depression”, “general
anxiety disorder”).33–35 We included codes recorded by
GPs any time prior to the ﬁrst antidepressant prescription
until three months later, to account for possible time lag
in recording diagnosis codes in electronic health
records.36,37 We categorized type of antidepressant,
according to British National Formulary headings, into
the following categories:4 selective serotonin reuptake
inhibitors (SSRIs), tricyclic antidepressants (TCAs), or
other antidepressants. Monoamine oxidase inhibitors
were grouped into other antidepressants because of a
small number of prescriptions. For each type of
antidepressant, we identiﬁed the proportion of patients
with each indication as well as those with none of the
three indications.
Choice of antidepressants and initial prescription dose
There are 26 antidepressants currently available in the
UK, only a few are indicated for anxiety and
neuropathic pain, whilst all 26 are indicated for
depressive conditions.4 Therefore, we restricted this
analysis to patients with a recorded diagnosis of
depression. We compared the pattern of antidepressant
choice (the proportion of patients prescribed each
antidepressant as their ﬁrst incident prescription)
between depressed patients with and without CKD.
We also compared the initial dose prescribed in
those with and without CKD to examine whether
antidepressants were started at a lower dose in patients
with CKD than those without.
Statistical analyses
We compared the baseline characteristics of
patients with and without CKD using χ2 tests. We
calculated crude prevalence and incidence rates for
antidepressant prescribing. We then conducted a
conditional logistic regression analysis (to account
for matching) to investigate the association between
CKD status and prevalence of antidepressant
prescription. After excluding existing users of
antidepressants (meaning matching was no longer
maintained), we conducted an unconditional Poisson
regression analysis to investigate the association
between CKD status and incidence of new
antidepressant prescription, adjusting for age, sex,
and ﬁnancial year, and taking account of clustering
by general practice using robust standard errors. We
adjusted for ﬁnancial year (by including ﬁnancial year
as a categorical variable, i.e. from 1 April to 31 March
for each year) because the frequency of antidepressant
prescribing has been increasing year by year.3 We
further adjusted for ethnicity, SES, smoking status,
and BMI, and, then, in a fully adjusted model, also
included chronic physical illnesses. In models
including smoking status and BMI, we included an
additional absent category for those with no recorded
smoking status or BMI. In a subsequent sensitivity
analysis, we dropped all those with missing smoking
or BMI status. All the data management and statistical
analyses were conducted using STATA version 14
(Stata Corp, Texas).
Renal function subgroup analyses
To examine the association between severity of kidney
function and antidepressant prescribing, we classiﬁed
patients with CKD according to the level of kidney
function on the index date into two categories: eGFR
30–59 (CKD stage 3), and <30 mL/min/1.73 m2 (CKD
stage 4 and 5).25 In patients without CKD, we
differentiated patients with and without serum creatinine
results recorded in CPRD prior to index date, because
these subgroups are expected to be systematically
different due to testing incentives for those at risk of
CKD in the UK Quality and Outcomes Framework.38
To compare the prevalence of existing users of
antidepressants between subgroups of renal function,
we used an unconditional logistic regression analysis,
adjusting for age, sex, and ﬁnancial year, and taking
account of clustering by general practice using robust
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standard errors. We also repeated all other principal
analyses (described under ‘Statistical analyses’
subheading) using renal function subgroups.
Additional analyses
Any difference in the duration of follow-up lengths
between patients with and without CKD may affect
the likelihood of starting antidepressants. Therefore,
as a post hoc analysis, we compared the proportion
of patients starting antidepressants within the ﬁrst six
months of follow-up in those with and without CKD.
We undertook a further analysis to investigate
whether patients with CKD were more likely to start
antidepressants for the ﬁrst episode of depression in
their life, or for a recurrent episode of depression. In
CPRD, GPs routinely record a patient’s past medical
history shortly after registration with a new practice,
and, therefore, a previous episode of depression would
be recorded between CPRD registration and index date
of the study (as index dates need to be at least one year
after CPRD registration by our deﬁnition). Therefore,
in patients starting antidepressants with a recorded
diagnosis of depression, we compared the proportion
of those with and without CKD who had: (i) their ﬁrst
depression diagnosis in CPRD recorded between
CPRD registration and index date (more likely to
suggest a recurrence); and (ii) their ﬁrst depression
diagnosis recorded in CPRD after index date (more
likely to suggest the ﬁrst ever depression diagnosis).
RESULTS
Among 4 070 806 eligible patients (median age 39 [IQR
27–56], male 48.8%), we identiﬁed 264 628 patients
with CKD (median age 77 [IQR 71–83], male 38.7%)
(Figure 1). Of those with CKD, 242 349 (91.6%)
(median age 76 [IQR 70–82], male 39.3%) were
matched with a control patient without CKD who had
the same age, sex, and general practice on the index date
of their CKD counterpart. Unmatched patients with
CKD (n = 22 279) were older and more likely to be
female (median age 88 [IQR 84–92], male 31.5%). Of
the 242 349 matched control patients without CKD,
41 151 (17.0%) were subsequently found to have CKD.
Compared to patients without CKD, patients with
CKD were more likely to be deprived, ex-smokers, and
overweight (BMI ≥25 kg/m2) (Table 1). Chronic
physical illnesses, except for Parkinson’s disease and
epilepsy, weremore common among patientswithCKD.
Prevalence of existing use of antidepressants at index
date was 16.3 and 11.9% in patients with and without
CKD, respectively (Table 2). The incidence rate of
new antidepressant prescription was 57.2 and 42.4/
1000 person-years in patients with and without CKD,
respectively (Table 3). After adjusting for confounding,
CKD remained positively associated with increased
prevalence and incidence of antidepressant prescribing
(Tables 2 and 3). Our results were similar to those in the
main analysis after excluding patients with missing
smoking status and BMI (data not shown).
The pattern of recorded diagnoses was broadly similar
between patients with and without CKD (Table 4).
Regardless of CKD status, the majority of patients
prescribed SSRIs had recorded diagnoses of depression
Figure 1. Flow chart for the selection of matched patients with and without chronic kidney disease. CKD = chronic kidney disease, CPRD = clinical practice
research datalink, HES = hospital episode statistics, RRT = renal replacement therapy. *Matched cohort: randomly selected individuals without chronic kidney
disease matched for age, sex, general practice, and calendar time
antidepressants in patients with chronic kidney disease 795
© 2017 The Authors. Pharmacoepidemiology &
Drug Safety Published by John Wiley & Sons Ltd
Pharmacoepidemiology and Drug Safety, 2017; 26: 792–801
DOI: 10.1002/pds
101
or anxiety, while TCAs were prescribed for neuropathic
pain or other reasons. Among patients with a recorded
diagnosis of depression, the choice of antidepressant
was similar between patients with and without CKD
(Table 5). Irrespective of CKD status, the most
commonly prescribed antidepressant was citalopram,
Table 2. Prevalence of antidepressant prescription by chronic kidney disease status
No. of patients receiving
antidepressants in the past 6 months
Prevalence %
(95%CI)
Adjusted odds ratio (95%CI)
Model 1* Model 2** Model 3***
Patients without CKD
(N = 242 349)
28 738 11.9 (11.7–12.0) 1 (Reference) 1 (Reference) 1 (Reference)
Patients with CKD
(N = 242 349)
39 428 16.3 (16.1–16.4) 1.46 (1.43–1.48) 1.43 (1.41–1.46) 1.35 (1.32–1.37)
CI = conﬁdence interval, CKD = chronic kidney disease.
*Model 1: Accounted for the matched nature of the groups (age, sex, general practice, and calendar time) in conditional logistic regression analysis.
**Model 2: Model 1 + adjusted by ethnicity, socio-economic status, smoking status, and body mass index.
***Model 3: Model 2 + adjusted by chronic physical illnesses.
Table 1. Baseline characteristics of matched patients with and without chronic kidney disease
Patients without CKD N = 242 349 Patients with CKD N = 242 349
p Valuen (%) n (%)
Age (years): 1.000
<55 6845 (2.8) 6845 (2.8)
55–64 23 556 (9.7) 23 556 (9.7)
65–74 71 112 (29.3) 71 112 (29.3)
75–84 102 594 (42.3) 102 594 (42.3)
≥85 38 242 (15.8) 38 242 (15.8)
Sex (male): 95 318 (39.3) 95 318 (39.3) 1.000
Ethnicity:
White/not-recorded* 238 533 (98.4) 238 138 (98.3) <0.001
South Asian 1796 (0.7) 2317 (1.0)
Black 1156 (0.5) 1060 (0.4)
Other ethnicity 864 (0.4) 834 (0.3)
Socio-economic status**:
1 (least deprived) 56 800 (23.4) 53 034 (21.9) <0.001
2 61 647 (25.4) 60 501 (25.0)
3 50 466 (20.8) 50 709 (20.9)
4 42 221 (17.4) 44 692 (18.4)
5 (most deprived) 31 215 (12.9) 33 413 (13.8)
Smoking status: <0.001
Non-smoker 92 363 (38.1) 80 721 (33.3)
Ex-smoker 107 737 (44.5) 131 510 (54.3)
Current-smoker 36 338 (15.0) 29 243 (12.1)
Missing 5911 (2.4) 875 (0.4)
Body mass index (kg/m2): <0.001
<18.5 6638 (2.7) 4562 (1.9)
18.5–25 85 473 (35.3) 70 102 (28.9)
≥25 80 458 (33.2) 88 083 (36.4)
≥30 40 326 (16.6) 63 183 (26.1)
Missing 29 454 (12.2) 16 419 (6.8)
Chronic physical illnesses:
Diabetes mellitus 24 292 (10.0) 52 802 (21.8) <0.001
Congestive heart failure 7581 (3.1) 23 774 (9.8) <0.001
Myocardial infarction 11 459 (4.7) 25 746 (10.6) <0.001
Stroke 12 243 (5.1) 19 982 (8.3) <0.001
Chronic obstructive pulmonary disease 14 996 (6.2) 18 229 (7.5) <0.001
Rheumatoid arthritis 4270 (1.8) 6031 (2.5) <0.001
Cancer 47 431 (19.6) 54 450 (22.5) <0.001
Parkinson’s disease 2691 (1.1) 2293 (1.0) <0.001
Epilepsy 3972 (1.6) 3682 (1.5) 0.001
CKD = chronic kidney disease.
*White/not-recorded: 136 119 (56.2%) and 140 784 (58.1%) patients with and without CKD, respectively, had no recorded ethnicity.
**Socio-economic status: 259 (0.1%) and 272 (0.1%) patients with and without CKD, respectively, did not have individual-level data; we therefore used the
socio-economic status of their general practice.
m. iwagami et al.796
© 2017 The Authors. Pharmacoepidemiology &
Drug Safety Published by John Wiley & Sons Ltd
Pharmacoepidemiology and Drug Safety, 2017; 26: 792–801
DOI: 10.1002/pds
102
Table 3. Incidence of new antidepressant prescription by chronic kidney disease status
Total follow-up
length
(person-years)
No. of patients
starting
antidepressants
Incidence rate
(/1000 person-years)
(95%CI)
Adjusted rate ratio (95%CI)
Model 1* Model 2** Model 3***
Patients without CKD
(N = 213 611)
774 660 32 846 42.4 (41.9–42.9) 1 (Reference) 1 (Reference) 1 (Reference)
Patients with CKD
(N = 202 921)
794 150 45 394 57.2 (56.6–57.7) 1.35 (1.33–1.37) 1.30 (1.28–1.32) 1.25 (1.23–1.26)
CI = conﬁdence interval, CKD = chronic kidney disease, IQR = interquartile range.
*Model 1: Adjusted by age, sex, and ﬁnancial year, and taking account of clustering by general practice with robust standard errors using unconditional
Poisson regression analysis.
**Model 2: Model 1 + adjusted by ethnicity, socio-economic status, smoking status, and body mass index.
***Model 3: Model 2 + adjusted by chronic physical illnesses.
Table 4. Recorded diagnoses for patients prescribed antidepressants stratiﬁed by chronic kidney disease status and type of antidepressant
Patients without CKD (N = 32 846) Patients with CKD (N = 45 394)
SSRI N = 12 924 TCA N = 17 672 Others N = 2250 SSRI N = 17 992 TCA N = 24 262 Others N = 3140
Depression, n (%)* 8123 (62.9) 4430 (25.1) 1035 (46.0) 11 363 (63.2) 6257 (25.8) 1456 (46.4)
Anxiety, n (%)* 4843 (37.5) 3902 (22.1) 708 (31.5) 6131 (34.1) 5055 (20.8) 935 (29.8)
Neuropathic pain, n (%)* 625 (4.8) 2536 (14.4) 152 (6.8) 997 (5.5) 3491 (14.4) 209 (6.7)
None of the above, n (%) 3188 (24.7) 9699 (54.9) 894 (39.7) 4683 (26.0) 13 259 (54.7) 1256 (40.0)
CKD = chronic kidney disease, SSRI = selective serotonin reuptake inhibitor, TCA = tricyclic antidepressants.
*Percentages are column percentages. Each patient may have one or more recorded diagnosis.
Table 5. Choice of antidepressants and initial prescription dose for patients with diagnosed depression by chronic kidney disease status
Patients without CKD N = 13 588 Patients with CKD N = 19 076
n (%)* Median initial dose (mg/day) [IQR] n (%)* Median initial dose (mg/day) [IQR]
Selective serotonin reuptake inhibitors
Citalopram 4934 (36.3) 10 [10–20] 7070 (37.1) 10 [10–20]
Escitalopram 353 (2.6) 5 [5–10] 429 (2.3) 5 [5–10]
Fluoxetine 1651 (12.2) 20 [20–20] 2270 (11.9) 20 [20–20]
Fluvoxamine <5 (<0.1) n/a <5 (<0.1) n/a
Paroxetine 132 (1.0) 20 [20–20] 144 (0.8) 20 [20–20]
Sertraline 1053 (7.8) 50 [50–50] 1449 (7.6) 50 [50–50]
Tricyclic and related antidepressants
Amitriptyline 3506 (25.8) 10 [10–20] 5024 (26.3) 10 [10–15]
Clomipramine 26 (0.2) 25 [10–37.5] 27 (0.1) 20 [10–37.5]
Dosulepin 407 (3.0) 37.5 [25–75] 512 (2.7) 37.5 [25–75]
Doxepin 19 (0.1) 25 [25–37.5] 24 (0.1) 25 [20–30]
Imipramine 30 (0.2) 25 [10–30] 45 (0.2) 25 [10–30]
Lofepramine 113 (0.8) 70 [70–140] 186 (1.0) 70 [70–140]
Nortriptyline 94 (0.7) 15 [10–15] 158 (0.8) 10 [10–15]
Trimipramine 15 (0.1) 25 [10–37.5] 26 (0.1) 25 [20–50]
Mianserin 7 (0.1) 30 [30–30] 5 (<0.1) 30 [30–30]
Trazodone 213 (1.6) 50 [50–100] 250 (1.3) 50 [50–75]
Monoamine oxidase inhibitors** <5 (<0.1) n/a <5 (<0.1) n/a
Other antidepressants:
Agomelatine <5 (<0.1) n/a <5 (<0.1) n/a
Duloxetine 98 (0.7) 40 [30–60] 169 (0.9) 40 [30–60]
Flupentixol 63 (0.5) 1 [0.5–1] 88 (0.5) 1 [0.5–1]
Mirtazapine 758 (5.6) 15 [15–15] 1045 (5.5) 15 [15–15]
Reboxetine <5 (<0.1) n/a <5 (<0.1) n/a
Venlafaxine 85 (0.6) 75 [75–75] 97 (0.5) 75 [75–75]
Two or more different antidepressants 27 (0.2) n/a 53 (0.3) n/a
CKD = chronic kidney disease, IQR = interquartile range.
*Cell counts less than ﬁve have been suppressed to preserve patient privacy.
**Phenelzine, isocarboxazid, tranylcypromine, and moclobemide are combined due to small sample sizes.
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followed by amitriptyline, ﬂuoxetine, sertraline, and
mirtazapine. There was no clear evidence that
antidepressants were started at a reduced dose in patients
with CKD, compared to those without CKD.
When we repeated our analyses in subgroups of
renal function (Appendix 2 Tables 1–5), as the level
of kidney function decreased, patients tended to be
older and sicker. Among patients without CKD, those
with serum creatinine results recorded in CPRD were
sicker than those without. Prevalence and incidence
of antidepressant prescribing increased among people
with more severe kidney function: prevalence was
16.1 and 18.3%, and incidence was 56.9 and
62.3/1000 person-years in patients with eGFR 30–59
and <30 mL/min/1.73 m2, respectively. This trend
remained after adjusting for confounders. Patterns of
indication for and choice of antidepressant, as well as
initial prescription dose, were broadly similar for
patients with different levels of kidney function.
In additional analyses with follow-up restricted to
the ﬁrst six months, the percentage of patients starting
antidepressants was higher amongst patients with
CKD (3.5%; 7155/202 921) than amongst those
without it (2.5%; 5233/213 611) (p < 0.001).
The proportion of patients starting antidepressants
with their ﬁrst depression diagnosis recorded between
CPRD registration and index date was larger among
patients with CKD (5.8%; 11 781/202 921) than those
without CKD (4.0%; 8476/213 611) (p < 0.001).
Similarly, the proportion of patients starting
antidepressants with their ﬁrst depression diagnosis
recorded in CPRD after index date was larger among
patients with CKD (3.6%; 7295/202 921) than those
without CKD (2.4%; 5112/213 611) (p < 0.001).
These results suggest that patients with CKD are more
likely than those without CKD to start antidepressants
both for recurrent episodes of depression, and for their
ﬁrst ever episode of depression.
DISCUSSION
Main ﬁndings
In this large study, we found that patients with CKD
were more likely than patients without CKD to be
receiving an antidepressant, or among non-users, to start
one during follow-up. The increase in prevalence and
incidence was graded according to severity of kidney
function, and the association remained after adjusting
for baseline characteristics including chronic physical
illnesses. The pattern of indication for and choice of
antidepressants, as well as initial prescription dose, were
broadly similar between patients with and without CKD.
Strengths and limitations
We used a detailed source of routinely collected
data that is representative of UK population
demographics.22 In the UK, GPs manage the vast
majority of non-refractory cases of mental health
disorders,39,40 and even when patients see psychiatrists
in secondary care, prescriptions are usually
administered by primary care.41 Therefore, we expect
that most antidepressant prescriptions are captured in
CPRD. To better understand the characteristics of
patients with CKD, we used a comparison group of
patients without CKD matched on age, sex, general
practice, and calendar time. Although previous studies
suggested that the proportion of patients with CKD
receiving antidepressants may be high as an absolute
value,42,43 we are not aware of any study that
has directly compared frequency and patterns of
antidepressant prescribing between patients with and
without CKD. We deﬁned CKD using eGFR
calculated from serum creatinine measurement. This
method is more accurate than using recorded diagnosis
of CKD, which has low sensitivity for detecting
people with CKD in UK primary care databases.44
We must acknowledge several limitations of our
study. First, serum creatinine testing in primary care
is not universal—currently, it is only recommended
and incentivized for people who are considered to be
at risk for CKD.9,38 We may have misclassiﬁed
patients with unmeasured CKD to the matched control
cohort, which could dilute the true association
between CKD and antidepressant prescription.
However, a recent study showed that the prevalence
of CKD identiﬁed in CPRD is similar to that estimated
in a nationally representative survey (Health Survey
for England), suggesting that most CKD patients are
captured in CPRD.45 Second, although we adjusted
for important confounders that may be associated with
mental health conditions,28,29 the observed association
between CKD status and the prevalence/incidence of
antidepressant prescribing could be inﬂuenced by
residual confounding due to un-coded poor health
status or access to talking therapies. Third, we
examined three common diagnoses associated
with antidepressant use (depression, anxiety, and
neuropathic pain). However, for patients with two or
more different diagnoses (e.g. depression and
neuropathic pain), it was not possible to determine
the most likely indication for antidepressant
prescription because diagnosis and prescription
records are separate in CPRD. Also, patients may
have received antidepressants for other reasons, such
as non-neuropathic pain and insomnia, but reliable
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identiﬁcation of these conditions has not been
established in CPRD. Finally, we demonstrated that
the initial dose of antidepressant prescribed was
similar in depressed patients with and without CKD.
However, this does not ensure that the subsequent
dose was also similar between those with and
without CKD (as doctors may increase or decrease
antidepressant dose after initial prescription, according
to perceived effectiveness or side effects).
Comparison with other studies
Two studies conducted in the USA have examined
antidepressant use in patients with CKD.42,43 The
Chronic Renal Insufﬁciency Cohort study investigated
the proportion of patients with CKD receiving an
antidepressant at recruitment.43 Of 3853 participants,
700 (18.2%) were taking antidepressants. This number
is close to the prevalence of existing users of
antidepressants in patients with CKD (16.3%) found
in our study. Another US cohort study showed
that around 30% of patients with CKD (with or without
diagnosis of depression) were receiving antidepressants
at any time during a 2-year period between 2004 and
2006.42 These antidepressant users appeared to include
both existing and new users of antidepressants. Our
study demonstrated the incident rate of antidepressant
prescription at 57.2/1000 person-years in patient with
CKD. Together with the prevalence of existing users
(16.3%), the cumulative effect of this was consistent
with over 30% of CKD patients exposed to
antidepressants during follow-up. Neither US study
included a comparison group of patients without CKD
in order to compare prescribing in CKD patients to that
in the general population. Indication and choice of
antidepressants were also not examined.
Explanation of ﬁndings and implication for future
studies
Patients with mild CKD generally do not have related
physical symptoms. However, a previous study has
suggested that negative perception of CKD is
associated with depression and lower quality of life,
even in the early stages of CKD.46 Patients with more
advanced CKD (eGFR <30 mL/min/1.73m2) tend to
have symptoms including fatigue, nausea, sleep
disturbances, itching, and peripheral neuropathy, any
of which could inﬂuence quality of life and mental
health. This is in line with our ﬁnding that patients
with advanced CKD were more likely to be prescribed
antidepressants, even without a speciﬁcally coded
diagnosis of depression and anxiety.
While most SSRIs were associated with a coded
diagnosis of depression or anxiety, more than half of
patients starting TCAs (mostly amitriptyline) did not
have any recorded diagnoses of depression, anxiety,
or neuropathic pain. Amitriptyline may have been
predominantly prescribed as an off-label indication
for non-psychiatric conditions such as chronic pain
and insomnia.5–7 When restricted to patients with a
coded diagnosis of depression, SSRIs accounted for
the majority of antidepressant prescribing, which is
in keeping with current guidelines for management
of depression.39 Patterns of antidepressant choice did
not differ substantially according to CKD status or
level of kidney function. This is probably because to
date there is no evidence of greater efﬁcacy or safety
concerns for speciﬁc antidepressants among patients
with CKD.20,21
Increased adverse events as renal function declines
are an important concern. For example, amitriptyline
clearance is reduced in patients with decreased
kidney function.47 As a result, amitriptyline may
accumulate, causing serious adverse outcomes through
neurotoxicity48 and cardiotoxicity.49 Another example
is the potential ampliﬁcation of bleeding risk both with
use of SSRIs and with decreased kidney function
itself.50 Finally, the results of our analyses stratiﬁed
by severity of renal function demonstrate that
many patients are prescribed antidepressants at levels
of renal function below those where cessation
is recommended by manufacturers (e.g. eGFR
<30 mL/min/1.73 m2). According to the British
National Formulary,4 escitalopram, paroxetine,
sertraline, imipramine, lofepramine, trazodone,
duloxetine, mirtazapine, and venlafaxine should be
used with caution or avoided in those with reduced
renal function, but our real-world data suggest that
these drugs are prescribed similarly in patients with
moderately or severely decreased kidney function,
compared to those with normal kidney function. Better
evidence regarding the potential adverse effects of
these drugs for patients with decreased kidney
function is needed.
CONCLUSIONS
This study using a large UK database suggests that
patients with CKD are more likely to be prescribed
antidepressants than the general population, whilst
prescribing patterns did not appear to be inﬂuenced
by kidney function. These real-world data emphasize
the need for research investigating the potential
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adverse effects of antidepressant therapy in people
with decreased kidney function.
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of routine medical record data. We deﬁned
chronic kidney disease using serum creatinine
measurements and compared people with and
without chronic kidney disease matched for
age, sex, general practice, and calendar time.
• Patients with chronic kidney disease were
exposed to antidepressants more frequently; with
higher prevalence and incidence of
antidepressant prescribing than the general
population. The positive association between
chronic kidney disease and increased frequency
of antidepressant prescribing remained after
adjusting for measured confounders such as
diabetes and cardiovascular disease.
• Among patients starting antidepressants,
indication for antidepressant prescription
(recorded diagnoses of depression, anxiety, or
neuropathic pain) was similar between patients
with and without chronic kidney disease.
Antidepressant choice was also similar between
depressed patients with and without chronic
kidney disease.
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Appendix 1. List of diagnosis codes indicative of depression, anxiety, and neuropathic pain in Clinical 
Practice Research Datalink. 
Read code Medcode* Read term 
Depression: 
E2B..00 324 Depressive disorder NEC 
Eu32z11 543 [X]Depression NOS 
E112.14 595 Endogenous depression 
E200300 655 Anxiety with depression 
E135.00 1055 Agitated depression 
E204.00 1131 Neurotic depression reactive type 
Eu31.11 1531 [X]Manic-depressive illness 
E290.00 1533 Brief depressive reaction 
2257.00 1908 O/E - depressed 
1B17.00 1996 Depressed 
1B1N.00 2147 Poor self esteem 
E11..12 2560 Depressive psychoses 
E204.11 2639 Postnatal depression 
1465.00 2716 H/O: depression 
62T1.00 2923 Puerperal depression 
1B17.12 2930 C/O - feeling unhappy 
Eu32z00 2970 [X]Depressive episode, unspecified 
E2B0.00 2972 Postviral depression 
Eu32z12 3291 [X]Depressive disorder NOS 
Eu33.00 3292 [X]Recurrent depressive disorder 
E2B1.00 4323 Chronic depression 
Eu32.00 4639 [X]Depressive episode 
E115.00 4677 Bipolar affective disorder, currently depressed 
Eu31500 4732 [X]Bipolar affect dis cur epi severe depres with psyc symp 
1B17.11 4824 C/O - feeling depressed 
Eu53012 4979 [X]Postpartum depression NOS 
E112.11 5879 Agitated depression 
Eu32z14 5987 [X] Reactive depression NOS 
E113700 6482 Recurrent depression 
E112.12 6546 Endogenous depression first episode 
Eu32y00 6854 [X]Other depressive episodes 
E113.11 6932 Endogenous depression - recurrent 
E112.13 6950 Endogenous depression first episode 
E112z00 7011 Single major depressive episode NOS 
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1BJ..00 7412 Loss of confidence 
Eu32.13 7604 [X]Single episode of reactive depression 
Eu34113 7737 [X]Neurotic depression 
Eu41211 7749 [X]Mild anxiety depression 
Eu34100 7953 [X]Dysthymia 
E130.00 8478 Reactive depressive psychosis 
Eu34111 8584 [X]Depressive neurosis 
Eu33.15 8826 [X]SAD - Seasonal affective disorder 
Eu33.11 8851 [X]Recurrent episodes of depressive reaction 
Eu33.13 8902 [X]Recurrent episodes of reactive depression 
1BT..11 8928 Low mood 
Eu32.11 9055 [X]Single episode of depressive reaction 
E11z200 9183 Masked depression 
Eu32100 9211 [X]Moderate depressive episode 
Eu32200 9667 [X]Severe depressive episode without psychotic symptoms 
1B1U.00 9796 Symptoms of depression 
1BT..00 10015 Depressed mood 
Eu34112 10290 [X]Depressive personality disorder 
1B1U.11 10438 Depressive symptoms 
E211200 10455 Depressive personality disorder 
E112.00 10610 Single major depressive episode 
Eu32400 10667 [X]Mild depression 
Eu32y11 10720 [X]Atypical depression 
E118.00 10825 Seasonal affective disorder 
Eu33212 11252 [X]Major depression, recurrent without psychotic symptoms 
Eu33211 11329 [X]Endogenous depression without psychotic symptoms 
E11y000 11596 Unspecified manic-depressive psychoses 
Eu32000 11717 [X]Mild depressive episode 
Eu41200 11913 [X]Mixed anxiety and depressive disorder 
Eu32300 12099 [X]Severe depressive episode with psychotic symptoms 
E115.11 12831 Manic-depressive - now depressed 
Eu53011 13307 [X]Postnatal depression NOS 
E113200 14709 Recurrent major depressive episodes, moderate 
E113.00 15099 Recurrent major depressive episode 
E112200 15155 Single major depressive episode, moderate 
E112300 15219 Single major depressive episode, severe, without psychosis 
Eu34114 15220 [X]Persistant anxiety depression 
E115000 15923 Bipolar affective disorder, currently depressed, unspecified 
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E112100 16506 Single major depressive episode, mild 
Eu31300 16562 [X]Bipolar affect disorder cur epi mild or moderate depressn 
E291.00 16632 Prolonged depressive reaction 
Eu33315 16861 [X]Recurrent severe episodes of psychotic depression 
E130.11 17770 Psychotic reactive depression 
Eu32.12 18510 [X]Single episode of psychogenic depression 
Eu3y111 19054 [X]Recurrent brief depressive episodes 
Eu33.12 19696 [X]Recurrent episodes of psychogenic depression 
Eu20400 20785 [X]Post-schizophrenic depression 
E002100 21887 Senile dementia with depression 
ZV11112 22080 [V]Personal history of manic-depressive psychosis 
Eu33400 22116 [X]Recurrent depressive disorder, currently in remission 
Eu32212 22806 [X]Single episode major depression w'out psychotic symptoms 
Eu31400 23713 [X]Bipol aff disord, curr epis sev depress, no psychot symp 
Eu33311 23731 [X]Endogenous depression with psychotic symptoms 
ZV11111 23963 [V]Personal history of manic-depressive psychosis 
Eu32313 24112 [X]Single episode of psychotic depression 
Eu32311 24117 [X]Single episode of major depression and psychotic symptoms 
E113400 24171 Recurrent major depressive episodes, severe, with psychosis 
1BQ..00 25435 Loss of capacity for enjoyment 
E113z00 25563 Recurrent major depressive episode NOS 
E113300 25697 Recurrent major depressive episodes, severe, no psychosis 
1BT..12 26028 Sad mood 
E11y200 27491 Atypical depressive disorder 
E001300 27677 Presenile dementia with depression 
Eu02z16 27759 [X] Senile dementia, depressed or paranoid type 
E115200 27890 Bipolar affective disorder, currently depressed, moderate 
Eu32z13 28248 [X]Prolonged single episode of reactive depression 
Eu33312 28677 [X]Manic-depress psychosis,depressed type+psychotic symptoms 
Eu33.14 28756 [X]Seasonal depressive disorder 
Eu32314 28863 [X]Single episode of reactive depressive psychosis 
E113100 29342 Recurrent major depressive episodes, mild 
Eu33213 29451 [X]Manic-depress psychosis,depressd,no psychotic symptoms 
Eu33100 29520 [X]Recurrent depressive disorder, current episode moderate 
R007z13 29527 [D]Postoperative depression 
Eu33000 29784 [X]Recurrent depressive disorder, current episode mild 
Eu3y011 30688 [X]Mixed affective episode 
1BP..00 30740 Loss of interest 
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Eu33314 31757 [X]Recurr severe episodes/psychogenic depressive psychosis 
E112400 32159 Single major depressive episode, severe, with psychosis 
Eu33313 32941 [X]Recurr severe episodes/major depression+psychotic symptom 
Eu33200 33469 [X]Recurr depress disorder cur epi severe without psyc sympt 
Eu31z00 33751 [X]Bipolar affective disorder, unspecified 
E112000 34390 Single major depressive episode, unspecified 
E115300 35607 Bipolar affect disord, now depressed, severe, no psychosis 
E113000 35671 Recurrent major depressive episodes, unspecified 
E115100 35734 Bipolar affective disorder, currently depressed, mild 
E290z00 36246 Brief depressive reaction NOS 
Eu33z11 36616 [X]Monopolar depression NOS 
E115z00 37296 Bipolar affective disorder, currently depressed, NOS 
Eu33316 37764 [X]Recurrent severe episodes/reactive depressive psychosis 
E002z00 41089 Senile dementia with depressive or paranoid features NOS 
Eu32211 41989 [X]Single episode agitated depressn w'out psychotic symptoms 
E004300 43292 Arteriosclerotic dementia with depression 
E112500 43324 Single major depressive episode, partial or unspec remission 
Eu33z00 44300 [X]Recurrent depressive disorder, unspecified 
E002.00 44674 Senile dementia with depressive or paranoid features 
Eu31600 44693 [X]Bipolar affective disorder, current episode mixed 
Eu33300 47009 [X]Recurrent depress disorder cur epi severe with psyc symp 
Eu33y00 47731 [X]Other recurrent depressive disorders 
Eu32312 52678 [X]Single episode of psychogenic depressive psychosis 
1BU..00 53148 Loss of hope for the future 
Eu31y00 53840 [X]Other bipolar affective disorders 
E113600 55384 Recurrent major depressive episodes, in full remission 
E113500 56273 Recurrent major depressive episodes,partial/unspec remission 
Eu32y12 56609 [X]Single episode of masked depression NOS 
E115600 57465 Bipolar affective disorder, now depressed, in full remission 
Eu32213 59386 [X]Single episode vital depression w'out psychotic symptoms 
1BP0.00 59869 Loss of interest in previously enjoyable activity 
E11y.00 60178 Other and unspecified manic-depressive psychoses 
E115400 63701 Bipolar affect disord, now depressed, severe with psychosis 
E115500 72026 Bipolar affect disord, now depressed, part/unspec remission 
Eu31y11 73924 [X]Bipolar II disorder 
Eu33214 73991 [X]Vital depression, recurrent without psychotic symptoms 
Eu32600 98252 [X]Major depression, moderately severe 
Eu32500 98346 [X]Major depression, mild 
111
Eu32700 98414 [X]Major depression, severe without psychotic symptoms 
Eu32800 98417 [X]Major depression, severe with psychotic symptoms 
Anxiety: 
1B13.00 131 Anxiousness 
E200111 462 Panic attack 
1B12.12 514 Tension - nervous 
E200.00 636 Anxiety states 
E200300 655 Anxiety with depression 
E20z.11 791 Nervous breakdown 
Eu41111 962 [X]Anxiety neurosis 
E205.11 1582 Nervous exhaustion 
E200400 1758 Chronic anxiety 
R2y2.00 2509 [D]Nervousness 
1BK..00 2524 Worried 
E202100 3076 Agoraphobia with panic attacks 
1B1..00 3328 General nervous symptoms 
E200100 4069 Panic disorder 
Eu41012 4081 [X]Panic state 
E200z00 4534 Anxiety state NOS 
E200500 4634 Recurrent anxiety 
E200200 4659 Generalised anxiety disorder 
Eu41.00 5385 [X]Other anxiety disorders 
1B13.11 5902 Anxiousness - symptom 
E292000 6221 Separation anxiety disorder 
Eu41011 6408 [X]Panic attack 
E200000 6939 Anxiety state unspecified 
Eu41211 7749 [X]Mild anxiety depression 
Z4L1.00 7999 Anxiety counselling 
Eu41000 8205 [X]Panic disorder [episodic paroxysmal anxiety] 
Eu60600 8424 [X]Anxious [avoidant] personality disorder 
2259.00 8725 O/E - nervous 
Eu41100 10344 [X]Generalized anxiety disorder 
E202D00 10390 Fear of death 
R2y2.12 10723 [D]Nervous tension 
1B1V.00 11890 C/O - panic attack 
Eu41200 11913 [X]Mixed anxiety and depressive disorder 
E280.00 11940 Acute panic state due to acute stress reaction 
E202200 12838 Agoraphobia without mention of panic attacks 
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2258.00 13124 O/E - anxious 
Eu40012 14890 [X]Panic disorder with agoraphobia 
Eu40011 16729 [X]Agoraphobia without history of panic disorder 
Eu51511 17687 [X]Dream anxiety disorder 
225J.00 19000 O/E - panic attack 
1B1Z.00 20089 General nervous symptom NOS 
1B1H.12 20163 Apprehension 
Eu41z00 23838 [X]Anxiety disorder, unspecified 
Eu41y00 24066 [X]Other specified anxiety disorders 
Eu41z11 25638 [X]Anxiety NOS 
225K.00 26331 O/E - fearful mood 
Eu41y11 28167 [X]Anxiety hysteria 
Z4I7200 28381 Alleviating anxiety 
8HHp.00 28925 Referral for guided self-help for anxiety 
1B12.00 29608 'Nerves' - nervousness 
Eu40z00 34064 [X]Phobic anxiety disorder, unspecified 
Eu41112 35825 [X]Anxiety reaction 
2255.00 38155 O/E - afraid 
1B1P000 40431 Cries easily 
Eu41300 44321 [X]Other mixed anxiety disorders 
Eu41113 50191 [X]Anxiety state 
E292400 56924 Adjustment reaction with anxious mood 
1B13.12 93401 Anxious 
16ZB100 101422 Feeling low or worried 
Neuropathic pain: 
F262500 321 Periodic migrainous neuralgia 
F301.00 1541 Other specified trigeminal neuralgia 
A531.11 1598 Post-herpetic neuralgia 
N242000 2284 Neuralgia unspecified 
F301z00 6581 Trigeminal neuralgia NOS 
F356100 6884 Morton's neuralgia 
F300.00 7584 Post-herpetic trigeminal neuralgia 
A531511 10223 Postherpetic neuralgia 
A531200 11498 Postherpetic trigeminal neuralgia 
N242300 11544 Neuropathic pain 
1475.00 16481 H/O: trigeminal neuralgia 
F321.00 16932 Glossopharyngeal neuralgia 
A531500 17180 Postzoster neuralgia 
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*There is a one-to-one correspondence between Medcode and Read code in Clinical Practice Research 
Datalink. 
 
N242z00 23839 Neuralgia, neuritis or radiculitis NOS 
F262100 33362 Horton's (histamine) neuralgia 
F372100 35785 Chronic painful diabetic neuropathy 
F372000 48078 Acute painful diabetic neuropathy 
N242.00 54992 Neuralgia, neuritis and radiculitis unspecified 
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Appendix 2. Subgroup analyses according to level of kidney function (among patients with CKD) and creatinine measurement (among patients without CKD). 
Table 1. Baseline characteristics. 
 Patients without CKD (N = 242,349) Patients with CKD (N = 242,349) 
P value 
 
without creatinine 
measurement in CPRD  
N = 62,971 
with creatinine 
measurement in CPRD 
N = 179,378 
with eGFR 30-59 
mL/min/1.73m2 at baseline 
N = 228,055 
with eGFR <30  
mL/min/1.73m2 at baseline 
N = 14,294 
n (%) n (%) n (%) n (%) 
Age (years):     <0.001 
 <55 3,279 (5.2) 3,566 (2.0) 6,022 (2.6) 823 (5.8)  
 55-64 7,693 (12.2) 15,863 (8.8) 22,531 (9.9) 1,025 (7.2)  
 65-74 17,450 (27.7) 53,662 (29.9) 68,494 (30.0) 2,618 (18.3)  
 75-84 23,536 (37.4) 79,058 (44.1) 96,868 (42.5) 5,726 (40.1)  
 ≥85 11,013 (17.5) 27,229 (15.2) 34,140 (15.0) 4,102 (28.7)  
Sex (male): 23,015 (36.6) 72,303 (40.3) 89,289 (39.2) 6,029 (42.2) <0.001 
Ethnicity:     <0.001 
 White/not-recorded 62,319 (99.0) 176,214 (98.2) 224,211 (98.3) 13,927 (97.3)  
 South Asian  302 (0.5) 1,494 (0.8) 2,141 (0.9) 176 (1.2)  
 Black 146 (0.2) 1,010 (0.6) 932 (0.4) 128 (0.9)  
 Other ethnicity 204 (0.3) 660 (0.4) 771 (0.3) 63 (0.4)  
Socio-economic status:     <0.001 
  1 (least deprived) 14,724 (23.4) 42,076 (23.5) 50,295 (22.1) 2,739 (19.2)  
  2 15,603 (24.8) 46,044 (25.7) 57,190 (25.1) 3,311 (23.2)  
  3 12,950 (20.6) 37,516 (20.9) 47,616 (20.9) 3,093 (21.6)  
  4 11,222 (17.8) 30,999 (17.3) 41,829 (18.3) 2,863 (20.0)  
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  5 (most deprived) 8,472 (13.5) 22,743 (12.7) 31,125 (13.7) 2,288 (16.0)  
Smoking status:     <0.001 
  Non-smoker 27,736 (44.1) 64,627 (36.0) 75,701 (33.2) 5,020 (35.1)  
  Ex-smoker 18,549 (29.5) 89,188 (49.7) 124,290 (54.5) 7,220 (50.5)  
  Current-smoker 11,791 (18.7) 24,547 (13.7) 27,374 (12.0) 1,869 (13.1)  
  Missing 4,895 (7.8) 1,016 (0.6) 690 (0.3) 185 (1.3)  
Body mass index:     <0.001 
  <18.5 1,628 (2.6) 5,010 (2.8) 4,189 (1.8) 373 (2.6)  
18.5 - 25 21,981 (34.9) 63,492 (35.4) 65,841 (28.9) 4,261 (29.8)  
  ≥25 17,526 (27.8) 62,932 (35.1) 83,733 (36.7) 4,350 (30.4)  
  ≥30 6,829 (10.8) 33,497 (18.7) 59,910 (26.3) 3,273 (22.9)  
  Missing 15,007 (23.8) 14,447 (8.1) 14,382 (6.3) 2,037 (14.3)  
Chronic physical illnesses:      
  Diabetes mellitus 669 (1.1) 23,623 (13.2) 49,017 (21.5) 3,785 (26.5) <0.001 
  Congestive heart failure 824 (1.3) 6,757 (3.8) 20,723 (9.1) 3,051 (21.3) <0.001 
  Myocardial infarction 783 (1.2) 10,676 (6.0) 23,664 (10.4) 2,082 (14.6) <0.001 
  Stroke 1,507 (2.4) 10,736 (6.0) 18,330 (8.0) 1,652 (11.6) <0.001 
  Chronic obstructive pulmonary disease 2,312 (3.7) 12,684 (7.1) 17,006 (7.5) 1,223 (8.6) <0.001 
  Rheumatoid arthritis 527 (0.8) 3,743 (2.1) 5,674 (2.5) 357 (2.5) <0.001 
  Cancer 8,593 (13.7) 38,838 (21.7) 50,799 (22.3) 3,651 (25.5) <0.001 
  Parkinson’s disease 500 (0.8) 2,191 (1.2) 2,143 (0.9) 150 (1.1) <0.001 
  Epilepsy 670 (1.1) 3,302 (1.8) 3,450 (1.5) 232 (1.6) <0.001 
CKD = chronic kidney function, eGFR = estimated glomerular filtration rate. 
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Table 2. Prevalence of antidepressant prescription. 
 
 No. of patients receiving 
antidepressants in the 
past 6 months 
Prevalence,  
% (95% CI) 
Adjusted odds ratio (95% CI) 
Model 1* Model 2** Model 3*** 
Non-CKD patients without creatinine measurement in CPRD (N = 62,971) 4,515 7.2 (7.0 – 7.4) 0.49 (0.47 – 0.51) 0.48 (0.46 – 0.50) 0.52 (0.49 – 0.54) 
Non-CKD patients with creatinine measurement in CPRD (N = 179,378) 24,223 13.5 (13.3 – 13.7) 1 (Reference) 1 (Reference) 1 (Reference) 
CKD patients with eGFR 30-59 mL/min/1.73m2 at baseline (N = 228,055) 36,815 16.1 (16.0 – 16.3) 1.24 (1.22 – 1.27) 1.23 (1.21 – 1.26) 1.19 (1.16 – 1.21) 
CKD patients with eGFR <30 mL/min/1.73m2 at baseline (N = 14,294) 2,613 18.3 (17.6 – 18.9) 1.35 (1.26 – 1.44) 1.31 (1.23 – 1.41) 1.20 (1.12 – 1.29) 
CI = confidence interval, CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate. 
*Model 1: Adjusted by age, sex and financial year, and taking account of clustering by general practices with robust standard errors using unconditional logistic regression analysis. 
**Model 2: Model 1 + adjusted by ethnicity, socio-economic status, smoking status and body mass index. 
***Model 3: Model 2 + adjusted by chronic physical illnesses. 
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Table 3. Incidence of new antidepressant prescription.  
 
 Total follow-up 
length  
(person-years) 
No. of patients 
starting 
antidepressants  
Incidence rate  
(/1000 person-years)  
(95%CI) 
Adjusted rate ratio (95%CI) 
Model 1** Model 2*** Model 3*** 
Non-CKD patients without creatinine measurement in CPRD (N = 58,456) 258,474 7,076 27.4 (26.7 – 28.0) 0.55 (0.53 – 0.56) 0.58 (0.56 – 0.59) 0.60 (0.59 – 0.62) 
Non-CKD patients with creatinine measurement in CPRD (N = 155,155) 516,186 25,770 49.9 (49.3 – 50.5) 1 (Reference) 1 (Reference) 1 (Reference) 
CKD patients with eGFR 30-59 mL/min/1.73m2 (N = 191,240) 762,310 43,410 56.9 (56.4 – 57.5) 1.14 (1.12 – 1.16) 1.13 (1.11 – 1.15) 1.10 (1.09 – 1.12) 
CKD patients with eGFR <30 mL/min/1.73m2 (N = 11,681) 31,839 1,984 62.3 (59.6 – 65.1) 1.24 (1.18 – 1.30) 1.23 (1.17 – 1.28) 1.16 (1.11 – 1.22) 
CI = confidence interval, CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate, IQR = interquartile range.  
*Model 1: Adjusted by age, sex and financial year, and taking account of clustering by general practices with robust standard errors using unconditional Poisson regression analysis. 
**Model 2: Model 1 + adjusted by ethnicity, socio-economic status, smoking status and body mass index. 
***Model 3: Model 2 + adjusted by chronic physical illnesses. 
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Table 4. Recorded diagnoses for patients prescribed antidepressants stratified by type of antidepressant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients without CKD (N = 32,846) 
without creatinine measurement in CPRD 
(N = 7,076) 
with creatinine measurement in CPRD 
(N = 25,770) 
SSRI 
N = 2,984 
TCA 
N = 3,591 
Others 
N = 501 
SSRI 
N = 9,940 
TCA 
N = 14,081 
Others 
N = 1,749 
Depression, n (%)* 1,741 (58.3) 759 (21.1) 197 (39.3) 6,382 (64.2) 3,671 (26.1) 838 (47.9) 
Anxiety, n (%)* 1,030 (34.5) 646 (18.0) 133 (26.6) 3,813 (38.4) 3,256 (23.1) 575 (32.9) 
Neuropathic pain, n (%)* 76 (2.6) 478 (13.3) 19 (3.8) 549 (5.5) 2,058 (14.6) 133 (7.6) 
None of the above, n (%) 850 (28.5) 2,149 (59.8) 244 (48.7) 2,338 (23.5) 7,550 (53.6) 650 (37.2) 
 
 
Patients with CKD (N = 45,394) 
eGFR 30-59 mL/min/1.73m2 
(N = 43,410) 
eGFR <30 mL/min/1.73m2 
(N = 1,984) 
SSRI 
N = 17,124 
TCA 
N = 23,286 
Others 
N = 3,000 
SSRI 
N = 868 
TCA 
N = 976 
Others 
N = 140 
Depression, n (%)* 10,871 (63.5) 6,017 (25.8) 1,390 (46.3) 492 (56.7) 240 (24.6) 66 (47.1) 
Anxiety, n (%)* 5,904 (34.5) 4,874 (20.9) 897 (29.9) 227 (26.2) 181 (18.6) 38 (27.1) 
Neuropathic pain, n (%)* 942 (5.5) 3,348 (14.4) 201 (6.7) 55 (6.3) 143 (14.7) 8 (5.7) 
None of the above, n (%) 4,395 (25.7) 12,715 (54.6) 1,195 (39.8) 288 (33.2) 544 (55.7) 61 (43.6) 
CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate, SSRI = selective serotonin reuptake inhibitor, 
TCA = tricyclic antidepressants. 
*Percentages are column percentages. Each patient may have one or more recorded diagnosis. 
119
Table 5. Choice of antidepressants and initial prescription dose for patients with diagnosed depression.  
 Patients without CKD (N = 13,588) Patients with CKD (N = 19,076) 
 
without creatinine measurement 
 in CPRD  
N = 2,697 
with creatinine measurement 
 in CPRD 
N = 10,891 
with eGFR 30-59  
mL/min/1.73m2 at baseline 
N = 18,278 
with eGFR <30 
mL/min/1.73m2 at baseline 
N = 798 
 n (%)* 
Median initial dose 
(mg/day) [IQR] 
n (%)* 
Median initial dose 
(mg/day) [IQR] 
n (%)* 
Median initial dose 
(mg/day) [IQR] 
n (%)* 
Median initial dose 
(mg/day) [IQR] 
Selective serotonin 
reuptake inhibitors 
 
   
 
   
Citalopram 1,051 (39.0) 10 [10 – 20] 3,883 (35.7) 10 [10 – 20] 6,760 (37.0) 10 [10 – 20] 310 (38.9) 10 [10 – 20] 
Escitalopram 80 (3.0) 10 [5 – 10] 273 (2.5) 5 [5 – 10] 407 (2.2) 5 [5 – 10] 22 (2.8) 5 [5 – 10] 
Fluoxetine 381 (14.3) 20 [20 – 20] 1,270 (11.7) 20 [20 – 20] 2,171 (11.9) 20 [20 – 20] 99 (12.4) 20 [20 – 20] 
Fluvoxamine <5 (<0.2) n/a <5 (<0.1) n/a <5 (<0.1) n/a <5 (<0.6) n/a 
Paroxetine 35 (1.3) 20 [20 – 20] 97 (0.9) 20 [20 – 20] 133 (0.7) 20 [20 – 20] 11 (1.4) 20 [20 – 20] 
Sertraline 194 (7.2) 50 [50 – 50] 859 (7.9) 50 [50 – 50] 1,399 (7.7) 50 [50 – 50] 50 (6.3) 50 [50 – 50] 
Tricyclic and related 
antidepressants  
   
 
 
 
 
Amitriptyline 548 (20.3) 10 [10 – 15] 2,958 (27.2) 10 [10 – 20] 4,847 (26.5) 10 [10 – 15] 177 (22.2) 10 [10 – 15] 
Clomipramine <5 (<0.2) n/a 22 (0.2) 20 [10 – 37.5] 27 (0.2) 20 [10 – 37.5] <5 (<0.6) n/a 
Dosulepin 105 (3.9) 50 [25 – 75] 302 (2.8) 37.5 [25 – 75] 481 (2.6) 37.5 [25 – 50] 31 (3.9) 37.5 [25 – 75] 
Doxepin <5 (<0.2) n/a 17 (0.2) 25 [25 – 37.5] 23 (0.1) 25 [20 – 25] <5 (<0.6) n/a 
Imipramine <5 (<0.2) n/a 27 (0.3) 15 [10 – 25] 44 (0.2) 25 [10 – 30] <5 (<0.6) n/a 
Lofepramine 26 (1.0) 70 [70 – 140] 87 (0.8) 70 [70 – 140] 179 (1.0) 70 [70 – 140] 7 (0.9) 70 [70 – 140] 
Nortriptyline 10 (0.4) 15 [10 – 25] 84 (0.8) 15 [10 – 15] 155 (0.9) 10 [10 – 15] <5 (<0.6) n/a 
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Trimipramine <5 (<0.2) n/a 12 (0.1) 25 [15 – 37.5] 24 (0.1) 30 [15 – 50] <5 (<0.6) n/a 
Mianserin <5 (<0.2) n/a <5 (<0.1) n/a <5 (<0.1) n/a <5 (<0.6) n/a 
Trazodone 55 (2.0) 50 [50 – 100] 158 (1.5) 50 [50 – 100] 233 (1.3) 50 [50 – 75] 17 (2.1) 50 [50 – 75] 
Monoamine oxidase 
inhibitors** 
<5 (<0.2) n/a <5 (<0.1) n/a <5 (<0.1) n/a <5 (<0.6) n/a 
Other antidepressants:         
Agomelatine <5 (<0.2) n/a <5 (<0.1) n/a <5 (<0.1) n/a <5 (<0.6) n/a 
Duloxetine  15 (0.6) 60 [40 – 60] 83 (0.8) 40 [30 – 60] 164 (0.9) 40 [30 – 60] 5 (0.6) 60 [60 – 60] 
Flupentixol 17 (0.6) 1 [0.5 – 1] 46 (0.4) 0.5 [0.5 – 1] 82 (0.5) 1 [0.5 – 1] 6 (0.8) 0.5 [0.5 – 0.5] 
Mirtazapine 139 (5.2) 15 [15 – 15] 619 (5.7) 15 [15 – 15] 998 (5.5) 15 [15 – 15] 47 (5.9) 15 [15 – 15] 
Reboxetine <5 (<0.2) n/a <5 (<0.1) n/a <5 (<0.1) n/a <5 (<0.6) n/a 
Venlafaxine 19 (0.7) 75 [75 – 75] 66 (0.6) 75 [75 – 75] 94 (0.5) 75 [75 – 75] <5 (<0.6) n/a 
Two or more different 
antidepressants  
7 (0.3) n/a 20 (0.2) n/a 48 (0.3) n/a 5 (0.6) n/a 
CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate, IQR = interquartile range. 
*Cell counts less than five have been suppressed to preserve patient privacy. 
**Phenelzine, isocarboxazid, tranylcypromine and moclobemide are combined due to small sample sizes. 
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8.3. Additional data and discussions  
Further to the results and discussions presented in the published paper, here I show the 
additional data of unmatched patients with CKD and discuss the influence of excluding them 
from the main analysis. I also show the prevalence of antidepressant prescribing by year of 
cohort entry (i.e. the date of satisfying CKD definition for CKD patients, and the same date for 
matched controls without CKD) to discuss the temporal trend of antidepressant prescription in 
patients with and without CKD. 
8.3.1. Characteristics of unmatched patients with CKD 
(i) Backgrounds and methods 
When establishing a matched cohort of 242,349 pairs with and without CKD (median age 76 
years [IQR 70–82]; male, 39.3%) in chapter 7, I excluded 22,279 unmatched patients with 
CKD (mean age 88 years [IQR 84–92]; male, 31.5%) because of a lack of comparable patients 
without CKD. It is important to check their characteristics in detail. Here, I compared the 
baseline characteristics, including the distribution of CKD stage at the time of cohort entry, 
between unmatched and matched patients with CKD by chi-squared test. I also estimated the 
prevalence and incidence of antidepressant prescribing in unmatched patients with CKD, and 
combined the results of unmatched and matched patients with CKD to see how much the 
inclusion of unmatched patients with CKD could change the overall results. 
(ii) Results and discussions 
In addition to the older age and higher proportion of females, unmatched patients were more 
likely to be deprived and had more comorbidities except for diabetes, myocardial infarction, 
and rheumatoid arthritis, than matched patients with CKD (see Table 11 below). The 
distribution of CKD stage at cohort entry was worse in unmatched patients with CKD.  
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Table 11. Baseline characteristics of unmatched and matched patients with CKD 
 
Unmatched patients 
with CKD 
N = 22,279 
Matched patients 
with CKD 
N = 242,349 P value 
 n (%) n (%) 
Age (years):   - 
 <55 <5 (<0.1) 6,845 (2.8)  
 55-64 <5 (<0.1) 23,556 (9.7)  
 65-74 129 (0.6) 71,112 (29.3)  
 75-84 5,848 (26.3) 102,594 (42.3)  
 ≥85 16,300 (73.2) 38,242 (15.8)  
Sex (male): 7,015 (31.5) 95,318 (39.3) <0.001 
Ethnicity:   <0.001 
 White/not-recorded 22,084 (99.1) 238,138 (98.3)  
 South Asian  97 (0.4) 2,317 (1.0)  
 Black 52 (0.2) 1,060 (0.4)  
 Other ethnicity 46 (0.2) 834 (0.3)  
Socio-economic status:   <0.001 
 1 (least deprived) 4,633 (20.8) 53,034 (21.9)  
 2 5,510 (24.7) 60,501 (25.0)  
 3 4,546 (20.4) 50,709 (20.9)  
 4 4,166 (18.7) 44,692 (18.4)  
 5 (most deprived) 3,424 (15.4) 33,413 (13.8)  
Smoking status:   <0.001 
 Non-smoker 9,465 (42.5) 80,721 (33.3)  
 Ex-smoker 10,881 (48.8) 131,510 (54.3)  
 Current-smoker 1,752 (7.9) 29,243 (12.1)  
Body mass index (kg/m2):   <0.001 
 <18.5 961 (4.3) 4,562 (1.9)  
18.5 – 25 8,536 (38.3) 70,102 (28.9)  
 ≥25 6,339 (28.5) 88,083 (36.4)  
 ≥30 2,638 (11.8) 63,183 (26.1)  
Chronic physical illnesses:    
 Diabetes mellitus 3,182 (14.3) 52,802 (21.8) <0.001 
 Congestive heart failure 2,974 (13.4) 23,774 (9.8) <0.001 
 Myocardial infarction 2,109 (9.5) 25,746 (10.6) <0.001 
 Stroke 2,424 (10.9) 19,982 (8.3) <0.001 
 COPD 1,681 (7.6) 18,229 (7.5) 0.899 
 Rheumatoid arthritis 466 (2.1) 6,031 (2.5) <0.001 
 Cancer 6,402 (28.7) 54,450 (22.5) <0.001 
 Parkinson’s disease 190 (1.3) 2,293 (1.0) <0.001 
 Epilepsy 327 (1.5) 3,682 (1.5) 0.547 
CKD stage at cohort entry:   <0.001 
 3a (eGFR 45-59 mL/min/1.73m2) 13,398 (60.1) 172,555 (71.2)  
 3b (eGFR 30-44 mL/min/1.73m2) 6,959 (31.2) 55,500 (22.9)  
 4/5 (eGFR <30 mL/min/1.73m2) 1,922 (8.6) 14,294 (5.9)  
Abbreviations: CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; 
eGFR = estimated glomerular filtration rate. 
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The prevalence and incidence of antidepressant prescription were slightly higher in unmatched 
patients with CKD than matched patients with CKD (see Tables 12 and 13 below). However, 
by adding the results of unmatched patients with CKD, the total prevalence and incidence of 
antidepressant prescription in all patients with CKD were very similar to those in matched 
patients with CKD. 
Unmatched patients with CKD had quite different characteristics from matched patients with 
CKD. The reason for failure to match was probably because almost all patients had CKD in 
the oldest age group (i.e. those aged >85 years), especially females. Accordingly, most of the 
differences in characteristics between unmatched and matched patients with CKD were 
probably ascribed to the large age-sex difference between the groups. The prevalence and 
incidence of antidepressant prescription were slightly higher in unmatched patients with CKD 
than matched patients with CKD. However, because of the small proportion of unmatched 
group (8.4% [22,279/264,628]), the exclusion of unmatched patients with CKD rarely affected 
the study results. Therefore, the exclusion of these patients from the main analysis, prioritising 
a fairer comparison between patients with and without CKD, is justified. 
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Table 12. Prevalence of antidepressant prescription in unmatched and matched patients with CKD 
 No. of prevalent users (i.e. patients receiving 
antidepressants in the past six months 
Prevalence, % (95% confidence interval) 
Unmatched patients with CKD (N = 22,279) 4,005 18.0 (17.5 – 18.5) 
Matched patients with CKD (N = 242,349) 39,428 16.3 (16.1 – 16.4) 
Total (N = 264,628) 43,433 16.4 (16.3 – 16.6) 
Abbreviation: CKD = chronic kidney disease. 
 
Table 13. Incidence of antidepressant prescription in unmatched and matched patients with CKD 
 Total follow-up length 
(person-years) 
No. of new users (i.e. patients 
starting antidepressants 
among non-prevalent users) 
Incidence rate (/1000 person-years) 
(95% confidence interval) 
Unmatched patients with CKD (N = 18,274) 47,894 3,015 63.0 (60.7 – 65.2) 
Matched patients with CKD (N = 202,921) 794,150 45,394 57.2 (56.6 – 57.7) 
Total (N = 221,195) 842,044 48,409 57.5 (57.0 – 58.0) 
Abbreviation: CKD = chronic kidney disease. 
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8.3.2. Temporal trend in the prevalence of antidepressant prescribing by CKD status 
(i) Backgrounds and methods 
In the published paper, I showed the overall prevalence of antidepressant users by CKD status 
at the time of cohort entry and estimated an adjusted odds ratio by assuming that the association 
between CKD and prevalence of antidepressant prescription was constant throughout the study 
period. Here, to examine the temporal trend, I show the prevalence of antidepressant 
prescription by financial year (i.e. from 1 April to 31 March) of cohort entry (i.e. the date of 
satisfying CKD definition for CKD patients, and the same date for matched controls without 
CKD) and test whether the adjusted odds ratio changed significantly over the study period. P 
value for trend was estimated by including an interaction term between CKD status and 
financial year (as a continuous variable) in the multivariable logistic regression model. 
(ii) Results and discussions 
The crude prevalence of patients with antidepressant prescribing gradually increased from 
15.4% in 2004 to 20.5% in 2013 among patients with CKD, while it also increased from 10.9% 
in 2004 to 15.3% in 2013 among patients without known CKD (see the left axis and lines in 
Figure 11 below). The fully-adjusted odds ratio (patients with versus without CKD) for the 
prevalence of antidepressant prescription was almost constant at around 1.35 (see the right axis 
and point estimates with CIs in Figure 11), with no statistically significant change over the ten 
years (P for trend = 0.318).  
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Figure 11. Prevalence of antidepressant prescription in patients with and without CKD 
and adjusted odds ratio by financial year of cohort entry 
 
Abbreviations: CKD = chronic kidney disease; CI = confidence interval. 
Note: The solid and dotted lines suggest the prevalence of antidepressant users at the time of 
cohort entry (i.e. the date of satisfying CKD definition for CKD patients, and the same date for 
matched controls without CKD) in patients with and without CKD, respectively, with the scales 
on the left axis. The point estimates and confidence intervals imply the fully-adjusted odds 
ratio comparing patients with and without CKD each year, with the scales on the right axis. 
 
The upward trend in the prevalence of antidepressant prescription, regardless of CKD status, 
is in line with an English study showing that the number of antidepressant prescription 
constantly increased from 1998 to 2010 [127]. The strength of the association between CKD 
and prevalence of antidepressant prescription was almost constant over the ten years. However, 
because of its continuous increase in absolute number and proportion of antidepressant users, 
examining the safety of antidepressant use in patients with CKD seems to be becoming more 
and more important. 
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8.4. Chapter summary 
CKD and antidepressant prescription 
- This study examined the prevalence, incidence, indication, and choice of antidepressants 
in patients with CKD, as compared with those without known CKD in the general 
population matched for age, sex, general practice, and calendar time. 
- The crude prevalence and incidence of antidepressant prescribing in patients with CKD 
were around one and half times as high as those without CKD. 
- After adjusting for potential confounding factors (e.g. diabetes and heart failure), there was 
an independent association between CKD status and prevalence/incidence of 
antidepressant prescription. 
- Indication and choice of antidepressant prescribing were similar between patients with and 
without CKD.  
- There was an upward trend in the prevalence of antidepressant prescription over the ten-
year study period, both in patients with and without CKD.  
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Chapter 9: Gastrointestinal bleeding risk of selective serotonin 
reuptake inhibitors by level of kidney function: a population-based 
cohort study (Paper 4) 
9.1. Introduction 
This chapter presents a cohort study estimating the GI bleeding risk of SSRIs by level of kidney 
function, accepted by British Journal of Clinical Pharmacology [128].  
The main research question is: Is the risk of GI bleeding associated with SSRIs increased in 
patients with lower kidney function? 
Briefly, I used the cohort established in chapter 7, including 242,349 patients with CKD 
(consisting of 172,555 patients with CKD stage 3a, 55,500 patients with CKD stage 3b, and 
14,294 patients with CKD stage 4/5 at the time of cohort inclusion) and 242,349 patients 
without known CKD.  
Exposure was time-dependent SSRI prescription, because SSRIs are frequently started and 
stopped in clinical care: a previous study in UK primary care suggested that, among older 
people with a diagnosis of depression, duration of antidepressant treatment per treatment 
episode was median 179 (IQR 56–528) days (including 90-day washout periods), and more 
than half of the study participants had two or more treatment episodes during follow-up [129]. 
Outcome was first hospitalisation for GI bleeding. I estimated the relative risk of GI bleeding 
associated with SSRIs (i.e. the fully-adjusted rate ratio between periods with and without SSRI 
prescription) and the excess risk of GI bleeding associated with SSRIs (i.e. the fully-adjusted 
rate difference between periods with and without SSRI exposure) by level of kidney function. 
Then, I tested whether the relative risk and excess risk increased as kidney function deteriorated.  
Later in this chapter, I am showing an additional sensitivity analysis by including diagnoses of 
GI bleeding recorded in the CPRD (in addition to HES Admitted Patient Care). 
 
9.2. Published paper 
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AIM
To estimate the risk of gastrointestinal (GI) bleeding associated with serotonin reuptake inhibitors (SSRIs) by level of kidney
function.
METHODS
We conducted a cohort study using the Clinical Practice Research Datalink linked to Hospital Episode Statistics. We identiﬁed
patients with chronic kidney disease (CKD; estimated glomerular ﬁltration rate <60 ml min–1 1.73 m–2 for ≥3 months), and a
comparison group of patients without it. Patients with CKDwere further classiﬁed as stage 3a (eGFR 45–59ml min–1 1.73m–2), 3b
(30–44 ml min–1 1.73 m–2) and 4/5 (<30 ml min–1 1.73 m–2). We excluded prevalent SSRI users at cohort entry. Exposure was
time-dependent SSRI prescription and outcome was ﬁrst hospitalization for GI bleeding. We estimated adjusted rate ratio (aRR)
and rate difference (aRD) of GI bleeding comparing periods with and without SSRI prescription at each level of kidney function.
RESULTS
The aRRs and aRDs were: (i) no CKD (n = 202 121) aRR: 1.66 (95%CI 1.37–2.01), aRD: 2.0/1000 person–years (5.5 vs. 3.5/1000
person–years in period with and without SSRIs); (ii) CKD stage 3a (n = 153 316) aRR: 1.86 (1.62–2.15), aRD: 4.2/1000
person–years (8.3 vs. 4.1/1000 person–years); (iii) CKD stage 3b (n = 46 482) aRR: 1.61 (1.27–2.04), aRD: 4.8/1000 person–years
(9.9 vs. 5.1/1000 person–years); and (iv) CKD stage 4/5 (n = 11 197) aRR: 1.84 (1.14–2.96), aRD: 7.9/1000 person–years (15.3 vs.
7.4/1000 person–years). While there was no evidence of increase in the aRR (P = 0.922), there was strong evidence that the aRD
increased as kidney function deteriorated (P = 0.001).
CONCLUSIONS
While the relative risk was constant, the excess risk of GI bleeding associated with SSRIs markedly increased among patients with
decreased kidney function.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Previous studies have suggested that use of selective serotonin reuptake inhibitors (SSRIs) is associated with increased risk
of gastrointestinal (GI) bleeding.
• Patients with decreased kidney function are known to have an increased risk of bleeding.
• However, no study has investigated the risk of GI bleeding associated with SSRIs at different levels of kidney function.
WHAT THIS STUDY ADDS
• We estimated the relative and absolute risks of GI bleeding associated with SSRI prescription at different levels of kidney
function.
• While the relative risk of GI bleeding associated with SSRIs was similar at different levels of kidney function, the excess
risk of GI bleeding associated with SSRIs increased as kidney function deteriorated.
• Therefore, we recommend careful use of SSRIs in patients with decreased kidney function.
Introduction
Chronic kidney disease (CKD) is a common condition in the
community [1], and is independently associated with
increased risk of bleeding in operative and nonoperative
settings [2–4]. Gastrointestinal (GI) bleeding is the most com-
mon manifestation of bleeding [5].
Patients with CKD are known to have increased
prevalence of mental-health problems such as depression
and anxiety [6, 7]. Accordingly, our recent study suggested
that patients with CKD (not on dialysis) have antidepressants
prescribed more frequently than patients without it [8].
Selective serotonin reuptake inhibitors (SSRIs) are currently
recommended as the ﬁrst choice of drug therapy for
depressed patients [9]. The number of SSRI prescriptions has
been steadily increasing in the UK and US [10, 11].
There is concern regarding the bleeding risk associated
with SSRIs, because SSRIs block serotonin reuptake in
platelets and inhibit platelet aggregation [12, 13]. A number
of studies have shown an association between the use of SSRIs
and GI bleeding [14–24]. However, none of these studies
focused on the risk of GI bleeding associated with SSRIs
among patients with CKD. SSRI-associated GI bleeding is of
particular concern among patients with CKD [25, 26],
because: (i) CKD is itself a risk factor for GI bleeding [3]; and
(ii) SSRIs may accumulate in patients with CKD due to
reduced renal clearance and altered pharmacokinetics [27].
Despite these concerns, the absolute and relative risks of
GI bleeding associated with SSRI use amongst patients with
reduced kidney function have not been quantiﬁed. We there-
fore undertook a population-based study addressing this
question in a large UK primary care database.
Methods
Data sources
The Clinical Practice Research Datalink (CPRD) is a database
of routinely recorded primary care electronic health record
data from 7% of the UK population [28]. The CPRD includes
the following information: patient demographics, coded di-
agnoses (Read codes), prescriptions, laboratory test results,
and referrals recorded by general practitioners (GPs). The
CPRD is linked with other resources, including Hospital
Episode Statistics (HES), Ofﬁce for National Statistics
mortality data and Index of Multiple Deprivation data. HES
contains details of all hospital admissions to the National
Health Service hospitals in England, and consists of primary
and subsidiary diagnoses recorded during admission using
the 10th revision of International Classiﬁcation of Disease
(ICD-10) codes [29]. Currently, around 400 general practices
in CPRD (accounting for 75% of general practices in CPRD
in England) have agreed to linkage with HES data for research
purposes. Study approval was obtained from the ethics
committee of the London School of Hygiene and Tropical
Medicine (reference: 9196) and the Independent Scientiﬁc
Advisory Committee, which oversees research involving
CPRD data (Protocol 15_219R).
Study cohort
We used a matched cohort including 242 349 patients with
CKD and 242 349 patients without it, which was established
in our previous study for the prevalence and incidence of an-
tidepressant prescribing by CKD status [8]. Using HES-linked
CPRD between 1 April 2004 and 31March 2014, we ﬁrst iden-
tiﬁed adult patients with CKD (not on renal replacement
therapy) based on two consecutive measurements of eGFR
<60 ml min–1 1.73 m–2 for ≥3 months [30] (Figure 1). Esti-
mated GFR was calculated from serum creatinine values re-
corded in CPRD, using the Chronic Kidney Disease
Epidemiology Collaboration equation [31]. Patients were eli-
gible for cohort entry from the latest of: 1 April 2004, 1 year
after practice registration (to allow GPs to record the past
medical history of newly registered patients) or the date the
patient’s general practice reached CPRD’s data quality stan-
dards [28]. Patients entered the cohort on the date when they
ﬁrst satisﬁed the CKD deﬁnition (i.e. second eGFR
<60 ml min–1 1.73 m–2) after meeting the eligibility criteria.
We then identiﬁed a comparison group of patients without
known CKD from the remaining HES-linked CPRD popula-
tion. To establish a balanced comparison group in terms of
basic patient characteristics, we randomly selected a patient
without known CKD with the same age, sex, general practice
and calendar time (i.e. same date of cohort entry) as a patient
with CKD.
Patients with CKD were further classiﬁed according to
eGFR on the date of cohort entry: CKD stage 3a (eGFR
45–59 ml min–1 1.73 m–2), stage 3b (30–44 ml min–1 1.73 m–2),
and stage 4 or 5 (<30 ml min–1 1.73 m–2) [30]. CKD stage
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was regarded as constant (i.e. non-time updated) during
follow-up. We then excluded the following patients:
(i) prevalent SSRI users (GI bleeding could occur shortly af-
ter SSRI initiation [17], therefore inclusion of prevalent SSRI
users with drug tolerance may cause bias [32]); (ii) those
with a history of GI bleeding (to capture new-onset GI
bleeding more likely to be related to drug exposure); and
(iii) those with missing values of smoking status and body
mass index (BMI).
Exposure and outcome
SSRIs are frequently started and stopped in clinical care [33].
Our exposure of interest was therefore time-dependent pre-
scription of SSRIs. The duration of each prescription was esti-
mated by dividing the total number of tablets prescribed by
the number of tablets to be taken each day (daily dose). When
the daily dose or total number of tablets was missing (9.6% of
the records), we imputed the median prescription duration
(28 days). We assumed that patients were continuously ex-
posed to SSRIs if there were no gaps of more than 30 days be-
tween the end of one prescription and the start of the next (to
allow potential medication stockpiling or prescribing in sec-
ondary care) [14]. If there was no subsequent prescription of
SSRIs, we considered patients could be inﬂuenced by the ef-
fect of SSRIs until 30 days after the end of the prescription.
Thus, each episode of SSRI treatment started at the ﬁrst SSRI
prescription (as a new treatment episode) and continued un-
til 30 days after a break in continuous prescribing of 30 days
(or more). A patient could contribute multiple episodes of
SSRI treatment during follow-up. In sensitivity analyses, we
changed our assumption of a 30-day duration of periods
between prescriptions and washout periods to 60 days and
90 days.
The outcome was the ﬁrst hospitalization with a primary
diagnosis of GI bleeding, based on a list of ICD-10 codes
(Appendix S1). Patients were followed up until the earliest
of: the outcome of interest, initiation of renal replacement
therapy, death, change of general practice, last data collection
from the practice or 31 March 2014.
Covariates
We considered the following potential confounders in the as-
sociation between SSRI prescription and GI bleeding [14–24]:
age and sex; ethnicity; socio-economic status; BMI; smoking
status; comorbidities (diabetes mellitus, chronic liver disease,
congestive heart failure, cancer, and rheumatoid arthritis);
and prescribed drugs including anticoagulants, antiplatelet
drugs (including aspirin), nonsteroidal anti-inﬂammatory
drugs (excluding aspirin), oral corticosteroids, and acid-
suppressing agents. We classiﬁed patients with no record of
ethnicity as white, consistent with previous UK studies [34].
Socioeconomic status was assigned at an individual level,
using quintiles of 2010 Ofﬁce for National Statistics estimates
of the Index of Multiple Deprivation (a composite area-level
marker of deprivation) [35]. Smoking status and BMI were
assigned using the data recorded closest to cohort entry and
assumed to be constant during follow-up. We deﬁned each
comorbidity as present or absent based on recording of a rel-
evant diagnostic code in CPRD on the day of, or prior to, co-
hort entry. For prescribed drugs, we used the same strategy
as SSRIs by regarding them as time-dependent confounding
factors.
Statistical analysis
We described baseline patient characteristics by level of kid-
ney function. We showed the length of time people received
an SSRI prescription and the time without, at each level of
kidney function (i.e. no CKD, CKD stage 3a, stage 3b, and
stage 4 or 5). We also showed the number of ﬁrst hospitaliza-
tions due to GI bleeding, providing the crude incidence rate
of the outcome by SSRI prescription status at each level of kid-
ney function.
We conducted prespeciﬁed analyses using two common
measures of effect to understand the GI bleeding risk
Figure 1
Flow chart for selecting the study participants. BMI = body mass index, CKD = chronic kidney disease, CPRD = Clinical Practice Research Datalink,
GI = gastrointestinal, HES = Hospital Episode Statistics, RRT = renal replacement therapy, SSRI = selective serotonin reuptake inhibitor
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associated with SSRIs: risk ratio and risk difference [36]. First,
we estimated an adjusted rate ratio for GI bleeding when pre-
scribed an SSRI, compared to time not prescribed an SSRI,
using multiplicative Poisson regression analyses. Multiplica-
tive models assume that the risk of the outcome is multiplied
by different risk factors. We established multiplicative
Poisson models for hospitalization due to GI bleeding com-
paring periods with and without SSRI prescription at each
level of kidney function, ﬁrst adjusting for age and sex; and
then further adjusting for ethnicity, socioeconomic status,
BMI, smoking status, comorbidities, and prescribed drugs.
We then conducted a test for multiplicative interaction (ef-
fect modiﬁcation) between SSRI prescription and kidney
function in the fully-adjusted model. A signiﬁcant multipli-
cative interaction would suggest that the risk ratio (period
with vs. without SSRI prescription) is different at different
levels of kidney function. We estimated a multiplicative in-
teraction P-value for trend, using the log-likelihood ratio test
comparing the Poisson models with and without an interac-
tion term between SSRI prescription status and kidney
function.
Next, we estimated an adjusted rate difference (between
period with and without SSRI prescription) for GI bleeding
at each level of kidney function and tested whether the ad-
justed rate difference increased as kidney function deterio-
rated, using additive Poisson regression analyses. Additive
models assume that risk differences from different risk factors
are added together to estimate the risk of outcome [37] and,
therefore, can directly test an additive interaction [38]. We
established a fully-adjusted additive Poisson model for GI
bleeding (Appendix S2 for more detail). We then calculated
an adjusted incidence rate with or without SSRI prescription
at each level of kidney function, by applying the average ef-
fect of each covariate on the risk of GI bleeding in the study
population in the fully-adjusted additive Poisson model
(Appendix S3 for more detail). Thus, the adjusted incidence
rate in each group stratiﬁed by SSRI prescription status and
level of kidney function represents a hypothetical incidence
rate if the confounders (e.g. diabetes) are equally distributed
between the groups. We then estimated an adjusted rate dif-
ference between the period with and without SSRI prescrip-
tion at each level of kidney function. Finally, we conducted
a test for additive interaction between SSRI prescription sta-
tus and kidney function. A signiﬁcant additive interaction
would suggest that the risk difference (between period with
and without SSRI prescription) is different at different levels
of kidney function. We calculated an additive interaction
P-value for trend, using the log-likelihood ratio test compar-
ing the models with and without an interaction term be-
tween SSRI prescription and kidney function.
All the data management and statistical analyses were
conducted using STATA version 14 (Stata Corp, Texas). A
P-value of < 0.05 was inferred as statistically signiﬁcant.
Subgroup analysis
We conducted posthoc subgroup analyses (separately) by
SSRI dose and receptor afﬁnity in the fully-adjusted multi-
plicative Poisson regression models. Based on the deﬁned
daily dose (DDD) of each SSRI (20 mg day–1 for citalopram,
10 mg day–1 for escitalopram, 20 mg day–1 for ﬂuoxetine,
100 mg day–1 for ﬂuvoxamine, 20 mg day–1 for paroxetine
and 50 mg day–1 for sertraline) [39], we dichotomized the pe-
riods of SSRI prescription into two categories: periods of low
dose (i.e. smaller daily dose thanDDD), and periods of normal
or high dose (i.e. same as or higher dose than DDD). Low and
normal/high dose periods were compared to periods without
SSRI prescription. For the serotonin receptor afﬁnity sub-
group analysis, we divided the periods of SSRI prescription
into two categories [17]: SSRIs with intermediate afﬁnity to
the serotonin receptor (including citalopram, ﬂuvoxamine
and escitalopram), and thosewithhigh afﬁnity (includingﬂu-
oxetine, paroxetine and sertraline).
Results
Among 4 070 806 adult patients without renal replacement
therapy [median age 39 years (interquartile range, IQR 27–
56), male 48.8%] registered in HES-linked CPRD between
2004 and 2014, we identiﬁed 264 628 patients with CKD [me-
dian age 77 years (IQR 71–83), male 38.7%]. Of those with
CKD, 242349 [92%; median age 76 years (IQR 70–82), male
39.3%] were matched with a patient without known CKD
who had the same age, sex, general practice, and same date
of cohort entry (Figure 1). After excluding (i) prevalent SSRI
users at cohort entry, (ii) those with a history of GI bleeding
and (iii) those withmissing values of BMI and smoking status,
there were 413 116 study participants including 202 121 pa-
tients without known CKD, 153316 patients with CKD stage
3a, 46 482 patients with CKD stage 3b, and 11197 patients
with CKD stage 4 or 5. The number of patients exposed to
SSRIs during the study period was 16 911 (4.1% of patients
without known CKD), 18 545 (12.1% of patients with CKD
stage 3a), 5803 (12.5% of patients with CKD stage 3b) and
1063 (9.5% of patients with CKD stage 4 or 5), respectively.
The patterns of prescribed SSRI and dose were similar at differ-
ent levels of kidney function (Appendix S4). Patients with
CKD were more likely to have a lower socioeconomic status,
had a higher prevalence of many comorbidities and were
more likely to be prescribedmedications at baseline (Table 1).
In the total cohort, there were 7249 ﬁrst hospitalizations
due to GI bleeding during total follow up of 1 801 316
person–years [median follow-up length 4.0 years (IQR 1.7–
6.8 years)]. Crude incidence rate for GI bleeding was generally
higher among patients with more advanced CKD stages, and
was higher during the period with SSRI prescription than the
period without SSRI prescription at each level of kidney func-
tion (Table 2).
In the fully-adjusted multiplicative Poisson regression
model, the adjusted rate ratio (period with vs. without SSRI
prescription) was 1.66 [95% conﬁdence interval (CI),
1.37–2.01] among patients with no CKD, 1.86 (1.62–2.15)
among patients with CKD stage 3a, 1.61 (1.27–2.04) among
patients with CKD stage 3b, and 1.84 (1.14–2.96) among pa-
tients with CKD stage 4 or 5 (Table 2). A test for multiplicative
interaction in the fully-adjusted multiplicative Poisson
model gave a P-value for trend of 0.922, suggesting that there
is no evidence of increased relative risk of GI bleeding related
to SSRI prescription among patients with more advanced
CKD stages.
SSRI and GI bleeding by kidney function
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Table 1
Baseline characteristics of patients by level of kidney function
Patients with no
CKD (N = 202 121)
Patients with CKD
stage 3a (N = 153 316)
Patients with CKD
stage 3b (N = 46 482)
Patients with CKD s
tage 4/5 (N = 11 197)
n (%) n (%) n (%) n (%)
Age (years):
<65 26 464 (13.1) 21 437 (14.0) 3835 (8.3) 1565 (14.0)
65–74 63 882 (31.6) 52 388 (34.2) 10 676 (23.0) 2292 (20.5)
75–84 86 433 (42.8) 63 509 (41.4) 22 241 (47.9) 4653 (41.6)
≥85 25 342 (12.5) 15 982 (10.4) 9730 (20.9) 2687 (24.0)
Sex (male) 81 861 (40.5) 62 828 (41.0) 17 928 (38.6) 5044 (45.1)
Ethnicity:
White/not recorded 198 618 (98.3) 150 538 (98.2) 45 673 (98.3) 10 855 (97.0)
South Asian 1657 (0.8) 1552 (1.0) 444 (1.0) 164 (1.5)
Black 1089 (0.5) 687 (0.5) 194 (0.4) 121 (1.1)
Other ethnicity 757 (0.4) 539 (0.4) 171 (0.4) 57 (0.5)
Socioeconomic status:
1 (least deprived) 47 706 (23.6) 34 538 (22.5) 9552 (20.6) 2083 (18.6)
2 51 542 (25.5) 38 806 (25.3) 11 362 (24.4) 2567 (22.9)
3 41 977 (20.8) 31 792 (20.7) 9749 (21.0) 2394 (21.4)
4 35 234 (17.4) 27 911 (18.2) 8860 (19.1) 2318 (20.7)
5 (most deprived) 25 662 (12.7) 20 269 (13.2) 6959 (15.0) 1835 (16.4)
Body mass index (kg m–2):
<18.5 6105 (3.0) 2590 (1.7) 1193 (2.6) 338 (3.0)
18.5–25 81 294 (40.2) 46 340 (30.2) 15 342 (33.0) 3898 (34.8)
≥25 76 780 (38.0) 61 231 (39.9) 17 618 (37.9) 3997 (35.7)
≥30 37 942 (18.8) 43 155 (28.2) 12 329 (26.5) 2964 (26.5)
Smoking status:
Non-smoker 74 991 (37.1) 48 878 (31.9) 15 173 (32.6) 3636 (32.5)
Ex-smoker 96 231 (47.6) 86 433 (56.4) 25 597 (55.1) 6056 (54.1)
Current-smoker 30 899 (15.3) 18 005 (11.7) 5712 (12.3) 1505 (13.4)
Comorbidities:
Diabetes mellitus 21 908 (10.8) 33 463 (21.8) 11 082 (23.8) 3205 (28.6)
Chronic liver disease 963 (0.5) 1068 (0.7) 348 (0.8) 95 (0.9)
Congestive heart failure 5873 (2.9) 10 700 (7.0) 6607 (14.2) 2344 (20.9)
Cancer 40 291 (19.9) 32 872 (21.4) 11 240 (24.2) 2864 (25.6)
Rheumatoid arthritis 3571 (1.8) 3667 (2.4) 1156 (2.5) 276 (2.5)
Prescribed drugs (at cohort entry)a:
Antiplatelet drugs 46 531 (23.0) 55 929 (36.5) 19 082 (41.1) 4655 (41.6)
Anticoagulants 6672 (3.3) 10 120 (6.6) 3882 (8.4) 904 (8.1)
Non-steroidal anti-inﬂammatory drugs 14 084 (7.0) 14 245 (9.3) 4810 (10.4) 933 (8.3)
Oral corticosteroids 5343 (2.6) 6319 (4.1) 2432 (5.2) 673 (6.0)
Acid-suppressing agents 32 476 (16.1) 37 370 (24.4) 12 803 (27.5) 3472 (31.0)
CKD, chronic kidney disease.
aprescribed drugs were time-updated during the follow-up.
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In the fully-adjustedadditivePoissonmodel (AppendixS2),
we applied the average effect of each covariate on the risk of
GI bleeding in the study population (Appendix S3) to esti-
mate adjusted rates for GI bleeding by SSRI prescription status
at each level of kidney function (Figure 2). The adjusted rate
difference increased from 2.0/1000 person–years among
patients with no CKD (due to the adjusted rate of 5.5 vs.
3.5/1000 person–years in period with and without SSRI
prescription, respectively), to 4.2/1000 person–years among
patients with CKD stage 3a (8.3 vs. 4.1/1000 person–years),
to 4.8/1000 person–years among patients with CKD stage 3b
(9.9 vs. 5.1/1000 person–years), and to 7.9/1000 person–years
among patients with CKD stage 4/5 (15.3 vs. 7.4/1000
person–years). A test for additive interaction gave a P-value
for trend of 0.001, suggesting that there is strong evidence
of increased risk difference of GI bleeding related to SSRI pre-
scription as kidney function deteriorates.
In sensitivity analyses, the results were similar after
changing our assumption about the length of periods be-
tween prescriptions and washout periods of SSRI prescription
from 30 days to 60 and 90 days (Appendix S5).
In subgroup analyses, at each level of kidney function, the
95% CIs of adjusted rate ratios for periods with low and
normal/higher dose of SSRIs largely overlapped, as did the
CIs for periods exposed to SSRIs with intermediate afﬁnity
and those for SSRIs with high afﬁnity (Appendices S6 and S7).
Discussion
In this large population-based study, we demonstrated that
the relative risk of GI bleeding associated with SSRI exposure
(i.e. the fully-adjusted rate ratio between periods with and
without SSRI prescription) was around 1.7 regardless of kid-
ney function. However, we showed strong evidence that the
excess risk of GI bleeding (i.e. the fully-adjusted rate
difference between periods with and without SSRI exposure)
increased substantially as renal function declined;
ranging from 2.0/1000 person–years among patients with
no CKD to 7.9/1000 person–years among patients with CKD
stage 4/5.
Table 2
Crude incidence rate by selective serotonin reuptake inhibitor prescription status and adjusted rate ratio for the ﬁrst hospitalization due to gastro-
intestinal bleeding among patients with different levels of kidney function
Length of follow-up
(person–years)
Number of
outcomes
Crude incidence
rate (95%CI)
(/1000 person–years)
Age- and sex-adjusted
rate ratio (95% CI)
Fully-adjusteda
rate ratio (95% CI)
Total in the cohort
(N = 413 116)
1 801 316 7249 4.0 (3.9–4.1) - -
Among patients with no
CKD (N = 202 121):
Period without SSRI
prescription
808 125 2413 3.0 (2.9–3.1) 1 (Ref.) 1 (Ref.)
Period with SSRI
prescription
19 152 110 5.7 (4.8–6.9) 1.98 (1.64–2.40) 1.66 (1.37–2.01)
Among patients with CKD
stage 3a (N = 153 316):
Period without SSRI
prescription
709 140 2962 4.2 (4.0–4.3) 1 (Ref.) 1 (Ref.)
Period with SSRI
prescription
23 311 204 8.8 (7.6–10.0) 2.16 (1.88–2.49) 1.86 (1.62–2.15)
Among patients with CKD
stage 3b (N = 46 482):
Period without SSRI
prescription
198 735 1174 5.9 (5.6–6.3) 1 (Ref.) 1 (Ref.)
Period with SSRI
prescription
6904 73 10.6 (8.4–13.3) 1.85 (1.46–2.34) 1.61 (1.27–2.04)
Among patients with CKD
stage 4/5 (N = 11 197):
Period without SSRI
prescription
34 894 295 8.5 (7.5–9.5) 1 (Ref.) 1 (Ref.)
Period with SSRI
prescription
1055 18 17.1 (10.8–27.1) 2.10 (1.30–3.38) 1.84 (1.14–2.96)
CI = conﬁdence interval, CKD = chronic kidney disease, SSRI = selective serotonin reuptake inhibitor.
aadjusted for age, sex, ethnicity, socio-economic status, body mass index, smoking status, comorbidities (diabetes mellitus, chronic liver disease,
congestive heart failure, cancer, and rheumatoid arthritis), and prescribed drugs (antiplatelet drugs, anticoagulants, non-steroidal anti-inﬂammatory
drugs, oral corticosteroids, and acid-suppressing agents).
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To our knowledge, this is the ﬁrst study examining the
risk of GI bleeding associated with SSRIs at different levels
of kidney function, and testing multiplicative and additive
interactions between SSRI prescription and kidney func-
tion. The relative risk of GI bleeding due to SSRI prescrip-
tion found in our study (around 1.7 regardless of kidney
function) was consistent with that of a recent
meta-analysis [13], which found a pooled relative risk of
GI bleeding associated with SSRI use of 1.55 (95% CI,
1.35–1.78) across 22 studies. However, none of the studies
included in the meta-analysis estimated an adjusted rate
difference between patients (or periods of time) with and
without SSRI prescription. This additional information is
extremely useful. Because there are likely to be many con-
founders between patients (or periods of time) with and
without SSRI prescriptions, a crude rate difference of the
outcome between the groups may be substantially different
from that attributable to the medication.
There are several reasons for being concerned about a
potential ampliﬁcation of the relative risk of GI bleeding as-
sociated with SSRIs among patients with decreased kidney
function. Firstly, there is some evidence that renal clearance
of SSRIs is decreased and their elimination half-life is
prolonged in patients with decreased kidney function [27].
Other aspects of pharmacokinetics, such as liver metabo-
lism and plasma protein binding, may also be altered
among patients with CKD [40]. Furthermore, polypharmacy
is common among patients with CKD [41], and, therefore,
a potential drug–drug interaction between SSRIs and other
drugs could increase the bleeding risk of SSRIs in the CKD
population. However, in our real-world data, the relative
risk of SSRIs was found to be similar irrespective of baseline
kidney function, with no evidence of multiplicative
interaction.
However, there was strong evidence that the excess risk of
GI bleeding associated with SSRI exposure increased substan-
tially as kidney function declined. This represents a public-
health interaction [42]; a larger absolute risk increase means a
larger number of patients experiencing the outcome, suggest-
ing a larger public-health burden in the population. Even
when the relative risk of a drug is constant across subgroups,
the absolute number of patients who experience an adverse
effect of the drug will be larger in a group with a high risk of
the outcome. We formally tested if this was the case in our
study by adjusting for comorbidities and medications, the
distribution of which was different between the groups at
each level of kidney function. Therefore, the observed graded
increase in the excess risk of GI bleeding (i.e. adjusted rate dif-
ference between periods with and without SSRIs) can be as-
cribed to CKD itself, rather than conditions associated with
CKD (e.g. diabetes, antiplatelet use). The pathophysiology
of bleeding tendency in patients with CKD is multifactorial,
including platelet dysfunction and vessel wall damage [43].
In addition, patients with CKD are more likely to have ante-
cedents of GI bleeding, such as peptic ulcer disease [44].
We need to acknowledge several limitations of the study.
Firstly, we deﬁned CKD using strict criteria based on two se-
rum creatinine results in CPRD, and identiﬁed a comparison
group sampled from the rest of the general population.
However, creatinine testing in primary care is not universal
(currently, this is recommended and incentivized for people
at risk of CKD [45, 46]), and therefore we may have
misclassiﬁed some patients with unmeasured CKD into the
comparison group. Nevertheless, because the prevalence of
CKD (eGFR <60 ml min–1 1.73 m–2) identiﬁed in CPRD is
known to be similar to that in a nationally-representative
survey (Health Survey for England) [47], we expect that the
proportion of unmeasured CKD is small in CPRD and people
Figure 2
Adjusted rates and rate difference (between period with and without selective serotonin reuptake inhibitor prescription) for the ﬁrst hospitaliza-
tion due to gastrointestinal bleeding among patients with different levels of kidney function. CKD = chronic kidney disease, CI = conﬁdence
interval, GI = gastrointestinal, SSRI = selective serotonin reuptake inhibitor
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without creatinine tests are unlikely to have CKD. It would
have been inappropriate for us to use a comparison group
sampled from people with creatinine testing in CPRD, be-
cause those with creatinine testing are a less healthy group
of individuals who were not representative of the general
population [48]. Secondly, consistent with a recent US study
[3], our outcome deﬁnition was based on hospitalization re-
corded in linked hospital inpatient data, because the timing
of GI bleeding recorded in HES is likely to be more accurate
than that recorded in CPRD [49]. Moreover, we expect that
hospitalization recorded with a primary diagnosis of GI
bleeding will capture most severe cases. However, we lack
greater detail such as endoscopy ﬁndings and requirement
for blood transfusion. Nevertheless, we would not anticipate
that these characteristics are substantially different between
patients (or periods of time) with and without SSRI prescrip-
tion. Thirdly, we adjusted for a variety of potential con-
founders of the relationship between SSRI prescription and
GI bleeding, including demographics, socioeconomic and
smoking status, BMI, comorbidities, and prescribed drugs
[14–24]. However, confounding cannot be fully removed in
observational studies. Unmeasured confounders could
include over-the-counter aspirin and nonsteroidal anti-
inﬂammatory drugs, as well as severity of depression or anx-
iety; although to our knowledge there is no clear evidence
that mental-health conditions directly increase the risk of
GI bleeding. Fourth, we excluded patients with missing re-
cords for BMI and smoking status, prioritizing the statistical
adjustment for these important confounding factors over
maximizing the sample size. Although the proportion of pa-
tients with missing data was not large [with 8.7% of study
participants (42 375/484698)], the exclusion of these pa-
tients could affect the generalizability of our study results.
This would imply that our study ﬁndings may be limited
to people who are well monitored in primary care and thus
have had these characteristics recorded. Finally, although
the current study is one of the largest studies of the associa-
tion between SSRIs and GI bleeding to date [13], the statisti-
cal power may still be insufﬁcient in the group with the
most severely reduced kidney function (as indicated by the
wide conﬁdence intervals). Study power also made it difﬁ-
cult to draw robust conclusions from our posthoc subgroup
analyses by SSRI dose and receptor afﬁnity.
It is recommended that any increase in the absolute risk of
adverse outcomes should be taken into account in clinical
decision-making [42]. In our study, we found that at more ad-
vanced stages of CKD, a larger number of patients suffered
from GI bleeding potentially related to SSRIs. Therefore, the
balance between risks and beneﬁts of SSRI prescription may
need to be considered differently in patients with decreased
kidney function. Careful consideration of the potential risks
of GI bleeding after SSRI prescription for patients with CKD
is recommended.
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Appendix 1. List of International Classification of Diseases 10th Revision codes used to identify hospitalisation due to gastrointestinal bleeding. 
I850 Oesophageal varices with bleeding K271 Peptic ulcer, site unspecified - Acute with perforation 
K226 Gastro-oesophageal laceration-bleed syndrome K272 Peptic ulcer, site unspecified - Acute with both bleed and perforation 
K250 Gastric ulcer - Acute with bleed K274 Peptic ulcer, site unspecified - Chronic or unspecified with bleed 
K251 Gastric ulcer - Acute with perforation K275 Peptic ulcer, site unspecified - Chronic or unspecified with perforation 
K252 Gastric ulcer - Acute with both bleed and perforation K276 Peptic ulcer, site unspecified - Chronic or unspecified with both bleed and perforation 
K254 Gastric ulcer - Chronic or unspecified with bleed K280 Gastrojejunal ulcer - Acute with bleed 
K255 Gastric ulcer - Chronic or unspecified with perforation K281 Gastrojejunal ulcer - Acute with perforation 
K256 Gastric ulcer - Chronic or unspecified with both bleed and perforation K282 Gastrojejunal ulcer - Acute with both bleed and perforation 
K260 Duodenal ulcer - Acute with bleed K284 Gastrojejunal ulcer - Chronic or unspecified with bleed 
K261 Duodenal ulcer - Acute with perforation K285 Gastrojejunal ulcer - Chronic or unspecified with perforation 
K262 Duodenal ulcer - Acute with both bleed and perforation K286 Gastrojejunal ulcer - Chronic or unspecified with both bleed and perforation 
K264 Duodenal ulcer - Chronic or unspecified with bleed K290 Acute haemorrhagic gastritis 
K265 Duodenal ulcer - Chronic or unspecified with perforation K920 Haematemesis 
K266 Duodenal ulcer - Chronic or unspecified with both bleed and perforation K921 Melaena 
K270 Peptic ulcer, site unspecified - Acute with bleed K922 Gastrointestinal bleed, unspecified 
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Appendix 2. Equation to estimate the adjusted incidence rate for the first hospitalisation due to gastrointestinal bleeding based on a fully-adjusted additive Poisson 
model.  
 
For the fitting of the additive Poisson model, we used the following commands in STATA version 14 (Stata Corp, Texas): 
(i) First, we generated a variable suggesting the observed rates of outcome in individual patients: 
gen rate = outcome/y  
(where outcome is a binary valuable for the first hospitalisation due to GI bleeding, and y suggests person-time-at-risk) 
(ii) Second, we used the glm command with the options f(p) and l(i) to fit a linear Poisson model, by taking the observed rates (rate) as the 
dependent variable and declaring the person-time-at-risk (y) as an “iweight”: 
glm rate i.age i.sex i.ethnicity i.SES i.BMI i.smoker i.diabetes i.CLD i.CHF, i.cancer i.RA i.antiplatelet i.anticoagulant i.NSAIDs 
i.corticosteroid i.acidsuppressing i.SSRI#i.CKDstage [iweight=y], f(p) l(i) 
 (where i.age ~ i.acidsuppressing suggest confounding factors (categorical or binary variables), and i.SSRI#i.CKDstage suggests SSRI prescription 
status (i.e. period with or without SSRI) at each level of kidney function (i.e. no CKD, CKD stage 3a, CKD stage 3b, and CKD stage 4 or 5)) 
 
Based on the STATA output showing the coefficient (95% confidence interval [CI]) of each variable, the following equation was finally established: 
Adjusted incidence rate for the first hospitalisation due to gastrointestinal bleeding (/1000 person-years) 
= 0 × [if age <65] + 0.43 (95%CI, 0.24 – 0.62) × [if age 65-74] + 1.77 (95%CI, 1.55 – 1.99) × [if age 75-84] + 3.28 (95%CI, 2.86 – 3.70) × [if age ≥85] 
+ 0.80 (95%CI, 0.62 – 0.97) × [if male]  
+ 0 (reference) × [if ethnicity White/not-recorded] + 0.06 (95%CI, -0.75 – 0.88) × [if ethnicity South Asian] + 0.09 (95%CI, -1.16 – 1.34) × [if ethnicity Black] + 0.43 
(95%CI, -0.98 – 1.83) × [if ethnicity others] 
+ 0 (reference) × [if socio-economic status (SES) 1st group] + 0.19 (95%CI, -0.02 – 0.39) × [if SES 2nd group] + 0.19 (95%CI, -0.02 – 0.41) × [if SES 3rd group] + 
0.66 (95%CI, 0.40 – 0.92) × [if SES 4th group] + 0.86 (95%CI, 0.56 – 1.15) × [if SES 5th group]  
+ 0.95 (95%CI, 0.24 – 1.65) × [if body mass index (BMI) <18.5] + 0.13 (95%CI, -0.05 – 0.31) × [if BMI 18.5-25] + 0 × [if BMI ≥25] + 0.14 (95%CI, -0.06 – 0.34) × 
[if body mass index (BMI) ≥30] 
+ 0.39 (95%CI, 0.16 – 0.63) × [if smoker] 
+ 0.27 (95%CI, 0.01 – 0.53) × [if diabetes mellitus] 
+ 6.27 (95%CI, 4.18 – 8.35) × [if chronic liver disease] 
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+ 1.78 (95%CI, 1.20 – 2.37) × [if congestive heart failure] 
+ 0.98 (95%CI, 0.73 – 1.22) × [if cancer] 
+ 0.59 (95%CI, -0.10 – 1.29) × [if rheumatoid arthritis] 
+ 0.90 (95%CI, 0.68 – 1.12) × [if antiplatelet prescription] 
+ 2.72 (95%CI, 2.12 – 3.31) × [if anticoagulant prescription] 
+ 0.59 (95%CI, 0.27 – 0.92) × [if non-steroidal anti-inflammatory drug prescription] 
+ 0.99 (95%CI, 0.37 – 1.62) × [if oral corticosteroid prescription] 
+ 1.26 (95%CI, 1.00 – 1.52) × [if acid-suppressing agent prescription] 
+ 0 × [if no chronic kidney disease (CKD) without selective serotonin reuptake inhibitor (SSRI) prescription] + 2.01 (95%CI, 0.98 – 3.04) × [if no CKD with SSRI 
prescription] + 0.62 (95%CI, 0.45 – 0.80) × [if CKD stage 3a without SSRI prescription] + 4.80 (95%CI, 3.61 – 5.99) × [if CKD stage 3a with SSRI prescription] + 
1.59 (95%CI, 1.23 – 1.94) × [if CKD stage 3b without SSRI prescription] + 6.40 (95%CI, 4.00 – 8.79) × [if CKD stage 3b with SSRI prescription] + 3.86 (95%CI, 
2.91 – 4.82) × [if CKD stage 4/5 without SSRI prescription] + 11.78 (95%CI, 3.92 – 19.63) × [if CKD stage 4/5 with SSRI prescription] 
+ 0.54 (95%CI, 0.33 – 0.75) (i.e. constant) 
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Appendix 3. Average effect of each covariate on the risk of gastrointestinal bleeding in the study population applied in the fully-adjusted additive Poisson model. 
 
(A) Coefficient 
(95% CI) 
(estimated in Appendix 2) 
Length of 
follow-up  
(person-years) 
(B) Length of follow-up/ 
total observational period 
 in the study population 
Average effect 
 in the study population 
= (A) × (B) 
(95% CIs are omitted) 
Total observational period in the study population (N = 413,116) - 1,801,316 - - 
Age <65 0 265,427 0.147 0 × 0.147 (=0) 
Age 65-74 0.43 (0.24 – 0.62) 637,583 0.354 0.43 × 0.354 
Age 75-84 1.77 (1.55 – 1.99) 738,822 0.410 1.77 × 0.410 
Age ≥85 3.28 (2.86 – 3.70) 159,484 0.089 3.28 × 0.089 
Sex (male) 0.80 (0.62 – 0.97) 705,263 0.392 0.80 × 0.392 
Ethnicity White/not-recorded 0 1,770,994 0.983 0 × 0.983 (=0) 
Ethnicity South Asian 0.06 (-0.75 – 0.88) 15,635 0.009 0.06 × 0.009 
Ethnicity Black 0.09 (-1.16 – 1.34) 8,282 0.005 0.09 × 0.005 
Ethnicity others 0.43 (-0.98 – 1.83) 6,406 0.004 0.43 × 0.004 
Socio-economic status 1st group (least deprived) 0 424,096 0.235 0 × 0.235 (=0) 
Socio-economic status 2nd group 0.19 (-0.02 – 0.39) 458,223 0.254 0.19 × 0.254 
Socio-economic status 3rd group 0.19 (-0.02 – 0.41) 368,558 0.205 0.19 × 0.205 
Socio-economic status 4th group 0.66 (0.40 – 0.92) 317,915 0.176 0.66 × 0.176 
Socio-economic status 5th group (most deprived) 0.86 (0.56 – 1.15) 232,524 0.129 0.86 × 0.129 
Body mass index <18.5  0.95 (0.24 – 1.65) 33,908 0.019 0.95 × 0.019 
Body mass index 18.5-25 0.13 (-0.05 – 0.31) 621,647 0.345 0.13 × 0.345 
Body mass index ≥25 0 716,744 0.398 0 × 0.398 (=0) 
Body mass index ≥30 0.14 (-0.06 – 0.34) 429,017 0.238 0.14 × 0.238 
Smoker 0.39 (0.16 – 0.63) 245,946 0.137 0.39 × 0.137 
Diabetes mellitus 0.27 (0.01 – 0.53) 285,945 0.159 0.27 × 0.159 
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We applied these values in the equation in the Appendix 2 to calculate the adjusted incidence rate by SSRI prescription status at each level of kidney function.  
For example, the adjusted incidence rate for the first hospitalisation due to gastrointestinal bleeding during SSRI prescription in the no CKD group (/1000 person-
years) 
= 0 × 0.147 + 0.43 (95%CI, 0.24 – 0.62) × 0.354 +1.77 (95%CI, 1.55 – 1.99) × 0.410 + 3.28 (95%CI, 2.86 – 3.70) × 0.089 + 0.80 (95%CI, 0.62 – 0.97) × 0.392 + 0 × 
0.983 + 0.06 (95%CI, -0.75 – 0.88) × 0.009 + 0.09 (95%CI, -1.16 – 1.34) × 0.005 + 0.43 (95%CI, -0.98 – 1.83) × 0.004 + 0 × 0.235 + 0.19 (95%CI, -0.02 – 0.39) × 
0.254 + 0.19 (95%CI, -0.02 – 0.41) × 0.205 + 0.66 (95%CI, 0.40 – 0.92) × 0.176 + 0.86 (95%CI, 0.56 – 1.15) × 0.129 + 0.95 (95%CI, 0.24 – 1.65) × 0.019 + 0.13 
(95%CI, -0.05 – 0.31) × 0.345 + 0 × 0.398 + 0.14 (95%CI, -0.06 – 0.34)× 0.238 + 0.39 (95%CI, 0.16 – 0.63) × 0.137 + 0.27 (95%CI, 0.01 – 0.53)× 0.159 + 6.27 
(95%CI, 4.18 – 8.35) × 0.005 + 1.78 (95%CI, 1.20 – 2.37) × 0.048 + 0.98 (95%CI, 0.73 – 1.22)× 0.186 + 0.59 (95%CI, -0.10 – 1.29) × 0.020 + 0.90 (95%CI, 0.68 – 
1.12) × 0.294 + 2.72 (95%CI, 2.12 – 3.31) × 0.045 + 0.59 (95%CI, 0.27 – 0.92)× 0.089 + 0.99 (95%CI, 0.37 – 1.62) × 0.030 + 1.26 (95%CI, 1.00 – 1.52) × 0.248  
+ 2.01 (95%CI, 0.98 – 3.04) × 1 (in the group of “no CKD with SSRI prescription”) 
+ 0.54 (95%CI, 0.33 – 0.75) (i.e. constant) 
= 5.50 (95%CI, 4.47 - 6.52)  
  
Chronic liver disease  6.27 (4.18 – 8.35) 8,929 0.005 6.27 × 0.005 
Congestive heart failure 1.78 (1.20 – 2.37) 85,889 0.048 1.78 × 0.048 
Cancer  0.98 (0.73 – 1.22) 335,372 0.186 0.98 × 0.186 
Rheumatoid arthritis 0.59 (-0.10 – 1.29) 35,606 0.020 0.59 × 0.020 
Antiplatelet drug prescription 0.90 (0.68 – 1.12) 530,433 0.294 0.90 × 0.294 
Anticoagulant prescription 2.72 (2.12 – 3.31) 80,897 0.045 2.72 × 0.045 
Non-steroidal anti-inflammatory drug prescription 0.59 (0.27 – 0.92) 159,598 0.089 0.59 × 0.089 
Oral corticosteroid prescription 0.99 (0.37 – 1.62) 54,151 0.030 0.99 × 0.030 
Acid-suppressing agent prescription 1.26 (1.00 – 1.52) 446,974 0.248 1.26 × 0.248 
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Appendix 4. Patterns in the choice of selective serotonin reuptake inhibitors and daily dose among patients with different levels of kidney function. 
  
 
No CKD (N = 16,911) CKD stage 3a (N = 18,545) CKD stage 3b (N = 5,803) CKD stage 4/5 (N = 1,063) 
Total number 
of prescription  
in the group†, 
n (%) 
Dose direction, 
median [IQR] 
(mg/day) 
Total number 
of prescription  
in the group†, 
n (%) 
Dose direction, 
median [IQR] 
(mg/day) 
Total number 
of prescription  
in the group†, 
n (%) 
Dose direction, 
median [IQR] 
(mg/day) 
Total number 
of prescription  
in the group†, 
n (%) 
Dose direction, 
median [IQR] 
(mg/day) 
Citalopram 157,474 (63.7) 20 [10 – 20] 213,068 (65.9) 20 [10 – 20] 69,293 (65.8) 20 [10 – 20] 11,829 (72.4) 20 [10 – 20] 
Escitalopram 14,174 (5.7) 10 [5 – 10] 13,833 (4.3) 10 [5 – 10] 4,826 (4.6) 10 [5 – 10] 588 (3.6) 10 [5 – 10] 
Fluoxetine 33,234 (13.5) 20 [20 – 20] 44,475 (13.8) 20 [20 – 20] 15,778 (15.0) 20 [20 – 20] 1,898 (11.6) 20 [20 – 20] 
Fluvoxamine 51 (<0.1) 50 [50 – 50] 90 (<0.1) 100 [50 – 100] <5 (<0.1) n/a <5 (<0.1) n/a 
Paroxetine 7,565 (3.1) 20 [20 – 20] 6,711 (2.1) 20 [20 – 20] 2,173 (2.1) 20 [20 – 20] 233 (1.4) 20 [20 – 20] 
Sertraline 34,600 (14.0) 50 [50 – 100] 45,207 (14.0) 50 [50 – 100] 13,311 (12.6) 50 [50 – 100] 1,784 (10.9) 50 [50 – 100] 
Total 247,098 (100)  323,384 (100)  105,384 (100)  16,332 (100)  
Abbreviations: CKD = chronic kidney disease; IQR = interquartile range. 
†counted as one per doctor visit. 
146
Appendix 5. Sensitivity analysis changing our assumption on the length of grace and washout periods of selective serotonin reuptake inhibitor prescription. 
 Adjusted rate ratio (95% CI) 
(period with versus without SSRI prescription) 
Adjusted rate difference (95% CI) 
(between period with and without SSRI prescription) 
Length of grace and 
washout periods of  
SSRI prescription 
No CKD 
CKD  
stage 3a 
CKD  
stage 3b 
CKD 
stage 4/5 
p-trend No CKD 
CKD 
stage 3a 
CKD  
stage 3b 
CKD  
stage 4/5 
p-trend 
30 days (main analysis)† 
1.66 
(1.37-2.01) 
1.86  
(1.62-2.15) 
1.61  
(1.27-2.04) 
1.84  
(1.14-2.96) 
0.922 
2.0  
(1.0-3.0) 
4.2 
(3.0-5.4) 
4.8 
(2.4-7.2) 
7.9 
(0.1-15.8) 
0.001 
60 days 
1.67 
(1.39-2.02) 
1.80 
(1.56-2.07) 
1.68  
(1.33-2.10) 
1.88 
(1.18-2.99) 
0.801 
2.0 
(1.0-3.1) 
3.9 
(2.8-5.0) 
5.1 
(2.6-7.5) 
8.1 
(0.3-15.9) 
<0.001 
90 days 
1.68 
(1.40-2.02) 
1.78 
(1.54-2.04) 
1.67 
(1.33-2.09) 
2.03 
(1.30-3.16) 
0.228 
2.2 
(1.2-3.2) 
4.0 
(2.9-5.1) 
5.1 
(2.7-7.5) 
9.8 
(1.8-17.8) 
<0.001 
Abbreviations: CKD = chronic kidney disease; CI = confidence interval; SSRI = selective serotonin reuptake inhibitor. 
†We assumed that patients were continuously exposed to SSRIs if there were no gaps of more than 30 days between the end of one prescription and the start of the next 
(to allow potential medication stockpiling or prescribing in secondary care). If there was no subsequent prescription of SSRIs, we considered patients could be influenced 
by the effect of SSRIs until 30 days after the end of the prescription. 
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Appendix 6. Subgroup analysis by dose of selective serotonin reuptake inhibitors. 
 
Abbreviations: CKD = chronic kidney disease; CI = confidence interval; SSRI = selective serotonin reuptake inhibitor. 
Note: Based on the defined daily dose (DDD) of each SSRI (20 mg/day for citalopram, 10 mg/day for escitalopram, 20mg/day for fluoxetine, 100 
mg/day for fluvoxamine, 20mg/day for paroxetine, and 50mg/day for sertraline), we dichotomised the periods of SSRI prescription into two groups: low 
dose period (i.e. smaller daily dose than DDD) and normal or high dose period (i.e. same as or higher dose than DDD). 
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Appendix 7. Subgroup analysis by affinity of selective serotonin reuptake inhibitors to the serotonin receptor. 
 
Abbreviations: CKD = chronic kidney disease; CI = confidence interval; SSRI = selective serotonin reuptake inhibitor. 
Note: SSRIs with intermediate affinity include citalopram, escitalopram, and fluvoxamine, whereas SSRIs with high affinity include fluoxetine, 
paroxetine, and sertraline. 
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9.3. Additional data and discussions  
Further to the results and discussions presented in the published paper, here I show an 
additional sensitivity analysis to treat potential uncertainties of the data in the CPRD and HES. 
9.3.1. Sensitivity analysis including GI bleeding diagnoses recorded in the CPRD 
(i) Backgrounds and methods 
In the main analysis, I focused on GI bleeding episodes requiring hospitalisation recorded in 
HES Admitted Patient Care. Episodes of hospitalisation are also supposed to be recorded in 
the CPRD, but may be less accurate than HES, because practice staff retrospectively enter the 
admission episode into the system based on a letter from the hospital.  
Indeed, a previous validation study on myocardial infarction suggested that some 
hospitalisation episodes in HES were not recorded in the CPRD [130]. In addition, there was a 
time lag between the date of event retrospectively recorded in the CPRD and the date of 
admission in HES in many cases with myocardial infarction. Provided that most patients with 
myocardial infarction are smoothly sent to the hospital, the retrospectively recorded event date 
was probably inaccurate in the CPRD. Furthermore, there were some cases which were 
recorded in neither of HES nor the disease registry (Myocardial Ischaemia National Audit 
Project). Although a possibility remains that HES and the registry were incomplete, it is likely 
that the CPRD included suspected cases or a previous history of myocardial infarction. 
I anticipated that misreporting of GI bleeding episodes is also possible in the CPRD. A previous 
study defined the GI bleeding outcome as hospitalisations recorded in HES only [126]. 
Therefore, I took the same approach to define the GI bleeding outcome in the main analysis. 
However, different from myocardial infarction, some GI bleeding cases may be just mild and 
do not require hospitalisation [131]. It is also possible that there is a true time lag between the 
onset of GI bleeding and hospital admission. Therefore, in a sensitivity analysis, I defined the 
GI bleeding outcome as the diagnoses of GI bleeding recorded either in HES Admitted Patient 
Care or CPRD (whichever occurred first). Diagnosis codes (Read codes) suggesting GI 
bleeding are shown in Appendix C. 
(ii) Results and discussions 
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Overall, by including the diagnoses suggestive of GI bleeding recorded in the CPRD, the 
number of outcomes slightly increased from 7,249 to 8,432 among 413,116 study participants. 
Accordingly, the adjusted rate ratio and adjusted rate difference changed to some extent in each 
kidney function group (see Table 14 below). However, the overall conclusion (i.e. the relative 
risk of GI bleeding associated with SSRIs was constant, while the excess risk of GI bleeding 
associated with SSRIs was significantly increased among patients with lower kidney function) 
did not change.  
The inclusion of GI bleeding diagnoses in the CPRD (in addition to the hospitalisation episodes 
in HES Admitted Patient Care) to define the study outcome may have both merits and demerits. 
Although more comprehensive assessment of the associating between SSRIs and GI bleeding 
(including mild GI bleeding cases not requiring hospitalisation) may be achieved, some of these 
diagnoses in the CPRD may be given to suspected cases or for justifying the endoscopic 
examination. Therefore, misclassification of the outcome status is more likely by the use of 
records in the CPRD. However, importantly, the extent of increase in the number of outcomes 
was found to be small, and the overall conclusion did not change with and without the inclusion 
of GI bleeding diagnoses in the CPRD. 
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Table 14. Sensitivity analysis including GI bleeding diagnoses recorded in the CPRD 
 Main analysis (in which the study outcome was defined as 
hospitalisation with GI bleeding recorded in HES) 
Sensitivity analysis (in which the study outcome was defined as 
hospitalisation with GI bleeding in HES or GI bleeding diagnosis 
recorded in the CPRD, whichever occurred first) 
 No CKD CKD  stage 3a 
CKD  
stage 3b 
CKD 
stage 4/5 p-trend No CKD 
CKD  
stage 3a 
CKD  
stage 3b 
CKD  
stage 4/5 p-trend 
Number of 
patients 202,121 153,316 46,482 11,197  202,121 153,316 46,482 11,197  
Number of 
outcomes 2,523 3,166 1,247 313  2,885 3,664 1,504 379  
Adjusted  
rate ratio  
(95% CI) 
1.66 
(1.37–2.01) 
1.86  
(1.62–2.15) 
1.61  
(1.27–2.04) 
1.84  
(1.14–2.96) 0.922 
1.87 
(1.58–2.21) 
1.98 
(1.75–2.25) 
1.92 
(1.57–2.33) 
1.92 
(1.26–2.92) 0.873 
Adjusted 
rate 
difference 
(95% CI) 
2.0  
(1.0–3.0) 
4.2 
(3.0–5.4) 
4.8 
(2.4–7.2) 
7.9 
(0.1–15.8) 0.001 
2.4 
(1.3–3.4) 
4.5 
(3.4–5.7) 
6.8 
(4.2–9.4) 
8.4 
(0.5–16.4) <0.001 
Abbreviations: CKD = chronic kidney disease; CI = confidence interval; CPRD = Clinical Practice Research Datalink; GI = gastrointestinal; HES 
= Hospital Episode Statistics. 
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9.4. Chapter summary 
GI bleeding risk of SSRIs by kidney function 
- This study estimated the relative and excess risks of GI bleeding associated with SSRI 
prescription at different levels of kidney function, and tested whether there was an 
interaction (effect modification) between baseline kidney function and the GI bleeding risk 
of SSRIs in multiplicative and additive scales. 
- The relative risk of GI bleeding associated with SSRIs (i.e. the fully-adjusted rate ratio 
between periods with and without SSRI prescription) was around 1.7 regardless of kidney 
function, with no evidence of multiplicative interaction.  
- The excess risk of GI bleeding associated with SSRIs (i.e. the fully-adjusted rate difference 
between periods with and without SSRI prescription) increased substantially as renal 
function declined, with strong evidence of additive interaction. 
- Due to the increase in the excess risk of GI bleeding associated with SSRIs among patients 
with lower kidney function, careful use of SSRIs may be recommended for patients with 
decreased kidney function. 
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Chapter 10. Overall discussions and conclusions 
10.1. Summary of main findings 
In this thesis, I examined the associations between CKD and both mental health disorders and 
psychoactive drugs in the UK general population, using a large linked primary care database. 
To fill the gap between what is known and what is unknown in this field, I focused on two main 
topics: (i) the association between SMI (with and without a history of lithium use) and CKD, 
and (ii) the association between CKD and antidepressants (mainly prescribed for common 
mental health disorders such as depression and anxiety) and associated adverse outcomes (for 
which I chose the GI bleeding risk of SSRIs as an example). 
I first conducted a cross-sectional population-level validation study comparing prevalence 
estimates of decreased kidney function (defined as the most recent eGFR prior to 31 March 
2014 of <60 ml/min/1.73 m2), CKD (defined as two or more consecutive measurements of <60 
ml/min/1.73 m2 for ≥3 months in the past five years) and RRT in the CPRD population with 
the nationally representative statistics (Health Survey for England 2009/2010 and UK Renal 
Registry 2014). Findings suggested that most patients with CKD and RRT are probably 
captured in the current CPRD, although a concern remained that patients with a single time-
point decreased kidney function and those satisfying the CKD criteria in the CPRD may be 
slightly different populations. 
Secondly, I conducted a cross-sectional study on the association between SMI and CKD. 
Patients with SMI, with or without a history of lithium prescription, had a higher prevalence of 
both CKD and RRT than the general population, and the association remained after adjusting 
for patients’ characteristics and known CKD risk factors. Subsequent analyses suggested that 
the proportion of patients receiving potentially beneficial drugs for CKD (ACEI/ARBs for 
patients with proteinuria, and statins) might be lower in CKD patients with SMI than those 
without SMI. 
Thirdly, I conducted a matched cohort study comparing the prevalence and incidence of 
antidepressant prescription between patients with and without CKD (matched for age, sex, 
general practice, and calendar time). Patients with CKD were approximately one and a half 
times more likely to receive antidepressants than matched patients without known CKD. 
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Regardless of CKD status, SSRIs were predominantly prescribed for depression or anxiety, 
while tricyclic antidepressants were prescribed for neuropathic pain or other reasons. 
Finally, I estimated the GI bleeding risk of SSRIs by level of kidney function (i.e. no CKD, 
CKD stage 3a, stage 3b, and stage 4/5 at baseline) and tested whether the relative risk (i.e. the 
fully-adjusted rate ratio between periods with and without SSRI prescription) and excess risk 
associated with SSRIs (i.e. the fully-adjusted rate difference between periods with and without 
SSRI exposure) increase as baseline kidney function declines. The relative risk for GI bleeding 
associated with SSRIs was constant at around 1.7, regardless of baseline kidney function, and 
with no evidence of multiplicative interaction. Meanwhile, the excess risk for GI bleeding risk 
associated with SSRIs increased markedly as baseline kidney function deteriorated, with strong 
evidence of additive interaction. 
 
10.2. Implications for clinical practice 
10.2.1. Greater awareness is needed for the burden of CKD in patients with SMI 
Paper 2 (SMI and CKD) identified the burden of CKD among patients with SMI. This may in 
part explain the fact that people with SMI tend to have a shorter life expectancy than the general 
population by around 10–20 years [27-32]. The mainstream of CKD-related care consists of 
early detection and prevention of CKD progression by intervening in modifiable risk factors 
(e.g. better control of diabetes, smoking cessation), and treatment of comorbidities such as high 
blood pressure and dyslipidemia. Subsequent analysis determined that, although the 
recognition of CKD (defined as receiving records of diagnostic Read codes suggesting CKD) 
and management of blood pressure in CKD patients with SMI were as good as for CKD patients 
in the general population, the proportion of people receiving potentially beneficial drugs for 
patients with CKD (i.e. ACEI/ARBs for patients with proteinuria, and statins) was lower in 
CKD patients with SMI than in those without SMI. Thus, greater awareness of the burden of 
CKD in patients with SMI (by GPs, clinical staff, patients, and patients’ family) may be 
important to improve the intervention associated with CKD in patients with SMI. 
10.2.2. Risk-benefit balance of antidepressants in patients with CKD may be different 
from the general population 
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Paper 3 (CKD and antidepressant prescription) demonstrated that patients with CKD are 
around one and a half times more likely to receive antidepressants than those without CKD, 
whereas Paper 4 (GI bleeding risk of SSRIs by kidney function) suggested that the GI bleeding 
risk of SSRIs (a good example of serious adverse outcomes associated with antidepressants) is 
increased in absolute terms among patients with lower kidney function.  
The present PhD was not able to assess the benefit of antidepressants in patients with CKD, 
because there was no valid way of ascertaining the temporal change in the degree of anxiety 
and depressive symptoms via the CPRD. Therefore, the risk-benefit balance or cost-
effectiveness of antidepressants could not be assessed in this PhD only. Ultimately, the decision 
of whether or not to use antidepressants for CKD patients with depression and anxiety should 
be based on the risk-benefit balance or cost-effectiveness of antidepressants in this population. 
Meanwhile, a recent RCT examined the efficacy of antidepressants among patients with CKD 
(stages 3 to 5) for the first time [69]. This randomised, double-blind, placebo-controlled trial, 
which involved 201 patients with non-dialysis-dependent CKD (stages 3 to 5), found that 12 
weeks of treatment with normal (50 mg/day) to higher dose (up to 200 mg/day) of sertraline 
(an SSRI with the most favourable balance between benefits, acceptability, and acquisition cost, 
according to a meta-analysis of RCTs assessing 12 antidepressants in the general population 
[132]) did not significantly improve depressive symptoms; the QIDS-SR16 score changed by 
-4.1 in the sertraline group and by -4.2 in the placebo group (between-group difference 0.1 
[95% CI, -1.1 to 1.3]; P = 0.82). The authors noted that one of the reasons for this lack of 
efficacy could be that depression comorbid with CKD is a different clinical entity than major 
depressive disorder among those without comorbidity. It should be noted that, although the 
study was conducted based on a reasonable sample size calculation to identify a clinically 
meaningful difference between the sertraline and placebo groups [69], the study might be still 
underpowered and not long enough.  
Although careful interpretation of this RCT and further research (e.g. a larger RCT assessing a 
different SSRI) is needed, the current best available evidence indicates that the risk-benefit 
balance of SSRIs for depression may be leaning toward the risk side in patients with CKD, 
compared to the general population. Therefore, careful use of SSRIs may be generally 
recommended in patients with decreased kidney function. 
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10.3. Implications for research  
10.3.1. The association between SMI and CKD should be further explored 
Paper 2 (SMI and CKD) was only a snapshot of the association between SMI and CKD in a 
cross-sectional study. To better indicate a causal link between SMI and CKD, a cohort study 
may be warranted. For example, a matched cohort study comparing the rate of kidney function 
decline in patients with and without SMI would better indicate causality. Furthermore, 
subgroup analyses in the SMI population would enable identification of a particularly high-risk 
group for kidney function decline. However, in order to conduct such a study, a method to 
appropriately estimate the rate of kidney function decline needs to be established in the CPRD. 
Another important question concerns the impact of stopping lithium on subsequent kidney 
function decline and the incidence of ESRD. Currently, there is marked variation in practice, 
with some nephrologists recommending continued treatment, while others choose to prioritise 
mental health. A cohort study, including patients stopping lithium and those continuing it, may 
be warranted to examine the impact of lithium cessation on the subsequent trajectory of kidney 
function, stratified by the level of kidney function at the time of lithium cessation. 
10.3.2. Further research is needed for the appropriate use of antidepressant in patients 
with CKD 
Many questions remain regarding the appropriate use of antidepressants in patients with CKD. 
Apart from depression and anxiety, Paper 3 (CKD and antidepressant prescription) suggested 
that many antidepressants may be prescribed as off-label in real-world clinical practice (e.g. 
amitriptyline for chronic pain), regardless of CKD status. This is in line with findings of a 
recent Canadian descriptive study of antidepressant prescriptions from an indication-based 
electronic prescribing system [133]. The authors of the Canadian study suggested that these 
indications were usually not supported by strong scientific evidence [133]. As such, the risk-
benefit balance of off-label use of antidepressant remains unknown in general, let alone among 
patients with CKD.  
In addition, the recently updated NICE guidance 2017 newly added mirtazapine (a 
noradrenergic and specific serotonergic antidepressant) as the first-line pharmacological 
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treatment for depression [134], although the previous NICE guidance 2009 included only 
SSRIs as the first-line [135]. Therefore, while mirtazapine prescription was uncommon in 
Paper 3 (CKD and antidepressant prescription) covering from 2004 to 2014 (5.6% and 5.5% 
of the choice to initiate antidepressants in patients with and without CKD, respectively), it is 
possible that mirtazapine prescription starts to increase in UK primary care. However, 
according to the British National Formulary, renal clearance of mirtazapine is reduced by 30% 
if eGFR less than 40 mL/min/1.73 m2, and therefore should be used with caution in patients 
with CKD [90]. Although the current PhD was not able to compare the risk of serious adverse 
outcomes between individual SSRIs and mirtazapine among patients with CKD due to a lack 
of statistical power, a future study may need to assess the comparative risk of mirtazapine use 
in patients with CKD.  
 
10.4. Strengths 
There are several strengths of the present PhD, which are mainly associated with the use of the 
CPRD. Here, I briefly summarise what I have discussed in each paper.  
10.4.1. Population representativeness  
This PhD has placed a high level of importance on describing the burden of a disease or drug 
in a certain population (i.e. the burden of CKD in the SMI population, the burden of 
antidepressants in the CKD population) rather than proving causality. The population 
representativeness of the CPRD was particularly useful when I prepared for a comparison 
group in each study. In Paper 2 (SMI and CKD), the comparison group consisted of all people 
registered to the CPRD except for those with SMI. In Paper 3 (CKD and antidepressant 
prescription), people without known CKD (matched for age, sex, general practice, and calendar 
year) were randomly sampled from the general population. If the CRPD was not representative 
of the UK general population, the crude prevalence of CKD in patients without SMI (in Paper 
2) and the crude prevalence/incidence of antidepressant prescription in patients without known 
CKD (in Paper 3) would not be very informative as a comparison group.  
10.4.2. Breadth of data 
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The CPRD includes not only disease diagnoses and prescriptions, but also information on 
lifestyle-related factors including smoking status and BMI. Following the crude analyses, I 
conducted adjusted analyses in each paper. Smoking status and BMI are known to be associated 
with CKD, SMI, common mental health disorders, and GI bleeding. Therefore, the inclusion 
of these important confounding factors in the adjusted analyses was vital for each study. 
In addition, the CPRD can be linked to other data sources including HES and IMD. Linkage 
with HES enabled me to obtain additional information about ethnicity. In a study examining 
the completeness of ethnicity information, the linkage with HES largely reduced the proportion 
of patients with missing ethnicity information [107]. The linkage with IMD was also effective 
for obtaining information about individual area-level socio-economic status, enabling this to 
be adjusted for as an important confounding factor. Furthermore, in Paper 4 (GI bleeding risk 
of SSRIs by kidney function), the study outcome was defined as hospitalisations for GI 
bleeding recorded in HES, which are expected to be more accurate than the GI bleeding 
episodes recorded in the CPRD. 
10.4.3. Sample size 
The CPRD is one of the largest electronic health records databases in the world, with coverage 
of over 11 million patients, 4.4 million of which are active (i.e. alive and currently registered) 
[73]. Generally, a large sample size improves the precision of estimates, although the accuracy 
of these estimates is another issue and associated with bias. A large sample size is generally 
required for pharmacoepidemiological studies examining serious but uncommon adverse 
outcomes of drugs, such as the GI bleeding risk of SSRIs. Indeed, the crude incidence rate of 
GI bleeding hospitalisation was only 4.0 (95% CI 3.9–4.1)/1000 person-years in the study 
population in Paper 4 (GI bleeding risk of SSRIs by kidney function). Notably, the present PhD 
has focused on patients with CKD (stages 3 to 5), the prevalence of which was around 6–7% 
in the general population. If the database was smaller, the number of GI bleeding outcomes 
among SSRI users with CKD would be extremely small, preventing any meaningful statistical 
analyses from being conducted. 
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10.5. Limitations 
Despite the many strengths of the present PhD, there may also be several limitations, which 
may be ascribed to the nature of CPRD as well as the strategy employed to define the study 
population, exposure of interest and outcomes. I here summarise what I have discussed in each 
paper. 
10.5.1. Misclassification 
Misclassification is itself subclassified into non-differential and differential misclassification. 
Generally, non-differential misclassification of the study outcome, exposure, and confounding 
factors will prejudice the study results towards the null association between exposure and 
outcome, whereas the direction of the bias due to differential misclassification varies according 
to each study. 
(i) Misclassification of CKD status and stage 
In Paper 1 (prevalence of CKD and RRT in CPRD), misclassification of CKD status could 
occur due to (i) measurement error of serum creatinine level in laboratories, and (ii) use of the 
GFR estimating equation (i.e. CKD-EPI creatinine equation). However, the apparent 
prevalence of CKD in the CPRD would not be changed by these misclassification, because it 
is expected that patients with and without CKD would be misclassified into the other group to 
similar extents. Therefore, caution is needed to interpret the study results; an overall agreement 
of the prevalence estimates of CKD in the CPRD with those in the Health Survey for England 
does not ensure an individual-level validity. In addition, in routine clinical practice, serum 
creatinine level may be temporarily increased because of AKI, recent exercise, and/or protein 
intake. This misclassification could result in the overestimation of the prevalence of CKD in 
the CPRD. On the other hand, among older and frail patients with decreased muscle mass, GFR 
calculated from serum creatinine records may be underestimated, meaning that the prevalence 
of CKD could be underestimated.  
In Paper 2 (SMI and CKD), in addition to the non-differential misclassification (due to 
measurement error of serum creatinine and use of the GFR estimating equation), differential 
misclassification of CKD status could occur due to differences in the frequency of blood testing 
between patients with and without SMI. If the probability of misclassification (i.e. that patients 
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with CKD were regarded as non-CKD because of non-testing) was larger in people without 
SMI than people with SMI, this would cause an overestimation of the association between SMI 
and CKD. However, the additional analysis suggested that the influence of this bias was small, 
mainly because GPs were selectively testing people at risk for CKD (meaning that those 
without serum creatinine testing were unlikely to have CKD) regardless of SMI status (see 
section 6.3.2). 
In Paper 3 (CKD and antidepressant prescription), some patients satisfying the CKD criteria in 
the CPRD may not have “true CKD” due to measurement error of serum creatinine, use of the 
GFR estimating equation, and temporarily increased serum creatinine (due to AKI, recent 
exercise, and/or protein intake). On the other hand, some patients in the matched comparison 
group (i.e. those without known CKD) may have CKD because of measurement error of serum 
creatinine, use of the GFR estimating equation, decreased muscle mass, and lack of 
measurement of serum creatinine in primary care. This misclassification of CKD status could 
dilute the association between CKD and antidepressant prescription.  
In Paper 4 (GI bleeding risk of SSRIs by kidney function), patients with CKD were further 
classified into subgroups according to eGFR on the date of cohort entry: CKD stage 3a (eGFR 
45–59 ml/min/1.73m2), stage 3b (30–44 ml/min/1.73m2), and stage 4 or 5 (<30 ml/min/1.73m2). 
Therefore, in addition to the potential misclassification of CKD status, misclassification of 
CKD stage is also possible. Misclassification of CKD stage is likely to be random, and could 
therefore dilute the adjusted rate ratios and rate differences (between periods with and without 
SSRIs) across groups with different levels of kidney function.  
(ii) Misclassification of SMI status 
According to a validation study of UK primary care, diagnosis codes (Read codes) suggesting 
SMI have high sensitivity (91%), specificity (99.9%), and positive predictive value (91%) 
[136]. Therefore, extensive misclassification of SMI status is unlikely. Due to the slightly 
decreased sensitivity, it is possible that a small number of people with SMI might have been 
misclassified into the group of those without SMI. However, the influence of this 
misclassification appears to be subtle, because the denominator (i.e. the number of people in 
the group without SMI) was huge (N = 2,387,988). 
(iii) Misclassification of antidepressant prescription and adherence 
161
162 
 
Prescription of drugs is automatically recorded in the current CPRD, meaning that 
misclassification of prescription records is very unlikely. In Paper 3 (CKD and antidepressant 
prescription), prescription by GPs itself was of interest, and adherence did not matter. However, 
in Paper 4 (GI bleeding risk of SSRIs by kidney function), adherence could influence the 
association between SSRIs and GI bleeding at each level of kidney function. If the adherence 
of SSRIs was poor, the observed association would be influenced towards the null association 
between SSRIs and GI bleeding. Furthermore, the possibility remains that the adherence was 
poorer among patients with lower kidney function, and the observed constant relative risk is 
thus ascribed to the different degree of adherence according to the level of kidney function.  
(iv) Misclassification of GI bleeding outcome 
Although the primary diagnosis in hospital discharge records generally has high specificity 
[137], there has been no study assessing the validity of ICD-10 codes suggesting GI bleeding 
in HES. However, this misclassification is unlikely to be related to SSRI prescription status in 
primary care, and therefore would not affect the relative risk between periods with and without 
SSRIs. However, if sensitivity of the GI bleeding ICD-10 codes was low, the absolute risks 
and risk differences between periods with and without SSRIs would have been underestimated. 
(v) Misclassification of comorbidities 
In the CPRD, it has been a common strategy to assume that people without recorded diagnoses 
of a comorbidity (e.g. diabetes) do not have the condition. According to previous validation 
studies, many diseases showed a high positive predictive value in the CPRD [138, 139], 
whereas sensitivity is unknown. If identification and recording of comorbidities were positively 
associated with the exposure of interest as well as the study outcome, statistical adjustment for 
comorbidities would result in underestimation of the (true) adjusted relative risk between the 
exposure and outcome. For example, for the association between CKD and antidepressant 
prescription, the identification and recording of comorbidities are expected to be positively 
associated with CKD as well as antidepressant prescription. Therefore, the fully-adjusted odds 
ratio of 1.35 (95% 1.32–1.37) and the fully-adjusted rate ratio of 1.25 (1.23–1.26) in the 
association between CKD and prevalence and incidence of antidepressant prescription, 
respectively, are probably underestimated due to misclassification of comorbidities. 
10.5.2. Confounding 
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Generally, confounding in observational studies includes unmeasured confounding factors 
(which are truly unknown, or which are known but unmeasured or unrecorded in the database) 
and residual confounding when dichotomising or categorising measured factors (e.g. diabetes) 
for statistical adjustment. Minimising the influence of confounding by adjusted analyses is 
particularly important when discussing a potential causal link between exposure and outcome 
of the study.  
(i) Paper 2 (SMI and CKD) 
After describing the burden of CKD among patients with SMI in a crude analysis, I conducted 
multivariable logistic regression analyses of the association between SMI and CKD. The 
purpose of this analysis was to examine (i) to what extent the association between SMI and 
CKD can be explained by each of the patients’ characteristics (e.g. socio-economic status) and 
known CKD risk factors (e.g. diabetes), and (ii) what remains after adjusting for all the selected 
covariates.  
Firstly, it should be noted that I was not able to differentiate potential confounding and 
mediating factors in the association between SMI and CKD in this cross-sectional study. For 
example, diabetes may be mediating the association between SMI and CKD (i.e. SMI has led 
to diabetes, and diabetes resulted in CKD), but diabetes also could be a confounding factor in 
the association between SMI and CKD (i.e. diabetes has resulted in both SMI and CKD). I only 
tried to remove the effect of diabetes regardless of the nature of this factor. I found that the 
odds ratio changed from 1.53 (95% CI 1.42–1.66) to 1.42 (95% CI 1.31–1.54) in the association 
between SMI (non-lithium users) and CKD after adjusting for diabetes status. However, this 
decrease in odds ratio does not reveal whether diabetes mediated or confounded the association 
between SMI and CKD.  
Secondly, after adjusting for all selected covariates, the fully-adjusted odds ratio was 1.45 
(1.34–1.58) for patients with SMI and no history of lithium use and 6.49 (5.84–7.21) for 
patients with SMI and history of lithium use. Apparently, the remaining association is a mixture 
of true causality, unmeasured confounding factors, and residual confounding. Causality 
between lithium and CKD has been widely suggested in basic research and previous 
observational studies [49, 51, 140]; indeed, I could argue that such a strong association (i.e. 
fully-adjusted odds ratio of 6.49) between the lithium group and CKD cannot be fully explained 
by unmeasured confounding factors and residual confounding. However, it is difficult to 
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discuss whether the weaker association between the non-lithium group and CKD (i.e. fully-
adjusted odds ratio of 1.45) can be fully explained by unmeasured confounding factors (e.g. 
low birth weight) and residual confounding due to dichotomisation of disease status (e.g. 
diabetes, heart failure). Given the limitations of cross-sectional design such as unknown 
temporality, the current study results provide limited information regarding the direction of 
causality between SMI and CKD.  
(ii) Paper 3 (CKD and antidepressant prescription) 
Similar to Paper 2, after describing the tendencies in antidepressant prescription for patients 
with and without CKD, adjusted analyses were subsequently conducted on the association 
between CKD and the prevalence/incidence of antidepressant prescription. The odds ratio of 
prevalent antidepressant prescription (CKD vs. non-CKD) decreased from 1.46 (1.43–1.48) to 
1.35 (1.32–1.37), whereas the incidence rate ratio of antidepressant prescription decreased from 
1.35 (1.33–1.37) to 1.25 (1.23–1.26) after adjusting for the potential confounding factors. 
These results suggest that the selected confounding factors explained some of the association 
between CKD and the high incidence/prevalence of antidepressant prescription, but CKD 
remained “independently” associated with more frequent antidepressant prescription by GPs. 
Nevertheless, caution is needed when interpreting this “independent” association as a causal 
link between CKD and antidepressant prescription by GPs, because unmeasured confounding 
factors (e.g. un-coded poor health status) and residual confounding due to dichotomisation of 
disease status (e.g. diabetes, heart failure) could explain the remaining association.  
(iii) Paper 4 (GI bleeding risk of SSRIs by kidney function) 
In this study, the primary comparison was between periods with and without SSRI prescription 
for the incidence of hospitalisation due to GI bleeding, at each level of kidney function. It is 
anticipated that periods with and without SSRI prescription are systematically different in two 
aspects: (i) periods without SSRI prescription include observational periods of people who 
have never received SSRIs, and there may be systematic differences between people with and 
without SSRI prescription (e.g. smoking history and disease status such as diabetes), and (ii) 
even among people receiving at least one SSRI prescription during follow-up, periods with and 
without SSRIs may be systematically different in terms of the prescription of other drugs and 
severity of depression/anxiety.  
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Therefore, when estimating the adjusted rate ratios and rate differences between periods with 
and without SSRI prescription, I adjusted for (i) basic patient characteristics (i.e. age, sex, 
ethnicity, socio-economic status, BMI, smoking status) and comorbidities known to be 
associated with GI bleeding (i.e. diabetes mellitus, chronic liver disease, congestive heart 
failure, cancer, and rheumatoid arthritis), in order to minimise between-person confounding, 
and (ii) time-dependent prescription of other drugs associated with GI bleeding (i.e. 
anticoagulants, antiplatelet drugs, non-steroidal anti-inflammatory drugs [NSAIDs], oral 
corticosteroids, and acid-suppressing agents), in order to minimise within-person confounding.  
I did not adjust for status or severity of depression and anxiety in the analysis. However, I 
consider that the lack of statistical adjustment for mental health conditions is not critical to 
examining the association between SSRIs and GI bleeding, because there is no strong evidence 
that mental health conditions directly increase GI bleeding. In other words, mental health 
conditions do not seem to satisfy the criteria for confounding factors, as a confounding factor 
needs to be independently associated with outcome (i.e. GI bleeding).  
However, the possibility remains that the fully-adjusted rate ratios of 1.66 (95% CI, 1.37–2.01) 
among patients with no CKD, 1.86 (1.62–2.15) among patients with CKD stage 3a, 1.61 (1.27–
2.04) among patients with CKD stage 3b, and 1.84 (1.14–2.96) among patients with CKD stage 
4 or 5 were still influenced by unmeasured confounding factors (e.g. over-the-counter aspirin 
and NSAIDs, and alcohol), and that there is residual confounding due to the dichotomisation 
of comorbidities and medication status.  
Generally, the influence of unmeasured confounding factors (named “confounding by 
indication” in the context of pharmacoepidemiology) could be minimised if a good comparator 
drug (class) exists in real-world clinical practice. For example, Crellin et al. compared several 
different antibiotic classes prescribed for urinary tract infection on the incidence of AKI, 
hyperkalaemia, and sudden death [141]. This is a reasonable comparison, as GPs may wonder 
which antibiotic class they should choose for their patients in daily practice. However, in the 
present study, is there a good comparator drug (group) for SSRIs? The answer may have been 
‘yes’ twenty years ago when GPs had a choice between SSRIs and tricyclic antidepressants for 
their patients with depression or anxiety. However, the current NICE guidance clearly suggests 
that SSRIs should be the first choice for common mental health disorders [25], which was 
confirmed in Paper 3 (CKD and antidepressant prescription). Therefore, patients receiving 
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SSRIs (mainly for depression and anxiety) and those receiving tricyclic antidepressants (mainly 
for neuropathic pain and other reasons) seem to be systematically different. This means that 
there is little to no benefit to regarding tricyclic antidepressant users as a comparator group for 
SSRIs to minimise “confounding by indication”. 
10.5.3. Generalisability 
Generalisability of the findings in this thesis (to the whole UK population) is expected to be 
good because of the population representativeness of the CPRD. However, the exclusion of 
patients not registered (e.g. migrants) and those who declined the data transfer from the CPRD 
could harm the generalisability of the findings to some extent.  
In Papers 3 (CKD and antidepressant prescription) and 4 (GI bleeding risk of SSRIs by kidney 
function), I restricted the study population to patients registered in general practices that agreed 
to HES linkage. The possibility remains that patient characteristics and prescribing habits of 
antidepressants by GPs are systematically different between general practices in the CPRD that 
do and do not contribute to the HES linkage. 
In Paper 4, I further excluded (i) prevalent SSRI users (because the inclusion of prevalent SSRI 
users with drug tolerance may have caused bias [142]); (ii) those with a history of GI bleeding 
(in order to capture new-onset GI bleeding); and (iii) those with missing values of smoking 
status and BMI (i.e. important confounding factors). I believe that these exclusion criteria were 
important to ensure the internal validity of the study, in return for limiting the external validity 
(i.e. generalisability). Consequently, the study results may be applicable only to non-prevalent 
users of SSRIs without a history of GI bleeding, who are highly monitored in primary care with 
records of smoking status and BMI.  
10.5.4. Sample size 
Although the large sample size of the CPRD was earlier listed as a strength, the statistical 
power of the study in Paper 4 (GI bleeding risk of SSRIs by kidney function) to examine the 
risk of SSRIs in the group with the most severely reduced kidney function (i.e. eGFR <30 
ml/min/1.73m2) may be still limited, as indicated by the wide CI (the fully-adjusted rate ratio 
of 1.84 [95% CI, 1.14–2.96]). Accordingly, the lack of statistical significance in the 
multiplicative interaction across different kidney function subgroups may be partly ascribed to 
166
167 
 
the limited statistical power. This issue of study power also made it difficult to draw robust 
conclusions from the post hoc subgroup analyses by SSRI dose and receptor affinity. Further 
subgroup analysis, for example by individual SSRIs, would not be informative. 
 
10.6. Personal learning 
Throughout this PhD, I have gained new knowledge and skills to deal with large electronic 
health records, especially in outpatient settings. Before coming to the UK, I had experience 
with a large Japanese inpatient database, named the Diagnosis Procedure Combination (DPC) 
database [143-147]. The DPC database is similar to HES in the UK, but includes more detailed 
inpatient information such as intravenous and oral drugs prescribed on a daily basis. I learned 
that the CPRD and DPC database have many differences in their characteristics (see Table 15 
below). 
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Table 15. Comparison of main characteristics between the CPRD and DPC database 
Abbreviations: GPs = general practitioners; HES = Hospital Episode Statistics. 
 
Due to these differences, my previous knowledge and skills gained through the use of the DPC 
database were not very helpful in some situations during my research using the CPRD. I 
encountered the following difficulties: 
Firstly, in most studies using inpatient databases (e.g. DPC database), the timing of cohort entry 
is simply the day of hospital admission for all study participants. However, this varies widely 
in the CPRD, because of differences in (i) the timing of the start of data collection (although 
this may be random, and therefore, unbiased), and (ii) the timing of cohort entry depending on 
the research questions. For example, in Paper 3 (CKD and antidepressant prescription), patients 
entered the CKD cohort on the day they first satisfied the CKD definition (i.e. second eGFR 
<60 ml/min/1.73m2) after their eligibility criteria have been met (one year after practice 
registration, the date that the general practice reached CPRD quality standards, or 1st April 
 CPRD DPC database 
Country  UK Japan 
Setting Outpatient Inpatient 
Nature of database Electronic medical records Administrative claims data 
Size of the data More than 11.3 million patients’ 
data, collected from nearly 700 
general practices (representative of 
the UK population in terms of age 
and sex) since around 1990 
Around 0.5 million hospitalisation 
episodes per month, collected 
from around 1000 hospitals (not 
representative of the Japanese 
hospitals) since 2002 
Data collection  Diagnoses are recorded by GPs and 
practice staff in primary care, 
prospectively or retrospectively. 
Prescriptions and laboratory results 
are automatically recorded on time. 
Diagnoses are recorded by 
attending physicians at the time of 
discharge. Prescribed intravenous 
and oral drugs are automatically 
recorded on time. 
Diagnosis coding  Read code ICD-10 code 
Timing of the start 
of data recording 
When a patient is registered to the 
general practice participating in the 
CPRD (but, data may not be valid 
until the general practice reaches 
the ‘up to standard’) 
Admission 
Timing of the end 
of data recording 
Death, change of general practice, 
last data collection from the general 
practice 
Discharge (with or without death) 
Laboratory results Available Not available 
Linkage  Available (e.g. HES) Not available 
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2004). I learned that, in this type of outpatient databases such as the CPRD, it is sometimes 
difficult to decide when to start follow-up for individual study participants. 
Secondly, in all of my five studies using the DPC database [143-147], the primary outcome 
was all-cause in-hospital death. This was mainly because (i) in-hospital death is almost always 
clinically important and relevant in acute inpatient settings, (ii) other outcomes (e.g. post-
admission events such as delirium and sepsis) may not be well recorded and have not been 
sufficiently validated in the DPC database, and (iii) post-discharge outcomes are not available 
due to the end of data collection upon discharge. Meanwhile, all-cause death, if accurately 
recorded, seems to be the easiest outcome to deal with, because (i) death is unlikely to be 
affected by ascertainment bias, (ii) death occurs only once, and (iii) there is no competing risk 
against death. 
Meanwhile, in the CPRD (with or without linkage with HES), a variety of conditions can be 
candidates for study outcomes. However, unlike death, some outcome definitions in the 
database may have low validity (e.g. low sensitivity). Therefore, researchers need to fully 
consider whether their outcome definitions are appropriate and whether there is no differential 
misclassification of outcome between those with and without exposure. Moreover, I had to 
learn competing risk analysis skills to account for death as a competing risk for my additional 
paper examining the association between CKD and cause-specific hospitalisation (see 
Appendix A for more detail) [113]. 
Thirdly, disease status and medications may change over time in outpatient databases with a 
long follow-up period. I learned that research on adverse outcomes associated with 
intermittently prescribed drugs (e.g. antidepressants) is difficult, especially when using a cohort 
design to estimate incident rates (instead of case-control design to estimate only relative risks). 
Previous studies suggested that one consecutive period of treatment was only 2–3 months for 
most patients receiving antidepressants, but they could have several treatment episodes over a 
longer follow-up in the CPRD [129]. Thus, in Paper 4 (GI bleeding risk of SSRIs by kidney 
function), I needed to consider the prescription of antidepressants as a time-dependent exposure. 
This knowledge would also be useful in my future studies dealing with time-dependent 
confounding factors. 
Research using routinely collected electronic health records has not been popular in Japan, 
especially in outpatient settings. However, the Japanese public and private organisations are 
169
170 
 
currently trying their best to establish a good database for clinical research. With the new skills 
and knowledge acquired during this PhD, I hope to lead clinical and epidemiological research 
in Japan using electronic health records. 
 
10.7. Conclusions 
In conclusion, a close association between CKD and mental health disorders (SMI and common 
mental health disorders such as depression and anxiety) in the UK general population was 
suggested. It is evident that patients with CKD are more likely to be prescribed antidepressants, 
and that this may increase the risk of serious drug-related adverse outcomes such as GI bleeding 
associated with SSRIs. The risk-benefit balance of antidepressants for patients with CKD 
should be reconsidered in light of this new evidence.  
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INTRODUCTION
Chronic kidney disease (CKD) is a common 
condition in the community.1,2 In the UK, 
according to the Quality and Outcomes 
Framework,3 GPs have been incentivised 
to register patients with CKD stages 
3–5 (estimated glomerular filtration 
rate [eGFR] <60 mL/min/1.73 m2 for 
≥3 months) since 2006. The majority of 
these patients are in CKD stage 3 (eGFR 
of 30–59 mL/ min/1.73 m2) and managed 
by GPs without referral to nephrology 
services.4 
There have been concerns, particularly 
among GPs, regarding potential 
overdiagnosis of CKD in older patients with 
mildly reduced kidney function.5,6 Some 
have argued that labelling people as having 
CKD may unnecessarily create anxiety, 
while only a minority of patients with CKD 
progress to end-stage kidney disease 
requiring renal replacement therapy.7,8 
However, patients with CKD are at higher 
risk of cardiovascular events, death, and 
all-cause hospitalisation,9 an important 
outcome for both patients and the national 
healthcare system.10 Awareness of the 
causes of admission among patients with 
CKD could offer opportunities for prevention. 
However, previous studies suggesting a 
positive association between CKD and 
hospitalisations have not investigated the 
specific causes in detail.11–13 
Accumulating evidence suggests that 
CKD is causally associated with a wide 
range of adverse outcomes, including 
acute kidney injury (AKI),14 cardiovascular 
(myocardial infarction,15,16 heart failure,17,18 
and stroke19,20) and non-cardiovascular 
conditions (infection,21,22 bleeding,23,24 venous 
thromboembolism,25,26 and fracture27,28). 
However, to the researchers’ knowledge, 
there has been no study examining the 
extent to which these conditions explain the 
increased risk of all-cause hospitalisation 
in patients with CKD. Identification of more 
common and specific causes of admission 
among patients with CKD is warranted to 
reaffirm the importance of identifying CKD 
in primary care and guide areas of focus for 
outpatient management of these patients.
Therefore, this study aimed to quantify 
the association between CKD and cause-
specific hospitalisation, using a primary 
care database linked to hospital admission 
data. The main purpose of the study was 
to estimate and rank the size of absolute 
risk difference and relative risk between 
patients with and without CKD (matched for 
age, sex, GP, and calendar time) across 10 
common causes of hospital admission.
METHOD 
Data sources
The Clinical Practice Research Datalink 
(CPRD) is a database of routinely recorded 
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primary care electronic health record data.29 
The database represents around 7% of the 
UK population and includes the following 
information: patient demographics; coded 
diagnoses (Read Codes); prescriptions; 
laboratory test results; and referrals made 
by GPs. The CPRD can be linked with 
Hospital Episode Statistics (HES), which 
contains details of all hospital admissions 
at NHS hospitals in England and consists of 
main and subsidiary diagnoses, using the 
10th revision of International Classification 
of Disease (ICD-10) codes.30 Currently 
around 400 GPs in CPRD have consented 
to linkage with HES, representing 75% of 
English practices in CPRD.29 
Study population and matched cohort
All adults in HES-linked CPRD from 1 April 
2004 to 31 March 2014 were potentially 
eligible for inclusion. Patients were eligible 
for inclusion at the latest of: 1 year after 
practice registration,31 the date that the 
GP reached CPRD quality standards,29 
and 1 April 2004. Patients already on renal 
replacement therapy (haemodialysis, 
peritoneal dialysis, or kidney transplantation) 
at cohort entry were excluded. 
First, patients with CKD (stages 
3–5) were identified, defined as two 
consecutive measurements of eGFR 
<60 ml/ min/1.73 m2 for ≥3 months.32 
Estimated GFR was calculated from 
serum creatinine records in CPRD (after 
multiplication of 0.95 to allow for lack of 
creatinine calibration33) using the Chronic 
Kidney Disease Epidemiology Collaboration 
equation.34 Patients, including those who 
had CKD before April 2004, were included 
in the cohort on the date when they first 
satisfied the CKD definition (second eGFR 
<60 mL/min/1.73 m2) after their eligibility. 
Second, for a comparison group, patients 
without known CKD were randomly selected 
from the rest of the study population in a 
1:1 ratio, matched for age, sex, GP, and 
calendar time. 
Outcomes and follow-up
The primary diagnosis in the first episode (a 
single period of care under one consultant 
team) within a spell (a patient’s entire stay 
in hospital) in the HES was examined; this 
was considered to be the main reason 
why a patient required hospital admission.30 
Outcomes of this study were hospitalisations 
for 10 common conditions as the primary 
admission diagnosis: heart failure; 
urinary tract infection; pneumonia; AKI; 
myocardial infarction; cerebral infarction; 
gastrointestinal bleeding; hip fracture; 
venous thromboembolism; and intracranial 
bleeding, defined using ICD-10 codes 
(Appendix 1). In this study, the researchers 
focused on the first hospitalisation for each 
condition after cohort entry.
For each outcome, a patient was followed 
up until the first hospitalisation for that 
outcome or the end of eligibility (initiation of 
renal replacement therapy, death, change 
of GP, last data collection from the GP, 
or 31 March 2014), meaning that every 
patient could develop more than one of the 
outcomes. In addition, individuals selected 
in the comparison group (patients without 
known CKD) could be found to have CKD 
later; in this situation they were censored 
at the time of satisfying the CKD definition 
because they were already included in the 
CKD group from that point forward. 
Covariates
In addition to the matched factors, the 
researchers accounted for potential 
confounders in the association between 
CKD and cause-specific hospitalisation: 
ethnicity; socioeconomic status; smoking 
status; body mass index (BMI); and 17 
comorbidities (asthma, atrial fibrillation, 
cancer, chronic obstructive pulmonary 
disease [COPD], coronary heart disease, 
dementia, depression, diabetes mellitus, 
epilepsy, heart failure, hypertension, 
hypothyroidism, severe mental illness, 
osteoporosis, peripheral arterial disease, 
rheumatoid arthritis, and stroke and 
transient ischaemic attack [TIA]).
Patients with no record of ethnicity were 
classed as white, based on previous studies 
in UK primary care.35,36 Socioeconomic 
status was assigned by quintile at an 
individual level using the Index of Multiple 
How this fits in
Although chronic kidney disease (CKD) is 
associated with a wide range of adverse 
outcomes, more strongly associated 
conditions with hospital admission 
among patients with CKD are unknown. 
This study is the first to examine the 
association between CKD and common 
reasons for hospital admission in a 
systematic way and highlights the high 
burden of hospitalisation due to heart 
failure, infection, and acute kidney injury 
among patients with CKD compared with 
the general population. These findings 
suggest that, aside from prevention of end-
stage kidney disease, there are important 
high-priority outcomes that warrant 
identification of CKD in primary care and 
improved preventive care of patients with 
CKD in the community.
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Deprivation as a composite area-level 
marker of deprivation.37 Smoking status and 
BMI were assigned using the data recorded 
closest to the cohort entry. The definitions 
of hypertension and diabetes were based 
on relevant diagnosis codes recorded 
before the cohort entry or prescription 
(antihypertensive and antidiabetic drugs, 
respectively) in the past 1 year prior to 
the cohort entry. Other comorbidities were 
based on relevant diagnosis codes recorded 
before the cohort entry.
Statistical analysis
The baseline characteristics of matched 
patients with and without CKD were 
compared using χ2 tests. Incidence rates 
of each outcome in matched patients 
with and without CKD, respectively, were 
estimated and a difference of incidence 
rates between the groups was calculated. 
Multivariate Cox regression analyses 
for each outcome were then conducted, 
stratified by matched set to account for the 
matching on age, sex, GP, and calendar 
time (Model 1). Further adjustments were 
made for ethnicity, socioeconomic and 
smoking status, BMI, and diabetes mellitus 
(Model 2). Instead of excluding patients with 
a missing status of smoking or BMI from 
the analysis, an additional absent category 
was included for these patients to maintain 
the matched set between patients with and 
without CKD. Subsequently, adjustments 
for comorbidities not directly related to 
CKD (asthma, cancer, COPD, dementia, 
depression, epilepsy, hypothyroidism, 
severe mental illness, osteoporosis, and 
rheumatoid arthritis)38 (Model 3) were made, 
and also for comorbidities, which may occur 
concordantly with CKD (atrial fibrillation, 
coronary heart disease, heart failure, 
hypertension, peripheral arterial disease, 
stroke and TIA)38 (Model 4). A fully adjusted 
sub-hazard ratio for each outcome using 
the Fine and Gray model was estimated 
to account for potential competing risk 
(initiation of renal replacement therapy and 
death) between patients with and without 
CKD. Because of the computational burden 
related to size of the dataset, this competing 
risk analysis was conducted using a 20% 
random sample of the whole dataset. All 
the statistical analyses were carried out 
using STATA (version 14).
Subgroup analyses
Several subgroup analyses were conducted. 
First, as previous studies suggested that the 
impact of CKD on outcomes may change 
with age,39,40 all the analyses were repeated 
by classifying the study population into two 
age groups; ≥75 and <75 years. Second, to 
examine the extent of graded association 
between CKD stage and cause-specific 
hospitalisation, the researchers conducted 
Cox regression analyses by dividing patients 
with CKD according to baseline CKD 
stage: 3a (eGFR 45–59 mL/ min/1.73 m2), 
3b (eGFR 30–44 mL/min/1.73 m2), and 4 
or 5 (eGFR <30 mL/min/1.73 m2).32 Third, 
to see the impact of CKD on cause-
specific hospitalisation among patients 
with no history of cardiovascular disease, 
patients with either diagnosis of atrial 
fibrillation, coronary heart disease, heart 
failure, peripheral arterial disease, and 
stroke and TIA at the cohort entry were 
excluded, and Cox regression analyses were 
performed by CKD stage. In the second 
and third subgroup analyses where the 
matched nature between patients with and 
without CKD was no longer maintained, 
adjustments for age, sex, and financial year 
were made, and robust standard errors 
to allow for clustering by GP were used, 
instead of stratification by matched set in 
the Cox regression models. 
RESULTS
Among 4 070 806 eligible patients not 
requiring renal replacement therapy (mean 
age 42.7 [SD 18.8] years, male 48.8%), the 
researchers identified 264 628 (6.5%) patients 
with CKD (mean age 76.4 [SD 10.0] years, 
male 38.7%) (Figure 1). Of those with CKD, 
242 349 (92%) were matched with patients 
without CKD (mean age 75.4 [SD 9.7] years, 
male 39.3%). Unmatched 22 279 patients 
with CKD (8% of those with CKD) were older 
and more likely to be female (mean age 87.9 
[SD 5.4] years, male 31.5%). Patients with 
CKD were more likely to have a deprived 
All adults in HES-linked CPRD between 1 April 2004 and 31 March 2014
N = 4 073 639
Patients on renal replacement therapy
N = 2833
All adults not on renal replacement therapy
N = 4 070 806
Patients with CKD
N = 264 628 (6.5%)
Patients with CKD
(matching available)
N = 242 349 (92%)
Patients 
without CKD 
N = 242 349
Matched for 
 - age
 - sex
 - GP
 - calendar time
Figure 1. Selection method of matched patients with 
and without CKD from the general population.
CKD = chronic kidney disease. CPRD = Clinical 
Practice Research Datalink. HES = Hospital Episode 
Statistics.
e514  British Journal of General Practice, August 2018 
186
socioeconomic status, be ex-smokers, 
and overweight, with a larger number of 
comorbidities (Table 1). Total length of follow-
up, if not censored for each cause-specific 
hospitalisation, was 2.0 million person-years 
(mean 4.2 [SD 2.9] years/person).
Among the 10 cause-specific 
hospitalisations, the largest incidence rate 
difference was seen for heart failure at 
6.6/1000 person-years (9.7/1000 versus 
3.1/1000 person-years in matched patients 
with and without CKD, respectively), followed 
by urinary tract infection at 5.2/1000 person-
years, pneumonia at 4.4/1000 person-years, 
and AKI at 4.1/1000 person-years (Table 
2). Hip fracture, venous thromboembolism, 
and intracranial bleeding marked relatively 
small differences of incidence rates 
between matched patients with and without 
CKD.
The relative risk was consistently highest 
for AKI, followed by heart failure in all the 
models, though the rank order of other 
outcomes varied depending on the extent of 
adjustment for confounding factors (Table 3). 
The age- and sex-adjusted hazard ratio for 
AKI in Model 1 was 6.49, 95% CI = 5.99 to 
7.03, followed by heart failure with 3.28, 95% 
CI = 3.15 to 3.41. The fully adjusted hazard 
ratio for AKI in Model 4 was 4.90, 95% 
CI = 4.47 to 5.38, followed by heart failure 
with 1.66, 95% CI = 1.59 to 1.75. Intracranial 
bleeding and hip fracture marked relatively 
small fully adjusted hazard ratios. Results 
of competing risk analyses were generally 
similar to or slightly higher than those 
estimated in the main analysis. Likewise, 
AKI and heart failure exhibited higher sub-
hazard ratios than others.
In subgroup analysis by age, the incidence 
rate difference between matched patients 
with and without CKD tended to be larger 
and the relative risk tended to be smaller 
in the older subgroup (≥75 years of age) 
than the younger subgroup (<75 years 
of age) for almost all the cause-specific 
hospitalisations (Table 4). However, the rank 
order in the size of absolute rate difference 
and relative risk was almost the same as 
the main results in each age group. 
Of 242 349 matched patients with CKD, 
71.2% (n = 172 555) , 22.9% (n = 55 500), and 
5.9%, (n = 14 294) patients were in stage 3a, 
3b, and 4 or 5, respectively. Patients tended 
to be older and sicker as kidney function 
declined. Details of baseline characteristics 
of patients with different stages of CKD 
are available from the authors. There were 
graded associations between CKD stage 
and all the cause-specific hospitalisations, 
but the strength of the association was 
larger for AKI and heart failure (Figure 2 and 
Appendix 2). 
Among patients with no history of 
cardiovascular disease, the strength of the 
association was similar to that in the main 
analysis for all the studied cause-specific 
hospitalisations (Appendix 3).
Table 1. Baseline characteristics of matched patients with and without 
chronic kidney disease
 Patients without CKD Patients with CKD 
 N = 242 349 N = 242 349  
Characteristic n (%) n (%) P-value
Age, years   1.000 
 <55 6845 (2.8) 6845 (2.8)  
 55–64 23 556 (9.7) 23 556 (9.7)  
 65–74 71 112 (29.3) 71 112 (29.3)  
 75–84 102 594 (42.3) 102 594 (42.3)  
 ≥85 38 242 (15.8) 38 242 (15.8) 
Sex (male) 95 318 (39.3) 95 318 (39.3) 1.000
Ethnicity   <0.001 
 White/not recorded 238 533 (98.4) 238 138 (98.3)  
 South Asian  1796 (0.7) 2317 (1.0)  
 Black 1156 (0.5) 1060 (0.4)  
 Other  864 (0.4) 834 (0.3) 
Socioeconomic status   <0.001 
 1 (least deprived) 56 800 (23.4) 53 034 (21.9)  
 2 61 647 (25.4) 60 501 (25.0)  
 3 50 466 (20.8) 50 709 (20.9)  
 4 42 221 (17.4) 44 692 (18.4)  
 5 (most deprived) 31 215 (12.9) 33 413 (13.8) 
Smoking status   <0.001 
 Non-smoker 92 363 (38.1) 80 721 (33.3)  
 Ex-smoker 107 737 (44.5) 131 510 (54.3)  
 Current smoker 36 338 (15.0) 29 243 (12.1)  
 Missing 5911 (2.4) 875 (0.4) 
Body mass index, kg/m2   <0.001 
 <18.5 6638 (2.7) 4562 (1.9)  
 18.5–25 85 473 (35.3) 70 102 (28.9)  
 ≥25 80 458 (33.2) 88 083 (36.4)  
 ≥30 40 326 (16.6) 63 183 (26.1)  
 Missing 29 454 (12.2) 16 419 (6.8) 
Comorbidities    
 Asthma 28 002 (11.6) 31 271 (12.9) <0.001 
 Atrial fibrillation 15 448 (6.4) 29 515 (12.2) <0.001 
 Cancer 47 431 (19.6) 54 450 (22.5) <0.001 
 Chronic obstructive pulmonary disease 14 996 (6.2) 18 229 (7.5) <0.001 
 Coronary heart disease 27 961 (11.5) 54 049 (22.3) <0.001 
 Dementia 8954 (3.7) 7345 (3.0) <0.001 
 Depression 38 490 (15.9) 46 233 (19.1) <0.001 
 Diabetes mellitus 24 372 (10.1) 52 927 (21.8) <0.001 
 Epilepsy 3972 (1.6) 3682 (1.5) 0.001 
 Heart failure 7581 (3.1) 23 774 (9.8) <0.001 
 Hypertension 128 828 (53.2) 203 963 (84.2) <0.001 
 Hypothyroidism 17 443 (7.2) 29 318 (12.1) <0.001 
 Severe mental illness 3522 (1.5) 4890 (2.0) <0.001 
 Osteoporosis 16 469 (6.8) 16 610 (6.9) 0.422 
 Peripheral arterial disease 7481 (3.1) 14 815 (6.1) <0.001 
 Rheumatoid arthritis 4270 (1.8) 6031 (2.5) <0.001 
 Stroke and transient ischaemic attack 12 243 (5.1) 19 982 (8.3) <0.001
CKD = chronic kidney disease
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DISCUSSION
Summary
In this population-based cohort study, 
among people with CKD (stages 3–5) 
large absolute increases in rates of 
hospitalisations due to heart failure, infection 
(urinary tract infection and pneumonia), 
and AKI were found, compared with age- 
and sex-matched controls without known 
CKD from the same GP. Before and after 
adjustment for confounding factors, the 
relative risk of hospitalisation was highest 
for AKI, followed by heart failure. Results 
were similar in subgroup analyses by age 
and CKD stage, and among patients with 
no history of cardiovascular disease. The 
vast majority of patients in the cohort had 
CKD stage 3a or 3b so would be primarily 
diagnosed and managed in primary care, 
making these findings useful and relevant 
Table 2. Difference in the incidence rate of cause-specific hospitalisation between matched patients with 
and without chronic kidney disease by rank order of rate difference
 Number of outcome, n Incidence rate per 1000 person-years (95%CI)
 Patients with CKD Patients without CKD Patients Patients Rate 
Cause of hospitalisation (N = 242 349) (N = 242 349) with CKD without CKD difference
Heart failure 10 394 2955 9.7 (9.5 to 9.9) 3.1 (3.0 to 3.2) 6.6 (6.4 to 6.8)
Urinary tract infection 14 266 7654 13.1 (12.9 to 13.3) 7.9 (7.7 to 8.1) 5.2 (4.9 to 5.5)
Pneumonia 13 483 7803 12.6 (12.4 to 12.8) 8.2 (8.0 to 8.4) 4.4 (4.1 to 4.7)
Acute kidney injury 5257 787 4.9 (4.7 to 5.0) 0.8 (0.8 to 0.9) 4.1 (3.9 to 4.2)
Myocardial infarction 7418 3590 6.9 (6.8 to 7.1) 3.8 (3.6 to 3.9) 3.2 (3.0 to 3.4)
Cerebral infarction 6142 3335 5.7 (5.6 to 5.8) 3.5 (3.4 to 3.6) 2.2 (2.0 to 2.4)
Gastrointestinal bleeding 5492 3048 5.1 (5.0 to 5.2) 3.2 (3.1 to 3.3) 1.9 (1.7 to 2.1)
Hip fracture  9336 6751 8.7 (8.6 to 8.9) 7.1 (7.0 to 7.3) 1.6 (1.4 to 1.9)
Venous thromboembolism 3299 1882 3.1 (3.0 to 3.2) 2.0 (1.9 to 2.1) 1.1 (1.0 to 1.2)
Intracranial bleeding 2144 1427 2.0 (1.9 to 2.1) 1.5 (1.4 to 1.6) 0.5 (0.4 to 0.6)
CKD = chronic kidney disease.
Table 3. Relative risk for cause-specific hospitalisation between matched patients with and without chronic 
kidney disease by rank order of fully adjusted hazard ratio
 Adjusted hazard ratio (95% CI)a Fully adjusted
    Model 4 sub-hazard 
Cause of hospitalisation Model 1 Model 2 Model 3 (fully adjusted model) ratio (95% CI)b
Acute kidney injury 6.49 (5.99 to 7.03) 5.95 (5.46 to 6.47) 5.82 (5.34 to 6.35) 4.90 (4.47 to 5.38) 4.98 (4.23 to 5.87)
Heart failure 3.28 (3.15 to 3.41) 2.84 (2.73 to 2.96) 2.79 (2.67 to 2.90) 1.66 (1.59 to 1.75) 2.07 (1.88 to 2.28)
Venous thromboembolism 1.60 (1.53 to 1.68) 1.57 (1.49 to 1.65) 1.54 (1.46 to 1.62) 1.55 (1.46 to 1.64) 1.57 (1.37 to 1.80)
Myocardial infarction 1.84 (1.78 to 1.91) 1.70 (1.64 to 1.76) 1.67 (1.61 to 1.73) 1.40 (1.34 to 1.46) 1.53 (1.38 to 1.69)
Urinary tract infection 1.62 (1.58 to 1.67) 1.53 (1.49 to 1.57) 1.50 (1.46 to 1.54) 1.39 (1.35 to 1.43) 1.59 (1.50 to 1.69)
Gastrointestinal bleeding 1.59 (1.53 to 1.66) 1.55 (1.49 to 1.62) 1.52 (1.46 to 1.58) 1.34 (1.28 to 1.40) 1.55 (1.41 to 1.72)
Cerebral infarction 1.55 (1.49 to 1.61) 1.51 (1.46 to 1.58) 1.51 (1.45 to 1.58) 1.27 (1.22 to 1.33) 1.45 (1.30 to 1.60)
Pneumonia 1.47 (1.43 to 1.51) 1.46 (1.42 to 1.50) 1.44 (1.40 to 1.49) 1.24 (1.20 to 1.29) 1.49 (1.39 to 1.59)
Hip fracture  1.11 (1.08 to 1.14) 1.18 (1.14 to 1.21) 1.17 (1.13 to 1.21) 1.11 (1.07 to 1.15) 1.37 (1.27 to 1.48)
Intracranial bleeding 1.28 (1.21 to 1.36) 1.30 (1.22 to 1.38) 1.29 (1.21 to 1.38) 1.10 (1.02 to 1.19) 1.30 (1.11 to 1.52)
aAdjusted hazard ratio (patients with chronic kidney disease versus those without) was estimated in the following Cox regression models: Model 1: Stratified by matched set to 
account for the matching on age, sex, general practice, and calendar time. Model 2: Model 1 + adjusted by ethnicity, socioeconomic and smoking status, body mass index, and 
diabetes mellitus. Model 3: Model 2 + adjusted by comorbidities not directly related to chronic kidney disease (asthma, cancer, chronic obstructive pulmonary disease, dementia, 
depression, epilepsy, hypothyroidism, severe mental illness, osteoporosis, and rheumatoid arthritis). Model 4: Model 3 + adjusted by all the other comorbidities that may occur 
concordantly with chronic kidney disease (atrial fibrillation, coronary heart disease, heart failure, hypertension, peripheral arterial disease, and stroke and transient ischaemic 
attack). bFully adjusted sub-hazard ratio was estimated by the model of Fine and Gray to account for competing risk (initiation of renal replacement therapy and death) between 
patients with and without chronic kidney disease, using a 20% random sample of the whole dataset.
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for routine clinical care. 
Strengths and limitations
A major strength of this study was that it 
compared those with CKD to those without, 
sampled from the general population. A 
comparison was possible because over 98% 
of the UK population are registered with 
a primary care practice. The study results 
obtained from HES-linked CPRD are likely 
to be generalisable to the entire English 
population.29
Limitations of the study include, first, that 
patients who had never had kidney function 
tested were kept in the denominator in order 
for the comparison group to be representative 
of the general population. Currently in the UK, 
serum creatinine testing is recommended 
and incentivised for people with known CKD 
risk factors.3,41 If some patients had been 
misclassified with unmeasured CKD to 
the matched comparison group, the true 
association between CKD and each cause-
specific hospitalisation may have been 
underestimated. However, the researchers 
have recently shown that the prevalence of 
patients with an eGFR <60 mL/min/1.73 m2 
identified in CPRD was similar to that in 
a population-representative survey (Health 
Survey for England),42 suggesting that 
most of these patients are captured with 
the current testing strategy in UK primary 
care, and people without creatinine tests are 
unlikely to have CKD stages 3–5.43 If healthy 
people without creatinine measurement 
were excluded from the denominator, severe 
selection bias would arise and estimated 
absolute risk differences between patients 
with and without CKD would not be 
informative.44
Second, relative risks between CKD status 
(stage) and cause-specific hospitalisation 
depend partly on the extent of adjustment 
for potential confounders. Previous studies 
on the association between CKD and 
outcomes adjusted for disease diagnoses 
(based on patient charts, administrative 
claim data, or questionnaire answered by 
patients), physiological measurements, 
blood test results, or prescriptions to 
various degrees conclude that CKD is 
‘independently’ associated with their studied 
outcomes.15–28 However, the possibility of 
residual confounding inevitably remains. 
In this study, adjustments were made for 
important patient characteristics as well as 
diagnoses of 17 comorbidities. Recording 
of these conditions has been incentivised 
since the introduction of the UK Quality and 
Outcomes Framework in 2004,3 resulting 
in marked improvements in data quality.29 
Further, differences of disease diagnosis 
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and coding among different GPs and over 
time was minimised by matching on GP 
and calendar time between patients with 
and without CKD. Therefore, the authors 
believe that the best available approach 
of adjustment for confounding was used 
to compare the relative risks between 
CKD and different types of cause-specific 
hospitalisations. 
Finally, although the researchers 
acknowledge that proteinuria is an 
important outcome prediction marker,32 
the authors of this study were not able to 
stratify patients by the level of proteinuria or 
quantify the association between proteinuria 
and cause-specific hospitalisation. This 
is because proteinuria was infrequently 
checked in CPRD: testing rate of proteinuria 
(including dipstick testing) in the year prior 
to cohort entry was 23.2% (56 431 out of 
242 349 patients) in the CKD group and 
12.6% (30 616 out of 242 349 patients) in 
the comparison group. It would not be 
appropriate to assume that people without 
urine testing did not have proteinuria. 
Comparison with existing literature
There have been several studies 
demonstrating an association between 
CKD and increased risk of all-cause 
hospitalisations.9,11–13 However, these 
studies did not clearly differentiate causes 
of hospitalisation, and therefore it remained 
unclear why this is the case. Meanwhile, 
a previous study recruiting patients with 
elevated serum creatinine suggested that 
cardiovascular disease and hypertension 
were the most common reason for 
hospitalisation, followed by infection.45 
However, in the absence of a comparison 
group without CKD, it remained unclear 
whether these hospitalisations were specific 
to CKD or common in the community 
regardless of CKD status.
As well as a known association between 
CKD and AKI,46 a number of studies have 
reported positive associations between CKD 
and incidence of non-renal conditions.15–28 
Many of these studies used hospital 
admission for their outcome definitions. 
However, these individual studies did 
not allow a comparison of the impact of 
CKD across different outcomes, because 
absolute and relative risk related to 
CKD were estimated in different study 
populations and with various degrees of 
statistical adjustment for confounders. To 
the authors’ knowledge, the current study is 
the first to quantify the association between 
CKD status (stage) and cause-specific 
hospitalisation.
Implications for research and practice 
After the classification of CKD, and the 
implementation of testing and registering 
of patients with CKD through the Quality 
and Outcomes Framework for CKD in 
2006,3 some have questioned the benefits 
of this approach.47 Patients with mild CKD 
may be perceived to have normal kidney 
ageing, or with multiple morbidities putting 
them at increased risk for many adverse 
outcomes. This study was planned to clarify 
the adverse outcomes (that were likely to 
be causally related to kidney function) that 
were more common and specific among 
patients with CKD in primary care, enabling 
the possibility of better-targeted care.
The adjusted hazard ratios were small 
for most of the outcomes in patients with 
CKD stage 3a (Figure 2), except for AKI 
with a threefold increase in the adjusted 
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Figure 2. Fully adjusted hazard ratio for cause-specific 
hospitalisation by chronic kidney disease stage 
estimated using Cox regression models, adjusted by 
age, sex, financial year, ethnicity, socioeconomic and 
smoking status, body mass index, and comorbidities 
(asthma, atrial fibrillation, cancer, chronic obstructive 
pulmonary disease, coronary heart disease, dementia, 
depression, diabetes mellitus, epilepsy, heart failure, 
hypertension, hypothyroidism, severe mental illness, 
osteoporosis, peripheral arterial disease, rheumatoid 
arthritis, and stroke and transient ischaemic attack) 
and clustered by general practice using robust 
standard errors (corresponding to Appendix 2). 
CKD = chronic kidney disease.
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hazard ratio for hospitalisations; and nearly 
one and a half-fold increase for heart 
failure. These results highlight the marked 
increase in risk of AKI and heart failure for 
patients with only mild reductions in kidney 
function, with implications for targeted 
prevention and medication management; 
for example, minimisation of non-steroidal 
antiinflammatory drug use. 
Both absolute and relative risk provide 
important information about the impact of 
CKD on cause-specific hospitalisation.40,48 
The relative risk (adjusted hazard ratio) is a 
measure of the strength of the association 
between CKD and each cause-specific 
hospitalisation, after taking into account 
a range of comorbidities. Meanwhile, the 
absolute risk difference reflects the relative 
risk and the baseline frequency of each 
outcome in the community, indicating the 
actual burden of each condition among 
patients with CKD as compared with 
the general population. For example, 
infections, such as urinary tract infection 
and pneumonia, showed intermediate 
relative risks among the studied outcomes, 
but their absolute risk differences between 
patients with and without CKD were large 
because hospitalisations for infection were 
common in the general population. The 
absolute risk difference is also useful for 
understanding the potential benefits of 
preventive strategies. For example, Table 
2 shows that 9.7 and 3.1 patients per 1000 
patients with and without CKD (stages 3–5), 
respectively, were hospitalised for heart 
failure in a year, meaning that, of 1000 
people with CKD, up to 6.6 could benefit 
from targeted heart failure admission 
prevention. This would translate to three 
people per year in a GP practice of 7400 
patients (average number of patients per 
practice)49 where 6.5% have CKD. Further 
estimates for all outcomes are available 
from the authors. However, these numbers 
are likely to be underestimates of the overall 
benefits because follow-up of patients at 
the time of first hospitalisation after cohort 
entry was stopped and, therefore, did not 
account for repeated admissions. 
Patients with CKD, even without renal 
replacement therapy, are known to incur 
substantive healthcare costs through 
frequent hospitalisations.10 Based 
on results from this study, a focus on 
strategies to reduce hospitalisations for 
heart failure, such as education on dietary 
salt restriction50 and improved medication 
adherence,51 could help to minimise the 
difference in the overall hospitalisation rate 
between patients with and without CKD. 
Similarly, a proportion of hospitalisations 
due to infections may be preventable 
through prompt antibiotic treatment and 
improvement of vaccination coverage 
among patients with CKD.52 Pneumococcal 
vaccination has been underutilised in 
patients with CKD (stages 4 and 5) to date.53
Funding
Ben Caplin and Dorothea Nitsch were part-
funded through a grant for the National 
CKD Audit commissioned by Healthcare 
Quality Improvement Partnership, which 
is funded by NHS England, the Welsh 
Government, and, with some individual 
audits, also funded by the Health 
Department of the Scottish Government, 
DHSSPS Northern Ireland, and the Channel 
Islands. Laurie A Tomlinson is funded by a 
Wellcome Intermediate Clinical Fellowship 
(reference: WT101143MA). Liam Smeeth 
is funded by a Wellcome Senior Research 
Fellowship in Clinical Science (grant 
number: 098504/Z/12/Z). Masao Iwagami 
is supported by Honjo International 
Scholarship Foundation. None of these 
funding sources had a role in the design, 
conduct, analysis, or reporting of the study.
Ethical approval
The study protocol was approved by the 
Independent Scientific Advisory Committee 
for Medicines and Healthcare products 
Regulatory Agency (reference number: 
17_055R).
Open access
This article is Open Access: CC BY 4.0 
licence (https://creativecommons.org/
licenses/by/4.0/).
Provenance
Freely submitted; externally peer reviewed.
Competing interests
The authors have declared no competing 
interests.
Discuss this article
Contribute and read comments about this 
article: bjgp.org/letters
British Journal of General Practice, August 2018  e519
191
REFERENCES
1. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-
based studies: systematic review. BMC Public Health 2008; 8: 117.
2. McCullough K, Sharma P, Ali T, et al. Measuring the population burden 
of chronic kidney disease: a systematic literature review of the estimated 
prevalence of impaired kidney function. Nephrol Dial Transplant 2012; 27(5): 
1812–1821.
3. Health and Social Care Information Centre. Quality and Outcomes Framework. 
http://www.nhsemployers.org/your-workforce/primary-care-contacts/general-
medical-services/quality-and-outcomes-framework (accessed 26 Jun 2018). 
4. McIntyre NJ, Fluck R, McIntyre C, et al. Treatment needs and diagnosis 
awareness in primary care patients with chronic kidney disease. Br J Gen Pract 
2012; DOI: https://doi.org/10.3399/bjgp12X636047.
5. Winearls CG, Glassock RJ. Classification of chronic kidney disease in the elderly: 
pitfalls and errors. Nephron Clin Pract 2011; 119(Suppl 1): c2–c4.
6. Ellam T, Twohig H, Khwaja A. Chronic kidney disease in elderly people: disease 
or disease label? BMJ 2016; 352: h6559.
7. Moynihan R, Glassock R, Doust J. Chronic kidney disease controversy: how 
expanding definitions are unnecessarily labelling many people as diseased. BMJ 
2013; 347: f4298.
8. Blakeman T, Protheroe J, Chew-Graham C, et al. Understanding the 
management of early-stage chronic kidney disease in primary care: a qualitative 
study. Br J Gen Pract 2012; DOI: https://doi.org/10.3399/bjgp12X636056.
9. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, 
cardiovascular events, and hospitalization. N Engl J Med 2004; 351(13): 1296–
1305.
10. Kent S, Schlackow I, Lozano-Kuhne J, et al. What is the impact of chronic kidney 
disease stage and cardiovascular disease on the annual cost of hospital care in 
moderate-to-severe kidney disease? BMC Nephrol 2015; 16: 65.
11. Nitsch D, Nonyane BA, Smeeth L, et al. CKD and hospitalization in the elderly: 
a community-based cohort study in the United Kingdom. Am J Kidney Dis 2011; 
57(5): 664–672.
12. Chan TC, Yap DY, Shea YF, et al. Chronic kidney disease and its association with 
mortality and hospitalization in Chinese nursing home older residents: a 3-year 
prospective cohort study. J Am Med Dir Assoc 2012; 13(9): 782–787.
13. Nishikawa K, Takahashi K, Yamada R, et al. Influence of chronic kidney disease 
on hospitalization, chronic dialysis, and mortality in Japanese men: a longitudinal 
analysis. Clin Exp Nephrol 2017; 21(2): 316–323. 
14. Hsu CY, Ordonez JD, Chertow GM, et al. The risk of acute renal failure in patients 
with chronic kidney disease. Kidney Int 2008; 74(1): 101–107.
15. Meisinger C, Doring A, Lowel H. Chronic kidney disease and risk of incident 
myocardial infarction and all-cause and cardiovascular disease mortality in 
middle-aged men and women from the general population. Eur Heart J 2006; 
27(10): 1245–1250.
16. Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, 
proteinuria, and adverse outcomes. JAMA 2010; 303(5): 423–429.
17. Kottgen A, Russell SD, Loehr LR, et al. Reduced kidney function as a risk factor 
for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J 
Am Soc Nephrol 2007; 18(4): 1307–1315.
18. Dhingra R, Gaziano JM, Djousse L. Chronic kidney disease and the risk of heart 
failure in men. Circ Heart Fail 2011; 4(2): 138–144.
19. Mahmoodi BK, Yatsuya H, Matsushita K, et al. Association of kidney disease 
measures with ischemic versus hemorrhagic strokes: pooled analyses of 4 
prospective community-based cohorts. Stroke 2014; 45(7): 1925–1931.
20. Koren-Morag N, Goldbourt U, Tanne D. Renal dysfunction and risk of ischemic 
stroke or TIA in patients with cardiovascular disease. Neurology 2006; 67(2): 
224–228.
21. Dalrymple LS, Katz R, Kestenbaum B, et al. The risk of infection-related 
hospitalization with decreased kidney function. Am J Kidney Dis 2012; 59(3): 
356–363.
22. Ishigami J, Grams ME, Chang AR, et al. CKD and risk for hospitalization with 
infection: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney 
Dis 2017; 69: 752–761. 
23. Molnar AO, Bota SE, Garg AX, et al. The risk of major hemorrhage with CKD. J 
Am Soc Nephrol 2016; 27(9): 2825–2832.
24. Ishigami J, Grams ME, Naik RP, et al. Chronic kidney disease and risk for 
gastrointestinal bleeding in the community: the Atherosclerosis Risk in 
Communities (ARIC) Study. Clin J Am Soc Nephrol 2016; 11(10): 1735–1743.
25. Wattanakit K, Cushman M, Stehman-Bree C, et al. Chronic kidney disease 
increases risk for venous thromboembolism. J Am Soc Nephrol 2008; 19(1): 
135–140.
26. Mahmoodi BK, Gansevoort RT, Naess IA, et al. Association of mild to moderate 
chronic kidney disease with venous thromboembolism: pooled analysis of five 
prospective general population cohorts. Circulation 2012; 126(16): 1964–1971.
27. Naylor KL, McArthur E, Leslie WD, et al. The three-year incidence of fracture in 
chronic kidney disease. Kidney Int 2014; 86(4): 810–818.
28. Daya NR, Voskertchian A, Schneider AL, et al. Kidney function and fracture risk: 
the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2016; 
67(2): 218–226.
29. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical 
Practice Research Datalink (CPRD). Int J Epidemiol 2015; 44(3): 827–836.
30. Herbert A, Wijlaars L, Zylbersztejn A, et al. Data resource profile: Hospital 
Episode Statistics Admitted Patient Care (HES APC). Int J Epidemiol 2017; 46(4): 
1093–1093i.
31. Lewis JD, Bilker WB, Weinstein RB, et al. The relationship between time since 
registration and measured incidence rates in the General Practice Research 
Database. Pharmacoepidemiol Drug Saf 2005; 14(7): 443–451.
32. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical 
Practice Guideline for the Evaluation and Management of Chronic Kidney 
Disease. Kidney Int Suppl 2013; 3: 1–150. 
33. Levey AS, Coresh J, Greene T, et al. Expressing the modification of diet in renal 
disease study equation for estimating glomerular filtration rate with standardized 
serum creatinine values. Clin Chem 2007; 53(4): 766–772.
34. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular 
filtration rate. Ann Intern Med 2009; 150(9): 604–612.
35. Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture 
algorithm to predict risk of osteoporotic fracture in primary care in the United 
Kingdom: prospective open cohort study. BMJ 2012; 344: e3427.
36. Hippisley-Cox J, Coupland C. Predicting risk of upper gastrointestinal bleed and 
intracranial bleed with anticoagulants: cohort study to derive and validate the 
QBleed scores. BMJ 2014; 349: g4606.
37. Ministry of Housing, Communities and Local Government. English indices of 
deprivation. https://www.gov.uk/government/collections/english-indices-of-
deprivation (accessed 29 Jun 2018). 
38. Tonelli M, Wiebe N, Guthrie B, et al. Comorbidity as a driver of adverse outcomes 
in people with chronic kidney disease. Kidney Int 2015; 88(4): 859–866.
39. James MT, Quan H, Tonelli M, et al. CKD and risk of hospitalization and death 
with pneumonia. Am J Kidney Dis 2009; 54(1): 24–32.
40. Hallan SI, Matsushita K, Sang Y, et al. Age and association of kidney measures 
with mortality and end-stage renal disease. JAMA 2012; 308(22): 2349–2360.
41. National Institute for Health and Care Excellence. Chronic kidney disease: early 
identification and management of chronic disease in adults in primary and 
secondary care. CG73. London: NICE, 2008.
42. Roth M, Roderick P, Mindell J. Kidney disease and renal function. In: Craig R, 
and Mindell J, eds. Health survey for England 2010: volume 1 respiratory health. 
2011. https://files.digital.nhs.uk/publicationimport/pub03xxx/pub03023/heal-
surv-eng-2010-resp-heal-ch8-kidn.pdf (accessed 26 Jun 2018).
43. Iwagami M, Tomlinson M, Mansfield KE, et al. Validity of estimated prevalence 
of decreased kidney function and renal replacement therapy from primary care 
electronic health records compared with national survey and registry data in the 
United Kingdom. Nephrol Dial Transplant 2017; 32(Suppl 2): ii142–ii150.
44. McDonald HI, Shaw C, Thomas, SL, et al. Methodological challenges when 
carrying out research on CKD and AKI using routine electronic health records. 
Kidney Int 2016; 90(5): 943–949.
45. Khan SS, Kazmi WH, Abichandani R, et al. Health care utilization among patients 
with chronic kidney disease. Kidney Int 2002; 62(1): 229–236.
46. Chawla LS, Eggers PW, Star RA, et al. Acute kidney injury and chronic kidney 
disease as interconnected syndromes. N Engl J Med 2014; 371(1): 58–66.
47. Spence D. Bad medicine: chronic kidney disease. BMJ 2010; 340: c3188.
48. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for 
cardiovascular disease, renal replacement, and death in the United States 
Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16(2): 489–495.
49. Health and Social Care Information Centre. General practice trends in the UK to 
2015. http://content.digital.nhs.uk/media/21726/General-Practice-Trends-in-the-
UK-to-2015/pdf/General_Practice_Trends_in_the_UK_to_2015.pdf. (accessed 29 
Jun 2018).
50. Mills KT, Chen J, Yang W, et al. Sodium excretion and the risk of cardiovascular 
e520  British Journal of General Practice, August 2018 
192
disease in patients with chronic kidney disease. JAMA 2016; 315(20): 2200–2210.
51. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic 
kidney disease. A clinical update from Kidney Disease: Improving Global 
Outcomes (KDIGO). Kidney Int 2011; 80(6): 572–586.
52. McDonald HI, Thomas SL, Millett ERC, et al. Do influenza and pneumococcal 
vaccines prevent community-acquired respiratory infections among older people 
with diabetes and does this vary by chronic kidney disease? A cohort study using 
electronic health records: BMJ Open Diabetes Res Care 2017; 5(1): e000332.
53. Health Quality Improvement Partnership. National Chronic Kidney Disease 
Audit: national report (Part 1). 2017. https://www.hqip.org.uk/resources/national-
chronic-kidney-disease-audit-national-report-part-1/ (accessed 30 Apr 2018).
British Journal of General Practice, August 2018  e521
193
Appendix 2. Fully adjusted hazard ratio for cause-specific hospitalisation by chronic kidney disease stage 
 Fully adjusted hazard ratio (95% CI)a by CKD stage
 Patients with CKD (N = 242 349)
 Patients without CKD CKD stage 3a CKD stage 3b CKD stage 4 or 5 
Cause of hospitalisation (N = 242 349) (N = 172 555) (N = 55 500) (N = 14 294)
Acute kidney injury 1b 2.94 (2.69 to 3.20) 7.03 (6.39 to 7.73) 20.22 (18.14 to 22.54)
Heart failure 1b 1.43 (1.37 to 1.50) 2.13 (2.02 to 2.24) 3.29 (3.06 to 3.54)
Venous thromboembolism 1b 1.36 (1.28 to 1.45) 1.68 (1.53 to 1.83) 2.09 (1.78 to 2.46)
Myocardial infarction 1b 1.25 (1.19 to 1.31) 1.58 (1.48 to 1.67) 2.18 (1.99 to 2.38)
Urinary tract infection 1b 1.23 (1.19 to 1.27) 1.61 (1.55 to 1.68) 2.40 (2.25 to 2.57)
Gastrointestinal bleeding 1b 1.24 (1.18 to 1.31) 1.53 (1.43 to 1.64) 2.12 (1.90 to 2.37)
Cerebral infarction 1b 1.21 (1.15 to 1.27) 1.39 (1.31 to 1.48) 1.58 (1.40 to 1.78)
Pneumonia 1b 1.11 (1.07 to 1.15) 1.50 (1.44 to 1.57) 1.97 (1.84 to 2.11)
Hip fracture  1b 1.04 (1.00 to 1.08) 1.29 (1.24 to 1.36) 1.72 (1.59 to 1.85)
Intracranial bleeding  1b 1.08 (1.00 to 1.16) 1.31 (1.19 to 1.45) 1.28 (1.03 to 1.60)
aFully adjusted hazard ratio was estimated using Cox regression models, adjusted by age, sex, financial year, ethnicity, socioeconomic and smoking status, body mass index, and 
comorbidities (asthma, atrial fibrillation, cancer, chronic obstructive pulmonary disease, coronary heart disease, dementia, depression, diabetes mellitus, epilepsy, heart failure, 
hypertension, hypothyroidism, severe mental illness, osteoporosis, peripheral arterial disease, rheumatoid arthritis, and stroke and transient ischaemic attack) and clustered by 
general practice using robust standard errors. bReference. CKD = chronic kidney disease.
Appendix 1. List of International Classification of Diseases 10th Revision codes used to identify cause-specific 
hospitalisations
Outcome International Classification of Diseases 10th Revision codes
Myocardial infarction I21, I22, I23
Heart failure I50
Cerebral infarction I63
Pneumonia B01.2, B05.2, B20.6, B25.0, J10.0, J11.0, J12, J13, J14, J15, J16, J17, J18, J85.1, U04
Urinary tract infection N10, N12, N13.6, N15.1, N15.9, N30.0, N30.8, N30.9, N39.0
Gastrointestinal bleeding I85.0, K22.6, K25.0, K25.1, K25.2, K25.4, K25.5, K25.6, K26.0, K26.1, K26.2, K26.4, K26.5, K26.6, K27.0, K27.1, K27.2, K27.4, K27.5, K27.6,  
 K28.0, K28.1, K28.2, K28.4, K28.5, K28.6, K29.0, K92.0, K92.1, K92.2
Intracranial bleeding I60, I61, I62, S06.5, S06.6
Venous thromboembolism I80.1, I80.2, I80.3, I81, I82.2, I82.3, I82.8, I82.9, I26
Hip fracture  S72
Acute kidney injury  N17
e522  British Journal of General Practice, August 2018 
194
Appendix 3. Fully adjusted hazard ratio for cause-specific hospitalisation by chronic kidney disease stage 
among patients with no history of cardiovascular disease
 Fully adjusted hazard ratio (95% CI)a by CKD stage
   Patients with CKD (N = 143 715)
 Patients without CKD CKD stage 3a CKD stage 3b CKD stage 4 or 5 
Cause of hospitalisation (N = 187 322) (N = 107 803) (N = 29 085) (N = 6827)
Acute kidney injury 1b  2.65 (2.39 to 2.93) 7.09 (6.29 to 8.00) 24.20 (21.22 to 27.61)
Heart failure 1b  1.25 (1.17 to 1.35) 1.95 (1.78 to 2.14) 3.41 (2.96 to 3.94)
Venous thromboembolism 1b  1.43 (1.33 to 1.54) 1.66 (1.48 to 1.85) 2.23 (1.80 to 2.76)
Myocardial infarction 1b  1.25 (1.16 to 1.34) 1.61 (1.47 to 1.76) 2.24 (1.92 to 2.60)
Urinary tract infection 1b  1.27 (1.21 to 1.33) 1.75 (1.66 to 1.85) 3.15 (2.87 to 3.46)
Gastrointestinal bleeding 1b  1.29 (1.20 to 1.38) 1.56 (1.41 to 1.72) 2.13 (1.79 to 2.54)
Cerebral infarction 1b  1.19 (1.11 to 1.28) 1.45 (1.33 to 1.58) 1.56 (1.31 to 1.86)
Pneumonia 1b  1.14 (1.09 to 1.19) 1.56 (1.47 to 1.65) 2.33 (2.11 to 2.58)
Hip fracture  1b  1.03 (0.98 to 1.08) 1.27 (1.19 to 1.35) 1.69 (1.50 to 1.91)
Intracranial bleeding  1b  1.10 (0.99 to 1.21) 1.42 (1.24 to 1.63) 1.35 (0.98 to 1.85)
aAfter excluding patients with a history of cardiovascular disease (atrial fibrillation, coronary heart disease, heart failure, peripheral arterial disease, or stroke and transient 
ischaemic attack) from the matched patients with and without CKD, fully adjusted hazard ratios were estimated using Cox regression models, adjusted by age, sex, financial year, 
ethnicity, socioeconomic and smoking status, body mass index, and comorbidities (asthma, cancer, chronic obstructive pulmonary disease, dementia, depression, diabetes mellitus, 
epilepsy, hypertension, hypothyroidism, severe mental illness, osteoporosis, and rheumatoid arthritis) and clustered by general practice using robust standard errors. bReference. 
CKD = chronic kidney disease.
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Appendix B: List of diagnosis codes indicative of severe mental 
illness in the Clinical Practice Research Datalink 
Read code Medcode Read term 
Schizophrenia: 
E104.00 576 Acute schizophrenic episode 
E10..00 854 Schizophrenic disorders 
E103.00 1494 Paranoid schizophrenia 
E100200 3984 Chronic schizophrenic 
1464.00 6325 H/O: schizophrenia 
E10z.00 8407 Schizophrenia NOS 
E103z00 9281 Paranoid schizophrenia NOS 
E100000 15733 Unspecified schizophrenia 
Eu20000 16764 [X]Paranoid schizophrenia 
Eu2..00 17281 [X]Schizophrenia, schizotypal and delusional disorders 
Eu20y13 18053 [X]Schizophrenifrm psychos NOS 
Eu20211 20572 [X]Catatonic stupor 
Eu20400 20785 [X]Post-schizophrenic depression 
ZV11000 22104 [V]Personal history of schizophrenia 
E100100 23616 Subchronic schizophrenia 
Eu20511 24107 [X]Chronic undifferentiated schizophrenia 
E102.00 25546 Catatonic schizophrenia 
Eu23112 26143 [X]Cycloid psychosis with symptoms of schizophrenia 
E101.00 30619 Hebephrenic schizophrenia 
E103200 31362 Chronic paranoid schizophrenia 
Eu20214 31493 [X]Schizophrenic flexibilatis cerea 
E100.00 32222 Simple schizophrenia 
E10y000 33338 Atypical schizophrenia 
E103000 33383 Unspecified paranoid schizophrenia 
Eu20.00 34236 [X]Schizophrenia 
Eu20z00 34966 [X]Schizophrenia, unspecified 
Eu20600 35848 [X]Simple schizophrenia 
Eu20213 35877 [X]Schizophrenic catatonia 
E103500 36172 Paranoid schizophrenia in remission 
E106.00 38063 Residual schizophrenia 
E10y.00 39062 Other schizophrenia 
Eu21.15 40386 [X]Prodromal schizophrenia 
Eu20100 43405 [X]Hebephrenic schizophrenia 
E100400 44498 Acute exacerbation of chronic schizophrenia 
E101z00 48054 Hebephrenic schizophrenia NOS 
Eu20y00 49420 [X]Other schizophrenia 
E10yz00 49761 Other schizophrenia NOS 
Eu21.16 49852 [X]Pseudoneurotic schizophrenia 
Eu20011 50060 [X]Paraphrenic schizophrenia 
E103300 51322 Acute exacerbation of subchronic paranoid schizophrenia 
E103400 53032 Acute exacerbation of chronic paranoid schizophrenia 
E100z00 53625 Simple schizophrenia NOS 
Eu20111 53985 [X]Disorganised schizophrenia 
Eu21.12 54387 [X]Borderline schizophrenia 
ZS7C611 57376 Schizophrenic language 
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E100300 57666 Acute exacerbation of subchronic schizophrenia 
E100500 58687 Schizophrenia in remission 
E102000 58716 Unspecified catatonic schizophrenia 
Eu20300 60013 [X]Undifferentiated schizophrenia 
Eu20200 61501 [X]Catatonic schizophrenia 
Eu21.14 62449 [X]Prepsychotic schizophrenia 
E102z00 63867 Catatonic schizophrenia NOS 
Eu20500 64264 [X]Residual schizophrenia 
Eu20212 64533 [X]Schizophrenic catalepsy 
Eu21.13 64993 [X]Latent schizophrenia 
E105.00 66410 Latent schizophrenia 
E101000 66506 Unspecified hebephrenic schizophrenia 
E101500 67768 Hebephrenic schizophrenia in remission 
Eu21.17 71250 [X]Pseudopsychopathic schizophrenia 
E100.11 73295 Schizophrenia simplex 
Eu21.11 91511 [X]Latent schizophrenic reaction 
Eu20311 91547 [X]Atypical schizophrenia 
E10y.11 92994 Cenesthopathic schizophrenia 
Eu20y12 94001 [X]Schizophreniform disord NOS 
E105200 94299 Chronic latent schizophrenia 
Eu23214 94604 [X]Schizophrenic reaction 
E105500 96883 Latent schizophrenia in remission 
E101400 97919 Acute exacerbation of chronic hebephrenic schizophrenia 
E107.11 99000 Cyclic schizophrenia 
E10y100 99070 Coenesthopathic schizophrenia 
E102100 99199 Subchronic catatonic schizophrenia 
E105000 102311 Unspecified latent schizophrenia 
E102500 102427 Catatonic schizophrenia in remission 
E105z00 102446 Latent schizophrenia NOS 
E103100 104760 Subchronic paranoid schizophrenia 
Eu25211 104763 [X]Cyclic schizophrenia 
E102400 107222 Acute exacerbation of chronic catatonic schizophrenia 
Bipolar disorder: 
Eu31.11 1531 [X]Manic-depressive illness 
Eu30000 2741 [X]Hypomania 
E114.00 3702 Bipolar affective disorder, currently manic 
E115.00 4677 Bipolar affective disorder, currently depressed 
Eu30z11 4678 [X]Mania NOS 
Eu31500 4732 [X]Bipolar affect dis cur epi severe depres with psyc symp 
Eu31.12 6710 [X]Manic-depressive psychosis 
Eu31.00 6874 [X]Bipolar affective disorder 
E11..11 8567 Bipolar psychoses 
Eu30.11 9521 [X]Bipolar disorder, single manic episode 
146D.00 11548 H/O: manic depressive disorder 
E11y000 11596 Unspecified manic-depressive psychoses 
Eu30.00 12173 [X]Manic episode 
E115.11 12831 Manic-depressive - now depressed 
Eu30100 13024 [X]Mania without psychotic symptoms 
E110100 14728 Single manic episode, mild 
E117.00 14784 Unspecified bipolar affective disorder 
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E115000 15923 Bipolar affective disorder, currently depressed, unspecified 
E114300 16347 Bipolar affect disord, currently manic, severe, no psychosis 
Eu31300 16562 [X]Bipolar affect disorder cur epi mild or moderate depressn 
Eu31000 16808 [X]Bipolar affective disorder, current episode hypomanic 
E114.11 17385 Manic-depressive - now manic 
E110.11 18909 Hypomanic psychoses 
E111000 19967 Recurrent manic episodes, unspecified 
E110000 20110 Single manic episode, unspecified 
Eu30200 21065 [X]Mania with psychotic symptoms 
ZV11112 22080 [V]Personal history of manic-depressive psy 
Eu31400 23713 [X]Bipol aff disord, curr epis sev depress, no psychot symp 
ZV11111 23963 [V]Personal history of manic-depressive psy 
E117600 24230 Unspecified bipolar affective disorder, in full remission 
E110200 24640 Single manic episode, moderate 
E116100 24689 Mixed bipolar affective disorder, mild 
E11..13 26161 Manic psychoses 
E111.00 26227 Recurrent manic episodes 
Eu31100 26299 [X]Bipolar affect disorder cur epi manic wout psychotic symp 
Eu31700 27584 [X]Bipolar affective disorder, currently in remission 
E111200 27739 Recurrent manic episodes, moderate 
E115200 27890 Bipolar affective disorder, currently depressed, moderate 
E117z00 27986 Unspecified bipolar affective disorder, NOS 
Eu31200 28277 [X]Bipolar affect disorder cur epi manic with psychotic symp 
Eu33312 28677 [X]Manic-depress psychosis,depressed type+psychotic symptoms 
Eu33213 29451 [X]Manic-depress psychosis,depressd,no psychotic symptoms 
ZRby100 30282 Profile of mood states, bipolar 
E116.00 31316 Mixed bipolar affective disorder 
E116000 31535 Mixed bipolar affective disorder, unspecified 
Eu30y00 32088 [X]Other manic episodes 
E111400 32295 Recurrent manic episodes, severe, with psychosis 
E11yz00 33426 Other and unspecified manic-depressive psychoses NOS 
Eu31z00 33751 [X]Bipolar affective disorder, unspecified 
E115300 35607 Bipolar affect disord, now depressed, severe, no psychosis 
E115100 35734 Bipolar affective disorder, currently depressed, mild 
E114000 35738 Bipolar affective disorder, currently manic, unspecified 
E114100 36126 Bipolar affective disorder, currently manic, mild 
E110z00 36611 Manic disorder, single episode NOS 
E110.00 37070 Manic disorder, single episode 
Eu30211 37102 [X]Mania with mood-congruent psychotic symptoms 
E111600 37178 Recurrent manic episodes, in full remission 
E115z00 37296 Bipolar affective disorder, currently depressed, NOS 
E110300 43093 Single manic episode, severe without mention of psychosis 
Eu30z00 44513 [X]Manic episode, unspecified 
Eu31600 44693 [X]Bipolar affective disorder, current episode mixed 
E111z00 46415 Recurrent manic episode NOS 
E111100 46425 Recurrent manic episodes, mild 
E114200 46434 Bipolar affective disorder, currently manic, moderate 
Eu30212 48632 [X]Mania with mood-incongruent psychotic symptoms 
E117000 49763 Unspecified bipolar affective disorder, unspecified 
E110400 50218 Single manic episode, severe, with psychosis 
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Eu31y12 51032 [X]Recurrent manic episodes 
Eu31y00 53840 [X]Other bipolar affective disorders 
E116400 54195 Mixed bipolar affective disorder, severe, with psychosis 
E116600 55064 Mixed bipolar affective disorder, in full remission 
E114400 55829 Bipolar affect disord, currently manic,severe with psychosis 
E115600 57465 Bipolar affective disorder, now depressed, in full remission 
E114z00 57605 Bipolar affective disorder, currently manic, NOS 
E111500 58863 Recurrent manic episodes, partial or unspecified remission 
E114500 59011 Bipolar affect disord,currently manic, part/unspec remission 
E11y.00 60178 Other and unspecified manic-depressive psychoses 
E116200 63150 Mixed bipolar affective disorder, moderate 
E116300 63284 Mixed bipolar affective disorder, severe, without psychosis 
E116z00 63583 Mixed bipolar affective disorder, NOS 
E116500 63651 Mixed bipolar affective disorder, partial/unspec remission 
E117100 63698 Unspecified bipolar affective disorder, mild 
E115400 63701 Bipolar affect disord, now depressed, severe with psychosis 
E114600 63784 Bipolar affective disorder, currently manic, full remission 
E111300 65811 Recurrent manic episodes, severe without mention psychosis 
Eu31.13 66153 [X]Mainc-depressive reaction 
E117400 68326 Unspecified bipolar affective disorder,severe with psychosis 
E117200 68647 Unspecified bipolar affective disorder, moderate 
E110600 70000 Single manic episode in full remission 
E11y300 70399 Other mixed manic-depressive psychoses 
E117500 70721 Unspecified bipolar affect disord, partial/unspec remission 
E11y100 70925 Atypical manic disorder 
E115500 72026 Bipolar affect disord, now depressed, part/unspec remission 
E117300 73423 Unspecified bipolar affective disorder, severe, no psychosis 
Eu31y11 73924 [X]Bipolar II disorder 
Other nonorganic psychotic illnesses: 
Eu2z.11 694 [X]Psychosis NOS 
Eu22011 2113 [X]Paranoid psychosis 
E107.00 2117 Schizo-affective schizophrenia 
E11..12 2560 Depressive psychoses 
E13z.11 3636 Psychotic episode NOS 
E121.00 3890 Chronic paranoid psychosis 
E12..00 4261 Paranoid states 
Eu22015 4843 [X]Paranoia 
E130.00 8478 Reactive depressive psychosis 
Eu25.00 9422 [X]Schizoaffective disorders 
E107z00 10575 Schizo-affective schizophrenia NOS 
Eu25100 11055 [X]Schizoaffective disorder, depressive type 
Eu22012 11172 [X]Paranoid state 
Eu2z.00 11244 [X]Unspecified nonorganic psychosis 
Eu23200 11778 [X]Acute schizophrenia-like psychotic disorder 
Eu24.13 11973 [X]Induced psychotic disorder 
Eu32300 12099 [X]Severe depressive episode with psychotic symptoms 
E12z.00 12771 Paranoid psychosis NOS 
146H.00 12777 H/O: psychosis 
E11..00 14656 Affective psychoses 
E120.00 14743 Simple paranoid state 
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E13z.00 14965 Nonorganic psychosis NOS 
E122.00 14971 Paraphrenia 
E133.00 15053 Acute paranoid reaction 
E1...00 15958 Non-organic psychoses 
E13y.00 16333 Other reactive psychoses 
E1y..00 16537 Other specified non-organic psychoses 
Eu33315 16861 [X]Recurrent severe episodes of psychotic depression 
Eu25011 16905 [X]Schizoaffective psychosis, manic type 
E130.11 17770 Psychotic reactive depression 
E13..11 20228 Reactive psychoses 
Eu23012 21455 [X]Cycloid psychosis 
Eu23100 21595 [X]Acute polymorphic psychot disord with symp of schizophren 
E13y000 22117 Psychogenic stupor 
E1z..00 22188 Non-organic psychosis NOS 
E13y100 23538 Brief reactive psychosis 
Eu33311 23731 [X]Endogenous depression with psychotic symptoms 
Eu32313 24112 [X]Single episode of psychotic depression 
Eu32311 24117 [X]Single episode of major depression and psychotic symptoms 
E113400 24171 Recurrent major depressive episodes, severe, with psychosis 
E134.00 24345 Psychogenic paranoid psychosis 
Eu23.00 25019 [X]Acute and transient psychotic disorders 
E13yz00 26119 Other reactive psychoses NOS 
Eu21.18 26859 [X]Schizotypal personality disorder 
Eu23312 27770 [X]Psychogenic paranoid psychosis 
Eu44.14 28168 [X]Hysterical psychosis 
Eu22.00 28562 [X]Persistent delusional disorders 
Eu32314 28863 [X]Single episode of reactive depressive psychosis 
Eu23z12 29651 [X]Reactive psychosis 
E131.00 29937 Acute hysterical psychosis 
Eu2y.00 30985 [X]Other nonorganic psychotic disorders 
E12yz00 31455 Other paranoid states NOS 
E12y.00 31589 Other paranoid states 
Eu3z.11 31633 [X]Affective psychosis NOS 
Eu23z11 31707 [X]Brief reactive psychosis NOS 
Eu2y.11 31738 [X]Chronic hallucinatory psychosis 
Eu33314 31757 [X]Recurr severe episodes/psychogenic depressive psychosis 
E13..00 31984 Other nonorganic psychoses 
E112400 32159 Single major depressive episode, severe, with psychosis 
Eu33313 32941 [X]Recurr severe episodes/major depression+psychotic symptom 
Eu25z11 33410 [X]Schizoaffective psychosis NOS 
E11zz00 33425 Other affective psychosis NOS 
Eu25200 33693 [X]Schizoaffective disorder, mixed type 
Eu25000 33847 [X]Schizoaffective disorder, manic type 
Eu23z00 34168 [X]Acute and transient psychotic disorder, unspecified 
Eu22000 34389 [X]Delusional disorder 
Eu25111 35274 [X]Schizoaffective psychosis, depressive type 
Eu23000 36720 [X]Acute polymorphic psychot disord without symp of schizoph 
Eu25212 37580 [X]Mixed schizophrenic and affective psychosis 
Eu25z00 37681 [X]Schizoaffective disorder, unspecified 
Eu33316 37764 [X]Recurrent severe episodes/reactive depressive psychosis 
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Eu21.00 39316 [X]Schizotypal disorder 
Eu22y11 40981 [X]Delusional dysmorphophobia 
Eu25112 41022 [X]Schizophreniform psychosis, depressive type 
E11z.00 41992 Other and unspecified affective psychoses 
E107200 43800 Chronic schizo-affective schizophrenia 
Eu23300 44307 [X]Other acute predominantly delusional psychotic disorders 
Eu23y00 44503 [X]Other acute and transient psychotic disorders 
Eu33300 47009 [X]Recurrent depress disorder cur epi severe with psyc symp 
Eu24.12 47230 [X]Induced paranoid disorder 
Eu22013 47947 [X]Paraphrenia - late 
Eu22z00 49223 [X]Persistent delusional disorder, unspecified 
Eu23011 50023 [X]Bouffee delirante 
Eu22y12 50248 [X]Involutional paranoid state 
E123.11 50868 Folie a deux 
Eu24.00 51302 [X]Induced delusional disorder 
Eu25012 51903 [X]Schizophreniform psychosis, manic type 
Eu32312 52678 [X]Single episode of psychogenic depressive psychosis 
Eu84314 53848 [X]Symbiotic psychosis 
E11z000 54607 Unspecified affective psychoses NOS 
Eu22111 55221 [X]Capgras syndrome 
Eu22y13 55236 [X]Paranoia querulans 
E107500 56438 Schizo-affective schizophrenia in remission 
Eu25y00 58532 [X]Other schizoaffective disorders 
E107000 58862 Unspecified schizo-affective schizophrenia 
E107300 58866 Acute exacerbation subchronic schizo-affective schizophrenia 
Eu23211 59096 [X]Brief schizophreniform disorder 
E107100 61098 Subchronic schizo-affective schizophrenia 
E212200 61969 Schizotypal personality 
Eu22100 62405 [X]Delusional misidentification syndrome 
E123.00 62680 Shared paranoid disorder 
E107400 63478 Acute exacerbation of chronic schizo-affective schizophrenia 
Eu22014 65127 [X]Sensitiver Beziehungswahn 
Eu22y00 66077 [X]Other persistent delusional disorders 
E12y000 66766 Paranoia querulans 
E133.11 68058 Bouffee delirante 
Eu23212 70884 [X]Brief schizophrenifrm psych 
E104.11 93167 Oneirophrenia 
Eu32800 98417 [X]Major depression, severe with psychotic symptoms 
Eu22200 98821 [X]Cotard syndrome 
Eu24.11 105606 [X]Folie a deux 
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Appendix C: List of diagnosis codes suggesting gastrointestinal 
bleeding in the Clinical Practice Research Datalink 
 
  
Read code Medcode Read term 
J68z.11 1642 GIB - Gastrointestinal bleeding 
J12y100 2814 Unspecified duodenal ulcer with haemorrhage 
J68..00 3097 Gastrointestinal haemorrhage 
J68z200 4354 Upper gastrointestinal haemorrhage 
J68zz00 4636 Gastrointestinal tract haemorrhage NOS 
14CA.00 10534 H/O: GIT haemorrhage NOS 
J110111 11124 Bleeding acute gastric ulcer 
J68z.00 12471 Gastrointestinal haemorrhage unspecified 
J68z000 15517 Gastric haemorrhage NOS 
J10y000 16114 Haemorrhage of oesophagus 
J120100 18001 Acute duodenal ulcer with haemorrhage 
J121111 18625 Bleeding chronic duodenal ulcer 
7619100 23813 Gastrotomy and ligation of bleeding point of stomach 
J12yy00 28366 Unspec duodenal ulcer; unspec haemorrhage and/or perforation 
J110100 30054 Acute gastric ulcer with haemorrhage 
14CD.00 34466 H/O: upper GIT haemorrhage 
J111111 36583 Bleeding chronic gastric ulcer 
J130100 44637 Acute peptic ulcer with haemorrhage 
J130300 45304 Acute peptic ulcer with haemorrhage and perforation 
J120300 48730 Acute duodenal ulcer with haemorrhage and perforation 
J121100 48951 Chronic duodenal ulcer with haemorrhage 
J131100 53126 Chronic peptic ulcer with haemorrhage 
J11y100 57958 Unspecified gastric ulcer with haemorrhage 
J111100 63582 Chronic gastric ulcer with haemorrhage 
J13y100 70456 Unspecified peptic ulcer with haemorrhage 
J110300 71403 Acute gastric ulcer with haemorrhage and perforation 
J121300 71881 Chronic duodenal ulcer with haemorrhage and perforation 
J111300 71897 Chronic gastric ulcer with haemorrhage and perforation 
J12y300 93436 Unspecified duodenal ulcer with haemorrhage and perforation 
J11yy00 94397 Unspec gastric ulcer; unspec haemorrhage and/or perforation 
J13y300 96622 Unspecified peptic ulcer with haemorrhage and perforation 
J140100 96628 Acute gastrojejunal ulcer with haemorrhage 
G852000 96756 Oesophageal varices with bleeding in diseases EC 
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Appendix D: List of diagnosis codes used to define covariates in the 
Clinical Practice Research Datalink 
Read code Medcode Read term 
Diabetes mellitus: 
C100112 506 Non-insulin dependent diabetes mellitus 
C10..00 711 Diabetes mellitus 
C10F.00 758 Type 2 diabetes mellitus 
C100011 1038 Insulin dependent diabetes mellitus 
F420.00 1323 Diabetic retinopathy 
C10FJ00 1407 Insulin treated Type 2 diabetes mellitus 
C10E.00 1549 Type 1 diabetes mellitus 
C108.00 1647 Insulin dependent diabetes mellitus 
C101.00 1682 Diabetes mellitus with ketoacidosis 
66A4.00 1684 Diabetic on oral treatment 
F381311 2340 Diabetic amyotrophy 
F372.12 2342 Diabetic neuropathy 
66AJ.00 2378 Diabetic - poor control 
K01x100 2471 Nephrotic syndrome in diabetes mellitus 
C104.11 2475 Diabetic nephropathy 
66AJ100 2478 Brittle diabetes 
F420200 2986 Preproliferative diabetic retinopathy 
F420100 3286 Proliferative diabetic retinopathy 
F420400 3837 Diabetic maculopathy 
C109.00 4513 Non-insulin dependent diabetes mellitus 
F372.11 5002 Diabetic polyneuropathy 
C109.11 5884 NIDDM - Non-insulin dependent diabetes mellitus 
66AS.00 6125 Diabetic annual review 
9NM0.00 6430 Attending diabetes clinic 
C108700 6509 Insulin dependent diabetes mellitus with retinopathy 
C108800 6791 Insulin dependent diabetes mellitus - poor control 
14F4.00 7045 H/O: Admission in last year for diabetes foot problem 
8H2J.00 7059 Admit diabetic emergency 
F420000 7069 Background diabetic retinopathy 
M037200 7328 Cellulitis in diabetic foot 
66A3.00 7563 Diabetic on diet only 
C106.12 7795 Diabetes mellitus with neuropathy 
C109700 8403 Non-insulin dependent diabetes mellitus - poor control 
66AR.00 8836 Diabetes management plan given 
66A5.00 8842 Diabetic on insulin 
66AJ.11 9013 Unstable diabetes 
2BBL.00 9835 O/E - diabetic maculopathy present both eyes 
M271200 9881 Mixed diabetic ulcer - foot 
42W..00 9958 Hb. A1C - diabetic control 
9N1v.00 9974 Seen in diabetic eye clinic 
C10yy00 10098 Other specified diabetes mellitus with other spec comps 
F420300 10099 Advanced diabetic maculopathy 
C10ED00 10418 Type 1 diabetes mellitus with nephropathy 
ZC2C800 10642 Dietary advice for diabetes mellitus 
F464000 10659 Diabetic cataract 
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C10EM00 10692 Type 1 diabetes mellitus with ketoacidosis 
F420600 10755 Non proliferative diabetic retinopathy 
9N1i.00 10824 Seen in diabetic foot clinic 
66Ac.00 10977 Diabetic peripheral neuropathy screening 
8HBG.00 11018 Diabetic retinopathy 12 month review 
66AH000 11047 Conversion to insulin 
9NND.00 11094 Under care of diabetic foot screener 
2BBQ.00 11129 O/E - left eye background diabetic retinopathy 
2BBP.00 11433 O/E - right eye background diabetic retinopathy 
8B3l.00 11471 Diabetes medication review 
7276.00 11599 Pan retinal photocoagulation for diabetes 
F420z00 11626 Diabetic retinopathy NOS 
M271100 11663 Neuropathic diabetic ulcer - foot 
8H7r.00 11677 Refer to diabetic foot screener 
8BL2.00 12213 Patient on maximal tolerated therapy for diabetes 
8I6G.00 12247 Diabetic foot examination not indicated 
8I3X.00 12262 Diabetic retinopathy screening refused 
66AU.00 12307 Diabetes care by hospital only 
C10E.11 12455 Type I diabetes mellitus 
66AP.00 12506 Diabetes: practice programme 
C10FC00 12640 Type 2 diabetes mellitus with nephropathy 
66AQ.00 12675 Diabetes: shared care programme 
66AI.00 13071 Diabetic - good control 
13AC.00 13078 Diabetic weight reducing diet 
2BBT.00 13097 O/E - right eye proliferative diabetic retinopathy 
2BBR.00 13099 O/E - right eye preproliferative diabetic retinopathy 
2BBV.00 13101 O/E - left eye proliferative diabetic retinopathy 
2BBW.00 13102 O/E - right eye diabetic maculopathy 
2BBS.00 13103 O/E - left eye preproliferative diabetic retinopathy 
2BBX.00 13108 O/E - left eye diabetic maculopathy 
C104y00 13279 Other specified diabetes mellitus with renal complications 
42WZ.00 14049 Hb. A1C - diabetic control NOS 
42c..00 14050 HbA1 - diabetic control 
C100100 14803 Diabetes mellitus, adult onset, no mention of complication 
C100111 14889 Maturity onset diabetes 
C103.00 15690 Diabetes mellitus with ketoacidotic coma 
C106.00 16230 Diabetes mellitus with neurological manifestation 
66AH.00 16490 Diabetic treatment changed 
C106.13 16491 Diabetes mellitus with polyneuropathy 
C104.00 16502 Diabetes mellitus with renal manifestation 
ZV65312 16881 [V]Dietary counselling in diabetes mellitus 
F171100 17067 Autonomic neuropathy due to diabetes 
2G5A.00 17095 O/E - Right diabetic foot at risk 
14P3.00 17236 H/O: insulin therapy 
F35z000 17247 Diabetic mononeuritis NOS 
C109600 17262 Non-insulin-dependent diabetes mellitus with retinopathy 
F440700 17313 Diabetic iritis 
C108F11 17545 Type I diabetes mellitus with diabetic cataract 
7L19800 17817 Subcutaneous injection of insulin 
C108.12 17858 Type 1 diabetes mellitus 
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C109.12 17859 Type 2 diabetes mellitus 
66AL.00 17869 Diabetic-uncooperative patient 
66AM.00 17886 Diabetic - follow-up default 
2G5C.00 18056 Foot abnormality - diabetes related 
N030000 18142 Diabetic cheiroarthropathy 
C109G11 18143 Type II diabetes mellitus with arthropathy 
66AT.00 18167 Annual diabetic blood test 
C109012 18209 Type 2 diabetes mellitus with renal complications 
C109.13 18219 Type II diabetes mellitus 
C108J12 18230 Type 1 diabetes mellitus with neuropathic arthropathy 
C109J12 18264 Insulin treated Type II diabetes mellitus 
C109J00 18278 Insulin treated Type 2 diabetes mellitus 
68A7.00 18311 Diabetic retinopathy screening 
C10E700 18387 Type 1 diabetes mellitus with retinopathy 
C10FM00 18390 Type 2 diabetes mellitus with persistent microalbuminuria 
C10FB00 18425 Type 2 diabetes mellitus with polyneuropathy 
C10F600 18496 Type 2 diabetes mellitus with retinopathy 
C108.11 18505 IDDM-Insulin dependent diabetes mellitus 
C10EH00 18642 Type 1 diabetes mellitus with arthropathy 
8HBH.00 18662 Diabetic retinopathy 6 month review 
C10E500 18683 Type 1 diabetes mellitus with ulcer 
8I6F.00 18747 Diabetic retinopathy screening not indicated 
C10F000 18777 Type 2 diabetes mellitus with renal complications 
8I3W.00 18824 Diabetic foot examination declined 
8HTk.00 19381 Referral to diabetic eye clinic 
68A9.00 19739 Diabetic retinopathy screening offered 
66AA.11 20696 Injection sites - diabetic 
C102.00 21482 Diabetes mellitus with hyperosmolar coma 
C108012 21983 Type 1 diabetes mellitus with renal complications 
66AJz00 22023 Diabetic - poor control NOS 
C106z00 22573 Diabetes mellitus NOS with neurological manifestation 
66Ab.00 22823 Diabetic foot examination 
C10EP00 22871 Type 1 diabetes mellitus with exudative maculopathy 
C10F.11 22884 Type II diabetes mellitus 
2BBF.00 22967 Retinal abnormality - diabetes related 
C350011 23479 Bronzed diabetes 
8A13.00 24363 Diabetic stabilisation 
C108.13 24423 Type I diabetes mellitus 
C109711 24458 Type II diabetes mellitus - poor control 
C100000 24490 Diabetes mellitus, juvenile type, no mention of complication 
F372200 24571 Asymptomatic diabetic neuropathy 
C109G00 24693 Non-insulin dependent diabetes mellitus with arthropathy 
C108B00 24694 Insulin dependent diabetes mellitus with mononeuropathy 
C109C12 24836 Type 2 diabetes mellitus with nephropathy 
ZC2CA00 25041 Dietary advice for type II diabetes 
C10FQ00 25591 Type 2 diabetes mellitus with exudative maculopathy 
C10F700 25627 Type 2 diabetes mellitus - poor control 
C10FL00 26054 Type 2 diabetes mellitus with persistent proteinuria 
2G5B.00 26664 O/E - Left diabetic foot at risk 
2G5E.00 26666 O/E - Right diabetic foot at low risk 
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2G5I.00 26667 O/E - Left diabetic foot at low risk 
C108400 26855 Unstable insulin dependent diabetes mellitus 
N030100 27891 Diabetic Charcot arthropathy 
2G51000 27921 Foot abnormality - diabetes related 
66AV.00 28769 Diabetic on insulin and oral treatment 
8CP2.00 28856 Transition of diabetes care options discussed 
66Ai.00 28873 Diabetic 6 month review 
66AN.00 29041 Date diabetic treatment start 
C109900 29979 Non-insulin-dependent diabetes mellitus without complication 
TJ23000 30247 Adverse reaction to insulins 
C10EL00 30294 Type 1 diabetes mellitus with persistent microalbuminuria 
C10EK00 30323 Type 1 diabetes mellitus with persistent proteinuria 
F420700 30477 High risk proliferative diabetic retinopathy 
9N4p.00 30648 Did not attend diabetic retinopathy clinic 
2G5J.00 31156 O/E - Left diabetic foot at moderate risk 
2G5F.00 31157 O/E - Right diabetic foot at moderate risk 
2G5G.00 31171 O/E - Right diabetic foot at high risk 
2G5K.00 31172 O/E - Left diabetic foot at high risk 
C108900 31310 Insulin dependent diabetes maturity onset 
F372.00 31790 Polyneuropathy in diabetes 
ZRbH.00 32359 Perceived control of insulin-dependent diabetes 
C10FN00 32627 Type 2 diabetes mellitus with ketoacidosis 
C105.00 33254 Diabetes mellitus with ophthalmic manifestation 
C10y.00 33343 Diabetes mellitus with other specified manifestation 
C10F200 34268 Type 2 diabetes mellitus with neurological complications 
C105z00 34283 Diabetes mellitus NOS with ophthalmic manifestation 
C10FK00 34450 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
3882.00 34528 Diabetes well being questionnaire 
C109400 34912 Non-insulin dependent diabetes mellitus with ulcer 
C104100 35105 Diabetes mellitus, adult onset, with renal manifestation 
C104z00 35107 Diabetes mellitus with nephropathy NOS 
2G5L.00 35116 O/E - Left diabetic foot - ulcerated 
C10E800 35288 Type 1 diabetes mellitus - poor control 
2G5H.00 35316 O/E - Right diabetic foot - ulcerated 
8H3O.00 35321 Non-urgent diabetic admission 
9OLD.00 35383 Diabetic patient unsuitable for digital retinal photography 
C10FH00 35385 Type 2 diabetes mellitus with neuropathic arthropathy 
F372100 35785 Chronic painful diabetic neuropathy 
C109K00 36633 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
C10D.00 36695 Diabetes mellitus autosomal dominant type 2 
7L10000 36798 Continuous subcutaneous infusion of insulin 
F3y0.00 37315 Diabetic mononeuropathy 
C109J11 37648 Insulin treated non-insulin dependent diabetes mellitus 
M21yC00 38076 Insulin lipohypertrophy 
ZRB6.00 38130 Diabetes wellbeing questionnaire 
C108711 38161 Type I diabetes mellitus with retinopathy 
C101y00 38617 Other specified diabetes mellitus with ketoacidosis 
C100.00 38986 Diabetes mellitus with no mention of complication 
C10EE00 39070 Type 1 diabetes mellitus with hypoglycaemic coma 
C106100 39317 Diabetes mellitus, adult onset, + neurological manifestation 
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F381300 39420 Myasthenic syndrome due to diabetic amyotrophy 
C108J00 39809 Insulin dependent diab mell with neuropathic arthropathy 
C102000 40023 Diabetes mellitus, juvenile type, with hyperosmolar coma 
C10E900 40682 Type 1 diabetes mellitus maturity onset 
C10EN00 40837 Type 1 diabetes mellitus with ketoacidotic coma 
C109H00 40962 Non-insulin dependent d m with neuropathic arthropathy 
C108712 41049 Type 1 diabetes mellitus with retinopathy 
C105100 41389 Diabetes mellitus, adult onset, + ophthalmic manifestation 
Cyu2000 41686 [X]Other specified diabetes mellitus 
C108C00 41716 Insulin dependent diabetes mellitus with polyneuropathy 
C101z00 42505 Diabetes mellitus NOS with ketoacidosis 
C103000 42567 Diabetes mellitus, juvenile type, with ketoacidotic coma 
C108E11 42729 Type I diabetes mellitus with hypoglycaemic coma 
C109612 42762 Type 2 diabetes mellitus with retinopathy 
C10E200 42831 Type 1 diabetes mellitus with neurological complications 
C102100 43139 Diabetes mellitus, adult onset, with hyperosmolar coma 
C10F311 43227 Type II diabetes mellitus with multiple complications 
C10C.00 43453 Diabetes mellitus autosomal dominant 
M21yC11 43493 Insulin site lipohypertrophy 
C109D00 43785 Non-insulin dependent diabetes mellitus with hypoglyca coma 
C10M.00 43857 Lipoatrophic diabetes mellitus 
C10E400 43921 Unstable type 1 diabetes mellitus 
66AK.00 43951 Diabetic - cooperative patient 
F345000 44033 Diabetic mononeuritis multiplex 
C108F00 44260 Insulin dependent diabetes mellitus with diabetic cataract 
9M10.00 44312 Informed dissent for diabetes national audit 
C108E00 44440 Insulin dependent diabetes mellitus with hypoglycaemic coma 
C108500 44443 Insulin dependent diabetes mellitus with ulcer 
C109E12 44779 Type 2 diabetes mellitus with diabetic cataract 
C10FE00 44982 Type 2 diabetes mellitus with diabetic cataract 
C10E312 45276 Insulin dependent diabetes mellitus with multiple complicat 
C109B00 45467 Non-insulin dependent diabetes mellitus with polyneuropathy 
C10z.00 45491 Diabetes mellitus with unspecified complication 
C109712 45913 Type 2 diabetes mellitus - poor control 
C108812 45914 Type 1 diabetes mellitus - poor control 
C109212 45919 Type 2 diabetes mellitus with neurological complications 
C108y00 46290 Other specified diabetes mellitus with multiple comps 
C10EC00 46301 Type 1 diabetes mellitus with polyneuropathy 
C10C.11 46624 Maturity onset diabetes in youth 
C108811 46850 Type I diabetes mellitus - poor control 
C10FD00 46917 Type 2 diabetes mellitus with hypoglycaemic coma 
C108000 46963 Insulin-dependent diabetes mellitus with renal complications 
8CS0.00 47032 Diabetes care plan agreed 
8Hg4.00 47058 Discharged from care of diabetes specialist nurse 
C10F711 47315 Type II diabetes mellitus - poor control 
C10F100 47321 Type 2 diabetes mellitus with ophthalmic complications 
2BBk.00 47328 O/E - right eye stable treated prolif diabetic retinopathy 
8A12.00 47341 Diabetic crisis monitoring 
8HLE.00 47370 Diabetology D.V. done 
C105y00 47377 Other specified diabetes mellitus with ophthalmic complicatn 
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C109B11 47409 Type II diabetes mellitus with polyneuropathy 
C10E000 47582 Type 1 diabetes mellitus with renal complications 
F420500 47584 Advanced diabetic retinal disease 
C10E100 47649 Type 1 diabetes mellitus with ophthalmic complications 
C10E300 47650 Type 1 diabetes mellitus with multiple complications 
C109H11 47816 Type II diabetes mellitus with neuropathic arthropathy 
C10F900 47954 Type 2 diabetes mellitus without complication 
F372000 48078 Acute painful diabetic neuropathy 
C109E11 48192 Type II diabetes mellitus with diabetic cataract 
ZV6DA00 48310 [V]Admitted for commencement of insulin 
C10F400 49074 Type 2 diabetes mellitus with ulcer 
C108211 49146 Type I diabetes mellitus with neurological complications 
C108100 49276 Insulin-dependent diabetes mellitus with ophthalmic comps 
C10EF00 49554 Type 1 diabetes mellitus with diabetic cataract 
2G5W.00 49640 O/E - left chronic diabetic foot ulcer 
C10F611 49655 Type II diabetes mellitus with retinopathy 
C109G12 49869 Type 2 diabetes mellitus with arthropathy 
6761.00 49884 Diabetic pre-pregnancy counselling 
C10E411 49949 Unstable type I diabetes mellitus 
66AW.00 50175 Diabetic foot risk assessment 
C109011 50225 Type II diabetes mellitus with renal complications 
C109100 50429 Non-insulin-dependent diabetes mellitus with ophthalm comps 
C10FB11 50527 Type II diabetes mellitus with polyneuropathy 
L180600 50609 Pre-existing diabetes mellitus, non-insulin-dependent 
C109A11 50813 Type II diabetes mellitus with mononeuropathy 
L180500 50960 Pre-existing diabetes mellitus, insulin-dependent 
C100z00 50972 Diabetes mellitus NOS with no mention of complication 
C10E.12 51261 Insulin dependent diabetes mellitus 
C10G.00 51697 Secondary pancreatic diabetes mellitus 
C10FP00 51756 Type 2 diabetes mellitus with ketoacidotic coma 
ZV6DB00 51939 [V]Admitted for conversion to insulin 
C108511 51957 Type I diabetes mellitus with ulcer 
2BBl.00 52041 O/E - left eye stable treated prolif diabetic retinopathy 
C108300 52104 Insulin dependent diabetes mellitus with multiple complicatn 
Cyu2.00 52212 [X]Diabetes mellitus 
9360.00 52237 Patient held diabetic record issued 
C108200 52283 Insulin-dependent diabetes mellitus with neurological comps 
C109000 52303 Non-insulin-dependent diabetes mellitus with renal comps 
2BBo.00 52630 O/E - sight threatening diabetic retinopathy 
C101000 53200 Diabetes mellitus, juvenile type, with ketoacidosis 
66AG.00 53238 Diabetic drug side effects 
C10F911 53392 Type II diabetes mellitus without complication 
C110.11 53630 Insulin coma 
R054200 53634 [D]Gangrene of toe in diabetic 
C10EJ00 54008 Type 1 diabetes mellitus with neuropathic arthropathy 
C10E412 54600 Unstable insulin dependent diabetes mellitus 
9NN8.00 54601 Under care of diabetologist 
C101100 54856 Diabetes mellitus, adult onset, with ketoacidosis 
C109411 55075 Type II diabetes mellitus with ulcer 
C10EQ00 55239 Type 1 diabetes mellitus with gastroparesis 
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L180X00 55431 Pre-existing diabetes mellitus, unspecified 
C109200 55842 Non-insulin-dependent diabetes mellitus with neuro comps 
C109D11 56268 Type II diabetes mellitus with hypoglycaemic coma 
C108A00 56448 Insulin-dependent diabetes without complication 
C10F011 57278 Type II diabetes mellitus with renal complications 
N030011 57333 Diabetic cheiropathy 
93C4.00 57389 Patient consent given for addition to diabetic register 
C108D00 57621 Insulin dependent diabetes mellitus with nephropathy 
8HHy.00 57723 Referral to diabetic register 
ZLD7500 58133 Discharge by diabetic liaison nurse 
8I3k.00 58159 Insulin therapy declined 
C109611 58604 Type II diabetes mellitus with retinopathy 
C10FG00 59253 Type 2 diabetes mellitus with arthropathy 
C103y00 59288 Other specified diabetes mellitus with coma 
C109C00 59365 Non-insulin dependent diabetes mellitus with nephropathy 
C109111 59725 Type II diabetes mellitus with ophthalmic complications 
C106.11 59903 Diabetic amyotrophy 
C10D.11 59991 Maturity onset diabetes in youth type 2 
C108411 60107 Unstable type I diabetes mellitus 
C108J11 60208 Type I diabetes mellitus with neuropathic arthropathy 
C10FL11 60796 Type II diabetes mellitus with persistent proteinuria 
68AB.00 61021 Diabetic digital retinopathy screening offered 
C109D12 61071 Type 2 diabetes mellitus with hypoglycaemic coma 
TJ23z00 61210 Adverse reaction to insulins and antidiabetic agents NOS 
C108011 61344 Type I diabetes mellitus with renal complications 
9M00.00 61461 Informed consent for diabetes national audit 
C110000 61520 Iatrogenic hyperinsulinism 
C106y00 61523 Other specified diabetes mellitus with neurological comps 
8HKE.00 61557 Diabetology D.V. requested 
C108212 61829 Type 1 diabetes mellitus with neurological complications 
C109300 62146 Non-insulin-dependent diabetes mellitus with multiple comps 
C10EM11 62209 Type I diabetes mellitus with ketoacidosis 
C108H11 62352 Type I diabetes mellitus with arthropathy 
2G5V.00 62384 O/E - right chronic diabetic foot ulcer 
C10EA11 62613 Type I diabetes mellitus without complication 
C10FA00 62674 Type 2 diabetes mellitus with mononeuropathy 
C108911 63017 Type I diabetes mellitus maturity onset 
U602312 63364 [X] Adverse reaction to insulins 
C10y100 63371 Diabetes mellitus, adult, + other specified manifestation 
8CR2.00 63412 Diabetes clinical management plan 
C10FR00 63690 Type 2 diabetes mellitus with gastroparesis 
C10z100 63762 Diabetes mellitus, adult onset, + unspecified complication 
8Hl1.00 64142 Referral for diabetic retinopathy screening 
C10zy00 64283 Other specified diabetes mellitus with unspecified comps 
C10zz00 64357 Diabetes mellitus NOS with unspecified complication 
C108z00 64449 Unspecified diabetes mellitus with multiple complications 
C109C11 64571 Type II diabetes mellitus with nephropathy 
C10FJ11 64668 Insulin treated Type II diabetes mellitus 
C103z00 65062 Diabetes mellitus NOS with ketoacidotic coma 
C10F300 65267 Type 2 diabetes mellitus with multiple complications 
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F420800 65463 High risk non proliferative diabetic retinopathy 
C108H00 65616 Insulin dependent diabetes mellitus with arthropathy 
U602311 65684 [X] Adverse reaction to insulins and antidiabetic agents 
C109412 65704 Type 2 diabetes mellitus with ulcer 
C10EN11 66145 Type I diabetes mellitus with ketoacidotic coma 
66Ah.00 66274 Insulin needles changed for each injection 
C108D11 66872 Type I diabetes mellitus with nephropathy 
C109H12 66965 Type 2 diabetes mellitus with neuropathic arthropathy 
C106000 67853 Diabetes mellitus, juvenile, + neurological manifestation 
C109211 67905 Type II diabetes mellitus with neurological complications 
C10EB00 68105 Type 1 diabetes mellitus with mononeuropathy 
C108512 68390 Type 1 diabetes mellitus with ulcer 
ZRB4.00 68546 Diabetes clinic satisfaction questionnaire 
C10z000 68792 Diabetes mellitus, juvenile type, + unspecified complication 
ZRB5.11 68818 DTSQ - Diabetes treatment satisfaction questionnaire 
C103100 68843 Diabetes mellitus, adult onset, with ketoacidotic coma 
TJ23.00 68928 Adverse reaction to insulins and antidiabetic agents 
ZC2C900 69043 Dietary advice for type I diabetes 
66Aj.00 69152 Insulin needles changed less than once a day 
C109E00 69278 Non-insulin depend diabetes mellitus with diabetic cataract 
C10EA00 69676 Type 1 diabetes mellitus without complication 
C105000 69748 Diabetes mellitus, juvenile type, + ophthalmic manifestation 
C109112 70316 Type 2 diabetes mellitus with ophthalmic complications 
C108E12 70766 Type 1 diabetes mellitus with hypoglycaemic coma 
C10yz00 70821 Diabetes mellitus NOS with other specified manifestation 
C109A00 72320 Non-insulin dependent diabetes mellitus with mononeuropathy 
8HME.00 72333 Listed for Diabetology admissn 
C102z00 72345 Diabetes mellitus NOS with hyperosmolar coma 
C10E812 72702 Insulin dependent diabetes mellitus - poor control 
66Am.00 83485 Insulin dose changed 
66Ao.00 83532 Diabetes type 2 review 
66An.00 85660 Diabetes type 1 review 
C10FM11 85991 Type II diabetes mellitus with persistent microalbuminuria 
66Ag.00 90301 Insulin needles changed daily 
ZRB4.11 91164 CSQ - Diabetes clinic satisfaction questionnaire 
C10F411 91646 Type II diabetes mellitus with ulcer 
C10E311 91942 Type I diabetes mellitus with multiple complications 
C10EC11 91943 Type I diabetes mellitus with polyneuropathy 
C10N100 93380 Cystic fibrosis related diabetes mellitus 
9OLH.00 93390 Attended DAFNE diabetes structured education programme 
9OLJ.00 93491 DAFNE diabetes structured education programme completed 
9OLL.00 93631 XPERT diabetes structured education programme completed 
8Hj3.00 93704 Referral to DAFNE diabetes structured education programme 
C10FE11 93727 Type II diabetes mellitus with diabetic cataract 
8Hj5.00 93870 Referral to XPERT diabetes structured education programme 
C10E712 93875 Insulin dependent diabetes mellitus with retinopathy 
C10E511 93878 Type I diabetes mellitus with ulcer 
C104000 93922 Diabetes mellitus, juvenile type, with renal manifestation 
9OLG.00 94011 Attended XPERT diabetes structured education programme 
ZRB5.00 94699 Diabetes treatment satisfaction questionnaire 
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9NiE.00 94955 Did not attend XPERT diabetes structured education programme 
8I84.00 94956 Did not complete XPERT diabetes structured education program 
C10E711 95343 Type I diabetes mellitus with retinopathy 
C10FA11 95351 Type II diabetes mellitus with mononeuropathy 
C10ER00 95636 Latent autoimmune diabetes mellitus in adult 
C108A11 95992 Type I diabetes mellitus without complication 
66Aq.00 95994 Diabetic foot screen 
66Ap.00 96010 Insulin treatment initiated 
9kL..00 96143 Insulin initiation - enhanced services administration 
C10E911 96235 Type I diabetes mellitus maturity onset 
C10G000 96506 Secondary pancreatic diabetes mellitus without complication 
C108912 97446 Type 1 diabetes mellitus maturity onset 
C108412 97474 Unstable type 1 diabetes mellitus 
8I82.00 97809 Did not complete DAFNE diabetes structured education program 
ZRB6.11 97824 DWBQ - Diabetes wellbeing questionnaire 
C10E912 97849 Insulin dependent diabetes maturity onset 
C10EP11 97894 Type I diabetes mellitus with exudative maculopathy 
C10E112 98071 Insulin-dependent diabetes mellitus with ophthalmic comps 
C10C.12 98392 Maturity onset diabetes in youth type 1 
C10F211 98616 Type II diabetes mellitus with neurological complications 
C10E512 98704 Insulin dependent diabetes mellitus with ulcer 
C10FD11 98723 Type II diabetes mellitus with hypoglycaemic coma 
3883.00 98954 Diabetes treatment satisfaction questionnaire 
C108B11 99231 Type I diabetes mellitus with mononeuropathy 
9NiC.00 99277 Did not attend DAFNE diabetes structured education programme 
C10E111 99311 Type I diabetes mellitus with ophthalmic complications 
Kyu0300 99628 [X]Glomerular disorders in diabetes mellitus 
C10EE12 99716 Insulin dependent diabetes mellitus with hypoglycaemic coma 
C10EA12 99719 Insulin-dependent diabetes without complication 
U60231E 100033 [X] Adverse reaction to insulins and antidiabetic agents NOS 
Cyu2300 100292 [X]Unspecified diabetes mellitus with renal complications 
C10EF12 100770 Insulin dependent diabetes mellitus with diabetic cataract 
C10F111 100964 Type II diabetes mellitus with ophthalmic complications 
C10EC12 101311 Insulin dependent diabetes mellitus with polyneuropathy 
C10E212 101735 Insulin-dependent diabetes mellitus with neurological comps 
2BBr.00 101881 Impaired vision due to diabetic retinopathy 
C10ED12 102163 Insulin dependent diabetes mellitus with nephropathy 
C10FC11 102201 Type II diabetes mellitus with nephropathy 
Hypertension: 
G2...00 204 Hypertensive disease 
G20..11 351 High blood pressure 
G20..00 799 Essential hypertension 
G201.00 1894 Benign essential hypertension 
14A2.00 2666 H/O: hypertension 
662O.00 3425 On treatment for hypertension 
G20z.11 3712 Hypertension NOS 
G202.00 4372 Systolic hypertension 
G22..00 4668 Hypertensive renal disease 
8HT5.00 5513 Referral to hypertension clinic 
G2z..00 7057 Hypertensive disease NOS 
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G24..00 7329 Secondary hypertension 
G2...11 8732 BP - hypertensive disease 
G21z011 8857 Cardiomegaly - hypertensive 
G20z.00 10818 Essential hypertension NOS 
662H.00 12948 Hypertension treatm.stopped 
662G.00 13188 Hypertensive treatm.changed 
G22z.00 15106 Hypertensive renal disease NOS 
G200.00 15377 Malignant essential hypertension 
G24z.00 16059 Secondary hypertension NOS 
G21zz00 16173 Hypertensive heart disease NOS 
G21..00 16292 Hypertensive heart disease 
6627.00 16565 Good hypertension control 
G22..11 17434 Nephrosclerosis 
662c.00 18482 Hypertension six month review 
662b.00 18590 Moderate hypertension control 
G2y..00 18765 Other specified hypertensive disease 
662d.00 19070 Hypertension annual review 
662F.00 21826 Hypertension treatm. started 
G232.00 21837 Hypertensive heart&renal dis wth (congestive) heart failure 
8I3N.00 22333 Hypertension treatment refused 
G241000 25371 Secondary benign renovascular hypertension 
6628.00 27511 Poor hypertension control 
9N1y200 27634 Seen in hypertension clinic 
G233.00 28684 Hypertensive heart and renal disease with renal failure 
G22z.11 29310 Renal hypertension 
6629.00 30776 Hypertension:follow-up default 
G24z100 31341 Hypertension secondary to drug 
G24z000 31387 Secondary renovascular hypertension NOS 
G21z.00 31464 Hypertensive heart disease NOS 
G240.00 31755 Secondary malignant hypertension 
G222.00 32423 Hypertensive renal disease with renal failure 
6146200 32976 Hypertension induced by oral contraceptive pill 
G244.00 34744 Hypertension secondary to endocrine disorders 
G220.00 39649 Malignant hypertensive renal disease 
G24zz00 42229 Secondary hypertension NOS 
G221.00 43935 Benign hypertensive renal disease 
G210.00 50157 Malignant hypertensive heart disease 
G241z00 51635 Secondary benign hypertension NOS 
G211100 52127 Benign hypertensive heart disease with CCF 
G211.00 52427 Benign hypertensive heart disease 
G241.00 57288 Secondary benign hypertension 
G234.00 57987 Hyperten heart&renal dis+both(congestv)heart and renal fail 
G240000 59383 Secondary malignant renovascular hypertension 
G21z000 61166 Hypertensive heart disease NOS without CCF 
G211000 61660 Benign hypertensive heart disease without CCF 
G21z100 62718 Hypertensive heart disease NOS with CCF 
G231.00 63000 Benign hypertensive heart and renal disease 
G23..00 63466 Hypertensive heart and renal disease 
G230.00 67232 Malignant hypertensive heart and renal disease 
G23z.00 68659 Hypertensive heart and renal disease NOS 
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Gyu2.00 69753 [X]Hypertensive diseases 
G210100 72668 Malignant hypertensive heart disease with CCF 
G240z00 73293 Secondary malignant hypertension NOS 
G203.00 83473 Diastolic hypertension 
G210000 95334 Malignant hypertensive heart disease without CCF 
662r.00 95359 Trial withdrawal of antihypertensive therapy 
Gyu2100 97533 [X]Hypertension secondary to other renal disorders 
662q.00 99259 Trial reduction of antihypertensive therapy 
662P000 102406 Hypertension 9 month review 
Gyu2000 102458 [X]Other secondary hypertension 
Myocardial infarction: 
G30..00 241 Acute myocardial infarction 
G30..14 1204 Heart attack 
G30..15 1677 MI - acute myocardial infarction 
G308.00 1678 Inferior myocardial infarction NOS 
G30..12 2491 Coronary thrombosis 
G307.00 3704 Acute subendocardial infarction 
G32..00 4017 Old myocardial infarction 
44H3.00 5221 Cardiac enzymes abnormal 
G301.00 5387 Other specified anterior myocardial infarction 
323..00 7783 ECG: myocardial infarction 
G302.00 8935 Acute inferolateral infarction 
G307000 9507 Acute non-Q wave infarction 
G307100 10562 Acute non-ST segment elevation myocardial infarction 
G300.00 12139 Acute anterolateral infarction 
G30X000 12229 Acute ST segment elevation myocardial infarction 
G30..11 13566 Attack - heart 
G30..16 13571 Thrombosis - coronary 
G30z.00 14658 Acute myocardial infarction NOS 
G301z00 14897 Anterior myocardial infarction NOS 
G305.00 14898 Lateral myocardial infarction NOS 
G310.11 15661 Dressler's syndrome 
G32..11 16408 Healed myocardial infarction 
G32..12 17464 Personal history of myocardial infarction 
G30..17 17689 Silent myocardial infarction 
G301100 17872 Acute anteroseptal infarction 
G35..00 18842 Subsequent myocardial infarction 
G310.00 23579 Postmyocardial infarction syndrome 
G361.00 23708 Atrial septal defect/curr comp folow acut myocardal infarct 
G304.00 23892 Posterior myocardial infarction NOS 
G360.00 24126 Haemopericardium/current comp folow acut myocard infarct 
32E3.00 26966 ECG: S-T elevation 
3234.00 26972 ECG:posterior/inferior infarct 
3233.00 26975 ECG: antero-septal infarct. 
G30y000 28736 Acute atrial infarction 
G366.00 29553 Thrombosis atrium,auric append&vent/curr comp foll acute MI 
G303.00 29643 Acute inferoposterior infarction 
G30X.00 29758 Acute transmural myocardial infarction of unspecif site 
G309.00 30330 Acute Q-wave infarct 
G30..13 30421 Cardiac rupture following myocardial infarction (MI) 
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G38..00 32272 Postoperative myocardial infarction 
G30B.00 32854 Acute posterolateral myocardial infarction 
7929100 33650 Percut transluminal coronary thrombolysis with streptokinase 
G30y.00 34803 Other acute myocardial infarction 
32B..00 34952 ECG: Q wave 
14A3.00 35674 H/O: myocardial infarct <60 
G36..00 36423 Certain current complication follow acute myocardial infarct 
G362.00 37657 Ventric septal defect/curr comp fol acut myocardal infarctn 
G351.00 38609 Subsequent myocardial infarction of inferior wall 
3232.00 39904 ECG: old myocardial infarction 
14A4.00 40399 H/O: myocardial infarct >60 
G301000 40429 Acute anteroapical infarction 
7929111 40996 Percut translum coronary thrombolytic therapy- streptokinase 
G30y200 41221 Acute septal infarction 
G384.00 41835 Postoperative subendocardial myocardial infarction 
G350.00 45809 Subsequent myocardial infarction of anterior wall 
G30yz00 46017 Other acute myocardial infarction NOS 
G380.00 46112 Postoperative transmural myocardial infarction anterior wall 
G35X.00 46166 Subsequent myocardial infarction of unspecified site 
32B2.00 46227 ECG: Q wave abnormal 
G381.00 46276 Postoperative transmural myocardial infarction inferior wall 
14AH.00 50372 H/O: Myocardial infarction in last year 
3236.00 52705 ECG: lateral infarction 
3235.00 55401 ECG: subendocardial infarct 
323Z.00 59032 ECG: myocardial infarct NOS 
G363.00 59189 Ruptur cardiac wall w'out haemopericard/cur comp fol ac MI 
G364.00 59940 Ruptur chordae tendinae/curr comp fol acute myocard infarct 
44H3000 60664 Cardiac enzymes abnormal - first set 
889A.00 61670 Diab mellit insulin-glucose infus acute myocardial infarct 
32B3.00 62270 ECG: Q wave pathological 
G30y100 62626 Acute papillary muscle infarction 
G306.00 63467 True posterior myocardial infarction 
32BZ.00 66285 ECG: Q wave NOS 
G31y100 68357 Microinfarction of heart 
G38z.00 68748 Postoperative myocardial infarction, unspecified 
G365.00 69474 Rupture papillary muscle/curr comp fol acute myocard infarct 
G353.00 72562 Subsequent myocardial infarction of other sites 
Gyu3400 96838 [X]Acute transmural myocardial infarction of unspecif site 
44p2.00 97001 Cardiac troponin positive 
Gyu3600 99991 [X]Subsequent myocardial infarction of unspecified site 
14AT.00 100139 History of myocardial infarction 
Chronic heart failure: 
G580.00 398 Congestive heart failure 
G581.00 884 Left ventricular failure 
G58..11 1223 Cardiac failure 
G58..00 2062 Heart failure 
G580.11 2906 Congestive cardiac failure 
G58z.00 4024 Heart failure NOS 
G581000 5255 Acute left ventricular failure 
G581.13 5942 Impaired left ventricular function 
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G580.14 9524 Biventricular failure 
1O1..00 9913 Heart failure confirmed 
G580.12 10079 Right heart failure 
G580.13 10154 Right ventricular failure 
G580300 11424 Compensated cardiac failure 
662T.00 12366 Congestive heart failure monitoring 
G58z.11 12590 Weak heart 
9N0k.00 12627 Seen in heart failure clinic 
662g.00 13189 New York Heart Association classification - class II 
14A6.00 15058 H/O: heart failure 
G58z.12 17278 Cardiac failure NOS 
8HBE.00 17851 Heart failure follow-up 
662f.00 18853 New York Heart Association classification - class I 
662h.00 19066 New York Heart Association classification - class III 
R2y1000 20324 [D]Cardiorespiratory failure 
G232.00 21837 Hypertensive heart&renal dis wth (congestive) heart failure 
G1yz100 22262 Rheumatic left ventricular failure 
G581.11 23481 Asthma - cardiac 
G580000 23707 Acute congestive heart failure 
8B29.00 24503 Cardiac failure therapy 
ZRad.00 26242 New York Heart Assoc classification heart failure symptoms 
G580200 27884 Decompensated cardiac failure 
G582.00 27964 Acute heart failure 
662W.00 30779 Heart failure annual review 
G580100 32671 Chronic congestive heart failure 
8H2S.00 32898 Admit heart failure emergency 
G581.12 43618 Pulmonary oedema - acute 
14AM.00 46912 H/O: Heart failure in last year 
G557100 49844 Beriberi heart disease 
662i.00 51214 New York Heart Association classification - class IV 
G211100 52127 Benign hypertensive heart disease with CCF 
G234.00 57987 Hyperten heart&renal dis+both(congestv)heart and renal fail 
G21z100 62718 Hypertensive heart disease NOS with CCF 
SP11111 66306 Heart failure as a complication of care 
G210100 72668 Malignant hypertensive heart disease with CCF 
G580400 94870 Congestive heart failure due to valvular disease 
G5y4z00 96799 Post cardiac operation heart failure NOS 
G583.11 101137 HFNEF - heart failure with normal ejection fraction 
G583.00 101138 Heart failure with normal ejection fraction 
Peripheral arterial disease: 
G700.00 1318 Aortic atherosclerosis 
G73z000 1517 Intermittent claudication 
G73..12 1826 Ischaemia of legs 
G73zz00 2760 Peripheral vascular disease NOS 
G73z.00 3530 Peripheral vascular disease NOS 
G73yz00 4325 Other specified peripheral vascular disease NOS 
R054.00 4970 [D]Gangrene 
G73..11 5702 Peripheral ischaemic vascular disease 
G73..00 5943 Other peripheral vascular disease 
M271.12 6308 Ischaemic leg ulcer 
G73..13 6827 Peripheral ischaemia 
G73z011 6853 Claudication 
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G732.00 9204 Peripheral gangrene 
G732100 12735 Gangrene of foot 
C10F500 12736 Type 2 diabetes mellitus with gangrene 
G702.00 14797 Extremity artery atheroma 
G742z00 15302 Peripheral arterial embolism and thrombosis NOS 
G702z00 16260 Extremity artery atheroma NOS 
G731000 23497 Buerger's disease 
G73y100 23871 Peripheral angiopathic disease EC NOS 
M271000 24327 Ischaemic ulcer diabetic foot 
R054300 31053 [D]Widespread diabetic foot gangrene 
C107.11 32403 Diabetes mellitus with gangrene 
C107.12 32556 Diabetes with gangrene 
C107200 33807 Diabetes mellitus, adult with gangrene 
G73y000 34152 Diabetic peripheral angiopathy 
G731.00 34638 Thromboangiitis obliterans 
C107.00 35399 Diabetes mellitus with peripheral circulatory disorder 
R054z00 37750 [D]Gangrene NOS 
C10FF00 37806 Type 2 diabetes mellitus with peripheral angiopathy 
G73y.00 38907 Other specified peripheral vascular disease 
G731100 40068 Presenile gangrene 
C109500 40401 Non-insulin dependent diabetes mellitus with gangrene 
C109512 46150 Type 2 diabetes mellitus with gangrene 
C109F00 54212 Non-insulin-dependent d m with peripheral angiopath 
C109F11 54899 Type II diabetes mellitus with peripheral angiopathy 
C107400 56803 NIDDM with peripheral circulatory disorder 
C108600 60499 Insulin dependent diabetes mellitus with gangrene 
C109F12 60699 Type 2 diabetes mellitus with peripheral angiopathy 
C109511 62107 Type II diabetes mellitus with gangrene 
C107100 63357 Diabetes mellitus, adult, + peripheral circulatory disorder 
C108G00 64446 Insulin dependent diab mell with peripheral angiopathy 
C107z00 65025 Diabetes mellitus NOS with peripheral circulatory disorder 
G731z00 67401 Thromboangiitis obliterans NOS 
C107300 69124 IDDM with peripheral circulatory disorder 
C10E600 69993 Type 1 diabetes mellitus with gangrene 
C107000 70448 Diabetes mellitus, juvenile +peripheral circulatory disorder 
Gyu7400 73961 [X]Other specified peripheral vascular diseases 
C10EG00 93468 Type 1 diabetes mellitus with peripheral angiopathy 
G733.00 98174 Ischaemic foot 
8HlP.00 100475 Referred for peripheral artery disease assessment 
G73z012 101866 Vascular claudication 
C10E611 102112 Type I diabetes mellitus with gangrene 
Stroke: 
G64..12 569 Infarction - cerebral 
G66..11 1298 CVA unspecified 
G66..00 1469 Stroke and cerebrovascular accident unspecified 
G64z.00 3149 Cerebral infarction NOS 
G61z.00 3535 Intracerebral haemorrhage NOS 
F051200 3585 Thrombosis lateral sinus 
G631.12 4152 Thrombosis, carotid artery 
G631.00 4240 Carotid artery occlusion 
216
217 
 
G61..00 5051 Intracerebral haemorrhage 
G64z111 5185 Lateral medullary syndrome 
G650.11 5268 Insufficiency - basilar artery 
G64..11 5363 CVA - cerebral artery occlusion 
G64z.12 5602 Cerebellar infarction 
14A7.12 5871 H/O: stroke 
G66..13 6116 CVA - Cerebrovascular accident unspecified 
G64..13 6155 Stroke due to cerebral arterial occlusion 
G68X.00 6228 Sequelae of stroke,not specfd as h'morrhage or infarction 
G66..12 6253 Stroke unspecified 
14A7.11 6305 H/O: CVA 
G61..11 6960 CVA - cerebrovascular accid due to intracerebral haemorrhage 
ZV12512 7138 [V]Personal history of cerebrovascular accident (CVA) 
G667.00 7780 Left sided CVA 
G614.00 7912 Pontine haemorrhage 
G663.00 8443 Brain stem stroke syndrome 
G64..00 8837 Cerebral arterial occlusion 
G678.00 9943 Cereb autosom dominant arteriop subcort infarcts leukoenceph 
G64z200 9985 Left sided cerebral infarction 
G64z300 10504 Right sided cerebral infarction 
G668.00 12833 Right sided CVA 
G613.00 13564 Cerebellar haemorrhage 
14AB.00 13567 H/O: TIA 
G641.00 15019 Cerebral embolism 
G64z.11 15252 Brainstem infarction NOS 
G640.00 16517 Cerebral thrombosis 
G664.00 17322 Cerebellar stroke syndrome 
G61..12 18604 Stroke due to intracerebral haemorrhage 
662e.00 18686 Stroke/CVA annual review 
G660.00 18689 Middle cerebral artery syndrome 
G61X100 19201 Right sided intracerebral haemorrhage, unspecified 
G662.00 19260 Posterior cerebral artery syndrome 
G661.00 19280 Anterior cerebral artery syndrome 
ZV12511 19348 [V]Personal history of stroke 
F051100 20161 Thrombosis of superior longitudinal sinus 
G62z.00 20284 Intracranial haemorrhage NOS 
G651000 21118 Vertebro-basilar artery syndrome 
F051000 22006 Thrombosis cavernous sinus 
G63y000 23671 Cerebral infarct due to thrombosis of precerebral arteries 
G650.00 23942 Basilar artery syndrome 
G671100 24385 Chronic cerebral ischaemia 
G63y100 24446 Cerebral infarction due to embolism of precerebral arteries 
G64z000 25615 Brainstem infarction 
G64z400 26424 Infarction of basal ganglia 
G641000 27975 Cerebral infarction due to embolism of cerebral arteries 
S62..14 28077 Traumatic cerebral haemorrhage 
F051300 28309 Thrombosis transverse sinus 
G61X000 28314 Left sided intracerebral haemorrhage, unspecified 
G616.00 30045 External capsule haemorrhage 
G617.00 30202 Intracerebral haemorrhage, intraventricular 
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G61X.00 31060 Intracerebral haemorrhage in hemisphere, unspecified 
F051.00 31390 Thrombosis of central nervous system venous sinuses 
G610.00 31595 Cortical haemorrhage 
G62..00 31805 Other and unspecified intracranial haemorrhage 
G630.00 32447 Basilar artery occlusion 
G651.00 33377 Vertebral artery syndrome 
G665.00 33499 Pure motor lacunar syndrome 
G6X..00 33543 Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
14A7.00 34135 H/O: CVA/stroke 
G641.11 34758 Cerebral embolus 
G640000 36717 Cerebral infarction due to thrombosis of cerebral arteries 
G676.00 37947 Nonpyogenic venous sinus thrombosis 
G676000 39344 Cereb infarct due cerebral venous thrombosis, nonpyogenic 
G683.00 39403 Sequelae of cerebral infarction 
G611.00 40338 Internal capsule haemorrhage 
G6W..00 40758 Cereb infarct due unsp occlus/stenos precerebr arteries 
G632.00 40847 Vertebral artery occlusion 
G605.00 41910 Subarachnoid haemorrhage from basilar artery 
ZLEP.00 42248 Discharge from stroke serv 
G682.00 43451 Sequelae of other nontraumatic intracranial haemorrhage 
G653.00 44765 Carotid artery syndrome hemispheric 
G63..00 45781 Precerebral arterial occlusion 
L440.11 47607 CVA - cerebrovascular accident in the puerperium 
G64z100 47642 Wallenberg syndrome 
G681.00 48149 Sequelae of intracerebral haemorrhage 
G654.00 50594 Multiple and bilateral precerebral artery syndromes 
G63y.00 51326 Other precerebral artery occlusion 
G677000 51759 Occlusion and stenosis of middle cerebral artery 
G666.00 51767 Pure sensory lacunar syndrome 
L417.00 52679 Obstetric cerebral venous thrombosis 
Gyu6400 53745 [X]Other cerebral infarction 
Gyu6200 53810 [X]Other intracerebral haemorrhage 
7P24200 55351 Delivery of rehabilitation for stroke 
G677300 55602 Occlusion and stenosis of cerebellar arteries 
L417100 55974 Cerebral venous thrombosis in the puerperium 
L440.12 56279 Stroke in the puerperium 
8HHM.00 56458 Ref to multidisciplinary stroke function improvement service 
G618.00 57315 Intracerebral haemorrhage, multiple localized 
G63..11 57495 Infarction - precerebral 
G677100 57527 Occlusion and stenosis of anterior cerebral artery 
F051z00 61366 Thrombosis of central nervous system venous sinus NOS 
G677200 65770 Occlusion and stenosis of posterior cerebral artery 
14AK.00 66873 H/O: Stroke in last year 
L417000 69686 Cerebral venous thrombosis in pregnancy 
G671000 70536 Acute cerebrovascular insufficiency NOS 
G677400 71274 Occlusion+stenosis of multiple and bilat cerebral arteries 
G63z.00 71585 Precerebral artery occlusion NOS 
Gyu6500 90572 [X]Occlusion and stenosis of other precerebral arteries 
Gyu6300 91627 [X]Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
Gyu6600 92036 [X]Occlusion and stenosis of other cerebral arteries 
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Gyu6G00 94482 [X]Cereb infarct due unsp occlus/stenos precerebr arteries 
Gyu6F00 96630 [X]Intracerebral haemorrhage in hemisphere, unspecified 
G633.00 98642 Multiple and bilateral precerebral arterial occlusion 
1M4..00 100639 Central post-stroke pain 
G67A.00 101733 Cerebral vein thrombosis 
C154211 101824 Adrenocortical haemorrhage 
Vesicoureteral reflux: 
K137.00 2421 Vesicoureteric reflux 
K137.11 4443 Ureteric reflux 
K19C.00 10880 Other obstructive and reflux uropathy 
K19X.00 12123 Obstructive and reflux uropathy, unspecified 
Kyu1300 105941 [X]Obstructive and reflux uropathy, unspecified 
Kyu1200 107866 [X]Other obstructive and reflux uropathy 
Renal stone: 
K12z.00 1256 Urinary calculus NOS 
K120.12 1858 Renal calculus 
K140.11 1912 Bladder stone 
K141.00 2105 Calculus in urethra 
K120.13 2258 Renal stone 
7B07.12 2315 Percutaneous lithotripsy of renal calculus 
K121.11 2410 Ureteric calculus 
K121.00 3308 Calculus of ureter 
7B1C.00 3449 Extracorporeal shockwave lithotripsy of ureteric calculus 
K12..12 3669 Urinary calculus 
K120z00 3906 Renal calculus NOS 
7B05000 4139 Unspecified open removal of calculus from kidney 
7B19.00 4216 Cystoscopic removal of ureteric calculus 
K120.00 4928 Calculus of kidney 
7B18.00 5366 Ureteroscopic operations for ureteric calculus 
K140.00 5729 Bladder calculus 
K121.12 6048 Ureteric stone 
4G8..00 6978 O/E - bladder calculus 
4G4..11 6979 O/E: kidney stone 
7B07z00 7119 Percutaneous renal stone surgery NOS 
7B0B.00 7682 Extracorporeal shockwave lithotripsy for renal calculus 
7B07.00 8190 Percutaneous renal stone surgery 
4G4..00 8399 O/E: renal calculus 
7B07211 8677 Endoscopic laser fragmentation of renal calculus 
K12..11 8777 Kidney calculus 
C341111 9162 Renal stone - uric acid 
7B29400 9323 Electrokinetic lithotripsy of bladder calculus 
K12..00 9950 Calculus of kidney and ureter 
K120000 10282 Staghorn calculus 
7B19211 10587 Basket extraction of ureteric calculus 
4G6..00 14276 O/E - ureteric calculus 
7B18100 16025 Other ureteroscopic fragmentation of ureteric calculus 
7B0B000 17685 ESWL for renal calculus of unspecified size 
7B19000 18190 Cystoscopic laser lithotripsy of ureteric calculus 
4G...00 18846 Calculus examination 
7B17111 20813 Other nephroscopic lithotripsy of ureteric calculus 
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7B0B.11 21401 Extracorporeal fragmentation of renal calculus 
7B25000 23381 Open removal of bladder calculus 
7B17100 23897 Other nephroscopic fragmentation of ureteric calculus 
Kyu3100 23917 [X]Calculus of urinary tract in other diseases CE 
7B19212 24933 Dormia basket extraction of ureteric calculus 
14D3.00 24994 H/O: urinary stone 
4G43.00 27786 O/E: uric acid renal calculus 
7B0Bz00 28514 Extracorporeal shockwave lithotripsy for renal calculus NOS 
7B29100 28595 Other endoscopic extraction of bladder calculus 
7B18011 28790 Ureteroscopic laser fragmentation of ureteric calculus 
7B43900 28953 Endoscopic removal of urethral calculus 
4G82.11 29242 Uric acid bladder stone 
7B1Cz00 29464 Extracorporeal shockwave lithotripsy ureteric calculus NOS 
7B1Cy00 29477 Extracorporeal shockwave lithotripsy of ureteric calculus OS 
4G81.11 31773 Oxalate bladder stone 
4G42.11 32858 Phosphate kidney stone 
K122.00 33746 Calculus of kidney with calculus of ureter 
7B42300 34097 Open urethrotomy and removal of calculus 
7B07400 34139 Endoscopic extraction of calculus of kidney nec 
7B19300 35743 Cystoscopic catheter drainage for ureteric calculus 
7B07011 36157 Endoscopic ultrasound fragmentation of renal calculus 
7B18000 36792 Ureteroscopic laser lithotripsy of ureteric calculus 
7B19200 37073 Cystoscopic extraction of ureteric calculus 
4G4Z.00 38461 O/E: renal stone NOS 
7B18200 38804 Ureteroscopic extraction of ureteric calculus 
7B19400 39048 Cystoscopic dilation of ureter for drainage of calculus 
7B17000 39511 Nephroscopic laser lithotripsy of ureteric calculus 
7B2B400 40272 Removal of bladder calculus by urethral catheter suction 
7B07000 41619 Nephroscopy and ultrasound lithotripsy of renal calculus 
7B19100 41871 Other cystoscopic fragmentation of ureteric calculus 
7B07200 43350 Nephroscopy and laser lithotripsy of renal calculus 
K14z.00 44648 Lower urinary tract calculus NOS 
4G7..00 45245 O/E - urethral calculus 
7B17200 45673 Nephroscopic extraction of ureteric calculus 
K14y.00 46291 Other lower urinary tract calculus 
K14..00 47869 Lower urinary tract calculus 
4G44.00 49783 O/E: cystine renal calculus 
7B1C000 51305 Extracorp shockwave lithotripsy of unspec ureteric calculus 
K1A..00 52569 Urinary calculus in schistosomiasis 
7B0B100 52721 ESWL for renal calculus less than 2 cm in diameter 
7B07.11 56462 Nephroscopic percutaneous lithotripsy of renal calculus 
PD31.00 56531 Congenital calculus of kidney 
7B17011 58004 Nephroscopic laser fragmentation of ureteric calculus 
7B19z00 58149 Cystoscopic removal of ureteric calculus NOS 
K140z00 59834 Bladder calculus NOS 
7B07100 60234 Nephroscopy & electrohydraulic lithotripsy of renal calculus 
7B1C100 61904 Extracorporeal shockwave therapy for stone in upper ureter 
4G8Z.00 64699 O/E - bladder calculus NOS 
4G83.11 65920 Phosphate bladder stone 
7B0By00 66113 Extracorporeal shockwave lithotripsy for renal calculus OS 
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7B07y00 66743 Other specified percutaneous renal stone surgery 
7B1C300 71131 Extracorporeal shockwave lithotripsy stone in lower ureter 
7B19y00 72447 Other specified cystoscopic removal of ureteric calculus 
7B42400 90777 Open extraction of calculus from urethra 
7B0B200 94219 ESWL for renal calculus 2 cm or more in diameter 
4G9E.00 96314 Calculus ammonium urate content 
7B1C200 101583 Extracorporeal shockwave lithotripsy for stone in mid-ureter 
7B1F000 102036 Endoscopic extraction of calculus of urinary diversion 
Kyu3000 106912 [X]Other lower urinary tract calculus 
Prostatic hypertrophy: 
K200.00 929 Prostatic hyperplasia unspecified 
K20..16 2627 Prostatism 
K20..00 3045 Benign prostatic hypertrophy 
1AA..00 5906 Prostatism 
K20..15 7555 BPH - benign prostatic hypertrophy 
K20..14 7702 Enlarged prostate - benign 
K20z.00 16035 Prostatic hyperplasia NOS 
K202.00 35676 Prostatic hyperplasia of the medial lobe 
K201.00 64296 Prostatic hyperplasia of the lateral lobe 
Systematic lupus erythematosus: 
M154.00 4125 Lupus erythematosus 
M154z00 7522 Lupus erythematosus NOS 
N000.00 7871 Systemic lupus erythematosus 
N000400 11920 Systemic lupus erythematosus with pericarditis 
N000000 20007 Disseminated lupus erythematosus 
K01x411 22205 Lupus nephritis 
M154700 25390 Subacute cutaneous lupus erythematosus 
N000300 29519 Systemic lupus erythematosus with organ or sys involv 
H57y400 31564 Lung disease with systemic lupus erythematosus 
M154000 33449 Lupus erythematosus chronicus 
N000200 36942 Drug-induced systemic lupus erythematosus 
M154200 40797 Lupus erythematosus migrans 
N000z00 42719 Systemic lupus erythematosus NOS 
F371000 44095 Polyneuropathy in disseminated lupus erythematosus 
M154500 44984 Lupus erythematosus tumidus 
ZRq9.00 45726 Systemic lupus erythematosus disease activity index 
M154400 46148 Lupus erythematosus profundus 
K01x400 47672 Nephrotic syndrome in systemic lupus erythematosus 
ZRq8.00 51798 Systemic lupus activity measure 
Nyu4300 58706 [X]Other forms of systemic lupus erythematosus 
M154600 63955 Lupus erythematosus unguium mutilans 
M154300 65391 Lupus erythematosus nodularis 
N000500 99435 Neonatal lupus erythematosus 
N000600 101433 Cerebral lupus 
Polycystic kidney disease: 
PD11.00 4503 Polycystic kidney disease 
PD1..13 4504 Polycystic kidney 
PD11100 4505 Polycystic kidneys, adult type 
12F1.00 11406 FH: Polycystic kidney 
PD11000 21381 Polycystic kidneys, infantile type 
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7B03300 45880 Rovsing's operation for polycystic kidney 
Z4B4.00 55233 Polycystic kidney disease counselling 
PD11z00 56852 Polycystic kidney disease NOS 
PD11111 105143 Autosomal dominant polycystic kidney disease 
PD11011 105919 Autosomal recessive polycystic kidney disease 
Chronic obstructivepulmonarydisease: 
H32..00 794 Emphysema 
H3...11 998 Chronic obstructive airways disease 
H3...00 1001 Chronic obstructive pulmonary disease 
H312200 1446 Acute exacerbation of chronic obstructive airways disease 
H31..00 3243 Chronic bronchitis 
H3z..00 5710 Chronic obstructive airways disease NOS 
H3y1.00 7884 Chron obstruct pulmonary dis wth acute exacerbation, unspec 
66YB.00 9520 Chronic obstructive pulmonary disease monitoring 
H38..00 9876 Severe chronic obstructive pulmonary disease 
H37..00 10802 Moderate chronic obstructive pulmonary disease 
H36..00 10863 Mild chronic obstructive pulmonary disease 
H322.00 10980 Centrilobular emphysema 
8H2R.00 11019 Admit COPD emergency 
H311.00 11150 Mucopurulent chronic bronchitis 
66YM.00 11287 Chronic obstructive pulmonary disease annual review 
H3y..00 12166 Other specified chronic obstructive airways disease 
H312100 14798 Emphysematous bronchitis 
H31z.00 15157 Chronic bronchitis NOS 
H310000 15626 Chronic catarrhal bronchitis 
66YL.11 18476 COPD follow-up 
66YI.00 18501 COPD self-management plan given 
66YL.00 18621 Chronic obstructive pulmonary disease follow-up 
9Oi..00 18792 Chronic obstructive pulmonary disease monitoring admin 
66Ye.00 19003 Emergency COPD admission since last appointment 
66Yd.00 19106 COPD accident and emergency attendance since last visit 
H3y0.00 21061 Chronic obstruct pulmonary dis with acute lower resp infectn 
H320z00 23492 Chronic bullous emphysema NOS 
H313.00 24248 Mixed simple and mucopurulent chronic bronchitis 
H310.00 25603 Simple chronic bronchitis 
66YS.00 26018 Chronic obstructive pulmonary disease monitoring by nurse 
H320.00 26306 Chronic bullous emphysema 
H312.00 27819 Obstructive chronic bronchitis 
9Oi0.00 28755 Chronic obstructive pulmonary disease monitoring 1st letter 
H32z.00 33450 Emphysema NOS 
9Oi1.00 34202 Chronic obstructive pulmonary disease monitoring 2nd letter 
9Oi2.00 34215 Chronic obstructive pulmonary disease monitoring 3rd letter 
H3z..11 37247 Chronic obstructive pulmonary disease NOS 
66YD.00 37371 Chronic obstructive pulmonary disease monitoring due 
H311100 37959 Fetid chronic bronchitis 
9Oi4.00 38074 Chronic obstructive pulmonary disease monitor phone invite 
H311000 40159 Purulent chronic bronchitis 
9Oi3.00 42258 Chronic obstructive pulmonary disease monitoring verb invite 
66YL.12 42624 COAD follow-up 
H312z00 44525 Obstructive chronic bronchitis NOS 
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66Yg.00 45770 Chronic obstructive pulmonary disease disturbs sleep 
66Yh.00 45771 Chronic obstructive pulmonary disease does not disturb sleep 
8CR1.00 45777 Chronic obstructive pulmonary disease clini management plan 
66YT.00 45998 Chronic obstructive pulmonary disease monitoring by doctor 
66Yi.00 46036 Multiple COPD emergency hospital admissions 
H321.00 46578 Panlobular emphysema 
H320000 56860 Segmental bullous emphysema 
H320200 60188 Giant bullous emphysema 
H310z00 61118 Simple chronic bronchitis NOS 
H311z00 61513 Mucopurulent chronic bronchitis NOS 
H464000 64721 Chronic emphysema due to chemical fumes 
Hyu3100 65733 [X]Other specified chronic obstructive pulmonary disease 
H31y.00 66043 Other chronic bronchitis 
H3y..11 67040 Other specified chronic obstructive pulmonary disease 
H31yz00 68066 Other chronic bronchitis NOS 
H39..00 93568 Very severe chronic obstructive pulmonary disease 
14OX.00 96931 At risk of chronic obstructive pulmonary diseas exacerbation 
9kf2.00 98283 COPD structured smoking assessment declined - enh serv admin 
9kf1.00 98284 Refer COPD structured smoking assessment - enhanc serv admin 
H320300 99536 Bullous emphysema with collapse 
9kf0.00 99948 COPD patient unsuitable for pulmonary rehab - enh serv admin 
8BMW.00 101042 Issue of chronic obstructive pulmonary disease rescue pack 
66YB000 102685 Chronic obstructive pulmonary disease 3 monthly review 
66YB100 103007 Chronic obstructive pulmonary disease 6 monthly review 
9kf1.11 103400 Referred for COPD structured smoking assessment 
Rheumatoid arthritis: 
N040.00 844 Rheumatoid arthritis 
N043.00 4186 Juvenile rheumatoid arthritis - Still's disease 
N042200 5723 Rheumatoid nodule 
N040P00 6916 Seronegative rheumatoid arthritis 
N040T00 8350 Flare of rheumatoid arthritis 
N047.00 9707 Seropositive errosive rheumatoid arthritis 
H570.00 9954 Rheumatoid lung 
N04X.00 12019 Seropositive rheumatoid arthritis, unspecified 
N040Q00 18155 Rheumatoid bursitis 
N040200 21358 Rheumatoid arthritis of shoulder 
N043200 21533 Pauciarticular juvenile rheumatoid arthritis 
N041.00 23552 Felty's syndrome 
N005.00 23834 Adult Still's Disease 
N043z00 27557 Juvenile rheumatoid arthritis NOS 
N04..00 27603 Rheumatoid arthritis and other inflammatory polyarthropathy 
N04y012 28853 Fibrosing alveolitis associated with rheumatoid arthritis 
N040N00 30548 Rheumatoid vasculitis 
N040S00 31054 Rheumatoid arthritis - multiple joint 
F396400 31209 Myopathy due to rheumatoid arthritis 
N045500 31360 Juvenile rheumatoid arthritis 
N04y000 31724 Rheumatoid lung 
N04y200 32001 Adult-onset Still's disease 
2G27.00 33264 O/E-hands-rheumatoid spindling 
N043300 36276 Monarticular juvenile rheumatoid arthritis 
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N042z00 37431 Rheumatoid arthropathy + visceral/systemic involvement NOS 
N040900 41941 Rheumatoid arthritis of PIP joint of finger 
N040800 42299 Rheumatoid arthritis of MCP joint 
G5yA.00 43816 Rheumatoid carditis 
N040100 44203 Other rheumatoid arthritis of spine 
N040000 44743 Rheumatoid arthritis of cervical spine 
N042100 46436 Rheumatoid lung disease 
N043100 47831 Acute polyarticular juvenile rheumatoid arthritis 
N040700 48832 Rheumatoid arthritis of wrist 
N040B00 49067 Rheumatoid arthritis of hip 
N042.00 49227 Other rheumatoid arthropathy + visceral/systemic involvement 
G5y8.00 49787 Rheumatoid myocarditis 
N043000 50644 Juvenile rheumatoid arthropathy unspecified 
N040D00 50863 Rheumatoid arthritis of knee 
N040K00 51238 Rheumatoid arthritis of 1st MTP joint 
N040F00 51239 Rheumatoid arthritis of ankle 
N040R00 53621 Rheumatoid nodule 
Nyu1G00 56202 [X]Seropositive rheumatoid arthritis, unspecified 
N04y011 56838 Caplan's syndrome 
N040500 59738 Rheumatoid arthritis of elbow 
F371200 62401 Polyneuropathy in rheumatoid arthritis 
N040A00 63198 Rheumatoid arthritis of DIP joint of finger 
N040600 63365 Rheumatoid arthritis of distal radio-ulnar joint 
Nyu1200 70221 [X]Other specified rheumatoid arthritis 
N040H00 70658 Rheumatoid arthritis of talonavicular joint 
N040J00 71784 Rheumatoid arthritis of other tarsal joint 
N040G00 73619 Rheumatoid arthritis of subtalar joint 
Nyu1100 93715 [X]Other seropositive rheumatoid arthritis 
N040L00 99414 Rheumatoid arthritis of lesser MTP joint 
N040C00 100776 Rheumatoid arthritis of sacro-iliac joint 
N040400 100914 Rheumatoid arthritis of acromioclavicular joint 
7P20300 102088 Delivery of rehabilitation for rheumatoid arthritis 
Parkinson's disease: 
F12..00 4321 Parkinson's disease 
Eu02300 9509 [X]Dementia in Parkinson's disease 
F12z.00 14912 Parkinson's disease NOS 
F11x900 96860 Cerebral degeneration in Parkinson's disease 
147F.00 101090 History of Parkinson's disease 
Epilepsy: 
F25..00 573 Epilepsy 
F251000 988 Grand mal (major) epilepsy 
F250011 1715 Epileptic absences 
F250000 2907 Petit mal (minor) epilepsy 
F254000 3175 Temporal lobe epilepsy 
F25z.11 3607 Fit (in known epileptic) NOS 
8B66.00 3784 Anticonvulsant therapy 
F253.11 4093 Status epilepticus 
SC20000 4109 Traumatic epilepsy 
667B.00 4602 Nocturnal epilepsy 
F251300 4801 Epileptic seizures - myoclonic 
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F253.00 5117 Grand mal status 
F251400 5152 Epileptic seizures - tonic 
F255011 5525 Focal epilepsy 
F251600 5668 Grand mal seizure 
F25X.00 6271 Status epilepticus, unspecified 
Eu05y11 6709 [X]Epileptic psychosis NOS 
2823.00 7809 O/E - petit mal fit 
2822.00 7811 O/E - grand mal fit 
2828.00 8097 Absence seizure 
F251500 8187 Tonic-clonic epilepsy 
F132z12 8487 Myoclonic seizure 
8BIF.00 9326 Epilepsy medication review 
F255000 9569 Jacksonian, focal or motor epilepsy 
F25z.00 9747 Epilepsy NOS 
F252.00 9886 Petit mal status 
F25y200 9887 Locl-rlt(foc)(part)idiop epilep&epilptic syn seiz locl onset 
F25yz00 9979 Other forms of epilepsy NOS 
667F.00 11015 Seizure free >12 months 
F250.00 11186 Generalised nonconvulsive epilepsy 
F254500 11394 Complex partial epileptic seizure 
1B26.00 11454 Trigger factor for seizure 
1B27.00 11505 Seizures in response to acute event 
8BL3.00 11752 Patient on maximal tolerated anticonvulsant therapy 
6677.00 13073 Epilepsy drug side effects 
667P.00 13219 No seizures on treatment 
667D.00 13220 Epilepsy control poor 
667R.00 13221 2 to 4 seizures a month 
F250400 17399 Juvenile absence epilepsy 
F251200 18471 Epileptic seizures - clonic 
667T.00 18899 Daily seizures 
F25y400 19170 Benign Rolandic epilepsy 
F25A.00 19363 Juvenile myoclonic epilepsy 
667S.00 19549 1 to 7 seizures a week 
667C.00 19550 Epilepsy control good 
667E.00 19551 Epilepsy care arrangement 
667L.00 19552 Epilepsy does not limit activities 
667A.00 20566 Epilepsy treatment stopped 
1O30.00 22341 Epilepsy confirmed 
F251011 22804 Tonic-clonic epilepsy 
667N.00 22991 Epilepsy severity 
F254100 23634 Psychomotor epilepsy 
F250200 24309 Epileptic seizures - atonic 
F25y300 25330 Complex partial status epilepticus 
F255.00 26015 Partial epilepsy without impairment of consciousness 
F251.00 26144 Generalised convulsive epilepsy 
6672.00 26511 Follow-up epilepsy assessment 
6678.00 26512 Epilepsy treatment changed 
667Q.00 26618 1 to 12 seizures a year 
667K.00 26619 Epilepsy limits activities 
667G.00 26620 Epilepsy restricts employment 
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F255y00 26733 Partial epilepsy without impairment of consciousness OS 
44WF000 26961 Anticonvulsant level therapeutic 
F255z00 27526 Partial epilepsy without impairment of consciousness NOS 
F25B.00 30604 Alcohol-induced epilepsy 
F25F.00 30635 Photosensitive epilepsy 
F25C.00 30816 Drug-induced epilepsy 
F250300 31830 Epileptic seizures - akinetic 
Eu05212 31877 [X]Schizophrenia-like psychosis in epilepsy 
F254z00 31920 Partial epilepsy with impairment of consciousness NOS 
F254.00 32288 Partial epilepsy with impairment of consciousness 
F254400 34079 Epileptic automatism 
6679.00 34473 Epilepsy treatment started 
F254200 36203 Psychosensory epilepsy 
F255200 37592 Somatosensory epilepsy 
F132100 37644 Progressive myoclonic epilepsy 
F251100 37782 Neonatal myoclonic epilepsy 
F25y.00 38307 Other forms of epilepsy 
1B1W.00 38919 Transient epileptic amnesia 
667V.00 39160 Many seizures a day 
F255600 40105 Simple partial epileptic seizure 
F251z00 40806 Generalised convulsive epilepsy NOS 
667J.00 40863 Epilepsy impairs education 
Eu80300 43679 [X]Acquired aphasia with epilepsy [Landau - Kleffner] 
F250z00 44252 Generalised nonconvulsive epilepsy NOS 
6671.00 45746 Initial epilepsy assessment 
F251y00 45927 Other specified generalised convulsive epilepsy 
667W.00 46603 Emergency epilepsy treatment since last appointment 
F255100 48134 Sensory induced epilepsy 
Eu06013 48462 [X]Limbic epilepsy personality 
ZS82.00 49889 Acquired epileptic aphasia 
6674.00 50012 Epilepsy associated problems 
667H.00 50702 Epilepsy prevents employment 
U606614 52273 [X] Adverse reaction to anticonvulsants NOS 
667X.00 52632 No epilepsy drug side effects 
F25y100 53483 Gelastic epilepsy 
F25y000 55260 Cursive (running) epilepsy 
F254300 55665 Limbic system epilepsy 
667M.00 55706 Epilepsy management plan given 
F255400 55739 Visual reflex epilepsy 
F25D.00 56359 Menstrual epilepsy 
Fyu5200 59120 [X]Other status epilepticus 
F250y00 59185 Other specified generalised nonconvulsive epilepsy 
TJ63z00 60306 Adverse reaction to anticonvulsants NOS 
TJ63.00 63234 Adverse reaction to other anticonvulsants 
F25E.00 65673 Stress-induced epilepsy 
F255012 65699 Motor epilepsy 
F255500 68946 Unilateral epilepsy 
Fyu5100 69831 [X]Other epilepsy 
F257.00 71719 Kojevnikov's epilepsy 
Fyu5900 71801 [X]Status epilepticus, unspecified 
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F255300 73542 Visceral reflex epilepsy 
U606600 73879 [X]Oth unspec antiepileptics caus adverse eff in therap use 
U606611 95658 [X] Adverse reaction to other anticonvulsant 
F255311 98870 Partial epilepsy with autonomic symptoms 
F250100 99548 Pykno-epilepsy 
Fyu5000 99731 [X]Other generalized epilepsy and epileptic syndromes 
R003400 99834 [D]Nocturnal seizure 
6110.00 100652 Contraceptive advice for patients with epilepsy 
67IJ000 100920 Pre-conception advice for patients with epilepsy 
8IB2.00 101143 Contraceptiv advice for patients with epilepsy not indicated 
8IAg.00 102190 Contraceptive advice for patients with epilepsy declined 
8IAi.00 102191 Pregnancy advice for patients with epilepsy declined 
8IB3.00 102264 Pre-conception advic fr patients with epilepsy not indicated 
8IAh.00 102265 Pre-conception advice for patients with epilepsy declined 
67AF.00 102359 Pregnancy advice for patients with epilepsy 
8IB4.00 102375 Pregnancy advice for patients with epilepsy not indicated 
Chronic liver disease: 
J615z13 1638 Cirrhosis of liver NOS 
J614.00 1754 Chronic hepatitis 
J614200 1755 Chronic aggressive hepatitis 
J61y200 1780 Hepatosplenomegaly 
J611.00 3216 Acute alcoholic hepatitis 
J615300 3450 Diffuse nodular cirrhosis 
J612.00 4743 Alcoholic cirrhosis of liver 
J616000 5638 Primary biliary cirrhosis 
J61..00 6863 Cirrhosis and chronic liver disease 
J617000 7602 Chronic alcoholic hepatitis 
J613.00 7885 Alcoholic liver damage unspecified 
J617.00 7943 Alcoholic hepatitis 
J614111 7957 Autoimmune chronic active hepatitis 
J614100 9029 Chronic active hepatitis 
J616.00 9494 Biliary cirrhosis 
J61y100 10234 Non-alcoholic fatty liver 
J61z.00 10539 Chronic liver disease NOS 
J61y700 10572 Steatosis of liver 
J610.00 10691 Alcoholic fatty liver 
J616100 15424 Secondary biliary cirrhosis 
J614z00 15489 Chronic hepatitis NOS 
J615z00 16455 Non-alcoholic cirrhosis NOS 
J615.00 16725 Cirrhosis - non alcoholic 
J613000 17330 Alcoholic hepatic failure 
J615z12 18739 Cryptogenic cirrhosis of liver 
J612000 21713 Alcoholic fibrosis and sclerosis of liver 
J615z11 22841 Macronodular cirrhosis of liver 
J614000 23578 Chronic persistent hepatitis 
J61y400 25383 Hepatic fibrosis 
J615700 27438 Cardiac portal cirrhosis 
J61yz00 33597 Other non-alcoholic chronic liver disease NOS 
J615600 40567 Capsular portal cirrhosis 
J61y300 40963 Portal fibrosis without cirrhosis 
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J61y.00 42843 Other non-alcoholic chronic liver disease 
J615400 44676 Fatty portal cirrhosis 
J615.11 47257 Portal cirrhosis 
J615H00 48928 Infectious cirrhosis NOS 
J614300 53480 Recurrent hepatitis 
J614y00 53877 Chronic hepatitis unspecified 
J615y00 55454 Portal cirrhosis unspecified 
J615812 58184 Indian childhood cirrhosis 
J616z00 58630 Biliary cirrhosis NOS 
J61y500 60104 Hepatic sclerosis 
J614400 66534 Chronic lobular hepatitis 
J612.11 68376 Florid cirrhosis 
J615100 69204 Multilobular portal cirrhosis 
J615z15 71453 Hepatic fibrosis 
J615D00 73482 Bacterial portal cirrhosis 
J616200 91591 Biliary cirrhosis of children 
J615500 92909 Hypertrophic portal cirrhosis 
J615800 96664 Juvenile portal cirrhosis 
J61y800 98148 Nonalcoholic steatohepatitis 
J615C00 100253 Xanthomatous portal cirrhosis 
J612.12 100474 Laennec's cirrhosis 
J61y600 100592 Hepatic fibrosis with hepatic sclerosis 
J61y900 103466 Fatty change of liver 
J61y911 103706 Fatty liver 
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